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Ithaca 
“When you set out on your journey to Ithaca, 
pray that the road is long, 
full of adventure, full of knowledge. 
The Lestrygonians and the Cyclops, 
the angry Poseidon, do not fear them. 
You will never find such as these on your path, 
if your thoughts remain lofty, if a fine 
emotion touches your spirit and your body. 
The Lestrygonians and the Cyclops, 
the fierce Poseidon you will never encounter, 
if you do not carry them within your soul, 
if your soul does not set them up before you. 
 
Pray that the road is long. 
That the summer mornings are many, when, 
with such pleasure, with such joy 
you will enter ports seen for the first time; 
stop at Phoenician markets, 
and purchase fine merchandise, 
mother-of-pearl and coral, amber and ebony, 
and sensual perfumes of all kinds, 
as many sensual perfumes as you can; 
visit many Egyptian cities, 
to learn and learn from scholars. 
 
Always keep Ithaca in your mind. 
To arrive there is your ultimate goal. 
But do not hurry the voyage at all. 
It is better to let it last for many years; 
and to anchor at the island when you are old, 
rich with all you have gained on the way, 
not expecting that Ithaca will offer you riches. 
 
Ithaca has given you the beautiful voyage. 
Without her you would have never set out on the road. 
She has nothing more to give you. 
 
And if you find her poor, Ithaca has not deceived you. 
Wise as you have become, with so much experience, 
you must already have understood what Ithacas mean. 
 
Konstantinos P. Cavafy (1911) 
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SUMMARY 
As Crohn’s disease (CD) is a disease of the gastrointestinal tract, nutrition is very important 
and is implicated in several aspects of the disease, from aetiology, management, and the 
long-term health of the patient. Nutritional therapy with EEN is the mainstream approach in 
the management of active paediatric CD and has a dual effect, inducing clinical remission 
and providing nutritional support and rehabilitation. Although its efficacy is well established 
by  human  trials  and  clinical  experience,  the  mode  of  action  remains  unknown.  Initial 
speculations  for  a  mechanism  of  action  mediated  through  gut  rest,  and  protein/energy 
reconstitution have not been established. On the other hand the strong evidence for the role 
of  the  indigenous  microbiota  and  micronutrients  in  disease  aetiology  and  mucosal  injury, 
challenged  the  researcher  to  explore  whether  the  action  of  EEN  is  mediated  through 
changes in these parameters.  
This study aimed to assess aspects of the nutritional status of paediatric patients with 
inflammatory bowel disease (IBD), to appraise the use of nutritional remedies in the same 
population, and to explore putative mechanisms of action of EEN, the nutritional therapy, with 
the most robust evidence of clinically efficacy. 
The first  of these  studies  was  a  questionnaire  survey  which  assessed  the  use  of 
special diets, nutritional supplements, herbals, and alternative medicine in a representative 
sample of paediatric patients with IBD. Use of these treatments was declared by two thirds of 
the patients with probiotic use and dairy free diet being the commonest forms used.  
Prevalence  of  anaemia and  predictors  of  its  progress  at  six  and  12  months  were 
assessed  in  a  large  retrospective  case  review  study.  Anaemia  was  as  high  as  73%  of 
patients  at  diagnosis  and  haemoglobin  concentration  improvement  at  six  and  12  post 
diagnosis  was  associated  with  the  use  of  oral  iron  supplementation,  improvement  of 
nutritional status markers, growth, and systemic markers of disease activity.  
In a mechanistic study the validity of a bedside method, used to assess the body 
composition of children with CD, was compared against a reference method. The agreement 
of the two methods was low and the inter-individual bias between them was substantial.     
The aim of this thesis was to study the effect of EEN on gut microbiota diversity, 
bacterial  metabolic  activity,  inflammatory  response  and  nutritional  status  in  paediatric 
patients with active CD.   
Newly diagnosed children with active CD, and patients with longstanding disease, on 
clinical  relapse,  who  started  treatment  with  EEN  as  part  of  their  standard  clinical 
management,  were  recruited.  Four  stool  samples  were  collected  while  on  treatment  with 
EEN and one when the patient returned to their normal diet. Bacterial diversity was assessed 
with molecular microbiology techniques, and bacterial metabolites were measured in serial   21 
stool samples and correlated with faecal calprotectin levels, systemic inflammatory markers 
and clinical activity. A single stool sample was collected from their first-degree relatives and 
two serial samples from healthy children with no family history of IBD. 
Significant  changes  were  observed  for  the  metabolic  activity  of  the  commensal 
microbiota  during  the  course  of  treatment.  In  particular,  faecal  butyrate  significantly 
decreased by more than 100%, faecal pH moved into the alkaline range, and a five-fold 
increase  was  observed  in  total  sulphide  but  only  in  those  patients  who  achieved  clinical 
remission, or in whom faecal calprotectin levels decreased at the end of treatment. No such 
changes were observed in children who did not achieve complete clinical remission or when 
the treatment failed. Gut bacterial diversity did not change significantly during treatment, but 
was  significantly  lower  than  in  healthy  children,  who  also  presented  a  higher  degree  of 
similarity between the two serial samples. Interestingly the gut microbiota of the healthy first 
degree relatives of CD children had significantly lower bacterial diversity compared with the 
healthy children but no such difference was observed compared with their CD relatives. The 
majority of the healthy relatives had also significantly high levels of calprotectin suggesting 
intestinal inflammation but no clinical presentation of gastrointestinal disease.    
A secondary outcome of this study was to measure changes in the systemic and gut 
specific markers of disease activity during treatment. Although systemic markers of disease 
activity improved to normal levels in the majority of the patients, intestinal inflammation was 
still ongoing and only one of the 16 children had normal calprotectin levels at the end of EEN. 
Moreover, only in those patients who achieved clinically complete remission, did calprotectin 
levels decrease significantly at the end of treatment. 
From the same cohort of patients three blood samples were also collected before, at 
the  end  of  treatment  and  on  normal  diet.  Changes  in  the  concentration  of  19  different 
micronutrients were measured in the serum and some in erythrocytes and correlated with 
systemic markers of disease activity. Serial changes in anthropometry and body composition 
were assessed during EEN and correlated with disease activity markers. 
Body  weight  increased  in  all  patients  at  the  end  of  treatment  but  fat  free  mass 
significantly  increased  only  in  those  patients  who  entered  in  clinical  remission.  Several 
micronutrients and mainly antioxidants were below the reference range for the majority of 
patients at the time of treatment initiation. Most of them improved by the end of treatment but 
the  serum  concentration  of  carotenoids  further  deteriorated  with  more  than  90%  of  the 
patients presenting concentration lower than the lower sensitivity level of the assay. A strong 
association  was  found  between  systemic  markers  of  disease  activity  and  antioxidant 
vitamins, but not with intestinal inflammation. 
In conclusion, paediatric patients with IBD, and mainly those with CD present with 
suboptimal protein/energy status, anaemia, and low circulating levels for many antioxidants.   22 
Treatment  with  EEN  corrected  the  majority  of these  markers  of  nutritional  status  but the 
carotenoid  levels  deteriorated.  Although  the  improvement  in  the  serum  levels  of  some 
micronutrients can be an epiphenomenon of the acute phase response, it does not explain 
the depleted levels of carotenoids at the end of EEN. This may be attributed to the lack of 
carotenoids  in  the  feeds  used  in  conjunction  with  excessive  utilisation  during  the  active 
course of the disease.  
On the other hand, the unhealthy intestinal microenvironment observed, in only those 
patients who clinically improved at the end of treatment; do not support a prebiotic mode of 
EEN action, as was proposed by a recent Italian study. These changes may be a secondary 
phenomenon,  associated  with  changes  in  gut  motility,  better  absorption  of  butyrate  with 
disease  improvement,  or  changes  in  the  availability  of  colonic  bacterial  substrates. 
Alternatively these changes may be associated with changes in the microbiota composition 
and  production  of  so  far  unknown  bacterial  bioproducts  which  may  have  a  causative 
association with the onset and propagation of intestinal inflammation in CD.  
These results may have significant implications in manufacturers of clinical nutrition 
products. Addition of carotenoids may improve the provision of antioxidant micronutrients 
and a dual nutritional therapy combining EEN with prebiotics, butyrate supplementation, or 
probiotics may increase the efficacy of the existing formulae. This should be addressed in 
future studies.         23 
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1.1. Inflammatory bowel disease 
 
rohn’s  disease  (CD)  and  ulcerative  colitis  (UC),  collectively  known  as 
inflammatory  bowel  disease  (IBD)  are  idiopathic,  lifelong,  inflammatory, 
destructive conditions of the gastrointestinal (GI) tract. The disease relapses 
and remits throughout its course (1-4). 
Crohn’s disease and UC, although part of the same constellation present distinct clinical, 
extraintestinal and pathological characteristics that constitute the basis for their differential 
diagnosis  (Table  1.1).  Ulcerative  colitis  is  characterized  by  continuous  diffuse  mucosal 
inflammation  limited  to  the  colon  and  rectum  whereas  CD  is  characterized  by  patchy, 
transmural inflammation, which may affect any part of the GI tract from the mouth to the anus 
(1-4).  
 
Table 1.1: Differential diagnosis of UC and CD (adapted from  (Baumgart & Sandborn 2007 (5)) 
  UC  CD 
Clinical features     
Haematochezia  Common  Uncommon 
Passage of mucus or pus  Common  Rare 
Small bowel disease  No  Yes 
Can affect upper GI tract  No  (except  backwash 
ileitis) 
Yes 
Abdominal mass  Rare  Sometimes on right side 
Extraintestinal manifestations  Common  Common 
Small bowel obstruction  Rarely  Common 
Colonic obstruction  Rarely  Common 
Fistulae and perianal disease  No  Common 
Biochemical features     
Anti-neutrophil cytoplasmic 
antibodies 
Common  Rarely 
Anti-saccharomyces cerevisiae 
antibodies 
Rarely  Common 
Pathological features     
Transmural mucosal 
inflammation 
No  Yes 
Distorted crypt architecture  Yes  Uncommon 
Cryptitis and crypt abscesses  Yes  Yes 
Granulomas  No  Yes  but  rarely  in  mucosal 
biopsies 
Fissures and skip lesions  Rarely  Common 
 
A small proportion of patients with chronic inflammatory colitis that cannot be classified 
into either of the two types of disease by endoscopic and histology findings are characterized 
as indeterminate colitis (IC) or IBD unspecified (IBDU) using new phenotypic classification 
systems (6). The disease is more extreme in children with IBD but there is no difference in 
the  spatial  distribution  (7).  Recently  a  new  consensus  classification  system  has  been 
proposed to characterise the diverse phenotypic presentation of IBD considering a) age of 
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disease onset b) disease location and c) disease behavior as the predominant phenotypic 
elements (Table 1.2) (6).  
 
Table 1.2: Montreal phenotypic classification of IBD 
Phenotype  Classification  Clinical features 
Crohn’s disease     
Age at diagnosis  A1  Below 16 y 
  A2  Between 17 and 40 y 
  A3  Above 40 y 
Location  L1  Ileal 
  L2  Colonic 
  L3  Ileocolonic 
  L4  Isolated upper disease 
Behaviour  B1  Non structuring, non penetrating 
  B2  Stricturing 
  B3  Penetrating 
    *p perianal disease modifier 
     
Ulcerative colitis 
Ulcerative proctitis  E1  Involvement limited to the rectum 
(rectosigmoid junction) 
Left side colitis  E2  Involvement limited to a proportion 
of the colorectum distal to the 
splenic flexure 
Extensive colitis  E3  Involvement extends proximal to the 
splenic flexure 
 
Inflammatory bowel disease unspecified  IBDU  IBD affecting the colon without small 
bowel involvement and no definitive 
histology or other evidence to 
suggest CD or UC 
 
1.1.1. Epidemiology of IBD 
Understanding the epidemiology of IBD may offer clues to the aetiology and pathogenesis of 
IBD and identify areas for further research (8). However defining the exact epidemiology of 
IBD is difficult mainly due to the insidious onset of the disease, the frequent marked delay in 
diagnosis, and the occasional misclassification of patients. In paediatrics the small number of 
cases hampers this further. 
Ulcerative  colitis  incidence  varies  from  1-5/10
5  cases  per  year  for  Latin  America, 
Africa and Asia to values up to 10-20/10
5 for the Northern America and Northern Europe. For 
CD the respective values are 5-10/10
5 for Northern America and Europe and 0.5-4/10
5 for 
Asia,  Africa,  Latin  America  and  Southern  Europe  (9).  CD  and  UC  are  most  commonly 
diagnosed in early adulthood but the diagnosis may occur at any age (9) with approximately 
15%-25% of IBD being diagnosed during childhood or adolescence (10).  
Juvenile UC and CD occur with an average incidence of 5.2/10
5 cases per year in the 
UK and Republic of Ireland (11). Scotland presents the highest prevalence for CD and is   26 
second after Ireland for UC (Table 1.3). The highest incidence occurs between 12-16 years 
(11;12) with almost 2/3 of the patients diagnosed with CD.  
Epidemiology in IBD is a dynamic process and recent data show that IBD incidence 
and prevalence is increasing with time (8;11-15) in both developing and developed countries 
(9). Armitage and her colleagues (16) using the Scottish hospital discharge linked database, 
showed  an  increasing  trend  of  both juvenile-onset  (<  16  y  old)  CD  and  UC  in  Scotland. 
Combining their results with those of Barton et al (17) they estimated a steady increase for 
the crude incidence of CD from 1 per 10
5 between 1971-1975 to 3.1 per 10
5 for 1991-1995. 
In UC the results from Barton’s study showed a marginal fall that reversed according to the 
results of Armitage (16). A higher incidence for juvenile CD but not UC onset was observed 
in the northern regions compared with the southern regions of Scotland (12). 
 
Table 1.3: Incidence (x10
5/y) of IBD by country (adapted from Sawczenko, 2001 (11)) 
  All IBD  CD  UC  IC 
UK  5.2  3.1  1.4  0.6 
England  5.2  3.1  1.4  0.7 
Scotland  6.5  4.2  1.8  0.6 
Wales  5.2  3.2  1.7  0.3 
Northern Ireland  3.6  2.4  1.0  0.2 
Republic of Ireland  4.4  2.3  2.0  - 
 
1.1.2. Pathogenesis of IBD 
While  IBD  has  been  studied  for  decades  it  remains  mysterious  in  its  pathogenesis  (18). 
Various factors keep researchers guessing why some individuals develop IBD while others 
are never afflicted. It is now speculated that a single and simple cause and effect relation 
probably does not account for most cases of IBD.  
The most consensual model of disease pathogenesis suggests that disease occurrence 
is an interaction of four elements: genetic susceptibility, environment, abnormal immune host 
response and commensal gut microbiota (18) as discussed later in this thesis (Section 1.7) 
Although the exact interaction of these elements remains unknown, IBD pathogenesis is 
believed to occur from errors in the interpretation or regulation of immune perception and 
responsiveness to endogenous microbiota, and thus disruption in the mucosal homeostasis, 
with initiation of immune response in genetically predisposed individuals (18). 
 
1.1.2.1. Genetic factors 
Clinical observations suggest that genetic factors are implicated in the pathogenesis of IBD. 
Family aggregation has long been recognized. First-degree relatives of an affected patient 
have an increased risk of IBD (13;14;19;20) whereas a substantially higher rate of disease 
concordance has been observed in monozygotic twins than in dizygotic ones, especially in   27 
those with CD (21-24). Over the past 20 years a wide variety of candidate genes have been 
implicated in the pathogenesis of IBD (21). Many of these putative associations have not 
been  reproducible  whereas  there  is  substantial  consensus  evidence  for  others  (21).  The 
region  on  chromosome  16  known  as  (IBD1)  was  first  identified  in  1996  by  French 
researchers (25). Detailed mapping of this chromosome, resulted in the identification of the 
NOD2/CARD15  gene  that  encodes  a  cytoplasmic  protein  designated  NOD2  or  CARD15 
which serves as a pattern recognition receptor for bacterial lipopolysaccharide, and regulates 
activation of nuclear factor-kβ and secretion of a-defensins by ileal paneth cells (26). People 
who are homozygous for variant NOD2 may have 20-fold or more increased susceptibility to 
CD  (27;28).  However  fewer  than  20%  of  patients  with  CD  are  homozygous  for  NOD2 
variants so it does not fully explain the disease pathogenesis. Since these first observations 
a number of other candidate genes have been identified with the strongest evidence for the 
HLA region, MDR-1, as well as the recently implicated IL23R and ATG16L1 genes (29). 
 
1.1.2.2. Environmental factors 
Despite the strong evidence implicating genetic factors in IBD, environmental factors may 
also be important.  Approximately 40%-50% of individuals with identical genetic makeup are 
discordant for CD, indicating that environmental influences play an important role particularly 
when the rapid increase in the incidence of IBD cannot be fully explained by slow long-term 
changes in the human genome.  
Several  epidemiological  studies  have  implicated  diet,  anti-inflammatory  drugs, 
vaccination  history,  smoking,  seasonal  variation,  appedicectomy,  use  of  swimming  pools, 
and water supply to the occurrence and increasing incidence of IBD (9).   
 
1.1.2.3. Gut microbiota  
There  is  substantial  evidence  to  incriminate  the  commensal  gut  microbiota  in  the 
pathogenesis of IBD (30). This is discussed in detail in Section 1.7.2. 
 
1.1.3. Symptoms and clinical manifestations of IBD 
For many patients, IBD imposes a substantial personal burden, with unpredictable fluctuating 
symptoms, time off work, intestinal and extra-intestinal complications (31) (Table 1.4), need 
for  drugs  with  substantial  side  effects,  possible  surgical  resection  of  part  of the gut,  and 
reduced quality of life (32). 
There is no feature, characteristic of disease presentation, which can differentiate IBD 
from other diseases. Furthermore intestinal symptoms of IBD can be insidious and subtle 
delaying  early  diagnosis.  Common  presenting  symptoms  and  clinical  manifestations  are   28 
abdominal pain, diarrhoea, perirectal bleeding, lethargy, anaemia, and weight loss that are 
often  misdiagnosed  as  infectious  gastroenteritis,  iron  deficiency  anaemia  (IDA),  thyroid 
disorders and eating disorders (15;33). In a British and Irish collaboration (33) 25% of CD 
children presented with the triad of abdominal pain, diarrhea and weight loss (Table 1.4). The 
variability in symptoms reflects and correlates with the different sites of GI involvement (34).  
Common extra-intestinal manifestations in IBD patients are orofacial granulomatosis, 
angular  stomatitis,  erythema  nodosum,  hepatobiliary  complications,  anaemia,  weight  loss 
and, particularly in children, growth retardation and sexual immaturity (31). The impact of IBD 
on nutritional status and body composition of the patients is presented in detail in Section 
1.3.2. Beyond the health related consequences of IBD, acute active disease may necessitate 
frequent  hospital  admittance,  causing  major  disruptions  in  social,  family  life,  professional 
career, and academic attendance in children that subsequently lead to low quality of life (32) 
and psychological concerns (35). Psychological support is now considered an integral part of 
the multidisciplinary approach to IBD management.   
 
Table 1.4: Presenting symptoms and signs of paediatric IBD in UK (adapted from Sawzcenko & 
Sandhu 2003 (33)) 
  CD (n=379)  IC (n=72)  UC (n=172) 
Common symptoms       
Abdominal pain   274   (72%)    54   (75%)    106   (62%) 
Diarrhoea   214   (56%)    56   (78%)    127   (74%) 
Bleeding    84   (22%)    49   (68%)    145   (84%) 
Weight loss   220   (58%)    25   (35%)    53   (31%) 
Lethargy   103   (27%)    10   (14%)    20   (12%) 
Anorexia    94   (25%)    9   (13%)    11   (6%) 
       
Other symptoms       
Arthropathy  28  3  11 
Nausea vomiting  22  1  1 
Constipation/soiling  4     
Psychiatric symptoms  3     
Secondary amenorrhoea  1    1 
       
Signs       
Anal fistula  17     
Growth failure/delayed 
puberty 
14  1   
Anal abscess, ulcer  8     
Erythema nodosum/rash  6    1 
Liver disease  3  2  5 
Appendicectomy  2     
Toxic megacolon      1 
 
1.1.4. Management of IBD 
Despite the progress in overall management of IBD over recent decades (36), no innovative 
curative  treatment  has  been  developed  and  contemporary  treatment  achieves  mainly 
symptom control. Recent therapeutic goals for pediatric patients with IBD were established   29 
and  were  described  in  the  workgroup  report  of  the  First  World  Congress  of  Pediatric 
Gastroenterology, Hepatology and Nutrition (37). 
The conventional treatment strategies in IBD are classified into inductive, to achieve 
disease  remission,  and  maintenance,  to  prolong  disease  remission  and  prevent  a 
subsequent  flare  up.  In  paediatric  patients  in  particular,  linear  growth  and  pubertal 
development  are  two  distinct  characteristics  that  differentiate  the  options,  and  choice  of 
management compared to adults. 
Due  to  the  chronicity  of  the  disease  and  the  lack  of  effective  curative  treatment 
patients with IBD are committed to stay on daily lifelong treatment. The choice of medication 
is determined by the type of disease (CD or UC), the severity, and the extent of disease 
involvement  (Table  1.5)  and  therefore  it  is  important  to  tailor  treatment  according  to  the 
particular individual needs of each patient (36;38-40). 
The medical therapy of IBD has improved considerably in recent years (36;38-40). 
Recently the British Society of Gastroenterology (41) published practice guidelines for the 
management  of  IBD  in  adults,  with  however,  negligible  reference  to  paediatric  patients. 
Medical  treatment  in  paediatric  IBD  is  extensively  reviewed  elsewhere  (38)  and  the 
mainstream options are presented in Table 1.5. 
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Table 1.5: Common medical treatment options and indications of use in paediatric IBD (compiled from (36;38;39;41-44)) 
Drug  Disease  Role in IBD  Action  Examples  Side effects 
Aminosalicylates 
 (5-ASA) 
Mild/moderate UC 
& CD 
Induction and maintenance of 
remission 
Control the release of 
lipid mediators, 
cytokines and oxygen 
species 
Mesalazine 
Sulfasalazine 
Nephritis 
Nephropathy 
Hepatotoxicity 
Pancreatitis, 
Pulmonitis 
Pericarditis 
Corticosteroids  Moderate/severe 
UC & CD 
Induction of remission  Potent immunologic and 
anti-inflammatory agents 
Prednisolone 
Prednisone 
Hydrocortisone 
Budesonide 
Infection 
Hypertension 
Weight gain 
Acne 
Myopathy 
Fluid retention  
Bone 
demineralization 
Immunosuppresants  UC & CD  Maintenance of remission  Inducing T cell apoptosis 
by modulating cell 
signaling 
Azathioprine (AZA) 
6-mercaptopurine 
Pancreatitis 
Fever 
Leukopenia, 
Hepatotoxicity 
Nausea 
Antibiotics  CD  Induction of remission in 
mild/moderate peri-anal disease 
Alteration of the bacterial 
flora 
Metronidazole 
Ciprofloxacin 
Nausea,  
Headache 
Glossitis  
Peripheral neuropathy 
Methotrexate  CD  Induction of remission in 
moderate/severe, refractory, 
intolerant of standard therapies 
Immunosuppression  Methotrexate  Myelosuppression 
Hepatotoxicity 
Biological agents  CD & UC  Induction of remission in moderate/ 
severe, alternative induction therapy 
to steroids or as a first-line agent for 
severe perianal fistulizing disease 
Antibody against 
proinflammatory 
cytokines 
Infliximab  Nausea 
Headache 
Upper respiratory 
infections 
Fatigue 
Fever   31 
With the treatment approach described in Table 1.5, most patients with active IBD will 
enter into a remission phase. However those who fail to respond to medical therapy can 
usually be operated and enter surgically induced remission. It is estimated that between 30% 
to 40% of patients with UC will need surgical intervention in the course of their disease, 
whereas between 70% and 80% of CD patients will have resection of a part of their GI tract 
(45). Indications for surgery include perforation, strictures, fistulae and toxic megacolon. 
In a retrospective study in Scotland by Watson et al (15) 48% of paediatric patients 
with CD underwent surgery compared with 23% of patients with UC. It is noteworthy that the 
same study reports that the incidence of surgical intervention appeared to be decreasing. 
Fifty-four percent of paediatric IBD patients underwent surgery in the 1980 to 1989 cohort 
compared with 34% in the 1990 to 1999 group although the mean length of follow-up in the 
latter group was shorter, and this figure may have risen with time. 
The use of nutritional therapy is a promising field in the treatment of IBD. A number of 
studies using in-vitro models, experimental animal models of colitis and human trials support 
the  use  of  a  range  of potential  nutritional  remedies  in  the  management  of  IBD  including 
exclusive  enteral  nutrition  (EEN),  administration  of  probiotics  and/or  prebiotics,  butyrate 
enemas or oral supplements, and the use of omega 3 fatty acids. These approaches are 
quite new and the evidence so far is controversial and inconclusive. The mostly studied and 
well established nutritional remedy in clinical practice is the administration of EEN in adult 
and paediatric patients with CD. This is described below (Section 1.5) 
When  conventional  treatment  fails  to  cure,  the  use  of  unconventional  treatment 
purchased over the counter and provided by alternative health professionals are often used. 
This is discussed below in Chapter 1.2. 
 
1.2. Complementary and alternative medicine in IBD 
It is probably due to the serious and relapsing nature of the symptoms of the disease that 
there  is  increasing  interest  in  the  use  of  unconventional  remedies  by  IBD  patients. 
Complementary and alternative medicine (CAM) encompass a group of diverse medical and 
health  systems,  therapies,  and  products  that  are  not  presently  considered  to  be  part  of 
conventional  medicine.  Within  this  definition,  there  is  no  firm  description  which  specific 
methods and remedies comprise CAM and which do not (Table 1.2.1) particularly as new 
branches of established disciplines are continually being developed. Thus some studies have 
considered prayer and exercise as a form of CAM (46) whereas others restricted definition 
solely to consultations with alternative therapists (47). Moreover therapies that are included 
in the definition of CAM in some countries are part of integrated conventional medicine in 
others (i.e. traditional Chinese medicine in China).    32 
 
Table 1.2.1: Common types of CAM  
Special diets  Nutritional 
supplements 
Herbals  Alternative 
therapists 
Dairy/Milk free  Probiotics  Aloe  Acupuncture 
Gluten/Wheat free  Prebiotics  Cat’s Claw  Chiropractic 
Low residue/Fibre  Fish/Omega 3 oils  Evening primrose  Hypnosis 
Low carbohydrate  Glutamine  Echinacea  Massage 
Gottschall diet  Vitamin/Minerals  Garlic  Relaxation 
therapy 
Vegeterian/Vegan    Ginseng  Chinese 
therapies 
    Grapeseed extract  Aromatherapy 
    Milk thistle  Reflexology 
    Slippery elm  Yoga 
    Gingko biloba  Homeopathy 
    Chinese herbs   
 
1.2.1. Prevalence of CAM in the general population 
The  use  of  CAM  is  common  in  the  general  population  (48;49)  and  has  increased 
substantially over time (50;51). Data from the National Health Interview Survey in 2002, in 
31044 adults, showed that 62% of adults in the USA used some form of CAM therapy over 
the  past  two  months  (52).  CAM  is  also  becoming  popular  in  the  UK  general  adult  and 
paediatric  population  (53;54).  Results  from  the  National  Omnibus  survey  in  Great  Britain 
estimated  that  10%  of  the  general  population  had  received  some  form  of  23  named 
unconventional  therapies  from  a  CAM  practitioner  in  the  last  year  without  assessing  the 
usage of self-prescribed CAM therapies (55). Estimates of CAM use were similar in England, 
Scotland and Wales. Likewise a paediatric survey in Bath, England, estimated that 17.9% of 
children in the general population had used CAM at least once, and 6.9% had a consultation 
with a complementary medicine practitioner (53).  
In  parallel  to  that,  the  proportion  of  patients  that  are  recommended  to  access  a 
complementary practitioner through their primary care health providers is increasing. Thomas 
et  al  (53;56)  interviewed  general  practitioners  in  England  throughout  1995-2001  and 
observed that the proportion of practitioners that provided some access to CAM increased 
from 39% in 1995 to 49.4% in 2001. 
The most common factor associated with the use of CAM is poor health esteem and 
increased morbidity (55). Ong et al (57) using a postal questionnaire in four English counties 
found that 60% of CAM users reported having a chronic illness or disability. Patients with 
increased mortality and morbidity risk, like cancer (58) and HIV infection (59) were among 
the  common  users  of  CAM.  Use  of  CAM  is  similarly  high  in  patients with functional  and 
organic GI disorders. Ganguli and his colleagues (60) estimated use of CAM, over the last 
year to be as high as 52.5% in gastroenterology patients and Kong et al (61) in a study of 
932 subjects from a gastroenterology clinic and 477 healthy controls found the incidence of   33 
CAM use to be 49.5% for IBD patients, 50.9% for irritable bowel disease, 20% for general GI 
disorders and 27% for the healthy control group.  
 
1.2.2. Literature review of studies on CAM use in IBD patients 
An extensive electronic literature search was conducted to retrieve relevant studies on the 
use  of  CAM  in  IBD  using  subject  specific  keywords.  Nineteen  adult  and  four  paediatric 
studies were identified. As it is outside the scope of this thesis to describe each of these 
studies separately, only well-designed studies with adequate sample size, reports from the 
UK, and all those conducted in pediatric IBD patients will be presented (Table 1.2.2).  
Overall the studies were heterogeneous in design, responding populations, definitions 
of  CAM  (Table  1.2.2)  and  did  not  allow  direct  comparison  or  to  draw  conclusive  results. 
Some studies were restricted to the use of CAM provided by specialized therapists (47;62), 
whereas  others  included  oral  remedies  and  nutritional  supplements  (multivitamins, 
probiotics) (61;63) bought over the counter. Dietary manipulations and special diets were 
included in most studies (63;64) but not all (65). Some studies assessed current use of CAM 
(66), whereas others looked into the overall past use since IBD diagnosis (67) or defined use 
within  a  specific  timeframe  (64).  Methodology  also  varied  between  studies.  Most  studies 
used postal surveys (64;65), others used personal interviews or questionnaires administered 
at the patients’ routine clinical appointments (61;67) and others a combination (62;65). The 
average prevalence of CAM use varied considerably between studies from as low as 4% (62) 
to up 72% of the responding population (66) subject to the CAM definition used (Table 1.2.2).  
Disease onset seemed to be the main trigger of CAM use, as the latter was significantly 
lower prior to disease diagnosis (63;68). Moreover the use of CAM in IBD is significantly 
higher compared with healthy people (61;67) or patients with other clinical conditions (47).  
Herbal  medicine,  nutritional  remedies  and  homeopathy  were  reported  among  the 
common types of CAM. Probiotics were used predominantly by IBD patients in some studies 
(64;66;69)  but  were  uncommon  in  others  (65).  Differences  in  the  prevalence  and 
predominant types of CAM among studies could be attributed to the different study design 
and  responding  populations  (Table  1.2.2).  In  particular  patients  recruited  from  tertiary 
hospitals may be patients with severe IBD or perhaps those that have benefited more from 
the conventional medicine. On the other hand geographical differences in the type of CAM 
may  denote  cultural  differences  and  beliefs  in  the  utility  of  CAM  as  well  as  different 
approaches to CAM by the medical staff and different promotion of CAM in countries that are 
traditional users of them.  
Disease severity (63), high education level (68), high socio-economic status, female 
gender (61), young age (68), internet usage (64), prior or parental CAM usage, longterm use   34 
of steroids (68) low quality of life and increased psychological stress (70),  have all been 
reported as predictors of CAM use by IBD patients (65;68).   
The main reasons given by IBD patients for use of CAM included the need for an 
optimum treatment (68), the wish to be actively involved in and personally responsible for 
their disease management (68), wish for a holistic therapeutic approach and, frustration with 
the ineffectiveness and side effects of conventional medicine (66;68). Common sources of 
information  on  CAM  were  magazines,  internet  search,  friends,  family  and  their  medical 
doctors (66). Many patients did not reveal the use of CAM to their primary health providers 
and actually a few CAM users discontinued or reduced their conventional treatment on their 
own or were advised to do so by their CAM practitioners (47). In a German survey, 31% IBD 
participants reported reduction or discontinuation of conventional medicine on CAM use (68). 
This is of great concern as some of these therapies exert only a placebo effect, or may 
interfere with the action of conventional treatments. In the study by Hilsden et al (63) 53% of 
the patients who tried CAM reported some form of harm ascribed to CAM use.  
Whatever the true action of CAM, many patients found CAM at least effective (68;70) 
and the majority of them would consider CAM use in the future (66;68).  
 
1.2.3. CAM effectiveness in IBD. How good is the evidence? 
Unlike CAM conventional medical treatment in IBD is supported by randomized control trials 
(RCT) evidence of their efficacy. On the contrary use of CAM is based mostly on theoretical 
foundations with a lack of well-designed clinical trials. The few studies that are reported in 
the literature are usually open label studies of poor design, although recent lines of evidence 
support the use of some of them (71). Probiotics, prebiotics, SCFA and omega 3 fatty acids 
have demonstrated some clinical efficacy in some studies in IBD whereas for other remedies 
such  as  acupuncture,  wheat  grass  juice,  aloe  vera,  and  special  diets  more  evidence  is 
accumulating (72-74).  
Ben Arye et al (72) in a double blind RCT showed that wheat grass juice appeared 
effective and safe as a single or adjuvant treatment of active distal UC. Treatment with wheat 
grass  juice  was  associated  with  significant  reduction  in  the  overall  disease  activity  and 
severity  of  rectal  bleeding.  Recently  Joos  et  al  (73)  in  a  single  blind  RCT  showed  that 
patients  with  mild  to  moderate  active  CD  treated  with  acupuncture  for  four  weeks, 
experienced a decrease in their clinical activity index, inflammatory markers, and a better 
general well being compared with a control group. Finally, Langmead et al (74) found that 
oral aloe vera taken for four weeks produced a clinical response more often than placebo 
treatment and it also reduced the histological disease activity without presenting side effects. 
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1.2.4. Conclusion 
In conclusion the use of CAM in adult IBD patients is well studied, but in children there is a 
lack of substantial evidence. Most of the paediatric surveys have been conducted in the US 
(64) and Australia (66) with only one multinational study which included only a small sample 
of UK patients from a single hospital in London, UK (65).  
Extrapolation of the results of adult studies is inappropriate and can be misleading as 
there  are  considerable  differences  in  disease  management  regimes  between  adult  and 
paediatric  patients  (34).  Furthermore,  the  use  of  CAM  by  paediatric  patients  reflects  the 
choice of their guardians and how they cope with their child’s disease.   
Further  studies  should  be  undertaken  to  address  the  use  of  new  non-medicinal 
products, like probiotics and prebiotics, with emerging evidence of efficacy in IBD (75;76). 
Characteristics of patients who may be more amenable to CAM use should be identified with 
a study. On the other hand health professionals that care for IBD children should be aware of 
CAM use by their patients as the latter can interfere with conventional medical treatment or 
may have serious health related side effects (77).  This was explored in the study described 
in Chapter 2 of this thesis. 
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Table 1.2.2: Major studies on the prevalence of use of CAM in adult and paediatric patients with IBD  
Study  Country; Setting  Sample; 
Methodology 
CAM definition  Prevalence of 
CAM use  
Predominant 
CAM 
Predictors of 
CAM use 
Comments 
ADULT STUDIES 
Langhorst et 
al 2005 (68) 
Germany; 
National IBD 
database 
N:864; Mailed 
questionnaire 
Self 
prescribed & 
CAM 
therapists 
51.3% overall; 
26.8% current 
users 
Homeopathy, 
herbals, ayurvedic 
medicine; 
traditional Chinese 
medicine; 
probiotics used by 
54.2% 
More UC users 
than CD; high 
education; young 
age; steroids 
intake more than 
10 g was the 
strongest 
predictor 
6.8% used 
exclusive CAM 
permanently; 
11.5% 
experienced side 
effects 
Kong et al 
2005 (61) 
Sheffield UK; 
Outpatient GI 
clinic 
N:1409:(311 IBD), 
healthy control group; 
Doctor-administered 
questionnaire  
Oral 
supplements 
49.5% IBD; 51% 
IBS; 20% general 
GI; 27% healthy 
controls 
Multivitamins  More women 
than men 
Most participants 
did not find CAM 
beneficial 
Hilsden et al 
2003 (63) 
Calgary 
Canada; 
National IBD 
database 
N:2847; Mailed 
questionnaire 
Vitamins 
were not 
included; 
Prayers and 
exercise 
excluded 
47.2%; 23.6% 
current users 
Herbals; 27.5% 
used dietary 
modifications  
Severe disease  15% used CAM 
before IBD 
diagnosis; 
Median number 
of therapies 
currently used:3; 
53% reported 
harm of CAM use 
Langmead 
et al 2002 
(70) 
London, UK; GI 
& general 
medicine 
outpatient clinic 
N:239; Questionnaire 
completed in the clinic 
  28%   Herbals  Low quality of life 
scores for the 
emotional and 
social factors; 
Fatigue 
No difference in 
use with non IBD 
patients; over 
50% found it 
beneficial 
Moody et al 
1998 (47) 
Leicestershire, 
UK; Database 
of chronic GI 
disorders 
N:572 (219 IBD, 145 
coeliac); Mailed 
questionnaire 
CAM 
therapists  
23% of Asians & 
18% of 
Europeans; 8% 
for coeliac  
Herbalists; 
homeopathists 
No difference 
between 
ethnicities 
Some patients 
were advised to 
reduce or stop 
conventional 
medication  
Smart et al 
1986 (62) 
Nottingham, 
UK; Outpatient 
GI clinic 
N=461 (96 IBS, 222 CD, 
143 general GI); 
Questionnaire completed 
in the clinic; postal survey 
for CD patients 
CAM 
Therapists  
16% of IBS, 6% 
of CD, 2% of 
general GI; 11% 
of IBS and 4% of 
CD current users 
Herbalists; 
homeopathists 
Failure of 
conventional 
therapy 
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PAEDIATRIC STUDIES 
McCann et 
al 2006 (67) 
Leeds, UK; 
Outpatient 
clinic 
N=75 with chronic 
illnesses (25 IBD) & 
25 healthy control; 
Face to face 
Interviews 
All types of CAM; 
Ever use of CAM 
  Only summary results 
for all GI patients 
   
Day et al 
2004 (66)  
Sydney, 
Australia; 
Outpatient GI 
clinic 
N=46; Mailed 
questionnaire 
All types of CAM; 
Ever use of CAM 
72% current 
users; 2.4 
agents in 
average 
Probiotics, fish oil, 
herbals 
  Reasons of use: 
To avoid 
medication side 
effects, 
dissatisfaction 
with medication, 
experience by 
others; 12% found 
CAM partially 
effective; 4% 
found it 
expensive; the 
majority would 
use CAM again  
Markowitz et 
al 2004 (64) 
Greater 
Philadelphia 
area, US; IBD 
database 
N=335; Mailed 
questionnaire 
CAM use last 12 
mth; No 
multivitamin only 
megavitamins  
50.8%  Nutritional therapies 
(22% probiotics, 
16.4% fish oils, 
megavitamins), 
special diets (dairy 
free diet) 
Internet use, 
caloric 
supplementation, 
IBD surgery, 
school absences, 
low quality of life 
 
Heuschkel 
et al 2002 
(65)  
Multinational; 
Boston, Detroit 
US, London 
UK; Outpatient 
clinic & 
database 
N=208 (51 from 
London); 
Questionnaire 
completed in the 
clinic or mailed  
CAM use last 12 
mth; No dietary 
modifications 
41% 
excluding 
dietary 
modifications; 
35% dietary 
modifications 
19% megavitamins, 
17% dietary 
supplements, 9% 
herbals, 6% 
homeopathy only 2% 
probiotics in London 
and 6% in total 
No of adverse 
effects from 
conventional 
medicine, 
parental use 
 Reasons of use: 
feel better, hoping 
for a cure, 
disappointment 
with conventional 
treatment 
IBS: Irritable bowel syndrome  38 
1.3. Nutrition considerations in IBD 
Beyond the GI manifestations of IBD, extraintestinal complications accompany the natural 
history  of  the  disease  and  often  appear  before  diagnosis.  Amongst  these,  nutritional 
complications are present in the majority of patients with IBD and comprise an additional 
burden for the health professionals and the patients. Intervention through dietary counseling, 
nutritional supplements, EN or parenteral nutrition may become necessary at some point to 
reconstitute nutritional balance (35;78). In 2004 the North American Society for Paediatric 
Gastroenterology,  Hepatology  and  Nutrition,  published  a  consensus  report  on  nutrition 
support  for  paediatric  patients  with  IBD,  highlighting  the  major  nutritional  problems,  and 
proposing guidelines for assessment and monitoring of the nutritional status (35).  
In  IBD  malnutrition  can  occur  with  all  its  different  facets  and  can  affect  clinical 
outcomes, immune system function, gut mucosa barrier (79), antioxidant mechanisms, body 
growth,  bone  health  and  quality  of  life  (35).  Protein-energy  undernutrition,  micronutrient 
deficiencies  and  poor  bone  health  are  commonly  reported  in  IBD,  whereas  in  paediatric 
patients  growth  failure,  and  pubertal  delay  are  additional  features.  Multiple  factors  are 
involved  in  the  manifestation  of  malnutrition  in  IBD  with  suboptimal  dietary  intake  and 
excessive losses being the main contributors (Table 1.3.1).  
 
Table 1.3.1: Causes of malnutrition in IBD 
Factor  Reason 
Suboptimal intake  Reduced appetite 
  Food aversions-fear of worsening symptoms 
Malabsorption  Intestinal inflammation 
  Intestinal resection 
Excessive losses  Protein loosing enteropathy 
  GI bleeding 
  Excessive GI mucosa sloughing  
  Fistula output 
  Diarrhoea-steatorrhoea 
Increased requirements  Increased metabolic needs 
  Increased GI mucosa turnover 
  Increased consumption of antioxidants 
  Altered lipid and muscle oxidation  
  Fever 
Disease activity  Pro-inflammatory cytokines-growth 
Drug nutrient interactions  Steroids-Inhibition of IGF-1 
  Steroids-Poor bone mineralization 
  Steroids-Impair fat and muscle metabolism 
  Methotrexate-Impair folate metabolism 
  Sulfasalazine-Inhibits folate absorption 
 
1.3.1. Protein-energy malnutrition 
IBD patients often suffer from protein energy malnutrition by the time of diagnosis, and their 
status fluctuates during the disease course (80;81). Recent weight loss is a common feature 
in  the  newly  presented  IBD  patient,  particularly  in  CD,  and  accompanies  almost  every   39 
relapse (82;83). Around 60% of newly diagnosed children with CD, compared to 35% in UC, 
present at diagnosis with a history of recent weight loss (33;82). 
As  a  subsequent  result  of  excessive  weight  loss  and  undernutrition,  basic 
anthropometry is affected. IBD patients and particularly those with CD, present with low BMI 
and  are  underweight  compared  with  the  national  reference  range  or  their  healthy  peers 
(33;84-88). Recent data, however, suggest that fewer patients at risk of undernutrition are 
now  seen  compared  with  previous  studies.  In  fact  a  large  proportion  of  patients  are 
overweight at diagnosis, particularly UC patients, and this has been linked to the obesity 
epidemic observed in the general population (82;87). In a North American study of 783 newly 
diagnosed IBD children, low BMI was seen in 22%-24% of the children with CD, and 7%-9% 
of children with UC. Ten percent of the CD children and 20%-30% of the UC had high BMI 
consistent  with  the  definition  of  overnutrition  (82).  Low  risk  of  undernutrition  has  been 
described recently (87) in a cross-sectional study of adult IBD patients, and an alternative 
explanation suggested was the progress in medical treatment with the evolution of new drugs 
that spare the use of steroids, and achieve not only symptomatic relief but also mucosal 
healing (89;90).  
Other than differences between the two types of IBD there is no consistent evidence 
to link specific disease characteristics with undernutrition. Some studies found an association 
with  small  bowel  disease  and  risk  of  underweight  (91)  but  others  did  not  (82).  A  higher 
prevalence of undernutrition was also reported in patients with active (60%) compared with 
inactive disease (13.7%) in a recent study using the Subjective Global Assessment to screen 
for undernutrition (80).  
 
1.3.2. Body composition 
Body size dimensions and BMI should best be seen as an index of nutritional status and 
body composition (92). Although BMI correlates well with obesity (93) and defines risk of 
undernutrition (94) in the general population, its diagnostic accuracy to distinguish between 
fat and muscle stores in chronic illness, like IBD, is unknown. 
There  are  several  reasons  that  body  composition  in  IBD  may  differ  from  that  of 
healthy  people.  Inflammation  and  the  secretion  of  pro-inflammatory  cytokines  may  alter 
energy  metabolism,  protein  turnover  and  substrate  utilization  (91),  whereas  the  use  of 
corticosteroids increases body fat and exerts negative catabolic effects on lean mass (95). 
Physical activity on the other hand was reported to be low in IBD patients and correlated 
inversely with fat mass (FM) in one recent report (87).  
Several studies assessed the body composition of IBD patients and compared it with 
reference norms or healthy subjects, but results were inconsistent. A lower FFM compared   40 
with healthy subjects and preservation of FM was found in some adult studies (85;87;91;96) 
but not all(97;98). A series of studies in newly diagnosed adult IBD patients (99) and other 
patients with longstanding disease in remission (100), failed to identify an overall difference 
in body composition between the two types of IBD and healthy control subjects, although 
gender specific differences were evident (101).  
  Strong  associations  between  body  composition  and  disease  characteristics,  like 
phenotypic characterization, duration of disease (85), and history of small bowel resection 
(87;96) have not been described extensively in adult studies. Sex differences have been 
reported occasionally in some adult studies (85;101) but not others (87) and one study found 
an inverse association between disease activity and body fat (100).  
There are only a few studies that assessed body composition in IBD children. Among 
these studies, body lean mass is reported as significantly lower than healthy control groups 
(84;88;100;102;103) whereas gender specific associations with FM were observed in some 
(84;88;100;103). Sentogo et al., in a cross-sectional study (103), found that boys and girls 
presented lower FFM by 3.5 and 2.9 kg respectively, compared with the control sample, 
whereas FM, although not different from the control group in CD boys was 3.7 kg higher in 
CD girls. Similarly Burnham et al. in a cross-sectional study (84) found that children with 
longstanding  CD  had  a  6%  reduction  in  lean  mass  compared  with  healthy  children  after 
correcting for stature, age, pubertal stage and race (84). No similar deficits were found for 
FM that conforms to the definition of nutritional cachexia. Recently Thayu et al. in a well-
designed study (88) of a cohort of newly diagnosed children with CD, also reported gender 
associated differences with body composition. Fat mass and lean mass for height (adjusted 
for age, race and pubertal stage) were lower in female than in male patients. Compared with 
a cohort of healthy controls, body composition in girls was more consistent with the definition 
of wasting (low lean and FM) whereas in boys there was mostly preservation of FM and 
deficits  in  lean  mass  consistent  with  the  definition  of  cachexia.  No  associations  were 
observed between body composition, clinical activity, disease location or delay of diagnosis.   
Different characteristics of patients, and the recruitment of new (88) compared with 
longstanding  patients  (84),  may  explain  some  of  the  discrepancies  found  in  adult  and 
paediatric studies. Although many authors compared the body composition of IBD patients 
with a cohort of healthy controls, of similar age and gender, they did not to match for body 
weight, height or BMI and this might explain differences found in the absolute fat or lean 
mass but not in their relative body proportions (85;87;96;99). In IBD children in particular, 
impaired growth and pubertal delay are frequently seen and a proper comparison of body 
composition  between  CD  and  healthy  children  needs  to  account  for  these  confounders 
(84;85;87;88;96;99).     41 
On the other hand as there is no method to measure body composition accurately 
(92), the use of different techniques makes a direct comparison between studies difficult. 
Indeed the results of each study are inherent to the limitations and theoretical assumptions of 
the  method  used,  that  may  additionally  not  be  valid  in  illness  (92).  Most  in  vivo  body 
composition  methods  have  been  tested  and  validated  in  healthy  individuals  or  animal 
cadavers  and  their  applicability  in  chronic  illness  is  questionable  given  the  changes  that 
occur in the hydration level and distribution of water fluids in the body compartments (104). 
Using IBD as a prime example, studies showed that the hydration level of lean mass is not 
the same as with healthy subjects (104) and in fact depends on gender (101). Therefore 
application of body composition methods that consider a constant hydration of FFM (DXA, 
bioimpedance,  double  labelled  water)  is  inaccurate  and  may  produce  erroneous  results. 
Comparison and validation of the commonly used body composition methods in disease are 
needed. This thesis is presenting a relevant study between bioimpedance measurements of 
body composition and DXA in Chapter 4.  
 
1.3.3. Growth  
Faltering linear growth is commonly encountered in children with IBD, and often precedes 
disease  diagnosis  (102;103;105-107).  Approximately  23%-25%  of  the  children  present 
deviations from their growth velocity and height for age centiles and are significantly shorter 
than  their  healthy  peers  (103).  Sentogo  et  al.  (103)  found  significant  growth  deficits  in 
children with CD, compared with healthy children, and failure to attain their genetic potential 
for linear growth when their heights deficits were compared with their estimated mid-parental 
target height. This effect was more profound in boys. Girls did not differ from the healthy 
controls. Nevertheless most children with IBD will eventually achieve final heights within the 
normal range for the general population or close or their genetic potential (108-110). 
The  exact  mechanisms  by  which  growth  impairment  occurs  in  IBD  are  unclear. 
Undernutrition,  the  effect  of  circulating  proinflammatory  cytokines  on  growth  promoting 
factors and growth plate (111), long-term use of steroids (84;111-113) and genetic make up 
(114) are all implicated (115). On the other hand skeletal or bone age is negatively affected 
in CD particularly in boys, and may explain to some extent the degree of growth deficits seen 
in IBD (103). This coincides with the fact that most of the patients will eventually achieve final 
adult heights within their normal or slightly lower than their genetic potential (110;112).  
 
1.3.4. Bone health 
Bone mineralization is another important aspect in the care of the growing child with IBD, 
particularly  as  peak  bone  mass,  attained  during  adolescence,  is  the  most  important   42 
determinant of lifelong skeletal health (116;117). Osteopenia and osteoporosis are important 
extraintestinal  manifestations  in  IBD  that  may  be  related  to  increased  risk  of  fractures 
(116;118-120)  although  adequate  evidence  in  children  is  missing.  Semeao  et  al  (121) 
reported five cases of vertebral compression fractures in paediatric patients with CD, but 
Persad et al. (122) found no difference in the prevalence of long bone fractures between 
paediatric IBD patients and their siblings.  
A  large  number  of  studies  reported  osteopenia  and  osteoporosis  in  adult  and 
paediatric patients with IBD (85;96;102;113;123-127). Total body or femoral neck and lumbar 
spine bone mineral content or density were significantly lower than the reference cut offs or 
compared with healthy individuals (101-103;117;128). A disease associated effect has been 
reported with poor bone health seen more often in CD than UC (85;102;129;130). Disease 
location, disease duration, and history of disease activity were risk factors in some studies 
but  not  others  (103;120;131-133).  In  a  study  by  Burnham  (113)  the  difference  in  bone 
mineral content between CD children and healthy control was eliminated when the authors 
accounted  for  the  differences  in  lean  mass  in  a  regression  model.  This  suggests  that 
decreased mechanical stress is an important factor for reduced bone health in children with 
CD (117) and opens the window of opportunity to improve bone mass by optimising lean 
tissue gain with nutrition and weight bearing exercise in patients with IBD. 
Poor  nutrition  and  nutritional  status,  vitamin  D  deficiency,  the  effect  of  pro-
inflammatory  cytokines  on  bone  resorption,  and  the  longterm  use  of  high  steroid  doses 
(85;102;132;134-139)  are  the  main  contributors  that  can  negatively  affect  bone 
mineralization in IBD. 
 
1.3.5. Delayed puberty 
Delayed puberty frequently complicates the clinical course of young patients with IBD, more 
often in CD than UC and in boys than in girls (84;102;103). In a study of young patients with 
CD, menarche occurred at age 16 years or later in 73% of female patients in whom disease 
onset preceded puberty. In a few patients, menarche was delayed until the early twenties. In 
contrast, menarche occurred at 14 years or younger in all patients with juvenile-onset UC 
(108). Likewise Boot et al. (102) found a mean delay of puberty of 0.7 y in Dutch children 
with IBD and Burnham (84) 1.5 y in CD children in the USA.  
Delayed pubertal onset may influence linear growth and final adult height. Moreover 
delayed  puberty  can  affect  quality  of  life  and  self-esteem  although  this  has  not  been 
addressed in a study to date. Undernutrition has always been thought to be the main reason 
for delayed puberty in IBD patients. However, puberty may be delayed despite a normal 
nutritional  status.  Observations  in  animal  models  of  experimental  colitis  suggest  that   43 
inflammatory mediators may have a direct adverse influence, independent of undernutrition, 
on the onset and progression of puberty (140).  
 
1.3.6. Micronutrient status in IBD 
Vitamins, minerals and trace elements, collectively known as micronutrients, are essential for 
the  normal  function  and  development  of  the  human  body  (Table  1.3.2).  In  IBD  some 
micronutrients may have additional importance or play additional roles in the pathogenesis 
and  clinical  course  of  the  disease  (Table  1.3.2).  Micronutrient  deficiencies  can  influence 
clinical outcomes and disease progression in IBD, by affecting the immune system, tissue 
repair,  antioxidant  defence  system,  body  growth  and  bone  mineralization.  A  consensus 
report  of  the  North  American  Society  of  Paediatric  Gastroenterology,  Hepatology  and 
Nutrition suggested routine screening for micronutrients status in paediatric patients with IBD 
(35).  
Of particular interest is the evidence that supports an association between the body’s 
antioxidant defense system, and the pathogenesis and gut injury of IBD (141;142). IBD is 
characterised  by  aggravation  of  inflammatory  cells  (granulocytes,  monocytes  and 
neutrophils) at the site of the intestinal lesion  and production of reactive oxygen species 
(ROS) as part of the normal immune properties of these cells. Reactive oxygen species are 
free  radicals  which  include  superoxide  anion,  hydrogen  peroxide,  nitric  oxide,  and 
hypochloride. In the human body the oxidative action of the free radicals is counteracted by 
antioxidant micronutrients and uncontrolled production coupled with reduced removal from 
an impaired endogenous antioxidant mechanism may cause tissue damage (143;144). 
There  is  good  evidence  to  suggest  that  IBD  patients  are  oxidatively  stressed 
(145;146).  This  is  believed  to  be  the  result  of  an  imbalance  between  increased  ROS 
production  (142)  and  a  suppressed  antioxidant  defence  mechanism  to  compensate 
adequately,  causing  damage  to  biological  macromolecules  (142;146-148)  and  possibly 
intestinal  lesions.  Wenland  et  al  (146)  found  that  lipid  peroxidation,  a  marker  of  ROS 
production, was higher in CD patients, compared with healthy controls. Indeed the plasma 
antioxidant  vitamins  were  low  despite  no  profound  differences  in  the  dietary  intake  of 
antioxidants between CD patients and healthy controls. A putative association between ROS 
and gut injury in IBD is also supported by the use of the aminosalicylates in IBD which are 
believed to work through an antioxidant property and scavenging of oxidative radicals (149).    
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Table 1.3.2: Micronutrient basic body functions and importance in IBD 
Micronutrient  Main functions  Main deficiency disease  Importance in IBD 
Retinol/b-carotene (A)  Visual pigments in the retina; 
antioxidant; normal development; 
differentiation of tissues 
Night blindness; xerophthalmia; 
keratinization;  
1.  Antioxidant 
2.  Deficiency exacerbates colitis (150) 
Calciferol (D)  Calcium balance  Rickets, osteomalakia; osteoporosis  3.  Bone health (151) 
4.  Fracture 
5.  Deficiency in IBD (136;152)  
6.  Antiinflammatory properties (153) 
Tocopherol/tocotrienols (E)  Antioxidant  Neurological dysfunction  1.  Antioxidant 
2.  Treatment of colitis (154) 
Phylloquinone/Manaquinones (K)  Blood clotting; bone formation  Impaired blood clotting; haemorrhagic 
disease 
1.  Bone health (155;156) 
Thiamin (B1)  Enzyme co-factors; carbohydrate 
alcohol metabolism 
Peripheral nerve damage (Beri-Beri); 
central nerve lesions (Wernicke-
Korsakoff syndrome) 
No data 
Riboflavin (B2)  Enzyme co-factors in oxidation and 
reduction reactions; nutrient 
metabolism 
Lesions of corner mouth, lips, tongue; 
seborrhoeic skin lesions 
No data 
Nicotinic acid/Nicotinamide 
(Niacin) 
Enzyme co-factors in oxidation and 
reduction reactions; part of NAD 
and NADP 
Pellagra: photosensitive dermatitis, 
depressive psychosis 
No data 
Pyridoxine/Pyridoxal/Pyridoxamine 
(B6) 
Coenzyme in transamination, 
decarboxylation of amino acids, 
glycogen metabolism; role in 
steroid hormone 
Disorders of amino acid metabolism, 
convulsions 
1.  Hyperhomocysteinemia more common in IBD 
(157) 
2.  Thromboembolic Complications (158) 
Folic Acid  Coenzyme in transfer of one 
carbon fragments; nucleic acids 
synthesis 
Megaloblastic anaemia  1.  Risk of deficiency in methotrexate & 
sulphasalazine users 
2.  Colorectal cancer (159-161) 
3.  Megalobastic anaemia 
Hyperhomocysteinemia (162) 
Cobalamin (B12)  Coenzyme in transfer of one 
carbon fragments; nucleic acids 
Percinious anaemia (megaloblastic 
anaemia with degeneration of the 
1.  Megalobalstic anaemia 
2.  Malabsorption  in  patients  with  ileal  disease  or   45 
synthesis; folate metabolism  spinal cord)   resection (163) 
3.  Hyperhomocysteinemia; Thrombosis risk (164) 
Pantothenic  Functional part of coenzyme A and 
acyl carrier protein 
Peripheral nerve damage (burning foot 
syndrome) 
No data 
Biotin (H)  Coenzyme in carboxylation 
reactions in gluconeogenesis and 
fatty acid synthesis 
Impaired fat carbohydrate metabolism, 
dermatitis 
No data 
Ascorbic Acid   Coenzyme in hydroxylation of 
proline and lysine in collagen 
synthesis; antioxidant, iron 
absorption 
Scurvy; impaired wound healing; loss 
of dental cement; subcutaneous 
hemorrhage 
1.  Antioxidant 
Carotenoids  Antioxidant system    1.  Decrease oxidative stress (150)  
2.  Deficient in CD (165) 
Calcium (Ca)  Growth and skeleton formation; 
muscle function; blood clotting 
Poor bone health; Osteoporosis; 
Fractures 
1.  Bone health (166) 
2.  Fractures  
Magnesium (Mg)  ATP stabilization  Abnormal muscle function; disruption 
of Ca metabolism 
1.  Malabsorption 
Phosphorus (P)  Growth and skeleton formation; 
blood buffering capacity; energy 
production 
Anorexia, bone pain, rickets; 
osteomalacia; muscle weakness, 
ataxia, susceptibility to infections 
No data 
Sodium (Na)  Osmotic and electrolyte 
homeostasis; water balance; nerve 
conduction; active cellular 
transportation; mineral bone of the 
apatite 
  1.  Electrolyte disturbances in severe diarrhoea 
Chloride (Cl)  Osmotic and electrolyte 
homeostasis; hydrochloric acid in 
the stomach 
  No data 
Potassium (P)  Osmotic and electrolyte 
homeostasis; enzyme cofactor in 
energy metabolism and cellular 
growth and division, nerve and 
muscle function 
Muscle and neural dysfunction; 
cardiac arrest;  
1.  Electrolyte disturbances in severe diarrhoea 
Iron (Fe)  Reaction catalyst, blood synthesis; 
oxygen transportation; energy 
production;  
Anaemia, fatigue, restlessness; 
impaired work performance; abnormal 
thermoregulation; suppressed immune 
system; adverse effect on 
psychomotor and mental development 
1.  Impaired absorption in IBD (167) 
2.  Anaemia 
3.  Oral iron exacerbate colitis and increase 
oxidative stress (159) 
Zinc (Zn)  Enzyme cofactor; antioxidant  Growth retardation; sexual and  1.  Decreased absorption (168)   46 
skeletal immaturity; neuropsychiatric 
disturbances; dermatitis, alopecia; 
diarrhea; loss of appetite; susceptibility 
to infections  
2.  Mucosal permeability (144;169)  
3.  Antiinflammatory properties (170)  
4.  Antioxidant 
Copper (Cu)  Enzyme cofactor; function of 
immune, nervous and 
cardiovascular system; bone 
health; iron metabolism; 
haemopoiesis; mitochondrial 
function; energy production; 
antioxidant  
Anaemia; neutropaenia; bone 
fractures; hypopigmentatio; impaired 
growth; abnormalities of glucose and 
cholesterol metabolism 
1.  Antioxidant 
 
Selenium (Se)  Enzyme cofactor; antioxidant; 
catalyst 
Keshan disease; immune system 
dysfunction;  
1.  Deficient in IBD (171;172) 
2.  Antioxidant  
Iodine (I)  Thyroid hormone synthesis  Goiter; cretinism;   No data 
Manganese (Mn)  Enzyme co factor  Impaired growth; skeletal 
abnormalities; impaired reproduction; 
nutrient metabolism; weight loss; 
dermatitis 
No data 
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Following these observations clinical trials found a reduction of markers of oxidative 
stress and improved antioxidant status on supplementation with antioxidant micronutrients 
(171;173;174). Nevertheless a positive association between improvement of disease activity 
and restoration of oxidative status has not been shown (174).  
Although clinical presentation of frank micronutrient deficiencies in IBD is very rare 
(175)    and  largely  limited  to  case  reports  (176),  suboptimal  circulating  levels  for  virtually 
every vitamin, mineral and trace element have been reported previously primarily in adult 
patients and a few paediatric IBD patients (Table 1.3.3). Antioxidant trace elements (eg. Zn, 
Se, Cu) and vitamins (vitamins A, E, C, carotenoids) were the main nutrients consistently 
reported in lower circulating concentrations in IBD patients compared with healthy controls or 
the normal reference range (Table 1.3.3).  
Suboptimal dietary intake, increased utilization, malabsorption and increased enteric 
losses  have  all  been  postulated.  Some  studies  have  linked  nutritional  deficiencies  with 
clinical disease activity and inflammatory markers (Table 1.3.3) but whether micronutrient 
depletion  plays  an  important  role  in  the  pathogenesis  and  perpetuation  of  the  mucosal 
lesions or is the result of it needs to be studied further.  
On the other hand the changes in the serum levels of many antioxidants and their 
association with systemic and clinical activity indexes (175-177) can be an epiphenomenon 
of the acute phase response that accompanies chronic inflammatory conditions, malignancy 
and infection. Reduced serum levels of micronutrients are often used to define deficiency 
states,  but  these  levels  may  correlate  better  with  markers  of  disease  activity  and 
inflammation rather than being reflective of body tissue stores or functional deficits (178). A 
prime example of this is the perturbation in trace elements and vitamin concentrations in 
patients  with  cancer  of  the  colon  which  can  be  partially  reversed  by  anti-inflammatory 
treatment, without supplementation (179). 
 
1.3.7. Principal causes of malnutrition in IBD 
The  aetiology  of  malnutrition  in  IBD  is  multifactorial  as  are  its  manifestations.  Poor  diet, 
increased  energy  needs,  altered  metabolism,  malabsorption,  excessive  GI  losses  and 
nutrient-drug interactions are among the major causes (Table 1.3.1).     48 
 
Table 1.3.3: Major studies assessed systemic levels of micronutrients in patients with IBD.  
Study  Age  Micronutrients   Results  Comments 
ADULTS STUDIES 
Hengstermann 
et al 2008 (80) 
132  quiescent  IBD;  35 
active; 45 controls 
Vit C, Vit E, carotenoids, Se, Zn, Cu,  Low to control: Vit C, carotenoids  No  major  differences  with  disease 
activity 
Filippi et al 
2006 (97) 
54 CD remission  Vit C, Vit A, Vit D, Vit E, Vit B1, Vit B6, Vit 
B12, Vit E, Folate, Niacin, β-carotene, Fe, 
Cu, Ca, P, Mg, Zn,  
Low to reference: Vit C, Cu, Niacin, Zn, 
Fe, B6, B1, B12, Folate, b-carotene, Vit E 
 
D’Odorico et al 
2001 (147)  
83 IBD; 386 controls  Vit A, Vit E, carotenoids  Low  to  control:  Vit  A,  Vit  E,  some 
carotenoids,  no  disease  type  effect, 
Difference  between  active  &  inactive; 
disease  activity  was  negatively 
associated with carotenoids 
Oxidative  DNA  damage  was 
increased  in  IBD;  no  association 
between impaired oxidative status & 
disease activity; Malnourished lower 
antioxidants than well nourished 
Wendland et 
al 2001 (146) 
37 CD; 37 controls  Vit C, Vit E, carotenoids, GSHPx, Se  Low to control: Vit C, Carotenoids  No association with disease activity; 
Some  inversely  correlated  with 
inflammatory  markers;  lipid 
peroxidation  markers  did  not 
correlated  with  disease  activity; 
Some  carotenoids  associated  with 
lipid peroxidation  
Geerling et al 
2000 (99) 
69 new IBD; 69 controls  Vit A, Vit E, Vit C, β-carotene, Mg, B1, B12, 
Folate, Cu, Zn, Se, GSHPx 
Low to control: UC: β-carotene, Mg, Se, 
Zn lower in UC; CD low B12 
 
Geerling et al 
1998 (100) 
32 CD in remission; 32 
controls 
Vit A, Vit E, Vit C, β-carotene, Mg, B1, B12, 
Folate, Cu, Zn, Se, GSHPx 
Low to control: β-carotene, Vit C, Vit E, 
Se, Mg, GSHPx, Zn, Vit D  
No  difference  for  Vit  E/cholesterol; 
Se  associated  with  %  body  fat;  A 
high proportion at risk of deficiencies 
Kuroki et al 
1993 (175) 
24  (plus  adolescents) 
CD; 24 controls 
A,  E,  B1,  B2,  B6,  B12,  C,  Niacin,  Biotin, 
Pantothenic acid, Folate,  
Low to control: Vit A, Vit E, B1, B2, B6; 
Folate; High to control: pantothenic acid 
No disease location or activity effect; 
B2  and  niacin  inversely  correlated 
with CDAI 
Fernandez-
Banares et al 
1989 (180) 
23  IBD  active ;  89 
controls 
Vit A, β-carotenoid, Vit E, B1, B2, B6, B12, 
Folate, Biotin, Vit C 
Low  to  control:  Vit  A,  β-carotenoid, 
biotin, folate, Vit C, Vit B1 
Vit  E  lower  in  colitis  but  Vit  E: 
Cholesterol normal; B2 lower but B6 
higher  in  colitis;  Vit  B12  lower  in 
upper GI disease  
 
PAEDIATRIC STUDIES 
Ojuawo & 
Keith 2002 
(181) 
74 new IBD; 40 controls  Zn, Se, Cu  Low to control: Se, Zn only for CD; Cu 
higher than UC and control 
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Levy et al 
2002 (145) 
22 CD & 10 control  Retinol,  β-carotene,  α-tocopherol,  γ-
tocopherol 
Low to control: Retinol  No  difference  between  active  and 
inactive disease 
Bousvaros et 
al 1998 (177)  
97  (plus  young  adults) 
IBD; 23 control 
Vit A, Vit E  Low  to  reference:  14.4%  low  Vit  A; 
6.2% low Vit E 
Deficiencies more prevalent in active 
CD  
Hoffenberg et 
al 1997 (182)  
24 IBD; 23 controls  Vit  C,  Vit  A,  Vit  E  β-carotenoid,  γ-
tocopherol,  retinol  binding  protein, 
glutathione, GSHPx, Se 
Low  to  control:  Vit  C;  High  to  control: 
GSHPx, Vit E & Vit E/ Cholesterol 
CD compared to control:  high 
glutathione, GSHPx, Vit E; UC 
compared to CD lower Vit A; 
antioxidants inverse correlation with 
anthropometry 
Thomas et al 
1994 (183) 
39  active  CD;  86 
controls 
Se, GSHPx in erythrocytes and serum  Low  to  control:  10%  low  Se,  GSHPx 
high in plasma but low in erythrocytes 
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1.3.7.1. Dietary intake  
Poor diet, with suboptimal intake in energy and nutrients, has always been considered the 
key contributor to undernutrition seen in IBD (184). Food aversion to avoid exacerbation of 
GI symptoms and anorexia mediated by the interaction of proinflammatory cytokines with 
appetite hormones (185-187) reduces intake in IBD patients, particularly during the active 
phase of the disease course (184;188). Nevertheless, results from studies that assessed 
dietary intake in IBD patients are conflicting. Some studies reported energy intakes close to 
the national guidelines or to healthy subjects (97;99;100;189) but others did not (87;190). In 
the only paediatric study Thomas et al. (190) showed that children with active CD consumed 
on average 420 kcals less than the intake of their siblings (matched for height, sex and 
weight)  whereas  for  21%,  the  energy  intake  was  lower  than  national  recommendations 
compared with 10% in the control group. 
Apart from the adequacy of energy intake there are also good reasons to assume that 
the  micronutrient  intake  of  CD  patients  is  impaired  despite  no  obvious  differences  in  the 
energy intake with compared wit the healthy population. Food aversion and elimination diets 
with  avoidance  of  high  fibre  foods  and  dairy  products  (87)  may  compromise  a  balanced 
micronutrient intake. Data on micronutrient intake are contradictory and no conclusions can 
be  drawn.  Some  authors  reported  suboptimal  intakes  of  micronutrients  in  IBD  patients, 
compared with the healthy control and the national recommendations, whereas others failed 
to confirm these findings (Table 1.3.4).  
 
1.3.7.2. Energy requirements and metabolism 
Dietary  intake,  along  with  resting  metabolic  rate,  physical  activity  expenditure  and  diet-
induced thermogenesis are major components of the energy balance equilibrium. Failure to 
find clear differences in the caloric intake of IBD patients in some studies, and the differences 
in body composition observed in some others, as discussed above (Section 1.3.2), led to 
investigation of the other components of the energy balance equation.   
Results of studies on the basal metabolic needs of patients with IBD are inconsistent 
and  no  obvious  differences  have  been  found  with  healthy  controls  (91;97;104).  However 
when normalisation of the basic metabolic rate for the amount of FFM was considered, a 
higher  basic  metabolic  rate/FFM  ratio  was  commonly  found  in  CD  compared  with  UC 
patients and healthy controls. This may show that IBD patients may have increased energy 
expenditure per unit of FFM but low lean body mass.  
Several studies on the energy metabolism of patients with IBD found that the non-
protein  respiratory  quotient  was  significantly  lower  in  CD  compared  with  UC  patients  or 
healthy controls suggesting an increased lipid oxidation rate in CD patients that    51 
 
 
 
Table 1.3.4: Major studies assessed dietary intake of micronutrients in patients with IBD 
Study  Subjects   Design  Results 
ADULT STUDIES 
Aghdassi et al 
2007 (189) 
74 CD   7d diet records  Low to recommendations: Vit A, Vit E, Vit D, Vit B1, Vit B2, Vit B6, Vit C, β-
carotenoid, Niacin, Folate, Mg, Ca, Fe, Zn; No difference between active & 
inactive disease 
Guerreiro et al 
2007 (87) 
78 CD mild disease; 80 controls  Semi-quant FFQ  Lower than controls: Ca, Vit C, Vit D, Vit E, Vit K;  
Lower than controls for recommendations: Ca, Vit A, Vit C, Vit D, Vit E  
Filippi et al 2006 
(97)  
54 CD in remission; 25 controls  3 d diet records  Lower than controls:  
       Females: β-carotene, Vit B1, B6, C, Mg; Higher for Zn 
       Males lower β-carotene, Vit C 
Low to controls for recommendations: Zn, β-carotene, Vit B1, Vit B6, Vit C, 
Vit E, Mg 
Geerling et al 
2000 (99) 
69 recent IBD; 69 controls  Diet history & FFQ  Lower than control: Ca, B2, P in UC; No differences in CD 
Geerling et al 
1998 (100)  
32 CD in remission; 32 controls  Diet history & FFQ  Lower than control: P 
Lower than controls for recommendations: Vit A 
 
PAEDIATRIC STUDIES 
Thomas et al 
1993 (190) 
24 CD; 17 control siblings  5 d dietary records  Lower than Control: Fe, Cu, Zn, Folate, Vit C 
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paralleled the lower FM seen in the former group of patients (91;98;191;192). Al-Jaouni et al 
(193) also found increased fat oxidation in CD patients that correlated positively with disease 
activity.  
Higher diet induced thermogenesis, another small component in the energy balance 
equation, was found in one study (98) which could explain the lower weight and higher risk of 
undernutrition in IBD. Although there was no difference in the resting metabolic rate between 
healthy  controls  and  CD  patients,  diet  induced  thermogenesis  was  higher  (6%  vs  10% 
respectively). However diametrically opposite results were presented by Al-Jaouni et al (193) 
who additionally found  that diet induced thermogenesis was lower in patients with active 
compared with inactive disease.  
 
1.3.7.3. Malabsorption  
Malabsorption and energy loss due to non-digestion of food or malabsorption of nutrients 
could  potentially  influence  energy  balance,  and  partially  explain  undernutrition  in  patients 
with IBD. However, apart from some reports on specific micronutrients (194-197) in patients 
with ileal resection or with bile acid malabsorption, (198), rigorous evidence is lacking to 
support loss of dietary energy or other micronutrients due to malabsorption. Recently a small 
study in Israel (199) found that malabsorption is a major contributor to underweight in adult 
CD  patients  in  remission.  The  authors  found  that  GI  energy  excretion  was  higher  in  an 
underweight group with CD than in a normal weight group despite no differences between 
the two groups for dietary energy intake or resting metabolic rate. Similarly in another study 
malabsorption and increased faecal fat were observed in severely undernourished patients 
with CD (200). Interestingly, gastric acid and pancreatic enzyme secretion were severely 
impaired in 80% of these patients, which may  be linked to the associated malabsorption 
(200). In fact following nutritional rehabilitation, stool fat output and malabsorption reduced 
with concomitant improvements in pancreatic enzyme synthesis, stores and secretion.      
In theory the absorption of specific nutrients should be impaired when the disease is 
located at the site of specific nutrient absorption or the area has been resected. CD patients 
with ileal disease or resection are traditionally susceptible to vitamin B12 deficiency due to 
inadequate absorption (201). Iron absorption may also be diminished in active paediatric CD 
due to the excessive production of hepcidin, a hepatic peptide mediating the absorption of 
iron at the level of the enterocyte (167).   
 
1.3.7.4. Gut losses 
Apart  from  malabsorption  in  IBD,  loss  of  nutrients  can  occur  as  a  result  of  excessive 
intestinal mucosal sloughing, and through protein enteropathy from the ruptured gut in the   53 
acute phase of the disease. Studies using whole gut lavage have shown that disease activity 
was closely paralleled by GI protein loss (202).  
 
1.3.7.5. Drug-nutrient interaction   
Several drugs used in IBD can interfere with the absorption, metabolism and excretion of 
nutrients.  Two  examples  are  the  antagonistic  interaction  of  methotrexate  with  folate 
metabolism and the long-term effect of steroids on calcium excretion and bone resorption.  
 
 
1.4. Anaemia in IBD 
Anaemia is one of the potential major nutritional issues in IBD.  The term anaemia originates 
from the Greek word ‘Αναι ία’ meaning without blood and is a deficiency of erythrocytes or 
functional haemoglobin (Hb). This results in a reduced ability of the blood to transfer oxygen 
to the tissues, causing tissue hypoxia.  
There  are  no  universal  established  guidelines  to  define  anaemia  or  a  lower 
concentration of haemoglobin below which a person is characterised as anaemic. As a result 
the  use  of  different  reference  range  data  often  classifies  the  same  subject  into  different 
states (anaemic or non anaemic) (203). The World Health Organization defines anaemia as 
a haemoglobin concentration less than 12 g/dl for non-pregnant women and <13 g/dl for 
adult men, whereas for children different age adjusted cut-offs are proposed (204) (Table 
1.4.1).  A  haemoglobin  concentration  below  10  g/dl  is  commonly  described  as  severe 
anaemia independent of sex and age. 
 
Table 1.4.1: Age and sex adjusted cut-offs for the definition of anaemia according to WHO (204) 
and Dallman et al (205).   
Age or gender group  Haemoglobin   
(g/dl) 
  Age or gender group  Haemoglobin 
(g/dl) 
 
WHO 
   
Dallman et al 1979   
6 to 59 mth  11    0.5-1.9 y  11 
5-11 y  11.5    2-4 y  11 
12-14 y  12    5-7 y  11.5 
Non-pregnant women 
(>15 y) 
12    8-11  12 
Pregnant women  11    12-14    Female 
             Male 
12 
12.5 
Men (>15 y)  13    15-17  Female   
             Male 
 
12 
13 
      18-49  Female 
             Male 
12 
14 
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As  the  characterisation  of  the  morphology  (size,  colour,  shape)  of  erythrocytes  is 
done with quick and cheap laboratory tests, it offers a starting point for the description of 
anaemia type. RBC can be characterized as microcytic (RBC too small), macrocytic (RBC 
too large), normocytic (normal size), hypochromic (Hb concentration too low), hyperchromic 
(Hb concentration too high), normochromic (Hb concentration normal), and combinations of 
RBC size and Hb concentration (206;207).   
Surrogates for the investigation of suspected anaemia and differentiation of different 
types are: serum ferritin, serum iron, serum transferrin, folate, and vitamin B12. Difficulties in 
diagnosis of anaemia arise when more than one type of anaemia with opposite effects on the 
haematological profile coexist (208). Moreover, as for many haematologically indices (serum 
iron, transferrin, ferritin) serum concentrations can be affected by the acute phase response, 
in  various  clinical  conditions  (IBD,  malignancies,  infection),  their  diagnostic  value  and 
interpretation can be ambiguous (209). A prime example of this is when active disease may 
result  in  a  spuriously  raised  serum  ferritin  concentration  masking  an  underlying  iron 
deficiency  caused  by  GI  bleeding  and  poor  dietary  intake  in  IBD.  When  the  diagnosis 
remains obscure, a bone marrow sample allows direct examination of the precursors to red 
cells.  
 
1.4.1. Anaemia in IBD 
Compared with the average awareness of other extraintestinal disease complications such 
as arthritis and nutritional status, the topic of anaemia in IBD receives little attention from 
clinicians. Anaemia is one of the most frequent comorbid conditions in IBD-related mortality 
(210). Overt or occult intestinal bleeding is a major symptom and a drop in haemoglobin 
occurs with each flare up in CD and UC. Anaemia alone or in conjunction with abnormal ESR 
levels demonstrates high positive predictive value for IBD diagnosis and in previous studies 
performed better than serologic antibodies (pANCA and ASCA) (211;212).  
Two predominant types of anaemia have been identified in the context of IBD. Iron 
deficient anaemia (IDA) and the anaemia of chronic disease (ACD), which account for the 
majority of the cases. Anaemias associated with vitamin B12 and folate deficiency, or drug 
associated  anaemia  due  to  the  long-term  use  of  medication  to  manage  IBD,  have 
occasionally been reported but these are uncommon (Table 1.4.2) (213;214).   55 
 
Table 1.4.2: Aetiology of IBD associated anaemia (adapted by Gasche et al. 2007 (215)) 
Common  Iron deficient anaemia 
  Anaemia of chronic disease 
 
Occasional 
 
Cobalamin (B12) deficiency 
  Folate deficiency 
  Drug induced anaemia 
 
Exceptional 
 
Haemolysis 
  Myelodysplastic syndrome 
  Aplastic anaemia (often drug induced) 
  Inborn haemoglobinopathies or disorders of erythropoiesis 
 
1.4.1.1. Iron deficient anaemia in IBD 
Iron  filings  dissolved  in  vinegar  were  consumed  by  the  ancient  Greeks  eager  to  acquire 
strength, and in 1600 AD iron was noted for its ability to restore “young girls when pallid, 
sickly  and  lacking  colour  to  health  and  beauty”  (216).  Iron  has  a  pivotal  role  in  many 
metabolic  processes  including  haemopoiesis,  immunity  and  energy  production,  and  the 
average adult contains 3-5 g of iron, of which two thirds are incorporated in haemoglobin 
(217). A normal balanced Western diet provides about 12-15 mg of iron daily, of which 5-
10%  is  absorbed,  principally  in  the  duodenum  and  upper  jejunum,  where  the  acidic 
conditions help the absorption of iron in the ferrous form. Absorption is facilitated by the 
presence  of  other  reducing  substances,  such  as  HCl  and  ascorbic  acid  and  inhibited  by 
reduction of gastric acidity (eg use of anti-acid) (207;218;219). The body has the capacity to 
increase its iron absorption in the face of increased demands like pregnancy, growth spurt, 
and iron deficiency status and reduce it when iron stores are excessively filled.  
Once absorbed from the bowel, iron is transported across the mucosal cell to the 
bloodstream, where it is carried by the protein transferrin to developing red cells in the bone 
marrow and also to immune and liver cells. Hepatic iron stores comprise ferritin, a labile and 
readily accessible source of iron, and haemosiderin, an insoluble form found predominantly 
in macrophages. About 1 mg of iron a day is shed from the body in urine, faeces, sweat, and 
cells turnover from the skin and the GI tract (220). Menstrual losses of an additional 20 mg a 
month happen in women of reproductive age (208). 
Iron deficient anaemia is classified morphologically as hypochromic and microcytic. In 
chronic  iron  deficiency  the  mean  cell  volume  (MCV),  mean  cell  haemoglobin  (MCH)  and 
mean  cell  haemoglobin  concentration  (MCHC)  are  all  reduced  compared  to  the  age  and 
gender  specific  reference  range.  Serum  iron,  ferritin  levels  and  transferrin  saturation  are 
reduced  too  whereas  the  total  iron  binding  capacity  is  elevated  (218;221)  (Table  1.4.3).  
Bone marrow aspirates or biopsies demonstrate micronormoblastic hyperplasia of erythroid 
elements and decrease or absence of stainable iron particularly in macrophages (220;222).   56 
Iron deficient anaemia is the major cause of anaemia in IBD, and this is ascribed to a 
negative  iron  balance  from  excessive  iron  loss  through  GI  bleeding,  increased  epithelial 
sloughing in chronic GI inflammation, reduced dietary intake (223), as well as impairment of 
iron absorption, particularly during the active phase of the disease (167) or when the disease 
is located at the major sites of iron absorption (224).  
As many of the systemic biological markers of the iron body stores are affected by the 
acute phase response, their diagnostic value in IBD is poor and can be misleading (Table 
1.4.3). Decrease in serum iron and downregulation of transferrin is part of the acute phase 
response,  causing  functional  iron  deficiency,  a  state  that  can  be  misinterpreted  as  iron 
deficiency in a patient with active inflammation (209). On the other hand inflammation can 
cause  false  elevation  of  ferritin  levels  bringing  ferritin  levels  of  patients  with  true  iron 
deficiency into the normal range (225). As a result higher cut offs have been proposed for 
ferritin in active IBD and evaluation in conjunction with other haematological parameters to 
detect iron depleted anaemic patients (215;226). Determination of serum transferrin receptor 
has been proposed as a diagnostic marker to distinguish IDA from other types of anaemia in 
IBD (227;228). This soluble transferrin receptor is elevated in iron deficiency and high rate 
erythropoiesis, whereas it is slightly  low to normal in ACD providing a reliable marker to 
distinguish between IDA and other types of anaemia in IBD such as ACD (228). 
  
1.4.1.2. Anaemia of chronic disease 
The  production  of  inflammatory  cytokines  in  chronic  inflammation,  and  malignancy  has 
significant  systemic  effects  including  impaired  haemopoiesis,  and  manifestation  of  ACD 
(216). Anaemia of chronic disease is second only to IDA in IBD (215;229).   
Anaemia of chronic disease is refractory to the use of iron supplementation and is 
usually  characterized  by  a  moderate  reduction  in  haemoglobin  whereas  the  erythrocytes 
morphology is normal although slight hypochromia and moderate microcytosis can also be 
present (216). In contrast to IDA the total iron binding capacity is reduced or unchanged and 
the  serum  ferritin  level  is  increased  (Table  1.4.3).  Bone  marrow  aspirates  often  show 
micronormoblastic hyperplasia with increased iron depots and a decrease in the number of 
iron  containing  erythroblasts  (222).  The  measurement  of  the  soluble  form  of  transferrin 
receptor in serum may be an alternative to differentiate ACD from other types of anaemia 
and particularly IDA as described above (216;230). 
The pathogenesis of ACD is not fully understood but recent evidence suggests this is 
immune driven and mediated by the action of inflammatory cytokines (231;232). Cytokines 
(IFN-γ,  IL-10,  TNF-ɑ)  and  cells  of  the  reticuloendothelial  system  induce  changes  in  iron 
absorption (167), iron metabolism (insufficient iron release from reticuloendothelial cells), the 
proliferation of erythroid progenitor cells, the production of erythropoietin, and the life span of   57 
red cells, all of which contribute to the pathogenesis of anaemia (231;232). Treatment of 
ACD  is  controversial  and  there  is  no  universally  accepted  approach.  The  primary  aim 
includes resolution of the inflammatory process, and downregulation of the expression of 
inflammatory cytokines. Use of human recombinant erythropoietin in conjunction with iron 
supplementation has been tested successfully in IBD studies (233-235).      
 
Table 1.4.3: Characteristics and differences of the haematological presentation of IDA and ACD 
in IBD (adapted from Weiss 2005 (231)) 
  Iron deficient anaemia  Anaemia of chronic disease 
RBC colour (MCH)  Hypochromic  Normo or slightly hypochromic  
RBC size (MCV)  Microcytic  Norma or slightly microcytic 
Plasma iron  Very Low   Low 
Transferrin  High  Low 
Transferrin saturation  Low  Low 
Total iron binding capacity  High (decrease in active 
inflammation) 
Low 
Ferritin  Low (increase in active 
inflammation) 
Normal to High 
Erythrocyte 
protoporphyrin 
High  High 
Serum transferrin receptor  High  Normal 
 
1.4.1.3. Megaloblastic anaemias (Vit B12 and folate deficiency) 
Folate  and  vitamin  B12  deficiency  cause  megaloblastic  anaemia  and  the  latter  pernicious 
anaemia.  Morphologically  megaloblastic  anaemias  are  characterized  by  large  immature 
dysfunctional RBC (macrocytic) and are confirmed diagnostically by low serum levels of B12 
and folate. Raised homocysteine concentrations are observed in folate and B12 deficiency 
and can also be used diagnostically. A bone marrow examination is usually performed to 
confirm megaloblastic hyperplasia. 
 
Vitamin B12 deficient anaemia 
Vitamin B12 is involved as an enzyme cofactor in a number of biochemical reactions and the 
synthesis of certain nucleic acids. In a state of B12 deficiency DNA replication is disturbed 
and nuclear maturation is arrested resulting in abnormally large dysfunctional red blood cells 
(megaloblasts)  and  anaemia  onset.  Reticulocyte  counts  are  low  and  aspiration  of  bone 
marrow shows upregulated cell proliferation with characteristic megaloblastic abnormalities 
such as enlarged erythroid lineage cells. An increased MCV in conjunction with decreased 
vitamin B12 levels are characteristic of B12 associated megalobIastic anaemia. With a daily 
requirement for vitamin B12 of 1-3  g and body stores of 5 mg clinical manifestation of B12 
deficiency occurs late.  
Formation of a protective complex with intrinsic factor produced by the gastric parietal 
cells is necessary for the absorption of vitamin in the terminal ileum. Any condition that alters   58 
intrinsic factor production, such as inflammation of the gastric mucosa or malignancy, may 
interfere with the supply of vitamin B12. Similarly as B12 absorption takes place in the terminal 
ileum, patients with active disease at this site or those who had their terminal ileum resected  
may have increased risk of developing B12 deficiency (236). Regular monitoring of the B12 
status of these patients has been suggested (215). 
 
Folate deficient anaemia 
Natural folates (237) are largely found in the polyglutamate form, and these are absorbed in 
the duodenum and jejunum after deconjugation and conversion to the  monoglutamate 5-
methyl tetrahydrofolate. On average 50-60% of dietary folate is absorbed. Similar to B12, 
folate participates in the synthesis of certain nucleic acids, and a deficit status presents the 
same  hematologic  findings  as  vitamin  B12  with  macrocytic  anaemia.  An  inadequate  diet, 
impaired absorption, or both usually cause folate deficiency. Of great concern are patients on 
medication  with  antagonists  of  folate  metabolism  or  absorption.  A  prime  example  in 
gastroenterology  is  the  patients  on  sulfasalazine,  and  the  effect  of  the  latter  on  the 
absorption of folate, as well as those on methrotrexate, an immunosuppressive agent, which 
interferes with the normal metabolism of folate. Diagnosis is based on macrocytic red blood 
cell maturation, as well as decreased serum or red blood cell folate levels. In combined iron 
and folate deficiency, the red blood cell folate level can be normal and the megaloblastic 
changes in erythroid cells may be obscured.  
 
1.4.1.4. Drug induced anaemia in IBD 
Long-term  use  of  specific  medication  in  chronic  illness  can  interfere  with  normal 
haemopoiesis and subsequently lead to anaemia. Drugs used in the treatment of IBD, such 
as  sulphasalazine,  and  methotrexate,  can  be  associated  with  development  of  macrocytic 
anaemia  attributed  to  secondary  deficiency  of  folic  acid.  Prophylactic  folic  acid 
supplementation  in  these  patients  is  recommended  although  as  sulfasalazine  has  been 
commonly replaced by mesalazine, any drug interaction with folate lacks clinical relevance.  
Azathioprine can cause myelosuppresion although nowadays monitoring of the bone 
marrow  function  by  continuous  blood  monitoring  protocols  and  the  exclusion  of  use  in 
patients with thiopurine methyltransferase deficiency has limited its incidence. Increase of 
MCV accompanies long term therapy  with azathioprine  (238) and is commonly used as 
marker of drug efficacy and compliance although it may also obstruct the early recognition of 
IDA (236).  
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1.4.2. Clinical consequences of anaemia 
Since  all  human  cells,  tissues  and  organs  depend  on  oxygen  supply,  anaemia  onset  is 
accompanied  by  a  wide  variety  of  clinical  consequences.  Significant  determinants  of  the 
clinical picture of an anaemic patient are the type of anaemia and its degree. Commonly 
patients with mild anaemia develop pallor, headaches, dizziness, weakness or fatigue and 
poor concentration, whereas in more severe conditions shortness of breath and tachycardia 
are often reported. Angular stomatitis, finger clubbing, pica (consumption of non-food such 
as dirt, paper, wax, grass and hair) are signs of severe iron deficiency. Glossitis, neural tube 
defects and neuropathy are signs of folate and B12 deficiency. In megaloblastic anaemia due 
to  folate  deficiency  central  nervous  system  symptoms  are  not  present  in  contrast  to  B12 
deficiency. Folate supplementation may improve the (reversible) haematologic symptoms of 
megaloblastic anaemia even if they are caused by vitamin B12 deficiency, but does not stop 
progression of the (partially irreversible) neurologic manifestations of vitamin B12 deficiency. 
Therefore it is indicated that folate supplementation in deficient patients be accompanied by 
B12  substitution  to  avoid  masking  of  B12  deficiency  by  improvement  of  the  haematologic 
presentation on folate replenishment.  
Anaemia  impairs  cognitive  function  and  reduces  quality  of  life  (239)  confirmed  in 
studies  where  resolution  of  anaemia  was  accompanied  by  improvement  in  quality  of  life 
(240). For a long time it was thought that the clinical symptoms of anaemia occurred only 
when the haemoglobin level dropped abruptly as it had been suggested that patients would 
adapt to low haemoglobin levels if anaemia developed slowly. This has led to the concept of 
asymptomatic anaemia. However it was later shown that the process of adaptation to chronic 
anaemia was in fact adaptation to lower quality of life and that this could be reversed. 
 
Table 1.4.4: Main therapeutic approaches in the management of anaemia in IBD 
Type of anaemia  Therapy 
Iron deficient anaemia  Diet rich in iron 
  Oral iron supplementation  
  Intravenous iron infusion 
  Recombinant erythropoietin 
 
Nutritional anaemias  Diet rich in micronutrients (B12 & folate) 
  Oral folate supplementation 
  Intramuscular B12 injection 
 
Anaemia of chronic disease  Recombinant erythropoetin & oral/intravenous iron  
Excessive bleeding/Very low haemoglobin  Blood donor transfusion  
 
1.4.3. Treatment of anaemia with particular reference to IBD 
Guidelines on the diagnosis and management of iron deficiency and anaemia in IBD have 
recently  been  published,  without  however  distinguishing  between  adults  and  paediatric   60 
patients (215). For the treatment of anaemia it is not only important to identify the type and 
the  severity  of  the  anaemia  but  also  the  nature  of  the  anaemia  so  that  therapy  can  be 
targeted at the underlying mechanism and be adjusted to the patient’s needs.  
With  the  advent  of  new  more  effective  medication,  that  makes  mucosal  healing 
possible (90) or affects the inflammatory cascade at the initial step, a lower prevalence of 
anaemia may be anticipated. However such a theoretical approach has not been tested in 
clinical  trials.  In  an  anaemic  patient  in  the  active  phase  of  disease  the  treatment  of  the 
underlying condition should be the primary target before any attempt to correct anaemia. 
This is particularly important in the management of ACD where the inflammatory response is 
the  major  contributor  to  the  aetiology  of  ACD.  The  choice  of  treatment  depends  on  the 
degree  of  anaemia.  Gasche  et  al  proposed  a  therapeutic  algorithm  in  IBD  associated 
anaemia together with consensus guidelines without however distinguishing between adult 
and  paediatric  patients  (215).  The  main  therapeutic  approaches  in  the  management  of 
anaemia in IBD are outlined in Table 1.4.4. 
 
1.4.4.  Review  of  the  studies  on  prevalence  and  predictors  of 
anaemia in IBD 
An extensive literature search was carried out, using Pubmed and searching the reference 
lists of original papers and reviews providing information on the prevalence of anaemia in 
IBD. Adult studies were excluded, as the primary scope of this review was to evaluate the 
prevalence of anaemia only in children with IBD.  
Overall nine original articles and one study published in abstract form reported the 
prevalence  of  anaemia  in  paediatric  IBD.  Two  systematic  reviews  including  mainly  adult 
studies (229;236) described in total four of these paediatric studies. In two other studies, 
measurements  of  haemoglobin  were  carried  out  and  mean  values  were  reported  without 
reference to the overall prevalence of anaemia (20;83). 
All but two studies were conducted in North America (Table 1.4.5); one study with 32 
UC children in Europe (237), and one from Israel (228). Most studies measured anaemia in 
children  younger  than  18  years.  Three  studies expanded  their  inclusion  criteria  to  young 
adults (228;241;242). The sample size varied from 11-526 children with only one reporting 
prevalence of anaemia in over 100 patients (243).  
The definition of anaemia within the studies varied remarkably. All but two (241;242) 
used  haemoglobin  measurements  to  define  anaemia,  two  used  haematocrit  cut  offs 
(241;242), and in another (244), no definition of anaemia was given. The lower haemoglobin 
cut offs to distinguish between anaemic and non anaemic patients ranged from 10.5 to 13 
mg /dl. All but three studies used generic cut offs to define anaemia in both girls and boys   61 
whereas three studies used age adapted thresholds, as age related changes in haematologic 
indices are well recognized (221). All but two studies assessed anaemia close to the time of 
diagnosis. One study enrolled only patients with severe colitis (Table 1.4.5). 
On the whole the prevalence of anaemia in paediatric IBD ranged between 41% and 
88%. A mean estimate cannot be drawn. Neither can temporal changes be evaluated due to 
differences  in  the  definition  of  anaemia  between  studies  (245).  Compared  with  the  two 
systematic reviews which reported studies in mainly adult patients, prevalence of anaemia in 
children  overall  is  reported  to  be  higher. Wilson  et  al  (229)  estimated  the  prevalence  of 
anaemia to be between 6-74% numerically lower than the range reported in the paediatric 
studies reviewed.      
As  documentation  of  anaemia  was  usually  a  secondary  outcome  in  most  of  the 
paediatric studies only a few authors linked anaemia with disease and sociodemographic 
characteristics. Mack and his colleagues (243) showed that anaemia was associated with 
severity of disease activity. They observed that anaemia was more common in patients with 
severe disease than those with mild disease activity. The same group showed that in young 
patients (6-11 y) with severe disease, haemoglobin concentration was higher in CD than in 
UC (p< 0.006). No such difference was observed for the older group of children (≥ 12 y) or 
for  children  with  mild  or  moderate  disease.  A  negative  association  between  haematocrit 
levels and disease activity has been described previously for CD patients particularly those 
who had isolated disease in the small intestine (246). Although Weinstein et al. (83) did not 
report  the  prevalence  of  anaemia,  they found  that  mean  haemoglobin  concentration  was 
lower in CD than UC, a finding that was more marked in the older group of patients (≥ 11 y). 
No such difference in the mean haemoglobin concentration was found between UC and CD 
in a state population based study in the United States (20). In a study published in abstract 
form only, Thayu et al (247) measured prevalence of anaemia in paediatric CD and tried to 
identify disease predictors associated with it. Anaemic patients had higher values of PCDAI 
and  ESR  than  non-anaemic  patients  and  the  presence  of  upper  GI  tract  disease  was 
significantly associated with anaemia. Gender, duration of symptoms, body composition, or 
growth parameters were not predictors of anaemia.  
Similar data from adult studies suggested an association between the presence of 
anaemia and high scores on the disease activity indices (214;235). Schreiber (235) found 
that anaemia was more common in CD than in UC patients whereas in a study from Israel, 
that accounted for the prevalence of anaemia by sex, the prevalence of anaemia was higher 
in women than in men (66.6% vs. 27.5% respectively) (248). Reilly (249) in a study of the 
impact of parenteral nutrition on clinical outcome found that the prevalence of anaemia was 
lower in CD patients with only small bowel involvement (33.3%) than in patients with disease 
involving the large bowel with or without small bowel. In contrast, RBC, haemoglobin and   62 
anaemia  were  lower  in  patients  with  ileocolitis  than  in  patients  with  small  intestine 
involvement in a Japanese cohort of CD patients (250). Undernourished patients were more 
likely to be anaemic than well-nourished CD patients in another study (251).    63 
 
Table 1.4.5: Studies that measured the prevalence of anaemia in paediatric IBD 
Study  Country  Age  n (Male)  Disease  Definition of anaemia  Prevalence of 
anaemia  Predictors of anaemia  Comments 
Mack et al 2007 (243)  US & 
Canada 
<16  526 (310)  392 CD  < 6 y;    Hb<11 
6-11 y;  Hb<11.5 
>11 y;   F: <12 
                M: <13 
68%  Severe disease; In 6-11 
y group with severe 
disease Hb was lower 
in UC than CD  
 
Howarth et al 2007 
(252) 
UK  <16  32 (11)  32 UC  Hb < 12  62.5%  N/A   
Khan et al 2002 (211)  US  ≤18  90 (45)  51 UC  1-10 y; Hb<10.5 
>10 y; Hb <11.5 
41%  N/A   
Thomas & Sinatra 
1989 (253) 
US  ≤18  24 (17)  24 CD  Hb < 12   71%  N/A   
Beeken 1979 (254)  US  8-21  11 (8)   11 CD  Hct < 36  72.7%  N/A  Did not 
measure 
anaemia at 
diagnosis 
Burbige et al 1975 
(213) 
US  <16  58 (37)  58 CD  Hb < 11  51.7%  N/A   
Revel-Vilk et al 2000 
(228)  
Israel  9-22  63 (34)  5 CD  MCV < 77 fl 
F: Hb < 12; Ferritin < 6  g/l  
M: Hb < 12.5; Ferritin < 23 
 g/l  
 
 
41.3% 
11 IDA 
15 ACD 
N/A  Did not 
measure 
anaemia at 
diagnosis 
Werlin & Grand 1977 
(242)  
US  6-20  19 (8)  5 CD   Hct £ 30  73.7%  N/A  New and 
patients with 
long-standing 
disease; Only 
with severe 
colitis 
Thayu et al 2005 (247)  US  5-18  78 (44)  78 CD  <5 centile for age & sex  77%  High PCDAI and ESR; 
Upper GI disease 
involvement 
 
Gryboski 1994 (244)   US  ≤10  N/A  40 CD  N/A  75% CD; 
88.4% UC 
Upper GI disease 
involvement 
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1.4.5. Conclusion 
The  prevalence  of  anaemia  in  paediatric  IBD  is  not  well  documented  and  the  evidence 
comes from a limited number of studies with methodological flaws. Most studies included 
small sample sizes with only one study documenting the prevalence of anaemia in more than 
100 patients. The definition of anaemia between the studies is heterogeneous and does not 
allow a direct comparison between the studies or assessment of secular trends in anaemia 
prevalence.  Indeed  the  prevalence  of  anaemia  in  most  of  the  current  studies  was  a 
secondary outcome rather than a primary aim, and may have resulted in unrepresentative 
selective  groups  of  patients  that  does  not  allow  the  extrapolation  and  generalization  of 
findings. Thus the need of population based studies measuring anaemia at diagnosis before 
medical treatment has been applied is necessary to appropriately characterise prevalence 
and determinants of anaemia in paediatric IBD.   
There is a lack of evidence on factors that might predispose to anaemia. Knowledge 
of  this  could  help  tackle  the  development  of  anaemia  at  an  early  stage.  In  light  of  new 
consensus guidelines on the categorization of disease location and behaviour new studies 
should  be  conducted  to  address  whether  disease  phenotype  favours  anaemia. 
Undernutrition, growth faltering or demographics may also differ between anaemic and non 
anaemic IBD patients and should be investigated further.   
To the best of our knowledge no study has measured the outcome and prognosis of 
anaemia  during  the  natural  history  of  the  disease.  As  new  treatments  are  now  available 
which achieve mucosal healing (90) and tackle inflammatory cascade activation at the initial 
stages, temporal changes in the prevalence of anaemia and lower incidence at follow up 
should  be  expected.  In  particular  possible  association  with  specific  treatment  modalities 
deserves to be studied further.  Such a study is described in Chapter 6 of this thesis. 
 
 
1.5. Nutritional therapy in IBD 
 
“Now to perform a true physician’s part, and show I am perfect master 
of my art, I will prescribe what diet you should use, what food you 
ought to take and what refuse. –Ovid 43 BC” 
 
It  is  very  attractive  for  the  health  professional  to  propose  that  he/she  can  improve  the 
patient’s condition by dietary manipulation. In contrast to coeliac disease, where the mucosal   65 
lesion  resolves  with  restriction  of  dietary  gluten,  the  role  of  dietary  treatment  in  IBD 
management is more complicated and controversial.  
In  paediatric  CD  the  main  focus  of  the  dietetic  intervention  is  on  the  artificial 
nutritional therapy which is defined as the provision of nutrients and energy in an artificial 
liquid  food  supplement.  These  can  be  administered  orally,  or  when  this  is  not  possible 
intranasally through a nasogastric tube, or a stoma in the GI tract, for long-term nutritional 
support.  
Artificial nutritional therapies can be classified by the nitrogen source; derived from 
either amino acids or intact protein component. Elemental feeds are developed by mixing 
single amino acids with other simple nutrient sources, are entirely free of dietary antigens 
and are commonly used in patients with food allergies. Semi-elemental feeds contain small 
oligopeptides (protein hydrosylates) and present less antigenic load than polymeric feeds, 
which contain whole protein. The protein comes predominantly from milk but also from egg 
and soya. Polymeric feeds are more palatable and cheaper than the other two forms and 
reduce the need for NG administration (255). In this thesis, wherever nutritional therapy is 
referred to it implies only artificial nutritional support unless otherwise stated. 
This section is a concise review of the role of nutritional therapy in the management 
of  IBD  with  a  particular focus  on  the  evidence  in  paediatric  CD. The role  of  EEN  in the 
induction  of  disease  remission  and  nutritional  rehabilitation  in  active  paediatric  CD  is 
discussed  in  detail  as  is  the  evidence  for  mechanisms  of  action.    Using  subject  specific 
keywords in Pubmed, more than 200 primary sources of evidence  were retrieved on the 
nutritional  management  of  CD.  All  the  paediatric  studies  were  reviewed  and  appropriate 
reference will be made to adult studies when evidence specific to children is scarce. Studies 
on the effect of EN on micronutrient status, and intestinal microbiota in IBD are described 
separately  in  the  text  in  more  detail.  A  summary  of  the  paediatric  studies  on  nutritional 
management of IBD is displayed in the evidence Table 1.5.1.   
 
1.5.1. Nutritional therapy and disease activity in IBD 
Nutritional  support  in  the  form  of  EEN,  or  rarely  as  total  parenteral  nutrition,  is  the 
mainstream treatment for induction of clinical remission in active paediatric CD in the UK, 
although  different  patterns  of  use  are  reported  worldwide  (256).  In  a  survey  of  practice 
patterns 62% of western European paediatric gastroenterologists reported use of nutritional 
therapy  compared  with  only  4%  of  their  North  American  colleagues,  who  preferred 
corticosteroid use (256). It is noteworthy that EEN was not even mentioned in a recent state 
of the art North American review on treatment options in paediatric CD (257). 
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Table 1.5.1: Evidence table of all paediatric studies on the nutritional therapy in paediatric IBD 
Study  Aim  Treatment  Patients  Outcomes  Results  Comments 
Rodrigues 
et al 2007 
(255)  
Comparison 
between ED & PD 
on compliance, 
remission effect, 
use of NG tube, 
use of EEN on 
subsequent relapse 
Retrospective; 
EEN (PD or 
ED); 6 wk 
98 with active 
disease newly 
diagnosed 
% remission rate; 
compliance rate; 
use of NG tube; 
reuse of EEN for 
subsequent relapse 
No difference in any of the 
outcome apart from the use 
of NG that was lower in PD  
Remission rate: 64% for 
ED and 51% for PD (ns) 
Day et al 
2006 (258)  
Effect of EEN on 
disease activity 
Retrospective; 
EEN (PD); 6-8 
wk, some 
continued on 
supplementary 
feeds 
27 with active 
disease; newly 
diagnosed and with 
longstanding disease 
CA; inflammatory 
markers 
89% completed their EEN 
course; no association 
between efficacy with 
disease location; most 
children improved within the 
first 4 wk; wt increased but 
in less degree in non 
responders 
Remission rate better in 
new than long-standing 
disease; Cs sparing effect 
from EEN; Long remission 
on follow up; CA 
improved; Inflammatory 
markers improved 
Borrelli et 
al 2006 
(259)  
Comparison 
between EEN & Cs 
on mucosal healing 
RCT; EEN 
(PD); 10 wk vs 
Cs 
37 children (19 EEN)  CA; histology; 
endoscopy; 
mucosal healing; 
albumin, CRP, 
ESR; 
anthropometry; 
side effects 
No difference in clinical 
remission between EEN & 
Cs (79% vs 67%); CRP, 
ESR and albumin improved 
towards reference; No 
difference for Ht; Wt gain 
higher in EEN; less side 
effects in EEN (23%) vs Cs 
(67%) 
14/19 in EEN vs 6/18 in 
the Cs showed mucosal 
healing; Only children on 
EEN presented 
improvement in histologic 
and endoscopic healing; 
good response for both 
colonic and ileal; well 
designed study; no 
concomitant treatment 
Johnson 
et al 2006 
(260) 
Effect or EEN and 
partial EN on 
disease activity 
RCT; EEN (ED 
or partial EN 
(50% ED & 
normal diet)); 6 
wk 
50 with active 
disease 
CA; anthropometry; 
skinfolds; CRP; 
ESR; Hb; platelets; 
albumin 
Remission in partial EN 
was 15% vs 42% in EEN; 
Only in EEN improvement 
of serum inflammatory 
markers, albumin, ESR and 
diarrhoea 
Skinfolds improved; no 
difference between 
formulas 
Berni-
Canani et 
al 2006 
(261) 
Effect of EEN on 
disease activity 
(short and long 
term efficacy) 
Retrospective, 
EEN (PD, SED, 
ED) vs Cs; 8 
wk 
47 newly diagnosed 
with active disease 
(37 on EEN & 10 on 
Cs) 
CA; endoscopy; 
albumin; iron; 
histology; % 
relapse in 1y follow 
up 
86.5% achieved remission; 
CA reduced in all groups; 
Endoscopic and histology 
improvement more 
pronounced in EEN (no 
difference between type of 
Duration of clinical 
remission longer in EEN 
than in Cs; wt increased 
by 12% but no difference 
between EEN and Cs; Ht 
gain higher in EEN than in   67 
EEN); 7 children on EEN 
achieved histological 
remission but none in Cs; 
albumin and iron status 
improved in EEN  
Cs; 90% reported adverse 
effects on Cs whereas 
32.4% in EEN 
Gavin et al 
2005 (262) 
Energy intake in 
EEN 
EEN (PD-
Modulen); 6-8 
wk 
40 with active 
disease 
CA; anthropometry; 
% of recommended 
dietary intake  
CRP decreased (78% less 
than 2mg/l); median wt 
increase 11%; energy 
intake in 82% of patients 
was around 118% of EAR; 
low BMI SDS at start was 
correlated with more wt 
gain 
No disease site effect on 
remission rate 
Knight et 
al 2005 
(263)  
Effect of EEN on 
short and long term 
outcome 
 (ED and 4 
PD); 8 wk EEN 
44 with active 
disease 
CA; albumin; CRP; 
time to relapse 
90% achieved remission; 
62% relapsed within a y; 
EEN postponed Cs use for 
68 wk; 
No disease site effect on 
remission rate but colonic 
a trend to relapse earlier 
Afzal et al 
2005 (264) 
Efficacy of EEN on 
disease activity; 
Association with 
disease location 
EEN (PD); 8 wk  65 with active 
disease 
CA; histology; 
endoscopy 
Remission rate lower in 
colonic than disease 
involving ileum; CA 
improvement was better in 
disease involving the ileum; 
endoscopy and histology 
improved only in disease 
involving ileum 
 
Afzal et al 
2004 (265) 
Effect of EEN on 
disease activity; 
Association 
between quality of 
life and mucosal 
healing 
 
 
EEN (PD); 8 wk   26 with active 
disease 
CA; quality of life ; 
endoscopy; 
histology;  
88.5% in remission; quality 
of life improved; histology 
and endoscopy improved; 
endoscopic or histological 
findings did not correlate 
with quality of life 
 
Ludvigsso
n et al 
2004 (266)  
Comparison of ED 
vs PD on disease 
activity 
Multicenter 
RCT; 6 wk  
31 with active 
disease 
CA; remission rates  No difference in remission 
rates; 69% in ED vs 82% 
PD achieved remission; no 
difference in disease 
improvement between new 
and old CD patients; no 
Higher wt gain in PD; 
patients had either quick 
(within 2 wk) or delayed 
(up to 6 wk) response   68 
association with disease 
location 
Bannerjee 
et al 2004 
(267)  
Effect of EEN on 
inflammatory 
markers, growth 
stimulating markers 
and nutritional 
restitution 
EEN (PD); 6 wk   12 with active 
disease 
CA; anthropometry; 
skinfolds; CRP; 
ESR; IL-6; IGF-1; 
IGFBP-3; leptin,  
ESR, IL-6 improved to 
normal by d 3; CA, CRP, 
IGF-1 improved by d 7; wt, 
skinfolds, leptin, improved 
later after 14-21 d 
Body composition markers 
measured not so sensitive 
to acute change as 
inflammatory and growth 
markers; anti-inflammatory 
and growth effects 
preceded nutritional status 
markers  
Cameron 
& 
Middleton 
2003 (268) 
Effect of ED on 
orofacial CD  
Case report; 
ED 
Case report  Disease improved 
within 2 d 
   
Akobeng  
et al 2002 
(269) 
Effect of EEN (low 
or high in 
glutamine) on IGF-
1  
DBRCT; EEN 
(ED); 2 types of 
ED (high & low 
in glutamine); 4 
wk 
15 with active 
disease 
IGF-1; 
anthropometry; 
MAC 
IGF-1 was low at baseline 
and did not differ at the end 
of the study; proportionally 
more children on low 
glutamine presented 
increase in IGF-1 compared 
with the high glutamine 
feeds  
MAC, and anthropometry 
improved only in the low 
glutamine group 
Akobeng 
et al 2000 
(270)  
Effect of EEN (low 
or high in 
glutamine) on 
disease activity 
DBRCT; EEN 
(ED high and 
low in 
glutamine) 4 wk 
18 with active 
disease 
CA; orosomucoid; 
platelets; ESR; 
abumin 
Not difference in remission 
rates (55.5% in normal vs 
44.4% in glutamine 
enriched); Improvement of 
CA was better in low than in 
high glutamine EEN 
 
Fell et al 
2000 (90)  
Effect of EEN on 
mucosal healing 
and mucosal 
inflammatory 
markers 
EEN (PD); 8 wk  29 with active 
disease 
CA; anthropometry; 
CRP; TNF-α; 
mucosal levels of 
IL-1β, IL-8, IL-10, 
INF-γ, TGF-β1; 
endoscopy; 
histology 
79% in remission; CA, 
CRP, TNF-α decreased; wt 
increased; histology and 
endoscopy improved; IL-1β, 
IL-8, INF-γ decreased after 
treatment; TGF-β1 
increased  
In TI, histologic 
improvement was 
observed in 13/20; colonic 
improvement was 
observed in 12/25; 
Complete healing 
occurred in 8 and 2 cases 
with TI and colonic 
disease respectively.   
Beattie et 
al 1998 
Effect of EEN on 
growth 
EEN; PD; 8 wk 
plus two mth on 
14 with active 
disease 
CA; IGF-1; IGFBP-
3; anthropometry; 
Wt increased, but not ht; 
skinfolds unchanged; CRP 
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(271)   supplementary 
feeds 
skinfolds, CRP  decreased within two wk; 
IGF-1 & IGFBP-3 increased 
Azcue et 
al 1997 
(104) 
Effect on EEN on 
body composition 
and energy 
expenditure 
EEN (ED) vs 
Cs; 4 wk  
24 children with 
active CD, 19 
anorexic, 22 healthy 
controls 
Body composition 
(double labelled 
water, BIA, total 
body K, extra and 
intracellular water 
with bromide 
dilution); REE with 
indirect calorimetric 
All body composition 
parameters improved in 
EEN; REE increased also 
in EEN; ht increased only in 
EEN 
Intracellular water and 
lean mass accretion were 
significantly higher 
in the EEN than in the 
prednisolone group; 
patients on Cs trend for 
higher FM at the end of 
treatment 
 
Khoshoo 
et al 1996 
(272) 
Comparison 
between low and 
high fat EEN on 
disease activity 
Crossover 
RCT; EEN; 
SED (high fat 
vs low fat); 
6wks 
14 adolescents   CA (PCDAI); 
skinfolds; body 
composition with 
bioimpedance 
No difference between the 
formulas; improvement on 
body composition & 
skinfolds; improvement in 
CA 
Patients on concomitant 
medication (Cs, 
antibiotics, 5-ASAs); Cs 
requirements decreased 
Wilschans
ki et al 
1996 (273) 
Effect of 
supplementary 
feeds following 
EEN on 
maintenance of 
remission 
EEN; (ED or 
SED) followed 
by nocturnal or 
not 
supplementary 
feeds 
65 with active 
disease 
CA (PCDAI); Hb, 
ESR; albumin; 
anthropometry 
CA, ESR reduced; 
haemoglobin and albumin 
improved; less patients 
relapsed in supplementary 
feeds; growth velocity 
improved with EEN 
compared with previous y 
and ht velocity higher in 
supplemented group  
72% got in remission; 60% 
relapsed within 12 mth 
Papadopo
ulou et al 
1995 (274) 
Comparison 
between Cs & EEN 
on disease activity 
EEN; ED vs Cs 
(historical 
control); 6 wk  
58 (30 on EEN)  CA; anthropometry  CA improved in both 
treatments; Disease 
improvement better on ED; 
patients with proximal 
disease had longer 
remission period; ht 
improvement was better in 
EEN than Cs; albumin and 
Hb improved in EEN but not 
on Cs 
 
Breese et 
al 1995 
(275)   
Effect of EEN on 
immunological 
response  
EEN (ED&PD) 
vs Cs vs 
cyclosporine; 8 
wk 
18 (6 on EEN) with 
small intestine 
involvement 
% lymphokine 
secreting cells that 
produce IL-2 & INF-
γ; histology 
Mucosal healing improved 
in EEN but not in Cs; % 
lymphokine secreting cells 
that produce IL-2 & INF-γ 
   70 
reduced 
Beattie et 
al 1994 
(276)  
Effect of EEN on 
disease activity 
Case series; 
EEN; PD 
(Nestle TGF-
beta2); 8 wk 
7 with small bowel; 
newly diagnosed 
CA; CRP, ESR, 
anthropometry; 
histology 
CRP, ESR decreased; wt 
increased; CA decreased; 
ht velocity improved; 
histology improved in 6/7; 
2/7 relapsed in 1 y 
 
Ruuska et 
al 1994 
(277)  
Comparison 
between Cs & EEN 
on disease activity 
RCT; EEN (PD) 
vs Cs; 8 wk 
exclusively and 
PEN for 
following 3 wk 
19 with active 
disease 
CA; CRP; ESR; Hb; 
IgG; IgA; 
Prealbumin; Iron 
No difference in remission 
rates, CRP, IgG, IgA, 
prealbumin, iron; more 
patients on EEN remained 
in remission at follow up 
CA reduced, improved 
within two wk of treatment 
initiation; Wt increased the 
first 4 wk and remained 
stable then after 
Thomas et 
al 1993 
(190) 
Comparison of 
EEN vs Cs 
RCT; EEN; ED; 
4 wk 
24 with active 
disease (12 EEN) 
CA; anthropometry  CA reduced in both 
treatments; no difference 
between treatments; ht 
velocity improved only in 
EEN; no difference with 
disease location 
 
Thomas et 
al 1993 
(278) 
Effect of EEN & Cs 
on IGF-1 and 
IGFBP-1 
RCT; EEN (ED) 
vs Cs & 
sulphasalazine; 
4 wk 
29 (13 on EEN) with 
active disease 
IGF-1; IGFBP-1; 
anthropometry 
IGF-1 increased in both 
treatments; higher increase 
in Cs; IGFBP-1 decreased 
only in Cs; ht velocity was 
greater in EEN than in Cs  
EEN improved growth 
despite higher increase of 
dietary intake in Cs; 
Perhaps Cs over-ride the 
benefits from increased 
energy intake, IGF-1 and 
reduced IGFBP-1 
Polk et al 
1992 (279)  
Effect of 
intermittent EEN on 
growth and disease 
activity  
One mth of 
EEN (ED) 
followed by 2 
wk of exclusion 
and low fibre 
diet and then 2 
mth on free diet 
6 with growth failure 
(only one patient with 
active disease) 
CA; anthropometry; 
IGF-1; albumin; 
skinfolds 
CA reduced; ht, wt, IGF-1, 
albumin improved; no 
changes in skinfolds 
Concomitant treatment 
(Cs, antibiotics, 5-ASA, 
mercaptopurine) 
Aiges et al 
1989 (280) 
Effect of nocturnal 
supplementation on 
growth 
Nocturnal 
partial 
supplementatio
n with PD; 1 y 
8 adolescents with 
growth failure and 
quiescent or mild 
disease & 4 controls 
CA; anthropometry   Wt gain and ht velocity 
increased compared with 
last y and controls; CA 
improved compared with 
last y in subjects but not in 
controls 
On concomitant treatment 
with Cs 
Belli et al 
1988 (281) 
Effect of 
intermittent EEN on 
EEN; 1 wk on 
ED followed by 
8 with growth failure 
and 4 controls 
CA; anthropometry; 
skinfolds; ESR; Hb; 
Wt, ht, skinfolds, urinary 
creatinine increased 
On concomitant treatment 
with Cs and 5-ASAs   71 
growth  3 wk on normal 
diet for 3 mth 
TIBC; folic acid; 
urinary creatinine 
compared with previous y 
and controls; CA decreased 
and use of Cs decreased 
compared with previous y 
and controls 
Sanderson 
et al 1987 
(282) 
Comparison 
between Cs & EEN 
on disease activity 
RCT; EEN; 
SED; 6 wk 
17 longstanding CD; 
(8 on EEN) with 
active disease; small 
bowel disease 
CA; ESR; CRP; 
albumin; 
anthropometry 
Improvement in CA, ESR, 
CRP, albumin, wt; No 
difference in CA between 
EEN and Cs; growth 
velocity improved only in 
EEN 
 
Sanderson 
et al 1987 
(283)  
Effect of EEN on 
gut permeability 
EEN; ED; 6 wk  14 with active 
disease with small 
bowel involvement & 
7 controls with no 
small bowel 
involvement 
CA; gut 
permeability 
(lactulose/rhamnos
e); ESR; 
anthropometry 
Gut permeability improved; 
50% had permeability 
levels within normal range 
after treatment; wt 
increased; CA & ESR 
decreased in parallel with 
permeability improvement 
 
Blair et al 
1986 (284)  
Preoperative 
nutritional support 
with EEN 
EEN; ED; 5 wk 
to 4.5 mth 
11 with small bowel 
involvement, 
preoperative 
CA; ESR; Hb; 
albumin; 
anthropometry, 
steroid reduction 
ESR reduced; Hb, albumin, 
anthropometry increased; 
steroid use reduced, 
fistulas improved; 
postoperative complication 
reduced, reduced rates of 
postoperative relapses  
 
O’Morain 
et al 1983 
(285)  
Effect of EEN on 
disease activity 
EEN; ED; 4 wk  15 with active 
disease and small 
bowel involvement 
ESR; Hb; albumin; 
anthropometry 
Inflammatory markers 
improved within 1-2 wk; 
ESR, decreased, Hb and 
albumin increased, some 
children had wt and ht 
improvement 
Patients on concomitant 
treatments 
Navarro et 
al 1982 
(286) 
Effect of EEN on 
disease activity 
EEN; 2 to 7 
mth; followed 
by 
supplementary 
feeds from 12-
22 mth 
17 underweight 
children; 10/17 
growth retarded 
CA  No difference between Cs 
and EEN; Improvement of 
patients with stenotic 
disease; reduced steroids 
dependency 
Patients on 5-ASA 
Morin et al 
1982 (287) 
Effect of EEN on 
disease activity, 
EEN; ED; 21 d   10 newly diagnosed 
with active disease 
CA; bacterial 
counts; folate; 
CA reduced; wt, skinfolds 
improved; No changes in 
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body composition, 
gut flora, vitamin 
levels  
carotene; 
anthropometry; 
skinfolds  
bacteria; folate increased 
carotene decreased 
Morin 
1980 (288)  
Effect of EEN on 
growth 
EEN; ED; 6 wk  4 with growth failure; 
some but not all 
active 
CA; anthropometry; 
skinfolds 
CA improved; ht (1.8 cm) 
and wt (3.8 kg) improved; 
skinfolds improved; children 
continued growing after end 
of EEN 
 
ED: Elemental diet; PD: polymeric diet; CA: clinical activity; Cs: corticosteroids; wt: weight; ht: height; TI terminal ileum; DBRCT: double blind randomized control trial  73 
As it is unethical not to treat patients with active disease, no placebo controlled trial has been 
conducted so far to test the efficacy of EEN in IBD. Instead the efficacy of EEN to induce 
disease remission in active CD has been compared with that of other treatments, mainly 
steroids, in several investigations (Table 1.5.1). These have been reviewed in a few review 
articles  and  recently  in  an  updated  Cochrane  meta-analysis  of  RCT  (289)  as  presented 
below. With regard to UC there is little information available, although overall it seems that 
nutritional support does not possess a particular role in the management of active UC.  
 
1.5.1.1. Nutritional therapy in adults with active CD 
It is now more than 30 years since a group of surgeons reported the benefits of EEN in 
adults  with  active  CD.  Patients  awaiting  surgery  for  management  of  treatment-resistant 
disease experienced disease remission while receiving nutritional support for preoperative 
nutritional rehabilitation and bowel rest (290). Following this observation, O’Morain et al (285) 
conducted  the  first  clinical  trial  in  adult  CD  patients  and  found  that  elemental  EEN  was 
comparable  in  inducing  clinical  remission  and  correcting  serum  inflammatory  markers 
compared  with  corticosteroids  treatment.  Subsequent  adult  studies  confirmed  these 
observations  (291;292)  although  a  European  multicentre  study,  involving  107  adults  CD 
patients showed that combined treatment of steroids and sulphasalazine was more effective 
than semi-elemental feeds in the induction of clinical remission (293). Three meta-analyses 
between 1995-1996 pooling the results of individual clinical trials concluded that although 
enteral feeding has a role in the management of CD it is inferior to steroids in achieving 
disease  remission  (294-296).  Similar  conclusions  were  recently  reached  by  a  Cochrane 
review in 2007 (289) which included eight trials with 212 patients treated with EEN and 179 
treated  with  steroids,  and  yielded  a  pooled  OR  of  0.33  (95%  CI  0.21  to  0.53)  favouring 
steroid therapy. Remission rates varied considerably (20% to 84.2%) in the individual studies 
which could be due to differences in the study populations, route of administration, outcome 
measurements and methodology (289). 
   
1.5.1.2. Nutritional therapy in children with active CD 
Despite the conclusions of the three metanalyses, reporting a clear superiority of steroids to 
induce  clinical  remission  in  active  CD,  two  subsequent  metanalyses  were  conducted, 
including RCTs in paediatric only CD patients (297;298). Pooling the results of five paediatric 
studies with a total number of 147 children Heuschkel et al (298) found no difference (RR = 
0.95  [95%  CI:  0.67-1.34])  between  EEN  and  corticosteroid  treatment  to  achieve  clinical 
remission  (Fig  1)  which  was  confirmed  in  an  updated  meta-analysis  (297)  including  two   74 
subsequent trials, (259;299). The overall reported remission rates on treatment with EEN 
varied from 42% (260) to 90% of cases (263) among the individual studies (Table 1.5.1). 
 
Figure  1: Forrest plot of RCT on the effect of EEN on induction of clinical remission in 
paediatric active CD (adapted from Heuschkel et al (298))  
 
 
1.5.1.3. Effect of nutritional therapy in remission maintenance 
As IBD is chronic in nature, and there is no effective curative treatment, a large number of 
patients are anticipated to relapse within a year of remission induction (300;301) with some 
relapsing soon after food re-introduction (302). Patients with complicated disease (ie fistulae, 
strictures, perianal disease) are more susceptible to early relapse (303). In a large (n=113) 
adult  retrospective  analysis,  22%  of  patients  relapsed  in  the  first  six  months  after  EEN 
treatment whereas the probability of maintaining remission at three years was 38% (303). 
Likewise 2/3 of the patients in paediatric studies are estimated to relapse within a year of 
EEN induction of remission (263;273). No difference in the time to first relapse has been 
found between clinical remission induced with EEN or steroids in both adult and paediatric 
reviews  (289;298)  although  a  recent  paediatric  trial  found  higher  relapsing  rates  in  the 
steroid,  compared  with  the  EEN  group,  which  was  ascribed  by  the  authors  to the  better 
mucosal healing achieved in the latter group of patients (261). 
Following establishment of disease remission, second line treatments are commonly 
applied to prevent a subsequent relapse. Retaining a patient on EEN to prolong remission is 
impractical, if not unethical, and therefore a few studies tested the efficacy of supplementary 
nutritional support to maintain clinical remission and tackle a subsequent clinical flare up. In a 
Japanese adult study (304), adult patients who received half their total energy requirements 
as elemental diet and the remaining half by normal diet had a significantly lower relapse rate 
(34.6%) than patients who received unrestricted normal diet (64%) (OR: 0.4 [95% CI 0.16 to 
0.98]). Similar results were presented recently by Yamamoto (305;306) and Verma (307;308) 
in two adult Japanese and two adult British studies respectively. In the Japanese studies   75 
supplementary  EN  in  parallel  with  a  low  fat  diet  prolonged  disease  remission,  prevented 
increase  in  mucosal  inflammation  and  inflammatory  markers  (306)  and  prevented  post-
surgical  clinical  recurrence  compared  with  an  unsupplemented  group  of  patients  (305). 
Likewise partial supplementation of an unrestricted diet was more likely to prolong remission 
(307)  compared  with  an  unsupplemented  control  group,  and  moreover  gradually  tapered 
steroid usage in British patients with steroid dependent disease (308).  
 
1.5.1.4.  Exclusive  vs  partial  nutritional  therapy  in  induction  of  disease 
remission 
The origin of the exclusivity aspect of EN treatment is unknown and is possibly based on a 
putative mechanism of action through bowel rest. This theoretical concept was only recently 
tested  in  a  randomized  controlled  trial  of  50  paediatric  patients  with  active  CD  who 
responded better on an exclusive course of nutritional therapy than to a partial regime (50% 
of dietary intake) in conjunction with free diet (260). The EEN group had a remission rate of 
42%, which was significantly higher than that of 15% observed in the partial EN group.      
 
1.5.2. Nutritional therapy and mechanisms of action in CD 
Although there is extensive clinical experience and literature supporting the use of nutritional 
therapy in CD, the mechanisms of action and ideal formulation remain unknown and are still 
under investigation. There is still much debate about putative mechanisms of action mainly 
because the gut is a difficult organ to study directly. Therefore most of the evidence derives 
from in-vitro models and other surrogate indices of intestinal events that may not always 
represent events occurring at the mucosal site. Some of these hypothetical mechanisms are 
presented in Table 1.5.2 and are discussed below in detail.  
 
Table 1.5.2: Proposed mechanisms of induction of remission with EEN in active CD 
Bowel rest  Low antigenic 
load 
Anti-inflammatory 
effect 
Mucosal trophic 
effect  Nutritional effect 
Reduces 
intestinal 
secretions 
Low in microbial 
antigens 
Reduction in systemic 
markers of 
inflammation 
Improves intestinal 
permeability 
Improves energy/protein 
status 
Reduces gut 
motility 
Low in dietary 
antigens/allergens 
Direct mucosal anti-
inflammatory effect 
Accelerates 
intestinal healing 
Replenishes micronutrient 
deficiencies 
 
1.5.2.1. Effect of nutritional therapy on inflammatory markers 
In  parallel  with  the  resolution  of  clinical  GI  symptoms  (stool  frequency,  abdominal  pain, 
perirectal  bleeding),  systemic  inflammatory  markers  improve  and  return  to  normal  levels 
within a few days of treatment with EEN (267). Several studies have shown that the clinical   76 
activity response to EEN coincides with reduction in ESR, circulating CRP and other pro-
inflammatory cytokines (Table 1.5.1).  
Although  the  fall  of  systemic  inflammatory  markers  is  essentially  a  secondary 
response  to  GI  inflammation  and  disease  improvement,  there  is  now  strong  evidence  to 
suggest direct anti-inflammatory and immunomodulatory properties of EEN at the mucosal 
level (275;309) such as downregulation of mucosal proinflammatory cytokine mRNA (IL-1, 
IFN-γ, IL-8) in both terminal ileum and colon of paediatric patients with CD. Indeed these 
changes  coincided  with  improvement  in  clinical  activity,  mucosal  healing  and  circulating 
inflammatory markers (ESR, TNF-α, CRP) (90). Meister et al (310) in an in vitro experiment 
observed  that  incubation  of  mucosal  biopsies  from  adult  CD  patients  with  elemental  diet 
resulted  in  an  increase  in  the  ratio  of  anti-inflammatory/pro-inflammatory  cytokines  (IL-1 
receptor antagonist/IL-1β). However incubation of biopsies from UC patients with elemental 
feeds did not improve the anti-inflammatory/pro-inflammatory ratio, in accordance with the 
lack  of  clinical  effectiveness  of  nutritional  therapy  to  suppress  inflammation  and  induce 
remission in patients with active UC. Likewise Yamamoto showed return of mucosal pro-
inflammatory cytokines (IL-1β, IL-1ra, IL-6, IL-8, TNF-a) to normal healthy levels in Japanese 
adult patients with active CD at the end of EEN (309), and prevention of increase in patients 
on long-term nutritional support (306). In fact the endoscopic and histologic improvement in 
the first of these studies was associated with a parallel decline of the mucosal cytokines and 
an increase of the IL-1ra/IL-1β ratio (309).    
As  assessing  mucosal  inflammation  with  blood  markers  may  not  be  sensitive  or 
specific to intestinal inflammation, and repeat endoscopies are impractical, expensive and 
require general anaesthesia in children, surrogate indices of local intestinal inflammation are 
required particularly for routine monitoring of disease activity. Nowadays new faecal markers 
of  intestinal  inflammation  have  recently  become  available  that  allow  assessment  of  the 
disease at the site of presentation. Calprotectin and lactoferrin are two potential candidate 
markers with excellent diagnostic value to differentiate between intestinal inflammation and 
other functional digestive disorders (311). Both are non-invasive, cheap and could offer a 
suitable means to monitor intestinal inflammation and response to treatment. No study has 
yet assessed changes of these markers during nutritional therapy. On the contrary a study of 
the  use  of  steroids  in  active  CD  failed  to  find  changes  in  calprotectin  levels  despite 
improvement  in  clinical  activity,  suggesting  that  steroids  offer  symptomatic  relief  without 
however resolving intestinal inflammation and achieving mucosal healing (312).  The effect of 
EEN on calprotectin is investigated in Chapter 6. 
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1.5.2.2.  Effect  of  nutritional  therapy  on  endoscopic,  histological 
improvement and mucosal healing   
There is a growing view that healing of the intestinal mucosa in IBD patients should be the 
principal therapeutic objective because only agents promoting mucosal healing may modify 
the longterm course of the disease. The primary objective of nutritional therapy is to induce 
clinical remission with minimal side effects. Because the inflammatory process is located in 
the  intestinal  mucosa,  clinical  remission  should  ideally  be  associated  with  a  reduction  of 
mucosal  inflammation  and  mucosal  healing.  Various  paediatric  (90;264;276)  and  adult 
studies (300;309) have shown that mucosal healing is achieved with EEN more often than 
treatment with steroids whereas endoscopic and histological lesions repair does not coincide 
with clinical improvement when using steroids (259;261;275;313;314). A recent Italian study 
(259) showed improvement in endoscopic and histological findings at the end of treatment 
only in the group of patients on EEN. The proportion of children showing mucosal healing 
was significantly higher in the EEN (14/19) than the steroid group (6/18). Failure to achieve 
mucosal healing on steroid treatment might account for the higher relapse rate observed 
compared with a EEN treated control group of children, in another recent Italian study (261). 
Similar results were presented by Yamamoto et al (309) in adult patients with CD. Endocopic 
healing  and  improvement  rates  were  40%  and  77%  whereas  histological  healing  and 
improvement  were  20%  and  55%  for  steroids  versus  EEN  respectively.  The  authors 
speculated that clinical remission occurs first, preceding endoscopic improvement, whereas 
histological improvement takes place last.     
 
1.5.2.3. Effect of nutritional therapy on intestinal permeability 
In active CD, intestinal permeability is increased and its extent is positively associated with 
disease activity (315) and is a strong predictor of clinical relapse (316). Impaired intestinal 
barrier  function  may  facilitate  contact  of  mucosal  immune-competent  cells  with  antigenic 
substances from food and bacterial products from the host’s intestinal flora activating the 
mucosal immune system. Some studies have shown that improvement in clinical disease 
activity coincides with reduction in intestinal permeability (283;317;318).   
 
1.5.2.4. Nutritional therapy and antigenic effect 
The initial speculation that the effectiveness of nutritional therapy in CD is due to a reduced 
antigenic load in the elemental feeds compared to the whole protein was revised in light of 
evidence suggesting no difference in the clinical efficacy of polymeric, semi-elemental and 
elemental  feeds  (300;302;319;320).  This  was  recently  reconfirmed  by  a  Cochrane  meta-
analysis in adult studies (289). Similarly in children a recent retrospective analysis of case   78 
series  (261)  and  a  randomized  multicenter  controlled  trial  (266)  found  no  difference  in 
disease activity improvement and remission rate between polymeric and elemental feeds. 
Remission rates were 69% on elemental diet compared to 82% in the polymeric feeding 
group.  
 
1.5.2.5. Nutritional therapy and gut rest  
One of the first indications and proposed modes of action of EEN in CD was the property of 
being  liquid  and  readily  absorbable  in  the  proximal  part  of  the  GI  tract,  minimizing 
participation of the digestive system in the chemical and mechanical process of digestion and 
absorption  of  the  nutrients.  This  was  postulated  to  provide  a  degree  of  bowel  rest  and 
subsequently to accelerate healing in the already traumatized intestinal mucosa. However 
subsequent  evidence  (321;322)  and  a  key  study  by  Greenberg  et  al  (323)  found  no 
difference  in  clinical  remission  between  patients  treated  with  TPN  and  bowel  rest,  a 
polymeric enteral feed, or peripheral nutrition with oral diet. This demonstrated that bowel 
rest  was  not  the  mechanism  responsible  for  diet-induced  remission  in  CD.  Indeed,  as 
colonocytes  depend  on  exogenous  nutrient  provision  through  the  diet,  there  are  valid 
reasons to recommend the addition of fibre, and prebiotics in nutritional therapy feeds as 
these  could  promote  intestinal  health  either  by  producing  SCFA  or  by  modulating  an 
imbalanced commensal intestinal flora, towards an optimal healthier one (324).   
 
1.5.2.6. Amount and type of fat 
Long  chain  fatty  acids  may  modulate  eicosanoid  synthesis  and  other  immunomodulatory 
mechanisms  thereby  influencing  disease  outcome.  It  was  therefore  speculated  that  the 
amount and type of fat may be a determinant of the efficacy of EEN. In particular, ingestion 
of ω-3 fatty acids might suppress mucosal inflammation whereas ingestion of ω-6 fatty acids 
might  stimulate  the  inflammatory  cascade  (325).  A  few  studies  compared  nutritional 
formulations  of  different  types  and  amounts  of  fat  without  however  clear-cut  results 
(261;320;326). The topic was recently reviewed by Zachos et al (289) in a Cochrane review 
that included only RCTs, which concluded that there is no evidence to suggest a difference in 
the efficacy to induce disease remission between low and high fat EEN. Moreover the equal 
therapeutic effect of polymeric and elemental feeds with high and low concentration of fat 
respectively, suggests a mechanism of action independent of the fat content in the feeds 
(319;320;327).  On the other hand the type of fat may be a clue to the efficacy of EEN. 
Bamba et al  observed decreased rates of remission with increasing amount of ώ-6 fatty 
acids  in  the  elemental  feeds.  In  contrast,  a  well  designed  double  blind  RCT  European   79 
multicenter  study  had  to  stop  early  because  of  low  remission  rates  achieved  in  the  low 
linolenic/high oleic compared with the high linolenic/low oleic formula (328). 
 
1.5.2.7. Other aspects of nutritional therapy in the management of active 
CD 
Nutritional therapy efficacy and disease location 
At the moment there is limited data to suggest a better efficacy of nutritional therapies in CD 
patients with a specific disease phenotype (289;303) despite scarce evidence suggesting 
that patients with small bowel involvement respond better to EEN (329). A recent paediatric 
study showed that children with active CD do not respond well to EEN when the ileum is not 
involved    although  these  results  were  not  replicated  by  a  Italian  paediatric  (259)  and  a 
Japanese adult study (309). Indeed there are case reports that EEN was even beneficial in 
orofacial presentation of CD (268). 
As far as maintenance of disease remission is concerned, Teahon et al (303) in a 
retrospective analysis of more than 100 case series found that adult patients with isolated 
ileal and small bowel disease were more likely to remain in long-term remission compared 
with  patients  with  colonic,  or  ileocolonic  disease  after  induction  of  clinical  remission  with 
nutritional therapy. Similarly Gavin et al (262) in a paediatric retrospective study, found that 
patients  with  colonic  disease  tended  to  relapse  earlier  despite  no  obvious  effect  of  the 
disease phenotype on induction of clinical remission with EEN.  
  
Effect  on  nutritional  therapy  on  disease  activity  in  new  and  longstanding 
disease 
Whether new patients respond better to EEN than those with long-standing disease, is quite 
controversial. Some studies showed that newly diagnosed patients are more able to respond 
to EEN than patients with long-standing disease (329) whereas others found no difference 
(266;330). 
 
1.5.2.8. Effect of EN on nutritional status 
1.5.2.8.1. Effect of nutritional therapy on weight and body composition in IBD 
Regardless of whether EEN therapy is equal to or slightly inferior to steroids in inducing 
remission,  its  use  is  advocated  by  its  nutrition  promoting  properties  contrary  to  the 
detrimental side effects of long-term steroid usage on growth, body composition, bone health 
and body image. Improvement of the patients’ protein-energy nutritional status has always 
been considered as one of the mechanisms of EEN action, although recent studies have   80 
shown  that  anti-inflammatory  properties  preceded  any  changes  in  nutritional  status 
(267;331). Moreover no difference in remission rates was found between malnourished and 
normal nourished adult CD patients on treatment with EEN. 
In  both  adult  (292;300;301;320)  and  paediatric  studies  (Table  1.5.1)  nutritional 
therapy is accompanied by significant improvement of pre-treatment anthropometry. Weight 
gain accompanies disease improvement (276) and is component of the PCDAI and other 
disease activity indices (332). 
A few authors have also used body composition techniques to assess changes in fat 
and lean mass during nutritional therapy in adults (300;301) and paediatric patients (Table 
1.5.1). Improvement in surrogate measures of body composition, like skinfolds thickness and 
upper arm circumference, were commonly reported by some (260;267;272;281;287;288) but 
not  all  the  studies  (271;279).  However  none  of  these  studies  appropriately 
expressed/converted  raw  measurements  of  body  composition  to  age  and  sex  reference 
standardized values, as z-scores, and therefore contradictory results could be attributed to 
differences in the age and gender characteristics between the comparison groups.  
Two paediatric studies assessed changes in the body composition of children with 
CD undergoing treatment with nutritional therapy. Khoshoo et al (272) used bioimpedance 
and  skinfold  measurements  to  assess  changes  in  body  composition  in  adolescents  with 
active  CD  on  treatment  with  EEN.  Although  their  results  may  have  been  flawed  by  the 
concomitant  use  of  steroids,  they  observed  significant  improvement  in FFM  assessed  by 
both methods. In the second study Azcue et al (104) using highly sophisticated techniques 
(isotope  dilution,  extracellular  bromide  dilution,  bioimpedance,  total  body  potassium) 
assessed body composition changes and body fluid distribution and observed increments in 
all  body  compartments  after  treatment  with  EEN.  Noteworthy  differences  in  fat  and  lean 
mass  accretion  were  observed  between  patients  on  EEN  and  corticosteroids.  Steroid 
patients tended to accumulate more fat whereas intracellular water and lean mass accretion 
were significantly higher in the EEN group. This observation coincides with recent evidence 
that  EN  promotes  protein  anabolism  by  suppressing  proteolysis,  and  increasing  protein 
synthesis  in  adolescents  with  CD  in  remission  (333),  an  effect  that  contrasts  to  the 
documented catabolic effects of steroids. 
 
1.5.2.8.2. Effect of nutritional therapy on growth in CD 
Linear growth retardation is commonly seen in children with IBD, predominantly CD (Section 
1.3.3).  Both  suboptimal  dietary  intake  and  an  inhibitory  effect  of  inflammatory  response 
cytokines are implicated (334). Substantial evidence suggests that nutritional therapy, both 
elemental and polymeric formulation, has growth-promoting effects (297). Nutritional therapy 
either  exclusively  (271;276),  supplementary  (273;280)  or  with  intermittent  course   81 
administration  (279)  improved  height  velocity  (271;276;278)  and  accelerated  linear 
development in growth retarded children (280;281;288). This is an important advantage over 
the use of steroids and their well-documented growth inhibiting effects. In particular growth 
velocity improved in patients on EEN but remained unchanged (282) or improved to a lesser 
extent in patients on steroids (261;271;274). 
The exact mechanism of the growth promoting effect of nutritional therapy is unknown 
and is speculated to be due to a composite effect from both nutritional replenishment and 
reversal of the inhibitory effect of inflammatory cytokines on growth hormonal mediators of 
growth like IGF-1 (267;271;278;279). It is noteworthy that a recent small study observed that 
the growth promoting effects of EEN preceded nutritional rehabilitation (267). 
 
1.5.2.8.3. Effect on nutritional therapy on micronutrient status 
Although a recent study showed that disease improvement precedes nutritional rehabilitation 
and may suggest that nutrition rehabilitation is not implicated as a mechanism of action of 
EEN, the authors of this study assessed only indices of energy-protein status (267). Whether 
disease improvement is a direct effect of improvement and replenishment of micronutrient 
status from EEN has not been investigated. Micronutrients play a vital role in metabolism, 
antioxidant status and the integrity of the colonic epithelium. Reactive oxygen species exhibit 
deleterious effects on epithelial cells in CD and studies have shown  decreased levels of 
antioxidant enzymes and vitamins in the intestinal mucosa and in the plasma of patients with 
CD (Section 1.3.6). Replenishment of micronutrient status during EEN is one of the possible 
modes of action mediating the efficacy of EEN in CD where micronutrient deficiencies and 
malnutrition are common as opposed to its inefficacy in UC were deficiencies in minerals and 
vitamins are unusual.  
Moreover,  there  are  additional  reasons  why  replenishment  of micronutrient  in  EEN  is 
important.  Conventional  EEN  regimes,  intended  for  use  in  active  CD,  provide  age  and 
gender  specific  energy  requirements,  as  reflected  by  the  increase  in  body  weight  and 
anabolic effects, but there is no evidence to ensure that the micronutrient content of these 
feeds is adequate to replenish deficiencies or supply the essential requirements of these 
patients. The dietary adequacy of micronutrients in these feeds has been ascribed to the 
provision of national reference daily intakes, originally established to cover the needs of the 
healthy  population,  but  whether  the  same  requirements  apply  to  patients  with  CD  is 
questionable. A study (335) 20 years ago failed to show improvement of vitamin status of 
IBD adults on EEN despite provision of higher amounts of micronutrients than the RDA.  
Moreover EEN feeds are “artificial food” made of composite simple food ingredients and 
nutrients for which recommended allowances have been established and therefore may lack   82 
‘non-nutrient compounds’ that occur naturally in food (e.g. polypenols), ave important role in 
the human health, but whose supplementation in artificial feeds is uncommon.  
An extensive literature search was carried out by the researcher in 2004 and updated in 
2008 to review all studies on the effect of EEN therapy on blood micronutrient status in IBD 
patients. Studies using total parenteral nutrition were excluded. Overall seven studies were 
retrieved. The studies were heterogeneous in design, subject characteristics, duration or type 
of  feeds  used,  and  the  mode  of  nutritional  support  (Table  1.5.3).  Four  studies  were 
conducted in CD adults, whereas two included UC patients. All but one study used EEN. One 
used partial supplementation of normal diet. The duration of nutritional therapy varied from 
12 days to one year. Only one adult study including UC patients assessed a wide range of 
micronutrients. The rest assessed a limited number of micronutrients, focusing mainly on 
antioxidant trace elements and vitamins. Some studies assessed changes of the enzymatic 
antioxidant systems and one study measured changes in oxidative stress (Table 1.5.3).  
The results were inconsistent and no overall conclusions could be drawn. Nutrients 
like Se increased in some studies but decreased in others (Table 1.5.3). Similar results were 
found for other nutrients like vitamin A. The use of different feed formulae and duration of 
administration among studies could explain some of these differences. No study in children 
as  investigated  changes  in  a  wide  range  of  vitamins. Thomas  et  al  (183)  assessed  only 
changes in Se, whereas Akobeng et al (336) studied additionally vitamins A, E and C. 
The as yet limited evidence does not support a mechanism for the therapeutic action 
of EEN that is mediated by micronutrient replenishment. Phylactos et al (148) showed that 
paediatric  CD  is  characterized  by  reduced  activity  of  enzymatic  antioxidant  systems  in 
erythrocytes,  but  this  did  not  improve  with  eight  weeks  treatment  with  EEN  despite 
improvement in disease activity and systemic markers of inflammation (CRP and TNF-α). 
Although these results imply that the anti-inflammatory action of EEN in CD is caused by 
some  mechanism  other  than  restitution  of  specific  antioxidants  it  still  remains  to  be 
addressed whether disease improvement is associated with changes in other micronutrients.  
Akobeng  et  al    (336)  did  not  find  significant  changes  in  the  antioxidant  mechanisms  or 
markers of oxidative stress of children with CD on four weeks of EEN. However the authors 
did not report changes of clinical activity or inflammatory markers and association. 
There is limited evidence to suggest any micronutrient changes during therapy with 
EEN  and  how  these  correlate  with  the  disease  activity  and  inflammatory  markers. 
Extrapolation of the results from adult studies to paediatric patients is inappropriate given the 
differences  in  the  nutrient  requirements  between  adults  and  children.  The  most 
comprehensive study in children included only four antioxidant nutrients and the duration of 
the  EEN  course  was  limited  to  one  month.  The  recommended  duration  of  EEN  is  now 
between six to eight weeks and different results might be expected. More evidence is needed   83 
as to whether EEN fully meets the nutritional needs of children with CD and whether or not it 
replenishes any deficiencies. Failure of EEN to cover the nutritional needs of children with 
CD will have implications for both the feed manufacturers and clinical practice.  
Changes in micronutrient status with EEN and correlation with disease activity need 
to  be  further  studied  although  the  interpretation  of  the results  is  difficult  as  other factors 
beyond nutritional status and actual nutrient stores can affect serum circulating levels. As 
discussed in Section 1.3.6 the acute phase response during inflammation can affect serum 
nutrient circulating levels irrespective of body stores and therefore measurements in other 
tissues or cells might be more appropriate measures of body micronutrient status (179). The 
effect of EEN on micronutrient status in investigated in Chapter 5   84 
 
 
 
 
 
 
Table 1.5.3: Studies on the effect of EN therapy on the systemic micronutrient status in adult and paediatric IBD. 
Study  Subjects   Nutritional therapy  Micronutrient  Micronutrient change 
ADULT STUDIES 
Johtatsu et al 2007 (337)  8 CD  Partial  EN;  1y;  Elental 
low in Se and Zn 
Se,  Zn,  Cu.  Serum 
selenoprotein, GSHPx 
Se  and  Zn  depleted;  Improved  by 
supplementation with Se and Zn 
Abad-Lacruz  et  al  1988 
(335)  
8 malnourished IBD  EEN; 12-28 d   Vit  A,  β-carotene,  Vit  E, 
Tocopherol:Cholesterol, 
B1,  B2,  B6,  B12,  Folate, 
Biotin, Vit C 
Folate,  biotin,  b-carotene,  vit  C, 
tocopherol/chol  unchanged;  B1,  B2 
decreased; vit A and E increased 
Teahon et al 1995 (331)  19 CD   EEN  5  wk;  E028  & 
Vivonex 
Fe, Mg, Cu, Zn    Fe increased, Cu decreased 
Fernandez-Banares  et  al 
1990 (294) 
7 malnourished IBD  EEN; 20 d  Zn, Se, Cu  Zn,  Cu  did  not  improve,  Cu:Zn  ratio 
decreased; Se increased 
PAEDIATRIC STUDIES 
Akobeng et al 2007 (336)   15 CD  EEN;  4  wk;  2  formulas 
with  different  glutamine 
content 
Vit  A,  Vit  E,  Vit  C; 
Malondialdehyde,  Se, 
urate, glutathione 
Se improved; Vit E and Vit C reduced; No 
effect on Vit A, glutathione, urate, MHA  
Phylactos et al 2001 (148)  14 CD  EEN;  8  wk;  Nestle 
(CT3211) 
Antioxidants  enzymatic 
system  (Se-GPx,  Cu/Zn-
SOD) 
No change 
Thomas et al 1994 (183)  11 CD  EEN E028  Se, GSHPx  Se decreased; Se increased on the steroid 
group 
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1.6. Intestinal microbiota in IBD  
1.6.1. Introduction to human intestinal microbiota 
It has been known from early in the history of microbiology that the gut of people and other 
animals is inhabited by microbial species, mostly bacteria. Louis Pasteur first expressed his 
views  to  the  French  Academy  of  Sciences  in  1885  on  the  importance  of  bacteria  in  the 
digestion of food believing that life in the absence of microbes would be impossible (338). 
Many species of bacteria have evolved and adapted to live and grow in the human 
gut. The human intestinal habitat contains 300–1000 different species of bacteria, and the 
number of microbial cells within the large bowel lumen is tenfold the number of eukaryotic 
cells in the human body (339). The stomach and small intestine contain only a few species of 
bacteria adhering to the epithelia and some other bacteria in transit. The scarcity of bacteria 
in the upper tract seems to be primarily because of the composition of the luminal milieu 
(acid, bile, pancreatic secretion), which kills most ingested microorganisms, and secondly 
due to the propulsive GI motor activity towards the ileum. In contrast, the large intestine 
contains a complex and dynamic microbial ecosystem with high densities of living bacteria 
(around 60% of faecal mass), which achieve concentrations of up to 10
11 or 10
12 cells/g of 
luminal contents  (340).  
Members of nine bacterial phyla were found to inhabit the human GI tract of which 
Firmicutes, Bacteroidetes, and Actinobacteria are dominant. Members of Proteobacteria are 
also common and diverse, but they are usually secondary to the above (Fig 2).  Anaerobic 
bacteria outnumber aerobic bacteria by a factor of 100-1000 (339). The genera bacteroides, 
bifidobacterium,  eubacterium,  clostridium,  peptococcus,  peptostreptococcus,  and 
ruminococcus are predominant in the human gut, whereas facultative anaerobes such as 
escherichia, enterobacter, enterococcus, klebsiella, lactobacillus, and proteus are among the 
subdominant  genera.  Although  the  human  gut  harbors  several  hundreds  of  species 
belonging to common genera, within individuals an idiosyncratic  combination of predominant 
species is present (341).  
Many  factors  determine  the  microbial  composition  of  the  intestinal  milieu  (Fig  3). 
Colonization of the human GI tract starts immediately after birth and occurs within a few days 
of life. Mode of delivery and feeding method are early determinants of bacterial colonization 
(342). Although stable throughout adulthood the composition of the individual’s flora changes 
in  old  age  (343)  and  can  also  fluctuate  due  to  circumstances,  for  instance  in  antibiotic 
treatment (344), or after dietary intervention with probiotics or fibre administration (345). Host 
genotype is also a determinant of gut microbiota diversity with a higher degree of bacterial 
similarity  existing  between  relatives,  particularly  twins,  than  between  people  who  are  not 
related but live in the same environment (318).    86 
The  characterization  of  intestinal  microbiota  in  vivo,  and  its  spatial  distribution  is 
limited by restrictions in the accessibility of the GI tract. Thus most of our knowledge on 
intestinal  microbiota  composition  and  function  comes  from  analysis  of  colonic  luminal 
material, mainly faeces.  Although faecal samples are easy to obtain, they represent only an 
approximate representation of the intestinal microbial environment, and metabolic activity, 
mainly that of the rectosigmoid region, which differs considerably from the microbiota in other 
segments of the GI tract (Fig 4) (346).  Marteau collected caecal and faecal samples from 
healthy  adults  and  found  that  the  caecum  harbored  100  times  fewer  anaerobes  and 
facultative anaerobes represented a substantial fraction compared with the faecal microbiota 
(346). Faecal microbiota differs considerably from the bacteria adherent to the mucosa lining 
(347) and considerable research is now undertaken on the importance of the latter and its 
interaction with the intestinal epithelium in health and disease (348).  
 
Figure  2: Small subunit rRNA-based phylogenetic tree of the distinct phylotypes that have 
been found in the human GI tract (adapted from Rajilic-Stojanovic et al 2007 (349))  
 
 
The  relative  proportion  of 
phylotypes that correspond to 
cultured  representatives  is 
indicated  by  different 
darkness  of  filling.  Black  fills 
indicate  phylotypes  detected 
in  cultivation  independent 
studies, while white indicates 
species  detected  in 
cultivation-base  studies.  The 
reference  bar  indicates  10% 
sequence  divergence. 
Numbers  of  distinct 
phylotypes are given for each 
phylogenetic group.    87 
 
Figure 3: Determinants of intestinal microbiota diversity and metabolic activity 
 
  
 
Figure 4: Regional differences in large bowel function in the human (adapted from Cummings 
1997 (350))  
 
 
 
 
1.6.2. Methods for characterization of the intestinal microbiota 
Much of our knowledge on the composition of the human gut microbiota is derived from 
bacteriological  analyses  that  used  traditional  techniques  of  cultures  on  growth  media, 
microscopy,  and  the  determination  of  the  fermentation  properties  and  other  biochemical 
specificities of bacterial isolates (340). Although these techniques are still useful in research 
and in clinical practice they are unable to culture all bacteria even under the most robust 
techniques and conditions (338). Even in the 1970 researchers had observed that the total 
counts  of  bacteria  measured  in  faecal  smears  were  higher  than  the  total  viable  colony-
forming units obtained by traditional culture methods on growth media. A recent approximate 
Gut Microbiota  Gastrointestinal disease 
Diet  Genes 
Gut motility 
Delivery and mode of setting 
Age 
Antibiotics & drugs 
Left Side 
• Protein rich 
• Low moisture 
• SCFAs low 
• Residence 12-36 h 
• pH neutral 
• Slow bacterial growth 
• Main gases H2 & CO2 & CH4 
• Ammonia, phenols 
Right Side 
• Carbohydrate rich 
• High moisture 
• SCFAs rich 
• Residence 6-16 h  
• pH acidic 
• High bacterial growth 
• Main gases H2 & CO2   88 
estimate is that 60% to 80% of the bacteria in the digestive tract remain uncultured with 
conventional microbiology techniques.  
This  problem  was  overcome  in  the  last  decade  by  the  emergence  of  molecular 
bacteriology techniques (351). Use of culture independent analytical approaches that utilize 
information from bacterial genetic material were the way forward. These techniques utilise 
the small subunit RNA (16S rRNA most commonly in the case of bacteria) that contains 
regions of nucleotide base sequence that are highly conserved and are interspersed with 
hypervariable regions, known as V regions. These regions contain signatures of phylogenetic 
groups  even  species  and  allow  the  characterization  of  bacteria  from  division,  down  to 
species level (338).  
The  combination  of  polymerase  chain  reaction  (PCR)  with  denaturating  or 
temperature gradient gel electrophoresis (TGGE) is a relatively new approach to monitor the 
diversity of complex bacterial ecosystems (352;353) and was firstly used by Zoetendal (341) 
for colonic contents. Bacterial DNA is extracted from the faecal sample and a variable region 
of the 16S rRNA gene is amplified by PCR from the DNA. The PCR product obtained from a 
sample contains 16S fragments of the same size but different sequence from all bacterial 
types present in that sample. Thereafter the various types are separated from each other by 
gel electrophoresis. The double stranded 16S fragments migrate through a polyacrylamide 
gel of homogenous consistency or containing a gradient of urea and formamide until they are 
partially denaturated by the temperature of the running buffer or the chemical conditions of 
the gel. Because of the variation in the 16S sequences of the different bacterial species, 
“DNA melting temperatures” are also different and therefore the different 16S species will 
stop “running” at different points across the gel. The separation of 16S fragments produces a 
profile  of  the  dominant  bacterial  community  “fingerprint”  in  which  each  bacterium  is 
represented by a single band (352;353).  
Another  robust  method  to  explore  the  intestinal  microbiota  is  fluorescent  in  situ 
hybridization (FISH). Oligonucleotide probes, labeled with fluorescent dyes target 16S rRNA 
sequences inside the bacterial cells. Although an array of different specific probes can be 
used to recognize from single strains up to whole bacterial groups the use of large numbers 
of probes is impractical and the technique is restricted to the identification of bacteria for 
which  specific  probes  exist.  The  method  is  best  for  enumeration  of  the  numerically 
predominant  members  of  the  microbiota  with  a  detection  limit  of  10
6  cells  per  g.  A  big 
advantage of this method is that bacteria can be detected in situ, which allows determination 
of the spatial organization of communities in the gut (354). 
As a detailed description of other molecular techniques of probing the gut microbiota 
is  beyond  the  scope  of  this  thesis  the  reader  is  referred  to  relevant  review  articles 
(340;355;356).   89 
1.6.3. Intestinal microbiota in health and disease 
This abundant endogenous microbial load plays an important role in the homeostasis of the 
colon  and  the  health  of  the  host.  Evidence  from  a  plethora  of  studies,  showed  that  this 
“neglected  organ”  exerts  important  metabolic,  trophic  and  protective  functions  under  a 
continual  “cross-talk”  between  the  commensal  bacteria  and  intestinal  epithelial  cells 
(339;357;358) (Table 1.6.1). 
The  tremendous  impact  of  indigenous  luminal  flora  on  the  development  and 
maturation of gut homeostasis is clearly illustrated by comparative studies of germ-free and 
conventionalized  animals.  Studies  in  gnotobiotic  animals  have  shown  that  experimentally 
colonizing the intestine of germ-free rodents with single species selected from the indigenous 
flora has profound impact on the anatomical, physiological, and immunological development 
of the host, including effects on the epithelial cell functions and the composition of the gut-
associated lymphoid tissue (357).  
On the other hand some commensal bacteria can be opportunistic pathogens and a 
source  of  infection  and  sepsis  under  certain  circumstances,  as  when  the  gut  barrier  is 
physically or functionally breached or when the bacterial profile is disturbed by the use of 
broad-spectrum  antibiotics  (359).  Similarly  a  breakdown  of  tolerance  to  the  indigenous 
microbiota  is  thought  to  be  the  key  step  in  the  development  of  intestinal  inflammatory 
disorders like CD and UC. This is presented in detail in the Section 1.7.2.3.4. 
Much current research aims to improve or sustain colonic health by modulating the 
profile and the metabolic activity of gut microbiota to a “healthier pattern” with the use of live 
beneficial food grade bacteria (probiotics) and the ingestion of food non-nutrient compounds 
that  promote  the  growth  and  metabolic  activity  or  the  beneficial  indigenous  microbiota 
(prebiotics) (345). 
 
Table 1.6.1: Main functions of commensal intestinal microbiota in health (adapted from O’Hara 
& Shahanan (360)) 
Protective functions  Structural functions  Metabolic functions 
Pathogen displacement  Barrier fortification  Salvage of energy 
Nutrient competition with 
pathogens 
Epithelial cells differentiation and 
proliferation 
Ion absorption and promotion 
of water absorption 
Receptor competition with 
pathogens 
Apical tightening of tight junctions  Vitamin K, folate, biotin 
production 
Production of antimicrobial 
factors 
Angiogenesis   Production of SCFA 
Immune system development    Production of harmful 
metabolites (NH3, H2S, amines) 
 
Perhaps the most interesting topic in GI physiology and microbiology is the delegate 
ability of the gut associated immune system (GALT) to interpret the intestinal ecosystem and   90 
to distinguish between episodic pathogens and commensal bacteria and whether or not to 
induce a subsequent immune response.  
The  epithelium  provides  the  first  line  of  defence  to  the  intestinal  luminal 
microenvironment and plays an important role in sampling of commensal bacteria, pathogens 
or  other  antigens.  Specialised  types  of  immunosensory  cells  located  at  the  intestinal 
epithelium are responsible and for the preservation of homeostasis or induction of immune 
response. Apart from the surface epithelial cells, M cells and dendritic cells have the ability to 
discriminate pathogenic from commensal bacteria in part, by using two major host pattern 
recognition  receptor  systems  the  family  of  Toll-like  receptors  and  the  nucleotide-binding 
oligomerization  domain/caspase  recruitment  domain  isoforms  (NOD/CARD)  (357;361). 
These receptors exert a fundamental role via immune-cell activation in response to specific 
microbial-associated  molecular  patterns  like  peptidoglycan,  lipotechoic  acids, 
lipopolysaccharide and flagellin. 
 
1.6.4. Main functions of intestinal microbiota 
How elephants grow and maintain their enormous body on an apparently poor diet consisting 
of leaves is noteworthy, particularly when they are actually monogastric and lack a rumen to 
maximise energy absorption.  The answer lies in the structure of the digestive tract and like 
in many other monogastric animals, they host a highly developed caecum and large intestine 
with an abundant microbiota that salvage what the digestive enzymes cannot digest in the 
upper GI tract (350). With more bacterial cells in the gut than eukaryotic cells in the human 
body the collective metabolic activity of the normal flora represents a virtual hidden organ 
that would rival the activity of the liver (362). 
 
1.6.4.1. Fermentation 
The major metabolic function of the colonic microbiota is the fermentation of food matrices 
that  escape  digestion  or  absorption  in  the  upper  digestive  tract,  along  with  endogenous 
mucus or sloughed epithelial cells. The substrate availability in the human colon is estimated 
to be 20-60 g of carbohydrates and 5-20 g of protein per day in healthy individuals (350). 
Fermentation  involves  a  variety  of  reactions  and  metabolic  processes  in  the  anaerobic 
microbial  milieu  of  the  GI  tract  yielding  metabolizable  energy  for  microbial  growth  and 
maintenance, and a variety of metabolic products for use by the host (363). The major end 
products of bacterial fermentation of carbohydrates in the large bowel are organic acids such 
as lactate, and short chain fatty acids (SCFA) together with hydrogen and carbon dioxide and 
methane. Protein fermentation also leads to SCFA, hydrogen and carbon dioxide. In addition 
branched chain fatty acids (BCFA) such as isobutyrate, isovalerate and 2-methylbutyrate are   91 
produced by the fermentation of the respective amino acids valine, leucine, and isoleucine. 
Ammonia, amines and phenols are also produced from protein fermentation (350). 
Fermentation is not the same throughout the large intestine (Fig 4) (364;365). In the 
caecum and right colon, fermentation is very intense with high production of SCFA, and a 
drop of the luminal pH to as low as 4.5 (364;365). In contrast as available substrate is limited 
in the distal colon fermentation of proteins occurs, with subsequent production of ammonia, 
branched chain amino acids and phenolic compounds, and increase of pH towards neutral. 
The average concentration of SCFA is as high as 70 to 140 mM in the proximal colon and 
falls to 20 to 70 mM in the distal colon (365;366). 
 
1.6.4.2. Short chain fatty acids 
Short chain fatty acids are organic fatty acids with a carbon chain of one to eight atoms. They 
are  the  primary  end  products  of  bacterial  fermentation  of  carbohydrates,  particularly 
indigestible polysaccharides and oligosaccharides, and to a lesser extent from proteins and 
amino  acids  (364;365).  The  predominant  SCFA  is  acetate  followed  by  propionate  and 
butyrate in a molar ratio of around 60:20:20 respectively in healthy people (364;365) but this 
may be modified by dietary intervention (350).   
SCFA  production  is  regulated  and  depends  on  a  number  of  factors  such  as  the 
amount and the type of microbiota and fermentable material present in the lumen, and the 
gut transit time (364;367). Different non-starch polysaccharides (fibre) yield different qualities 
and quantities of SCFA. For example resistant starch is more fermentable than oat bran or 
cellulose and produces more butyrate than pectin (366;368). Disease, mainly GI disorders, 
can also determine the qualitative and quantitative characteristics of SCFA production.  
The absorption of SCFA in the caecum and the colon is a very efficient process with 
only a small amount excreted in faeces (369). Passive diffusion of protonated SCFA and 
anion  Na
+/K
+  exchange  with  parallel  transport  of  water  are  two  major  mechanisms  of 
absorption.   Once absorbed, SCFA are metabolized at three major sites (369). 
1)  Colonic epithelial cells use butyrate and to a lesser extent propionate and acetate for 
energy production and maintenance 
2)  Liver cells metabolize propionate eg for gluconeogenesis and acetate for lipogenesis 
3)  Muscle cells and other tissues produce energy from the oxidation of residual acetate 
Acetate 
Acetate is the principal SCFA produced in the colon by fermentation. In humans acetate is 
not  metabolized  locally  at  the  colon  but  is  absorbed  and  transferred  in  the  circulation 
(369;370). Acetate is mainly a fuel source for the host and participates in the de novo lipid 
and cholesterol synthesis sparing fatty acid oxidation.    92 
Propionate 
Propionate, the second major fermentation product, is readily absorbed and taken up by the 
liver where it constitutes a precursor of glucose production in gluconeogenesis (364;371). It 
can  be  used  as  metabolic  fuel  by  colonocytes  but  with  less  efficiency  than  butyrate. 
Propionate may also be a mediator in the regulation of cholesterol synthesis most likely by 
inhibition of the cholesterol synthesis enzyme 3-hydroxy-3-methylglutaryl-CoA sythetase and 
reductase  (372).  A  few  studies  examining  the  use  of  propionate  supplementation  as  a 
potential cholesterol lowering agent gave contradictory results (373).   
Butyrate 
Butyrate has attracted the most attention. Compared with acetate and propionate, it is mostly 
taken up and used by the colonocytes although a small amount is absorbed and circulates in 
the  bloodstream.  Butyrate  is  the  preferred fuel  of  the  colonic  epithelial  cells  and  is  used 
preferentially  over  propionate  and  acetate  in  a  ratio  of  90:30:50  and  it  is  preferred  over 
glucose  or  glutamine  supplied  by  the  blood  stream  (374-376).  The  percentage  oxygen 
consumption attributable to butyrate, when this is the only colonic substrate, is around 70%. 
There is good evidence from animal models and in vitro experiments that butyrate has cell 
proliferative properties triggering differentiation in normal mucosa and in cancer cells induces 
growth arrest and apoptosis (377-379).    
 
1.6.4.2.1. Function of SCFA in health and disease 
The role of SCFA has been the topic of extensive research over the last 30 years. SCFA play 
an important role in the homeostasis and function of the large bowel (Table 1.6.2).  
 
Table 1.6.2: Biological role and health benefits of SCFA in human 
SCFA  Health benefits 
All SCFA  Absorption of Na, K, Ca and water (380) 
  Gut motility (381-383) 
  Energy fuel for gut epithelium (375;376) 
  Gut mucosa blood flow (384;385) 
  Inhibit growth of pathogens and formation of carcinogenic compounds 
Acetate  Energy substrate for the host 
  Substrate for lipogenesis 
Propionate  Substrate for gluconeogenesis 
  Cholesterol metabolism 
Butyrate   Gut epithelial proliferation and differentiation (386;387) 
  Trophic effect (388;389) 
  Induces apoptosis to cancinogenic cells (379)  
  Anti-inflammatory properties (390) 
 
Appraisal of the important biological role of SCFA in colonic health was the spark for 
scientists  to  investigate  SCFA  metabolism  and  production  as  determinants  of  the 
pathogenesis of several digestive disorders.    93 
Harig  et  al  (391)  proposed  that  diversion  colitis  was  secondary  to  a  nutritional 
deficiency of the colonic epithelium due to the absence of SCFA and Kiely et al  presented 
five cases studies of children with diversion colitis that improved in all cases with treatment 
on SCFA. However these results were not replicated (391) in a prospective double blind 
placebo control trial.  
It is suggested that dietary fibre will provide prophylaxis from colonic cancer although 
the  exact  mechanism  by  which  this  happens  is  unclear.  This  protective  effect  may  be 
mediated  by  the  production  of  SCFA  and  particularly  butyrate  (392).  Butyrate  exerts  two 
contradictory effects on normal host and cancer cells. It inhibits proliferation and stimulates 
differentiation on human cells lines whilst inducing apoptosis in carcinoma cells lines (379).   
However, increased concentrations of butyrate may have detrimental effects in some 
GI  conditions  and  this  has  been  implicated  in  the  mucosal  injury  seen  in  necrotizing 
enterocolitis (393;394). Data from preterm infants suggested that excessive production of 
butyrate during the third week of life may be involved  in the pathogenesis of necrotizing 
enterocolitis  commonly  seen  in  this  group  of  patients  (395).  Nevertheless  excessive 
concentrations  of  butyrate  may  be  an  indication  of  alterations  in  the  composition  of 
microbiota, rather than a cause of enterocolitis, as full term children produce predominantly 
acetate and lactate during the first weeks of life (396).  
In  a  recent  in-vitro  experiment  on  cancer  cell  lines,  butyrate  at  low  concentration 
promoted  intestinal  barrier  function  whereas  the  opposite  effect  was  observed  at  high 
concentrations (397).  The role of SCFA in IBD is discussed later in Section (1.7.1.1). 
 
1.6.4.3. Lactate 
Lactic  acid  is  another  product  of  fermentative  action  of  the  colonic  microbiota  on 
polysaccharides, predominately produced by lactobacilli and bifidobacteria, in the caecum 
(398). Lactate is found in D and L isomer form in the intestinal lumen and does not normally 
occur in high concentrations as it is further metabolized to other SCFA, mainly butyrate by 
colonic bacteria (399;400). D-lactate is produced solely by the colonic microbiota. L-lactate is 
also  produced  by  the  intestinal  epithelium  making  the  discrimination  of  origin  difficult  in 
colonic contents.  
Of particular interest is D-lactate as it has been implicated in clinical GI conditions 
involving short segments of small intestine, such in necrotizing enterocolitis, and short bowel 
syndrome  (398).  Delivery  of  unabsorbed carbohydrates  in  these  conditions  increases the 
colonic supply of fermentative material and subsequently increases production of lactic acid 
and SCFA. This lowers the colonic pH and favors the growth of acid-resistant lactic acid 
bacteria that further ferment sugars to lactic acid and further reduce pH. In fact a lowering of   94 
pH in acidic values although does not affect the production of lactate it inhibits its utilization 
by other lactate-utilizing bacteria (401). All these events subsequently result in the excessive 
accumulation  of  lactic  acid  in  the  colon  and  transmission  to  the  circulation  resulting  to 
acidemia and metabolic acidosis (398).   
In  addition,  similar  to  the  other  bacterial  metabolites  in  the  colon,  lactate 
concentration in the large intestine may depend on a balance between production, intestinal 
absorption, and utilization by the commensal microbiota.   
 
1.6.4.4. Other bacterial metabolites 
Anaerobic metabolism of peptides and proteins by the intestinal microbiota along with the 
production of SCFA, generates a series of other metabolites such as, ammonia, amines, 
phenols, thiols, methane, and sulphide. Although the exact role of these molecules is not fully 
understood, in vitro and animal studies have implicated them in the aetiology of GI disorders 
such as colonic cancer and IBD (Section 1.7.1).    
      
1.6.4.4.1. Hydrogen 
Hydrogen gas production is an integral part of bacterial fermentation and it is excreted in 
breath  and flatus. In  addition,  a  large  proportion  is  disposed  by  three  bacterial  reactions 
(350). 
1)  Methanogenic bacteria reduce CO2 to CH4 consuming H2 in this process 
2)  Sulphate reducing bacteria (SRB) and protein fermenting bacteria reduce sulphate 
and sulphur from amino acids to sulfide and hydrogen sulphide 
3)  Variable  amounts  of  hydrogen  are  also  consumed  by  acetogenic  bacteria  which 
reduce CO2 to acetic acid.  
 
1.6.4.4.2. Sulphide 
The large intestine harbours a class of gram-negative anaerobes that reduce sulphate and 
sulphites to sulphide. Sulphate reducing bacteria inhabit the distal colon and compete with 
methanogenic  bacteria  for  utilization  of  the  colonic  hydrogen  pool  (402;403).  Their 
predominant genus, Desulfovibrios, use gaseous hydrogen as an electron donor in sulphate 
reduction reactions and account for substantial deposit of hydrogen in the colon. Sulphide is 
also  produced  by  protein-fermenting  bacteria  via  the  metabolism  of  unabsorbed  sulphur 
containing  amino  acids.  Thus  dietary  protein  and  inorganic  sulphur  can  increase  faecal 
excretion of sulphide in human studies in a dose response fashion (404).  
Faecal sulphide concentrations represent a small amount of the actual production in 
the gut. Levitt et al (405) estimated that more than 95% of the produced sulphide leaves the   95 
colonic content and is absorbed by the mucosa. In the colonic lumen, sulphide occurs in two 
chemical forms; free as hydrogen sulphide, and bound to divalent metal ions (Fe, Cu, Zn). In 
healthy subjects bound sulphide constitutes about 75-95% of total sulphide and its metabolic 
toxicity, although unknown, is believed to be negligible (406).  
Sulphide’s  biological  role,  beyond  the  disposal  of  colonic  hydrogen,  is  not  well 
understood.  In  vitro  experiments  suggested  toxic  properties  and  inhibition  of  butyrate 
oxidation at the colonocyte (407) whereas recent evidence attributed potential beneficial anti-
inflammatory effects to sulphide in GI health (408). 
   
1.6.4.4.3. Ammonia 
Ammonia  is  produced  by  the  action  of  bacteria  on  dietary  peptides,  endogenous  cellular 
debris  and  intestinal  secretions  (409)  in  the  distal  colon,  particularly  in  the  absence  of 
fermentable fibre. Faecal ammonia may be associated with colon carcinogenesis, whereas 
excess  accumulation  in  the  circulation  in  liver  disease  is  responsible  for  hepatic 
encephalopathy in these disorders.   
 
1.6.4.4.4. Faecal pH 
Colonic pH is used as an index of bacterial activity and the colonic microenvironment, but it is 
also important for the delivery of pH controlled-release drugs (410). Inaccessibility of the 
digestive tract does not allow direct pH measurements at the different segments of the colon 
and therefore faecal samples are used as a rough estimate of the colonic conditions and 
metabolic activity although on the whole it better reflects  bacteria activity and conditions in 
the rectum.  
Most studies that measured pH values at the different parts of the digestive tract, in 
health and disease, are derived from gut autopsy of cadavers, or in vivo investigations with 
the  use  of  radiotelemetry  capsules  (411)  that  are  not  practical  for  routine  continuous 
surveillance. Measurements of luminal pH in the normal GI tract have shown a progressive 
increase from pH 6.6 at the jejunum to 7.5 at the terminal ileum, a decrease to pH 6.4 on 
passage to the caecum and then a further rise to pH 7 at the left colon (412).   96 
 
1.7. Intestinal microbiota in IBD 
The enormous bacterial concentration and its close contact to the GI mucosa, the largest 
surface of the body, equipped with a highly sophisticated gut associated lymphoid tissue 
(GALT) immune system has always been incriminated luminal bacteria in the pathogenesis 
of IBD. This in parallel with the lesson learned with the discovery of the role of Helicobacter 
pylori in peptic ulcer disease, gastritis and gastric cancer triggered a considerable amount of 
research into the interaction between the intestinal microbiota and the mucosal epithelium in 
the pathogenesis of IBD. In IBD the most widely held view is that the development of disease 
reflects an immune response to the normal microbiota, rather than to a pathogen. The exact 
mechanism remains unknown and may be multifactorial which could explain the different 
phenotypic  presentations  of  the  disease.  There  is  good  evidence  to  suggest  intestinal 
microbiota composition and its metabolic activity in the pathogenesis of IBD and perpetuation 
of  intestinal  injury.  The  following  section  (Section  1.7.1)  is  an  outline  of  the  evidence 
published thus far.  
 
1.7.1. Metabolic activity of intestinal microbiota in IBD 
1.7.1.1. Short chain fatty acids and IBD 
A  considerable  amount  of  research  has  been  undertaken  on  the  metabolic  activity  of 
commensal bacteria in IBD, on the basis of evidence suggesting a central role of SCFA in 
colonic health. A potential association between bacterial metabolites and IBD pathogenesis 
was  further  intensified  in  light  of  evidence  suggesting  that  butyrate  modulates  mucosal 
inflammation  and  proinflammatory  cytokine  expression  via  a  mechanism  that  involves 
inhibition of activation of the nuclear factor-kappaB (NfκB) pathway (390;413-416). 
For the purposes of this study, an extensive review of all studies on SCFA in IBD was 
carried out using Pubmed. The retrieved studies were classified into four subject categories.  
1.  Colonic concentration of SCFA in IBD 
2.  Metabolism of SCFA in IBD 
3.  Animal experiments on the effect of SCFA in IBD 
4.  Clinical trials on SCFA use in IBD 
Colonic concentration of SCFA in IBD 
In total six studies measured the colonic concentration of SCFA in IBD patients and all but 
one (417) were done in adults (Table 1.7.1). A recent study  by van Nuenen et al (418) 
described the metabolic activity of the faecal microbiota of eight IBD patients, in an in-vitro   97 
model  of  the  colon,  and  found  significantly  increased  production  of  SCFA  and  BCFA 
compared with stool samples of six healthy controls.  
Different  results  were  found  among  the  studies,  which  measured  SCFA 
concentrations in colonic contents of IBD patients, and therefore it is not possible to draw 
firm conclusions. Vernia et al (419) found significantly lower concentrations of SCFA and 
butyrate in 24 hour stool collections of 18 UC patients (87±11 mmol/kg) compared with 16 
healthy controls (133±12 mmol/kg) and 20 CD patients (132±13 mmol/kg). These results are 
in contrast to those by Roediger (420) in faecal dialysates of UC adults and Treem et al (417) 
in  spot  stool  samples  of  IBD  children,  who  found  significant  higher  levels  of  butyrate 
compared with healthy controls.  
Inconsistent results have been reported for an association linking disease activity with 
the  concentration  of  colonic  SCFA  in  IBD  patients  (Table  1.7.1).  Hove  et  al    found  no 
association with the faecal concentration of SCFA, whereas Roediger et al (420) observed 
high levels of butyrate increasing with disease severity in faecal dialysates of UC patients 
and Treem et al (417) found high levels of butyrate in active and low levels of acetate in 
quiescent UC children but no effect in spot stool samples of CD children.  
Indeed Roediger et al (420) found that increased levels of butyrate in faecal dialysate 
correlated positively with the histological disease activity scores in mucosal biopsies whereas 
in a subsequent paper by Vernia (421) SCFA were found to be high in quiescent and mild 
UC (163±47 mmol/kg) and (148±63 mmol/kg) respectively, but were significantly decreased 
in  severe  disease  (65±47  mmol/kg).  In  particular  butyrate  levels  were  low  in  severe  UC 
(4.3±5 mmol/kg) compared to controls (13.7±8.4 mmol/kg) with the inference being that in 
severe disease there is relative butyrate deficiency and energy deficits to colonocytes. 
The use of different methodologies among the studies with the use of different types 
of material for analysis (faecal water, spot samples, 24hrs collection) may partially explain 
these contradictory results (Table 1.7.1). 
Metabolism of SCFA in IBD 
The  failure  to  confirm  the  hypothesis  that  IBD  pathogenesis  is  the  result  of  low  SCFA 
production and on the contrary the increased concentrations observed in some of the studies 
(417;420) redirected subsequent research towards the colonocyte metabolism of SCFA. 
In  1980,  Roediger  was  the  first  to  report  that  butyrate  oxidation,  was  significantly 
impaired  in  UC,  both  during  the  active  phase  of  the  disease  and  in  remission  (422). 
Enhanced glucose and glutamine oxidation resulted as a compensatory mechanism. Their 
hypothesis,  that  IBD  pathogenesis  was  the  result  of  impaired  butyrate  metabolism  was 
supported by the same group which showed that inhibition of beta-oxidation of fatty acids 
induced  experimental  colitis  in  rats  and  hence  may  be  primarily  associated  with  the   98 
pathogenesis of UC (423). Nevertheless a causative association between butyrate and colitis 
was  disputed  by  others  who  although  observing  diminished  oxidation  of  butyrate  in 
experimental models of colitis, reported that histological abnormalities preceded the defects 
in  butyrate  oxidation  (424).  Indeed  the  fact  that  disease  remission  was  associated  with 
normal  oxidation  and  active  disease  with  decreased  oxidation  in  another  study  (425), 
suggests that UC mucosa is not intrinsically altered in butyrate oxidation, making this unlikely 
to be a primary causal defect leading to inflammation in UC. 
Recently two studies attracted interest in the defects of butyrate metabolism in IBD. 
Santhana et al (426) suggested that the impaired oxidation of butyrate in UC was the result 
of impairment in the last enzyme (mitochondrial acetoacetylCoA thiolase) that participates in 
butyrate  oxidation  inside  mitochondria.  Suboptimal  enzymatic  activity  was  found  both  in 
normal  and  inflamed  mucosa  of  UC  patients.  This  was  the  result  of  increased  oxidative 
stress at the mucosal level, which modified protein structure, and functionality of the enzyme. 
Interestingly similar defect was not found in CD patients. In the second study Thibault et al. 
(427) proposed that impaired butyrate oxidation was not a primary defect but the result of a 
decreased intracellular concentration of butyrate, due to low cellular uptake of butyrate in IBD 
patients.  This  was  due  to  a  defect  in  the  production  of  one  of  the  butyrate  transporters 
caused  by  the  action  of  pro-inflammatory  cytokines.    Thus  there  is  some  evidence 
suggesting impaired butyrate metabolism in IBD mainly UC. Evidence in CD is limited and 
non supportive thus far.  
Use of SCFA for the treatment of IBD 
The suggestion that diminished butyrate metabolism may cause energy deficiency in UC 
colonocytes (422), coupled with some observations of low colonic SCFA in patients with UC  
prompted the use of SCFA in animal models and in clinical trials for the management of UC 
primarily of the distal colon.  
Animal  model  of  colitis,  have  been  used  to  study  the  efficacy  of  exogenous 
administration of SCFA on disease activity and mechanisms of action (Table 1.7.2). All of the 
studies reviewed used rectal enemas of butyrate, alone or in conjunction with 5-ASAs and 
compared the results against a placebo control group (eg saline). Butyrate improved disease 
activity, colonic macroscopic and microscopic histological findings in most studies (428-430) 
and improved mucosal barrier function and colonocytes viability in one (415).  
The  mechanisms  that  might  be  involved  in  the  amelioration  of  colitis  by  butyrate 
administration  include  decreased  expression  and  activation  of  the  NFκB  proinflammatory 
cascade with subsequent reduction in the secretion of pro-inflammatory cytokines (415;430). 
Moreover butyrate administration improved the expression of trefoil factor 3 that is implicated 
in epithelium integrity, protection and wound healing (430).    99 
The first clinical report of the use of SCFA to treat IBD was an open label trial of a 
mixture of the three basic SCFA in 12 patients with refractory distal colitis. Of the ten patients 
who completed a six week trial, nine improved (431). Since then 12 additional clinical trials 
were identified that used SCFA in IBD (Table 1.7.3). All apart from one study (432) were 
done  in  UC  patients  mainly  with  distal  colitis.  The  most  common  vehicle  for  butyrate 
administration was a sodium butyrate enema. Two studies used oral derivatives of butyrate 
(432;433). Five studies had a randomized double blind placebo controlled group although 
actual blinding was difficult, if not impossible, due to the strong odor of butyrate in rectal 
enemas. The number of patients in the studies varied between nine and 51. None of the 
studies was performed in paediatric patients.    100 
Table 1.7.1: Colonic concentration of SCFA in IBD patients  
Study  Design  Results 
Van Nuenen  et al 2004 
(418) 
In-vitro colonic model; Production of 
bacterial metabolites in faecal samples; 8 
IBD & 6 healthy controls;  
SCFA & BCFA production was higher in IBD than control samples  
Hove & Mortensen 1995 
(434) 
Spot stool samples (103 UC, 127 CD, 70 
other GI), 20 healthy controls; including 
patients with gut resection 
No difference with controls; No effect of disease activity or length of small or 
large bowel on faecal SCFA concentration.  
Treem et al 1994 (417)  Spot stool samples children (17 UC, 22 
CD, 12 healthy) 
No difference between CD & UC for SCFA; Acetate lower & butyrate higher in 
CD & UC compared with healthy controls; No difference between active & 
inactive for CD; In UC changes with activity: SCFA low in moderate-severe UC; 
Butyrate high in quiescent/mild UC 
Vernia et al 1998°  (421)  Faecal water (62 UC )  SCF A high in quiescent/mild but decreased in severe disease 
Vernia et al 1988b (419)  24 hours faecal collections (18 UC & 20 
CD), 16 controls  
SCFA and particularly butyrate lower in UC than CD and healthy controls 
Roediger et al 1982 (420)  Faecal dialysates (65 UC), 16 control  SCFA and mainly butyrate increased in severe disease; raised butyrate 
correlated with severity of mucosa 
 
 
Table 1.7.2: Effect of SCFA administration in animal models of colitis 
Study  Intervention  Outcome  Results 
Song et al 2006 (430)   Sodium butyrate enema, 
5-ASAs, combination, 
saline  
Colonic damage; Tissue 
Myeloperoxidase; Trefoil factor 3 mRNA 
expression; Serum IL-1β production ; 
NFκΒ expression 
All apart from saline reduced diarrhoea, improved 
colonic damage, myeloperoxidase activity, increased 
trefoil factor 3 mRNA expression, decreased serum IL-
1β production and NFκΒ expression; Better effect with 
combination 
Venkatraman et al 2003 
(415) 
Butyrate enema, saline  Intestinal permeability; Cell viability  Improved cell viability & mucosal permeability & PMN 
neutrophil infiltration; Inhibited heat shock protein 
expression & activation of NFκB 
Butzner et al 1996 (428)   Butyrate enema, saline, 
no treatment 
Colonic damage; Tissue 
Myeloperoxidase; Sodium absorption  
In butyrate treated group diarrheoa stopped; Colonic 
damage and sodium absorption improved; 
Myeloperoxidase activity decreased 
D’Argenio et al 1994 (429)   Sodium butyrate, 
mesalamine, combination 
or saline enema 
Throboxane B2  Sodium butyrate alone or plus mesalamine reduced 
histological activity; Transglutaminase increased, in 
butyrate and in combination; Combination reduced 
throboxane B2 synthesis  
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Table 1.7.3: Clinical trials of the effect of SCFA in IBD patients 
Study  Subjects  Intervention  Outcome  Results 
Di Sabatino et al 
2005 (432) 
13 mild/moderate CD  Open label; 4 g/d butyrate for 
8 wk  
Endo, Hist, CA, cytokines, NFκB 
before and after treatment  
69% clinical improvement; Endo, Hist 
improved in ileocaecum, ESR, NFκB and 
IL-1β decreased 
Vernia et al 2003 
(435) 
51 distal UC, refractory to 
topical 5-ASA/steroids 
RDBPC multicenter; 2 g 5-
ASA and 160mM sodium 
butyrate enema or placebo 
for 6 wk  
Endo; Hist; CA  Remission rate and disease improved, 
bowel movements & urgency better in 
intervention 
Luhrs et al 2002 
(414) 
11 distal UC  Open label; butyrate enema 
100 mM or placebo for 8 wk 
Endo; Hist; CA  Hist, CA improved; less mucosal 
macrophages positive for NFκB 
translocation 
Vernia et al 2000 
(433) 
30 mild/moderate UC  RDBPC; Oral butyrate 4g/d 
plus mesalazine  2.4g/d or 
placebo 
Endo; Hist; CA  Endo, Hist, CA improved in both arms; 
better improvement vs baseline for 
intervention 
Scheppach et al 
1996 (436) 
47 active distal UC  RDBPC; SCFA or butyrate 
enema vs placebo 
Endo; Hist; clinical, inflammatory 
markers activity at 4 and 8 wk 
Fewer segments were endoscopically 
affected on butyrate subjects than 
placebo 
Steinhart et al 
1996 (437)  
38 active distal UC  RDBPC; Butyrate enema vs 
placebo for 3 wk 
Endo; Hist; CA at baseline 3 and 6 
wk 
No difference between intervention and 
placebo 
Patz et al 1996 
(438) 
10 distal UC refractory to 
5-ASA & steroids 
Open label; SCFA enema for 
6 wk 
Endo; Hist; CA at baseline and 6 wk  50% had clinical and endoscopic 
improvement; no histological 
improvement 
Vernia et al 1995a 
(439) 
40 mild/moderate distal 
UC 
RDBPC; SCFA enema vs 
placebo for 6 wk 
Endo; Hist; CA at baseline and 6 wk  Endo; Hist; CA improved 
Vernia et al 1995b 
(440)  
9 refractory to therapy  Open label; Sodium butyrate 
and 5-ASA for 4 wk 
Endo; Hist; CA  Endo; Hist; CA improved in 7 out of 9 
patients 
Steinhart et al 
1994 (441) 
10 distal UC; refractory to 
rectal therapy/ oral 5-ASA 
Open label; Butyrate enemas 
for 6 wk 
Endo; CA at 3 & 6 wk  6 out of 10 improved; disease score 
decreased 
Senagore et al 
1992 (442) 
45 proctosigmoiditis 
 
Open label; Steroid enema vs 
5-ASA enema vs SCFA 
Endo; Hist; CA at 6 wk  Same proportion of patients improved in 
the three groups 
Scheppach et al 
1992 (443) 
10 distal UC refractory to 
therapy 
Single blind crossover; 
Butyrate enema and placebo 
for 2 wk 
Endo; Hist; CA  Stool frequency ⇓; PR blood decreased; 
Endo and Hist improved 
Breuer et al 1991 
(444) 
12 distal UC reftractory to 
therapy 
Open label; SCFA enema  Endo; Hist; CA  CA and Hist improved 
RDBPC: Randomised double blind placebo control trial; Endoscopy: endo; Histology: hist: Clinical activity: CA  102 
All the open label studies and the majority of the randomized control trials favored the 
use of butyrate enemas in distal refractory UC although those with relatively large sample 
size did not find any difference in histological and endoscopic outcomes between treatment 
and placebo groups (Table 1.7.3). In most studies with a positive outcome, improvement of 
clinical  disease  activity  was  accompanied  by  improvement  of  inflammatory  markers, 
histology and endoscopic findings. In two studies that tried to clarify mechanisms of action, 
use of butyrate was associated with decreased expression and activation of NFκB pathway 
(414;432).  
In  summary  considering  the  available  evidence,  the  cost  of  treatment,  and  drug 
associated side effects, butyrate could be a promising adjuvant in the management of distal 
colitis. On the other hand, considering the limited evidence in CD, in conjunction with current 
evidence linking commensal intestinal microbiota with CD aetiology (see Section 1.7), more 
studies should be anticipated. In particular use of butyrate enemas should be considered in 
the context of paediatric trials as a possible agent for sparing the use of other medication 
with  severe  side  effects  on  bone  health  and  linear  growth.  In  addition  other  vehicles  of 
butyrate administration should be developed for extensive disease as the use of butyrate 
enemas is practically limited to distal colitis only.   
 
1.7.1.2. Lactate in IBD 
Previous studies reported high colonic concentrations of lactic acid and particularly of the L-
isomer in active distal UC (421;434;445). This may suggest increased mucosal production or 
impaired metabolism of lactic acid by lactate utilizing bacteria in the low luminal pH that may 
be encountered in IBD patients (410). A recent in vitro study in faecal samples, showed that 
although lactate production was sustained at pH less than 5.2, the utilization of lactate was 
reduced  resulting  in  its  excessive  accumulation  (401).  On  the  other  hand  lactic  acid 
concentration  is  positively  associated  with  stool  volume,  steatorrhoea,  and  malabsorption 
(446) and might explain the increased levels seen in patients with active disease and severe 
diarrhoea.  
In  the  only  paediatric  study  that  measured  faecal  lactate  in  IBD,  no  statistical 
significant differences were found between the two types of IBD diseases or compared with a 
healthy  control  group  (417).  Van  Nuenen  et  al  (418)  in  an  in-vitro  model  of  colonic 
fermentation  found  comparable  results  in  lactate  production  rates  in  faecal  microbiota  of 
healthy and IBD patients.  
 
1.7.1.3. Ammonia in IBD   103 
Two studies measured colonic ammonia in IBD and in both cases this was higher than the 
healthy  control  group.    Roediger  et  al  (420)  measured  ammonia  among  other  bacterial 
metabolites in the colon of patients with UC and healthy controls and found that UC patients, 
particularly those with histological findings of severe disease, had higher levels of ammonia 
compared with non-inflammatory conditions. Similarly Van Nuenen et al (418) in an in-vitro 
model of colonic fermentation found higher production of ammonia by the faecal microbiota 
of eight IBD (5 CD) patients compared with healthy subjects. Increased concentration and 
production of ammonia could infer increased proteolytic action or impaired utilization by the 
intestinal microbiota in IBD patients.  
 
1.7.1.4. Colonic pH in IBD 
In IBD patients different and contradictory patterns of luminal pH have been reported in the 
literature (410). Ewe et al (447) did not find any difference in luminal pH values across the GI 
tract between patients with active IBD and healthy controls. Similar results were presented 
by Press et al (448) although higher luminal pH was measured in the terminal ileum, caecum, 
and  ascending  colon  of  UC  patients  compared  with  healthy  controls.  In  the  same  study 
comparable results were found between active and inactive disease.  
In contrast very low pH values (2.3-3.4) were recorded in the caecum and right side 
of  the  colon  in  severely  active  UC  (449)  compared  with  healthy  subjects  but  not  in  CD 
patients with ileocaecal resection (450). Luminal pH in the right colon of the patients with 
ileocaecal resection was higher by 0.5 units compared with healthy controls (450). Sasaki et 
al (411) measured comparable luminal pH in the stomach and small intestine of CD and 
healthy controls, but the colonic pH profiles differed with lower values observed in active or 
quiescent CD than seen in controls. The overall mean luminal pH in the right colon was 
5.3±0.3 for the patients versus 6.8±0.2 for the healthy controls (p < 0.01) and that in the left 
colon was 5.3±0.7 versus 7.2± (p < 0.01). 
Many factors can determine colonic pH including the amount and type of fermentable 
material  in  the  colon,  the  type  and  number  of  the  bacterial  species,  colonic  motility, 
production, absorption, or utilisation of the fermentation products by other colonic bacterial, 
as well as abnormalities in the secretion of bicarbonate and the buffering effect of mucus and 
blood in active colonic disease (410). Alterations in these factors may explain the different 
results observed in the studies above.    104 
 
1.7.1.5. Sulphide in IBD 
Several lines of evidence pointed to sulphur metabolism, being implicated in the aetiology of 
mucosal injury in IBD. A prime example is the use of sulphated polysaccharides, to induce 
features of colitis in animal models (451).  
First Roediger and colleagues  found that fatty acid oxidation at the epithelium lining 
could  be  hampered  by  a  range  of  sulphur  containing  compounds.  Among  those  tested, 
sodium hydrogen sulphide selectively reduced fatty acid beta oxidation at the level of short 
chain acyl dehydrogenation (407;452) and caused greatest mucosal injury. Based on these 
observations a hypothesis was proposed that cellular inhibition of butyrate by sulphides can 
induce energy deficient state in colonocytes resulting in mucosal inflammation and injury.  
An extensive literature review was carried out to identify studies linking IBD with sulphide 
metabolism. The retrieved studies in IBD were categorized into the following four categories. 
 
1.  Prevalence of Sulphate Reducing Bacteria (SRB) in UC and comparison with healthy 
subjects. 
2.  Luminal concentrations and production rate of sulphide in UC and comparison with 
healthy controls. 
3.  Functionality of sulphide detoxification pathways in IBD. 
4.  Pharmaceutical intervention and sulphide metabolism. 
 
Prevalence of SRB in UC and comparison with healthy subjects  
Increased numbers of SRB bacteria in faecal samples of UC patients have been reported in 
some studies. Loubinoux et al (453) using cultivation techniques on selective growth media 
linked with multiplex PCR found that SRB were more frequently observed in IBD patients 
(68%) than in healthy controls (24%) or patients with other GI disorders (37%). Moreover 
different SRB strains were observed between healthy and IBD subjects suggesting strain 
specific  differences  between  IBD  and  healthy  controls.  In  particular  the  prevalence  of 
Desulfovibrio Piger was significantly higher in IBD (55%) compared with healthy individuals 
(12%) or patients with other GI disorders (25%). Association of SBR counts with disease 
activity was reported by one study (454), which found that total viable counts of SRB were 
increased  in  patients  with  clinical  and  endoscopic  active  disease  activity  compared  with 
patients with quiescent disease (454).   
On  the  other  hand  recent  studies  using  robust  molecular  biology  techniques  of 
bacterial  community  analysis  failed  to  confirm  the  results  from  bacteriological  studies  of 
increased  growth  or  number  of  SRB  counts.  For  example  Fite  et  al  detected  SRB  in  all   105 
mucosal  samples  of  IBD  patients  and  healthy  individuals  using  molecular  microbiology 
techniques (455).  
 
Sulphide concentration and production 
There is inadequate evidence to suggest that luminal sulphide concentrations are different in 
IBD patients. A group from the University of Dundee, Scotland, showed that in untreated UC 
patients faecal sulphide excretion was higher than in healthy controls and treatment with 5-
ASAs  lowered  both  concentration  and  production  of  sulphide  (454;456).  On  the  contrary 
comparable free and total faecal sulphide concentrations in IBD and healthy controls were 
presented by others (406;457). No association between luminal sulphide concentration and 
disease activity or location have been found (457).  
Compared with healthy subjects, a two to threefold increase in sulphide production 
rate has been found in faecal and mucosal samples of UC patients (458;459). Addition of 
various organic sulphur containing substrates (mucin and taurocholate) increased hydrogen 
sulphide  release  much  more  readily  than  sulphate  intake  implicating  the  action  of  other 
protein fermenting bacteria in the production of sulphide over and above the SRB. Increased 
production of sulphide has been reported also in pouchitis, an inflammatory condition of the 
ileal-anal pouch of UC patients (460).  
 
Different form of sulphide, different effect?  
Only a few studies have tried to account for the origin of the measured concentrations of 
faecal sulphide in samples from IBD patients. Sulphide occurs in two forms in the intestinal 
tract, free as hydrogen sulphide and bound to divalent metal ions. Differences in the toxicity 
of the two forms and failure to distinguish between them in the studies might explain some of 
the  discrepancies  reported  above.  Jorgensen  &  Mortensen  (406)  hypothesized  that  the 
binding ability of faecal material to sulphide was low in UC compared with healthy controls 
but they failed to prove this. 
 
Functionality of sulphide detoxification pathways in IBD 
Faecal sulphide concentrations represent a balance between production and removal of this 
toxic  metabolite.  Epithelial  enzymes  react  with  this  and  produce  other sulphur  containing 
compounds  which  are  less  harmful  for  the  colonic  mucosa  (461;462).  Thus  elevated 
concentrations  of  sulphide  could  be  a  secondary  result  of  defective  detoxification 
mechanisms in the large bowel (463) although the evidence so far is circumstantial and not 
supportive (462). 
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Pharmaceutical intervention and sulphide metabolism  
In  view  of  a  possible  causative  role  of  sulphide  in  IBD  mucosal  injury,  a  few  studies 
investigated whether the action of mainstream IBD drugs is mediated through changes in the 
metabolism of sulphide in the gut. Among them, 5-ASAs such as sulphasalazine reduced the 
production  of  sulphide  but  not  the  growth  of  SRB  in  in-vitro  experiments  (454;456)  and 
subsequently  differences  in  the  concentration  of  faecal  sulphide  were  observed  between 
patients on treatment with 5-ASAs and those not. Moore et al (457) however did not confirm 
these results and indeed found comparable sulphide concentrations between patients on 5-
ASAs and others on different medical regimes. Difference in disease activity between these 
studies may explain this discrepancy.  
The  results  of  the  effect  of  metronidazole  and  ciprofloxacin,  two  commonly  used 
antibiotics, on the production of sulphide and SRB counts have been contradictory (460;464). 
Recently prebiotic ingestion reduced hydrogen sulphide concentrations but not SRB counts 
in healthy volunteers and may thus have a putative place in the treatment of patients with UC 
(464). Other new agents, like bismouth based derivatives, have also been proposed for use 
in IBD to inhibit the growth of SRB and suppress production of hydrogen sulphide (460).  
 
Hydrogen Sulphide in IBD. History Revised? 
Despite the evidence that hydrogen sulphide can be a toxic mediator in gut health, recent 
studies found paradoxical actions depending on its concentration and the circumstances in 
which it is generated. For example, hydrogen sulphide may play a role in protecting gastric 
mucosal  tissue  from  injury  and  exerts  anti-inflammatory  actions,  and  potentially  inhibits 
leukocyte adherence to the vascular endothelium (465). Fiorucci and his colleagues (466) in 
a  recent  study  compared  the  regular form  of mesalamine  with  a  new  hydrogen  sulphide 
releasing derivative and found that the latter was more effective than mesalamine in reducing 
the severity of animal colitis. In particular the new derivative was more effective in reducing 
granulocyte  infiltration  into  the colonic  tissue, and furthermore reduced  the  expression  of 
mRNA for several key proinflammatory cytokines and chemokines.  
 
Effect  of  dietary  sulphate  and  sulphur  containing  nutrients  on  sulphide 
production 
Diet is a strong determinant of faecal sulphide concentration (467). A diet rich in sulphur 
containing  amino  acids  increases  the  production  and  excretion  of  sulphide  in  a  dose 
dependent manner (404) by the action of protein fermenting bacteria. Similarly ingestion of 
sulphate products increased generation of sulphide by the action of SRB in the colon in one 
study (468) but not in a rat model given sulphate supplemented drinking water for one year   107 
(469).  An  association  with  dietary  sources  of  sulphur  may  justify  discrepancies  found 
between studies, such as the elevated levels of sulphide previously reported by Pitcher (454) 
in active UC but not by Moore. The high sulphide concentrations observed in the first study 
could  actually  be  an  epiphenomenon,  related  to  sulphur  amino  acid  fermentation  of  the 
mucus  and excessive sloughed cells in active disease or increased dietary intake of sulphur 
containing food that has been shown to precede disease exacerbation (470).   
 
Effect of transit time on sulphide production  
Gut transit time can also affect sulphide production and comprise a confounding factor in the 
interpretation of sulphide’s role in health and disease. Concentration of faecal sulphide and 
reduction  rates  of  faecal  sulphate  are  increased  in  faster  intestinal  transit  times  and  are 
decreased  in  slower  transit  (468)  and  may  explain  any  differences  between  active  and 
inactive disease.   
 
1.7.2. Gut microbiota composition and IBD 
An imbalanced enteric microenvironment may provide a constant stimulus that activates the 
inflammatory  cascade  in  patients  with  genetic  defects  in  gut  barrier  function,  innate  and 
adaptive immune system. In the following section (Section 1.7.2.1) the topic will be reviewed 
and the essence of the enormous amount of evidence that implicates the enteric microbiota 
in the pathogenesis of IBD will be presented. For an in depth review of the state of the art the 
reader is referred to the recent report by Sartor (30).  
 
1.7.2.1. Clinical human evidence associating the gut microbiota in IBD 
There is both clinical and experimental evidence to implicate the intestinal microbiota in the 
onset and perturbation of IBD microbiota. Further to the localization of disease to intestinal 
segments  with  the  highest  bacteria  concentration,  clinical  evidence  linking  the  intestinal 
microbiota to IBD, comes from the observation that faecal stream diversion prevents and 
treats CD, whereas exacerbation occurs upon restoration of the faecal flow (471).  
Therapeutic  intervention  with  selective  antibiotics  to  decrease  postoperative 
recurrence of ileal disease (472), along with the beneficial use of probiotic preparations in 
maintenance of remission in UC, and prevention of pouchitis, implicates the endogenous 
intestinal microbiota as a key player in the intestinal inflammation seen in IBD (75;76;473). 
Moreover there is persuasive evidence for loss of immunologic tolerance to components of 
the commensal flora in patients with IBD as this is reflected in serologic and cellular immune 
reactivity to enteric microbes (474;475).  
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1.7.2.2. Experimental evidence from animal models of colitis 
Studies in animal models of colitis have made a major contribution to our understanding of 
the importance of dysregulation of interactions between host mucosal cells and the resident 
luminal bacteria in the pathogenesis of IBD.  Several genetically engineered rodents develop 
chronic intestinal inflammation under conventional conditions but fail to develop colitis in a 
germ-free state (476). Administration of a normal colonic microbiota induces inflammation, 
although  different  bacteria  exhibit  different  effects  (477)  or  lead  to  different  phenotypic 
disease characteristics. For example in interleukin-10 deficient mice, E. coli induced proximal 
colitis whereas Enterococcus faecalis led to the development of distal colitis (478). Similar to 
human studies, the involvement of intestinal microbiota in disease aetiology is supported by 
the  administration  of  probiotic  bacterial  strains  in  animal  models  of  colitis  which  modify 
disease  expression  by  favorably  altering  bacterial  composition,  immune  status,  and 
inflammatory response (479).  
 
1.7.2.3. Putative mechanisms to implicate intestinal microbiota in IBD 
Compared  with  the  scientific  progress  from  epidemiological  evidence  in  identification  of 
genes implicated in IBD onset, the exact mechanisms by which gut bacteria are involved in 
IBD pathogenesis remain largely elusive. Four mechanistic theories have been proposed and 
are described in the following section (30;474).  
 
a.  Microbial pathogens or functional changes in commensal bacteria trigger intestinal 
inflammation. 
b.  Defective intestinal barrier function allows bacteria or their components/products to 
contact and activate the gut-associated immune system. 
c.  Intolerance and defective host immune response to commensal microbiota initiates 
and perpetuates inflammation. 
d.  IBD  is  the  result  of  disruption  of  a  harmonic  microbial  symbiosis  in  the  intestinal 
ecosystem. 
 
1.7.2.3.1. Microbial pathogens or functional changes in commensal bacteria  
Since the first descriptions by Samuel Wilks in 1859 and Burrel Crohn in 1932, extensive 
work has been directed to the identification of a specific pathogen that could be of aetiologic 
importance in IBD. Among the microbes of historical interest that have been postulated to 
play  a  role  in  the  pathogenesis  of  IBD  are:  Mycobacterium  avium  subspecies 
paratuberculosis, Listeria, Pseudomonas species, and Helicobacter pylori (474). Although no 
definite bacterium has yet been identified a few have been suggested. However identifying a   109 
pathogen as a cause of IBD is rather difficult, as many of the bacteria in the human intestinal 
ecosystem are not yet culturable or a potential pathogen may be part of the subdominant 
intestinal microbiota that current molecular methods of analysis are not able to identify.  
Mycobacterium  avium  subspecies  paratuberculosis  has  been  most  intensely 
investigated but there are still arguments regarding its role in the causation of IBD, mainly 
CD  (30).  In  ruminants  infection  with  Mycobacterium  causes  spontaneous  granulomatous 
enterocolitis similar to CD and it was first cultured from resected CD tissues in 1984 (480). 
Since this first observation a few studies have reported detection of Mycobacterium avium 
subspecies paratuberculosis in IBD patients using slow growing culture (481), polymerase 
chain reaction, FISH (482), or a metagenomic approach (483) but the detection rates varied 
between 0% and 100% (456;484) suggesting other or additional causes of IBD. Recently a 
metagenomic  analysis  of  the  gut  microbiota  (483),  did  not  detect  Mycobacterium  avium 
subspecies paratuberculosis 16S rRNA in mucosal specimens of a large number or patients 
with IBD. Likewise a large well-designed double-blinded placebo controlled RCT using an 
antibiotic cocktail failed to sustain remission in CD (485).  
Among  the  non-mycobacterial  species,  E.  coli  warranted  considerable  attention. 
Prevalence of E. coli has been reported as 3-4 times higher in the mucosal microbiota of 
patients with IBD (486) whereas novel adherent-invasive E.coli have also been described to 
colonize  the  ileal  epithelium  of  patients  with  CD  (487;488).  In  ileal  specimens,  adherent-
invasive E. coli were found in 22% of CD chronic lesions compared with 6% of controls. 
Similar findings were found by Baumgart et al (487) who observed adherent-invasive E. coli 
in more than a third of CD patients with active ileal disease but there was a low recovery in 
healthy  controls.  Recently  Darfeuille-Michaud  and  his  colleagues  found  that  adherent-
invasive  E.coli  adhesion  occurs  via  specific  binding  sites  on  the  bacterial  surface  and  is 
secondary  to  increased  expression  of  a  carcinoembryonic  antigen-related  cell  adhesion 
molecule 6 propagated by the action of IFN-gamma or TNF-a stimulation, prior adherence by 
adherent-invasive E. coli (AIEC) bacteria (224).  
Although  an  infection  from  a  potentially  unknown  pathogen  cannot  be  excluded 
completely, currently there is not enough evidence to implicate one in the pathogenesis of 
IBD. In addition, the strongest argument against a persistent infection in IBD aetiology is the 
beneficial  effect  of  host  immunosuppression  and  steroids  in  disease  management  that 
indirectly precludes a pathogen as the sole causative mediator in IBD.  
 
1.7.2.3.2. Defective intestinal barrier function  
Preservation  of  intestinal  homeostasis  and  inactivation  of  GALT  depends  on  the 
maintenance of an impermeable mucosal barrier, and rapid repair of epithelial defects when 
the latter is breached. Abnormalities in the mucus-epithelial layer composition may facilitate   110 
direct  contact  between  colonic  bacteria  and  the  intestinal  mucosa.  This  may  exert  an 
antigenic  stimulus  that  activates  the  immune  system,  initiates  inflammation,  and  further 
promotes intestinal permeability and tissue injury.  
There are several lines of evidence suggesting enhanced mucosal permeability in 
IBD (489;490) but it is still unknown whether this is a primary defect in IBD patients or a 
consequential event following disease onset. The importance of effective barrier exclusion in 
the pathogenesis of IBD is better illustrated by experimentally altered tight epithelial junctions 
in  mouse  models  tend  to  predispose  to  severe  gut  inflammation  (491).  Genetically 
determined  changes  in  the  mucus,  particularly  glycosylation  of  the  mucous  glycoproteins 
may result in weakening of the mucous barrier in patients with IBD. Endogenous luminal 
bacteria or their components could degrade mucus, penetrate into the mucus layer, activate 
the  local  immune  system,  enhance  recruitment  of  inflammatory  cells  and  provoke 
inflammation (492;493). 
 
1.7.2.3.3. Defective host immune response to bacteria 
A defect in the innate immune response of the GALT may be implicated in the inflammatory 
process seen in IBD. Recognition of commensal bacteria and prevention of an acute immune 
response is regulated through bacterial-host crosstalk at the level of the mucosal epithelium. 
This cross-talk occurs through microbial associated molecular patterns that are recognized 
by  pattern  recognition  receptors,  such  as  toll-like  receptors.  Toll  like  receptor  expression 
appears to be carefully regulated to mute a proinflammatory response towards mutualistic 
organisms  in  healthy  individuals  but  to  initiate  inflammatory  response  in  the  case  of 
pathogens (30).  
Polymorphisms in toll like receptors have been linked to CD pathogenesis. In 2001 
two independent groups identified the CARD15 gene on chromosome 16q as a susceptibility 
gene  in  CD  (27;28).  Three  common  polymorphisms  were  found  to  be  associated  with 
development  of  CD.  The  CARD15  protein  functions  as  an  intracellular  receptor  for  a 
structural motif (muramyl dipeptide) of peptidoglycan a common component of bacterial cell 
walls. Upon recognition of muramyl dipeptide, CARD15 activates the NF-κB pathway a key 
step in the inflammatory response. Because of this CARD15 is considered a proinflammatory 
molecule. In CD the associated mutations impair the proinflammatory function of CARD15 
that  has  potentially  serious  consequences  involving  reduced  antibacterial  action  from 
impaired production of defensins and other antimicrobial peptides from Paneth cells in both 
ileal and colonic CD (26;494;495). Other CD related genetic polymorphisms in the pattern 
recognition  receptors  such  as  toll  like  receptor  4,  the  autophagy  gene  ATC  16L1  which 
regulates intracellular microbial processing and killing further support the hypothesis that a 
subset of CD patients may have defective innate immune response to microbial antigens   111 
(496;497).  Defective  mechanisms  of  bacteria  killing  could  lead  to  defective  clearance  of 
bacterial antigens with parallel activation of the T cells mediated immune response.   
 
1.7.2.3.4 Dysbiosis of commensal microbiota 
Failure to identify a pathogen in IBD along with supportive clinical and experimental evidence 
suggesting involvement of normal gut microbiota in IBD, directed the focus of the subsequent 
research on the dominant intestinal microbiota. It is now generally accepted that commensal 
enteric  bacteria  provide  the  constant  antigenic  stimulus  that  continuously  activates 
pathogenic  T  cells,  causing  chronic  intestinal  injury.  The  exact  mechanism  still  remains 
unidentified but a disruption of colonic bacterial balance is incriminated.  
It  has  been  postulated  that  disruption  of  commensal  microbiota  homeostasis  may 
spark an aberrant immune response. A decreased ratio of protective to unprotective bacterial 
species, might reduce the production of epithelial energy substrates, increase exposure of 
bacterial proinflammatory antigens to mucosal T cells, activate the local immune response 
and  overall  disrupt  the  host  tolerance  to  its  endogenous  bacteria.  This  concept  of  a 
breakdown of balance between putative species of “protective” versus “harmful” intestinal 
bacteria  has  been  termed  “dysbiosis”  (498)  and  has  been  the  objective  and  subsequent 
outcome of several investigations that tried to explain the association of gut bacteria with IBD 
pathogenesis.  
Previous  studies  that  used  conventional  microbiology  techniques  and  cultures  on 
selective  growth  media,  reported  substantial  differences  in  the  microbiota  composition 
between  IBD  patients  and  healthy  controls,  with  increasing  prevalence  of  streptococci, 
reduced numbers of bifidobacteria (499;500) and increased presence of Bacteroides fragilis 
(501;502). However due to the inability of traditional microbiology methods to culture the 
majority of luminal bacteria these results had to be revisited in the era of the new molecular 
bacteriology techniques. 
 
Review of studies on the composition of commensal microbiota in IBD 
In  the  following  section  the  recent  evidence  suggesting  dysbiosis  as  the  causative 
mechanism of the initiation and perpetuation of inflammatory response is summarised. Due 
to the plethora of relevant studies and as it is out of the primary scope of this thesis, the 
literature review is limited to studies published in the last decade which coincides with the 
flowering of applied molecular bacteriology in clinical gastroenterology.   112 
 
Research strategy and description of studies 
A comprehensive literature search was carried out to retrieve all studies published on the 
topic from 1998 to May 2008. Identification of additional articles was achieved via scrutiny of 
reference lists of major reviews articles. In total 27 original studies were identified with a 
boom in publications after 2004. At the beginning of this PhD there were six studies in total 
on the diversity and composition of intestinal microbiota in IBD. Twenty-one studies have 
been published since (Table 1.7.4) with the majority focusing on the mucosal associated 
microbiota.  
Most  studies  used  a  healthy  control  group  for  comparison  whereas  others  looked  into 
differences with other GI disorders or differences between the two types of IBD (CD & UC). A 
few studies looked into the spatial organization of the mucosal associated microbiota and 
some  attempted  to  link  the  bacterial  diversity  and  phylogeny  with  disease  activity  and 
dissimilarities in the bacterial composition profiles between inflamed and healthy mucosa. 
Two studies assessed temporal changes of the intestinal microbiota using colonic contents.  
Molecular bacteriology with analysis of bacterial community profiles using molecular 
fingerprinting techniques (TGGE, TTGE, DGGE) and/or characterization of the microbiota 
with species-specific bacterial probes (FISH, PCR) were most common methods used. Some 
authors used PCR amplification, with subsequent cloning and sequencing and recently two 
studies used a broad metagenomic approach to characterize the whole indigenous bacterial 
intestinal diversity in IBD patients. It is noteworthy that all but one study (503) assessed the 
microbiota  of  adult  patients  with  IBD.  The  only  paediatric  study  explored  the  mucosal 
microbiota  of  children  with  IBD.  Thus  far  no  study  has  been  published  on  the  bacterial 
composition of faecal microbiota of paediatric CD.    
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Table 1.7.4: Evidence table of studies on the diversity and composition of faecal and mucosal microbiota of IBD patients 
Study  Aim  Disease  Methods  Results-Comments 
Martinez et al 2008 
(504) 
Temporal changes in 
faecal microbiota on 
longstanding remission 
UC on remission 
for 1 year; H 
DGGE  Similarity index declined in UC but was stable in H; Biodiversity was 
significantly lower in UC than H  
Swidsinski et al 2008 
(505)  
Composition & spatial 
organization of faecal 
microbiota; Disease activity 
effect 
CD, UC, IC, 
coeliac, self limiting 
colitis, other GI 
disorders 
Microscopy & 
FISH 
Bacterial profile opposite for 6 out of 11 FISH probes between UC & 
CD; Disease diagnosis based on analysis of the spatial organization 
&  composition  of  bacteria  &  leucocytes  in  stool  samples;  Spatial 
differences  between  bacteria  of  IBD  &  H  or  other  G  disorders; 
Common habitual bacteria lower in IBD than H; C Coccoides group 
reduced  in  CD  &  UC;  Bacteroidaceae  higher  in  UC  than  CD; 
Faecalibacterium  prausnitzii  reduced  in  CD  only  but  not  UC;  
Bifidobacteriaceae absent in 56% of CD; Bifidobacteriaceae mean 
concentration higher in UC than H; Enterobacteriaceae increased in 
CD with increasing activity but not in UC; Concentration of habitual 
decreased with increasing inflammation in UC & CD; Occurrence & 
concentrations of Bifidobacteriaceae in CD lower in active disease 
than in remission & significantly lower than UC 
Baumgart et al 2007 
(487)  
Composition & spatial 
organization of ileal 
mucosal microbiota 
CD colitis & ileitis, 
H 
Culture, FISH, 
quantitative 
PCR, RAPD-
PCR, cloning 
sequencing 
In ileitis E. coli higher &  Clostridiales depleted compared  with CD 
colitis, or H; The number of E. coli correlated with severity of ileal 
disease; Invasive E coli was restricted to inflamed mucosa; E coli 
novel  in  phylogeny  with  pathogen  like  behaviour;  No  evidence  of 
Mycobacterium  avium  subspecies  paratuberculosis,  Shigella  & 
Listeria 
Frank et al 2007 
(483) 
Composition of mucosal 
microbiota 
CD, UC non-IBD 
patients 
Metagenomics, 
quantitative 
PCR 
Depletion of Firmicutes-Lachnospiraceae subgroup & Bacteroidetes 
phyla;  Increase  in  Proteobacteria  &  Bacillus  subgroup;  Abnormal 
microbiota was associated with occurrence of abscesses 
Sokol  et al 2007 
(506) 
Comparison of mucosal 
microbiota in inflamed & 
healthy tissue 
UC  TTGE  No difference was found. 
Vasquez et al 2007 
(507)  
Composition of mucosal 
microbiota; comparison 
between healthy & 
inflamed ileal tissue 
CD surgical 
samples 
TTGE, FISH  High similarity between inflamed & non inflamed, No intraepithelial 
bacteria were detected or bacteria in direct contact  
Martinez et al 2006 
(508) 
Composition of mucosal 
microbiota  
CD, UC, ischemic 
colitis, H 
DGGE, 
sequencing 
Patient-to-patient bacterial variability higher in CD than in H & UC; In 
CD prevalence of Clostridia, Ruminococcus torques, E. coli higher 
whereas  for  Faecalibacterium  prausnitzii  lower  than  H;  Some 
opportunistic  pathogens  (Enterobacter,  Proteus,  Haemophilus, 
Klebsiella occasionally found in CD but not in H   114 
Conte et al 2006 
(503) 
Composition of mucosal 
microbiota 
Newly diagnosed 
CD, UC, IC, 
lymphonodular 
hyperplasia, H, 
children 
Culture, real 
time RT-PCR 
Higher  number  of  aerobic  &  facultative  anaerobic  bacteria  in  IBD 
than in H; Increased concentration of mucosa associated bacteria; 
Occurrence of B. vulgatus lower in IBD whereas E. coli higher than 
H;  Klebsiella  occurred  in  IC;  Pathogens  were  not  isolated;  No 
differences for bifidobacteria, C coccoides group, Faecalibacterium 
prausnitzii; Higher colonization in rectum & ileum 
Bibiloni et al 2006 
(509)  
Composition of mucosal 
microbiota; comparison 
between healthy & 
inflamed tissue 
Active, newly 
diagnosed, 
untreated CD & 
UC, H;  
DGGE, cloning, 
PCR & RT-
PCR 
UC patients higher number of mucosa associated bacteria than CD 
or H; No difference in bacteria between inflamed & healthy tissue; 
High number of unclassified bacteria belonging to Bacteroidetes in 
CD; Different bacteria composition between CD & UC & with healthy; 
No differences for M. avium, paratuberculosis, H. Pylori, C. difficile, 
SRB, lactic acid bacteria & bifidobacteria 
Gophna et al 2006 
(510)  
Composition of mucosal 
microbiota; comparison 
between healthy & 
inflamed tissue 
 
 
CD, UC, H  PCR, cloning, 
sequencing 
Proteobacteria  (Acinetobacter  junni,  Klebsiella  pneumoniae,  SRB), 
Bacteroidetes (B. fragilis) higher in CD than H or UC but Firmicutes 
(clostridia  class)  lower;  No  difference  between  UC  &  H;  No 
differences between inflamed & healthy tissue 
Ott et al 2006 (511)  Composition of mucosal 
fungal microbiota 
IBD, H  FISH, DGGE, 
cloning, 
sequencing 
Diversity has increased in IBD; different composition with H 
Sokol et al 2006 
(512) 
Composition of faecal 
microbiota  
CD, UC, infectious 
colitis, H 
FISH   IBD microbiota comprises of unusual bacteria; C. coccoides group 
was reduced in UC & C. leptum group in CD 
Manichanh et al 2006 
(513)  
Composition of faecal 
microbiota 
CD in remission, H  Metagenomics 
& FISH 
Reduced diversity of Firmicutes phyla in CD; C leptum group was 
less  abundant  in  CD  than  H;  Presence  of  unknown  species  was 
more common in CD than in H  
Scanlan et al 2006 
(514) 
Temporal changes in 
faecal dominant & 
selective subdominant 
microbiota; Disease activity 
effect   
CD, H  DGGE  Dominant microbiota stability changed in CD; Reduced diversity in 
CD compared with H; In remission diversity & stability more stable 
compared  with  active  disease;  Clostridium  &  Bacteroides  were 
reduced in a proportion of CD but in none of the H; Inter-individual 
similarity  was  higher  in  H  than  CD;  No  temporal  changes  for 
bacterial stability or diversity for Bifidobacteria for CD or H; Lactic 
acid bacteria were complex & host specific & changed with time in 
both CD & H. Diversity higher in H than CD 
Seksik et al 2005 
(515) 
Composition of mucosal 
microbiota; comparison 
between healthy & 
inflamed tissue 
CD  TTGE  Bacterial  diversity  remained  high  in  ulcerated  &  non  ulcerated 
mucosa   115 
Mylonaki et al 2005 
(516)  
Composition of rectal 
mucosa microbiota 
CD, UC, H  FISH  In UC less bifidobacteria but more E coli; E coli & Clostridia higher in 
active than inactive UC; E coli higher in CD; Individual bacteria & 
clusters were detected in the lamina propria of CD & UC. None was 
detected in H  
Swidsinski et al 2005 
(517) 
Composition & spatial 
organization of mucosal 
microbiota  
CD, UC, self 
limiting colitis, IBS, 
H 
FISH  Higher  concentrations  of  mucosal  bacteria  in  IBD;  Bacteroides 
fragilis prevalent in IBD; Eubacterium rectale-clostridium coccoides 
less  prevalent  in  IBD;  No  patient  with  bacterial  infiltration  of  the 
mucosa  
Lepage et al 2005 
(518) 
Comparison of mucosal 
microbiota composition 
along the GI tract; 
Comparison with faecal 
microbiota 
CD, UC, H  TTGE  Mucosal microbiota diversity stable along the GI tract; No differences 
with disease activity but differences with faecal microbiota 
Bullock et al 2004 
(519) 
Composition of faecal 
microbiota; Disease activity 
effect  
UC  FISH & DGGE  Lactobacilli number lower in active disease 
Ott et al 2004 (520)  Composition of mucosa 
microbiota 
CD, UC, non-IBD 
GI inflammatory 
conditions, H 
SSCP, cloning, 
sequencing, 
real time PCR  
Diversity  was  reduced  to  50%  in  CD  &  to  30%  in  UC;  Anaerobic 
bacteria  (Bacteroides,  Eubacterium,  Lactobacillus  species  were 
reduced) 
Macfarlane et al 2004 
(340) 
Composition of mucosal 
rectal microbiota 
UC, H  Culture, FISH  UC  lower  ratio  of  anaerobes  to  facultative  anaerobes  than  H; 
Bifidobacteria  counts  30  times  higher  in  H  than  UC: 
Peptostreptococci were only detected in UC; Bacteria diffused in the 
mucus of UC but not in H 
Prindiville et al 2004 
(521) 
Composition of mucosal 
microbiota  
CD (some surgical 
specimens too), H;  
PCR, cloning, 
sequencing 
In  CD  colon  more  facultative  aerobes  than  H;  In  small  bowel 
Ruminococcus  gravus  (C  Coccoides)  was  increased  whereas  C 
leptum  &  Prevotella  nigrescens  decreased  in  CD;  No  difference 
between healthy & inflamed mucosa 
Mangin et al 2004 
(522)  
Composition of faecal 
microbiota 
CD, H  PCR, cloning, 
sequencing 
All CD shared B. Vulgatus but none in H; E coli isolated in 50% of 
CD  but  not  in  H;  Numerous  other  clones  belonged  to  uncommon 
bacteria in CD 
Seksik et al 2003 
(523) 
Composition of faecal 
microbiota; Disease activity 
effect 
CD colitis, H  TTGE, 
quantitative 
dot-blot 
hybridisation 
Enterobacteria higher in CD; Diversity remained high but varied in 
active & quiescent disease  
30% of microbiota belonged to yet undefined phylogenetic groups 
Kleessen et al 2002 
(524)  
Composition & spatial 
organization of mucosal 
microbiota  
CD, UC, H  FISH  Mucosa adherent & invading bacteria in IBD; Bacterial invasion of 
the mucosa was evident in 83.3% of colonic specimens from the UC 
patients, in 55.6% of the ileal and in 25% of the colonic specimens 
from the CD patients; No bacteria were detected in the tissues of the 
H.   116 
Swidsinski et al 2002 
(525) 
Composition & spatial 
organization of mucosal 
microbiota 
CD, UC, IC, self 
limiting colitis, H 
Culture, FISH, 
quantitative 
PCR, cloning, 
sequencing, 
electron 
microscope 
Mucosal  bacteria  concentration  high  in  IBD;  Higher  in  CD; 
Concentration increasing with severity; no phylogenetic differences;  
No evidence of mycobacteria or listeria; Bacteroides & E coli higher 
in  IBD;  Intracellular  bacteria  observed  in  mucosa  with  the  high 
bacterial load; No bacteria in lamina propria 
Schultsz  et al 1999 
(493) 
Composition & spatial 
organization of mucosal 
microbiota of the rectum 
Active CD, UC, H  In situ 
hybridization 
Bacteria more common & in higher concentration in IBD; Bacteria 
were  localized  within  mucus  layer,  but  were  not  adherent  to 
epithelium; No presence in lamina propria; No correlation between 
the bacterial counts & the degree of inflammation or the use of anti-
inflammatory medication 
H: healthy  117 
 
Characterization of intestinal microbiota in IBD 
Microbial diversity and abundance is reported to be decreased in IBD compared with healthy 
controls (504;513;520) with a decrease up to 50% in CD and to 30% in UC. Only one study 
investigated the diversity of yeasts which was found to be increased in IBD patients (526). 
Inter-individual similarity of bacterial community profiles is reportedly high in healthy or UC 
but  not  CD  subjects  indicating  that  the  former  two  groups  share  more  common  bacteria 
among individuals than CD patients (504;514). 
With regard to the composition of the intestinal microbiota, higher numbers of aerobic 
and  facultative  anaerobic  bacteria  have  been  reported  in  IBD  (503;521;527)  signalling  a 
different intestinal ecosystem compared with healthy people. Frequently characterization of 
the bacterial composition revealed increased numbers of enterobacteriaceae (523), mainly E. 
coli  (516;522) and decrease in Firmicutes (483;513) with selectively decreased Clostridium 
species (487;505;510;512;514;517;521;525). Recently in a comprehensive analysis of 190 
IBD  tissue  samples  Frank  et  al,  using  a  metagenomic  approach,  (483)  confirmed  these 
previous  observations  and  found  decreased  numbers  of  the  phylum  Firmicutes  and 
Bacteroidetes and a parallel increase in Proteobacteria and Actonibacteria (483). 
An “unhealthy” colonic microbiota mucosa with reduced putative beneficial species 
like bifidobacteria or lactobacilli and occasionally an  increase in commensal opportunistic 
pathogens like E. coli has been reported by few (505;516;519;520) but not all investigators 
(509). It is noteworthy that bifidobacteria was found at 30-fold higher levels in healthy than 
UC mucosal cultures and the presence of peptostreptococci was only identified in the latter 
specimens (527). 
Undefined new bacterial species that do not belong to common dominant microbiota 
were typically seen in IBD mucosal and faecal specimens and the possible contribution of 
these strains to IBD remains elusive (509;513;520;522;523;528).  
Comparisons of the faecal microbiota of patients with CD, UC and infectious colitis 
showed significant differences suggesting that observed modifications of the flora are not 
only because of the ecological changes induced by colitis (512).  
 
Evidence of bacterial pathogens in IBD 
Identification of pathogens was only a secondary objective in the studies reviewed, and the 
majority did not find clear evidence for pathogens such as Mycobacteria, Listeria, (487;525) 
H.  pylori,  C.  difficile,  and  SRB  (509).  Occasionally  some  authors  detected  opportunistic 
pathogens in mucosa samples of patients with CD only but not in healthy or UC subjects 
(503;504;510). Bacteroides vulgatus, a mucus degrading bacterium which initiates colitis in   118 
transgenic HLA-B27 rats (477), was detected, in most of the faecal samples of patients with 
CD  but  was  rarely  retrieved  from  healthy  participants  in  a  French  study    and  this  is  in 
agreement with previous studies using traditional microbiology on growth media.   
 
IBD microbiota and disease activity 
The notion that intestinal microbiota composition might influence disease activity and explain 
the  remitting  and  relapsing  disease  course  has  been  challenged  by  a  few  researchers, 
although it is difficult to distinguish whether any difference seen has a primary causal effect 
or is a secondary to the disease process. Some authors found that the diversity of microbiota 
or individual bacterial species (505) were different between active and inactive disease (523) 
(Table 1.7.4).  
An association between disease activity and specific bacterial species was recently 
reported by Baumgart et al (487) who found that in CD with ileal involvement E. coli numbers 
in situ correlated with the severity of ileal disease. Likewise in a previous study Swidsinski et 
al  found increased concentration of mucosa adherent bacteria with increasing severity and 
Bullock et al (519) found lower concentration for lactobacilli in active compared to quiescent 
UC disease. Swidsinski et al (505) recently found that with increasing intestinal inflammation, 
loss of the habitual microbiota occurred in both CD and UC. In the same study, species-
specific  changes  were  observed  between  active  and  quiescent  disease  in  CD  with 
Enterobacteriaceae increased and bifidobacteria decreased in active compared with inactive 
CD. 
A  localized bacterial dysbiosis, and alterations in the mucosal microbiota between 
inflamed  and  healthy  tissue  has  not  been  found  in  the  majority  of  studies 
(506;507;509;510;521). Only Baumgart et al (487) observed a high presence of adherent and 
invasive  E.  coli  in  the  inflamed  but  not  in  healthy  mucosa  of  CD  patients  with  ileum 
involvement.  Failure  to  identify  any  difference  between  the  microbiota  of  healthy  and 
inflamed areas is contrary to the hypothesis of a localized “dysbiosis” which could explain the 
intestinal lesions and the disease distribution mainly in CD.  
 
Spatial organization of bacterial microbiota 
The well documented differences between faecal and mucosal associated microbiota (347) 
and  the  direct  contact  of  the  latter  to  the  intestinal  epithelium  prompted  a  considerable 
amount of research to be directed towards the spatial organization of the mucosal associated 
microbiota. 
Several studies have repeatedly shown that the epithelial surface or mucus layer of 
IBD  patients  contains  a  higher  number  of  bacteria  compared  with  controls   119 
(487;493;509;517;524;525). Bacterial infiltration and detection of intracellular bacteria in the 
intestinal  epithelium  and  lamina  propria  of  patients  with  IBD  were  reported  by  some 
investigators    particularly,  in  specimens  with  increased  number  of  mucosal  associated 
bacteria, but not by all (493;507;517). An interesting observation is that intracellular E. coli 
were  observed  in  the  inflamed  tissue  of  ileal  but  not  CD  colitis,  despite  the  higher 
concentration of bacteria lining the villi of the latter.  
 
Differences in the gut microbiota between CD and UC 
Disease specific differences in the commensal microbiota profiles were described in several 
studies  (505;509;510;524;525).  Swidsinski  et  al  (525)  found  a  higher  concentration  of 
mucosal adherent bacteria in CD than in UC, but no phylogenic differences were described. 
In a following study, the same group (505) showed a different bacterial profile between UC 
and CD for six out of 11 FISH probes used. In particular Faecalbacterium prausnitzii was 
dramatically  reduced  in  CD  only  but  was  unaffected  in  UC.  In  56%  of  the  CD  patients 
bifidobacteria were undetectable, whereas the mean concentration of the latter was higher in 
UC  than  in  healthy  faecal  specimens.  Based  on  these  overt  disease  specific  bacterial 
differences  and  in  conjunction  with  differences  in  the  faecal  leucocytes  concentrations, 
diagnostic cutoffs were proposed by the authors to discriminate between active CD and UC. 
Similarly Gophna et al (510) found significant phylogenetic differences between CD and UC 
and an overall more unbalanced microbiota in CD than in UC.    120 
 
Temporal changes of microbiota in IBD 
Stability  of  the  diversity  and  composition  of  the  dominant  intestinal  microbiota  is 
characteristic  of  healthy  adults.  Disturbance  occurs  in  some  GI  diseases  as  well  as  with 
dietary or pharmaceutical intervention. Only two studies assessed temporal changes of the 
intestinal microbiota in IBD. Martinez observed a decline in the bacterial similarity index of 
UC patients on longstanding remission of one year. No changes were seen for the healthy 
subjects who preserved both their bacterial diversity and similarity (504). Likewise Scanlan et 
al (514) found unstable microbiota profiles and decreasing diversity in CD patients who had 
achieved  clinical  remission  with  steroid  treatment.  However  no  changes  in  the  bacterial 
profile stability or diversity of bifidobacteria species were observed. A disease activity effect 
was observed with a more stable diversity in quiescent than in active disease (514).  
 
Microbiota diversity along the GI tract in IBD 
No  major  differences  were  observed  in  the  diversity  of  the  dominant mucosal-associated 
microbiota along the digestive tract in IBD patients (518) although Baumgart et al (487) found 
that  invasive-adherent  E.  coli  occurred  more  often  in  CD  with  ileal  involvement  than  in 
inflammation confined to the colon. 
 
Paediatric studies of intestinal microbiota in IBD 
To the best of my knowledge only one study has investigated the intestinal microbiota of 
paediatric patients with IBD. Conte and his colleagues (503) investigated and characterized 
the predominant composition of the mucosa associated intestinal microbiota in colonoscopic 
specimens  of  paediatric  patients  with  newly  diagnosed  IBD,  children  with  lymphonodular 
hyperplasia  and  healthy  controls.  Using  traditional  culturing  procedures  linked  with  novel 
molecular  biology  techniques,  the  authors  found  more  mucosa  associated  bacteria  and 
measured higher numbers of aerobic and facultative aerobic bacteria in IBD than in healthy 
controls. Pathogens were not isolated (Yersinia, Campylobacter, etc), nor were differences 
for bifidobacteria, C. coccoides group, Faecalibacterium prausnitzii, observed, as opposed to 
some  adult  studies  (Table  1.7.4).  Occurrence  of  B.  vulgatus  was  lower  and  E.  coli  was 
increased in IBD compared with healthy children. 
 
1.7.2.3.5. Conclusion 
Bacterial dysbiosis in the luminal microenvironment rather than a single pathogen has been 
proposed  as  a  putative  mechanism  in  IBD  aetiopathogenesis  (498),  and  overall  this 
comprehensive review supports this hypothesis. However a pathogen as causative factor in   121 
IBD cannot be entirely excluded. One should bear in mind that these studies have mostly 
assessed the dominant intestinal microbiota qualitatively and therefore cannot fully exclude 
quantitative differences, qualitative differences in the subdominant bacteria or a pathogen 
that which is unable to be isolated and be studied with contemporary techniques. 
In summary commensal intestinal microbiota is distinguishable in IBD from that of 
healthy subjects: 
a.  With increased numbers of bacteria in the mucus layer or in contact with 
epithelial cells 
b.  Reduced bacterial diversity 
c.  Unstable bacterial diversity over time 
d.  Colonisation by uncommon, unidentified bacteria 
e.  Reduction  in  several  “beneficial”  species  and  increase  of  opportunistic 
pathogens 
f.  Disease activity associated changes 
Changes  in  the  microbiota  of  patients  with  IBD  are  difficult  to  interpret  clinically 
although many of the depleted bacteria are major butyrate producers and their reduction 
might therefore compromise production of epithelial energy substrates (513).  
In considering dysbiosis as a key factor in the pathogenesis of IBD, perhaps the most 
difficult question is to distinguish between cause and effect: “Is dysbiosis just a secondary 
phenomenon of IBD or is it actually the cause of it?” All the former studies were unable to 
answer  this  as  they  recruited  patients  with  established  disease.  Only  a  large  cohort 
longitudinal  study  with  follow  up  measurements  prior  to  disease  onset  could  identify 
differences in gut microbiota diversity and metabolism between healthy people and patients 
who developed IBD at follow up. It was surprising that evidence concerning gut microbiota in 
paediatric IBD comes from a single study in patients with active disease. Extrapolation of the 
results from adult studies may not be appropriate. Although both adults and children share 
common pathology and clinical characteristics, the phenotypic characteristics and response 
to treatment are different. Paediatric IBD is more extensive and aggressive than in adults and 
perhaps  differences  in  adult  microbiota  might  explain  that.  More  studies  are  needed  to 
explore the composition of the intestinal microbiota in paediatric IBD and how this fluctuates 
with disease activity.   
 
1.7.2.4. Enteral nutrition, gut flora and metabolism in patients with IBD 
Although  the  commensal  gut  microbiota  is  stable  over  time  (341),  its  composition  can 
fluctuate  under  circumstances  such  as  in  health  and  disease.  Nutrition  is  a  strong 
determinant of the microbiota composition and metabolic activity, and although daily changes 
in a normal diet are coupled with minor modifications of the faecal flora, radical changes of a   122 
person’s diet such as artificial nutrition can affect the composition and metabolic activity of 
the commensal bacteria (529).  
On  the  other  hand  commensal  intestinal  microbiota  is  implicated  in  the  disease 
pathogenesis in IBD, and “dysbiosis” is considered as one of the putative mechanisms that 
may be implicated in intestinal inflammation and mucosal injury (Section 1.7.2.3.4). Thus 
modification of the commensal microbiota to a more beneficial/balanced microbiota could be 
a possible mechanism of action for EEN and could also explain the better efficacy of EEN in 
sites  of  the  GI  tract  (264)  where  abnormal  microbiota  is  usually  encountered.  Although 
modification of the intestinal microbiota has always been suggested as one of the potential 
mechanisms of action in relevant topic reviews (276;530) none of those cited an appropriate 
study. Thus far the only peer-reviewed evidence comes from an Italian study by Lionetti et al 
(531) and a recent Australian by Leach et at (532). 
The first by Lionetti et al (531) in a clinical study, collected serial stool samples from 
nine  patients  on  EEN  treated  with  a  polymeric  feed  for  eight  weeks.  Using  molecular 
methods of bacterial community profile analysis, they found evident changes in the dominant 
gut  microbiota  as  a  consequence  of  EEN  treatment.  Ongoing  changes  were  also  seen 
beyond eight weeks whilst children maintained supplementary formula. In contrast, samples 
from  healthy  children  showed  stable  bacterial  profiles  with  no  variation  over  time.  In  the 
second study Leach et al (532) collected serial stools samples from six CD children during 
EEN, and at four weeks and at four months after treatment, and compared their bacterial 
composition patterns and diversity with seven healthy children. The diversity of bacteria was 
assessed with DGGE and changes in the global bacterial, and group specific diversity and 
similarity  patterns  were  measured.  Although  bacterial  diversity  did  not  differ  significantly 
between healthy and CD children at treatment initiation a lower diversity was found at the 
end of treatment in the CD group compared with the healthy controls. Bacteroides-prevotella 
and Clostridium coccoides bacterial species were significantly decreased in the CD group 
compared with the healthy controls at the end of EEN treatment. Moreover the similarity 
index of bacterial diversity was low during treatment for all bacterial groups studied, and was 
significantly  lower  than  healthy  subjects.  However  no  pairwise  comparison  of  changes  in 
bacterial diversity and similarity patterns were reported during EEN to investigate changes 
during treatment.     
Disease improvement and amelioration of intestinal inflammation might be a result of 
changes  in  the  production  of  bacterial  metabolites  which  have  been  implicated  in  the 
pathogenesis of IBD, like SCFA and sulphide. Such a putative mode of action has been 
proposed by Day et al (533) in a recent review whereas possible prebiotic properties have 
also been attributed to the feeds (531). However to the best of our knowledge most of the 
commercial feeds commonly used for the management of CD, and particularly those tested   123 
by the studies above lack non-digestible carbohydrate which could impart a prebiotic effect to 
the supplement.  
  Beyond  the  limited  evidence  of  relevant  studies  in  the  area  of  IBD,  studies  that 
assessed the effect of EEN on the gut microbiota of healthy people or patients with other 
morbidities may be of relevance. The evidence on this topic has been recently reviewed by 
Whelan et al. (529) In a series of studies, it was concluded that the evidence of an effect of 
EN  on  the  intestinal  bacterial  metabolism  is  inconclusive.  Results  from  individual  studies 
were  contradictory  with  some  showing  large  reductions  in  the  total  number  and  type  of 
bacteria, and others suggesting no changes or increase in particular bacterial species. Apart 
from  differences  in  study  design,  methodological  flaws,  and  different  types  of  nutritional 
formulae,  the  additional  limitations  of  the  use  of  conventional  bacteriological  techniques 
might explain these discrepancies (529). In keeping with the ability of nutritional therapy to 
affect  colonic  fermentation,  most  of  the  studies  observed  reduction  in  the  production  of 
SCFA, particularly butyrate, in healthy subjects on low residue feeds (529).  
In a recent double blind RCT with cross over design, Whelan et al (324) administered 
a standard low residue diet or one high in fructoligosaccharides and fibre in 10 healthy adults 
exclusively for 14 days with a six week wash out period. In both treatments reductions in total 
faecal bacteria were observed  with FISH analysis although these were higher in the low 
residue regime. Although the low residue diet did not alter the diversity of microbiota, the 
high residue diet increased bifidobacteria and reduced clostridia concentration and relative 
proportion compared with baseline. Similarly the low residue feed reduced the concentration 
of total and major SCFA compared with baseline values whereas in the fortified feeds group, 
reductions were observed only for butyrate. Marked changes were observed in the relative 
proportion  of  each  SCFA,  following  consumption  of  the  feeds.  Consumption  of  the  low 
residue feed resulted in an increase in the relative proportion of acetate, isobutyrate, and 
isovalerate and a reduction in the percentage of butyrate compared with baseline values. For 
the high residue formulae similar changes with the alternative feeds were observed only for 
acetate and butyrate. Regarding changes in  faecal pH, administration of both low and high 
residue diet, increased pH significantly although the increase was lower in the latter.  
  In other GI disorders Schneider et al (534) in a cross sectional study of eight patients 
on nutritional therapy with feeds low in residue, demonstrated concentrations which were 
lower  for faecal  anaerobes  and  higher for  aerobes,  despite  no  difference  compared  with 
healthy  controls  for  bacteroides,  clostridia,  and  bifidobacteria.  In  a  third  group  on  total 
parenteral  nutrition,  both  aerobes  and  anaerobes  decreased  dramatically.  Despite 
differences in bacterial populations, there were no differences between patients, and healthy 
controls  in the  concentrations  of total  SCFA,  acetate,  propionate  or  butyrate. In the total 
parenteral group, total SCFA were decreased compared with the EN group.      124 
Extrapolating the results from studies in healthy subjects or similar investigations in 
other digestive disorders, in the context of IBD is inappropriate. Changes in gut bacteria 
population and metabolic activity can be attributed to both the effect of nutritional therapy and 
disease-mediated  effects  as  commensal  microbiota  are  strongly  implicated  in  IBD 
pathogenesis. In  the  studies  reviewed  by Whelan  (529)  in  healthy  subjects  any  changes 
could be ascribed mainly to the effect of the nutritional therapy. In IBD this could be the 
additional outcome of disease improvement. The effect of EEN on the gut microbial flora 
deserves further exploration. Alterations in the bacterial populations and metabolic activity 
may  alter  interactions  with  the  intestinal  epithelium,  thereby  leading  to  modulation  of 
inflammation. With the advent of new methods of analysis of bacterial flora, more evidence is 
anticipated. 
 
1.8. Overall conclusions and proposed areas of research 
From the pathogenesis of the disease to its management, nutrition plays an important role in 
paediatric IBD. The extensive literature review presented above was a compilation of the 
evidence  on  nutritional  aspects  in  IBD  and  aimed  to  identify  areas  of  interest  for  further 
research.  Although  good  evidence  is  emerging  from  research  and  clinical  experience  to 
advocate  the  role  of  EEN  in  disease  management  there  is  a  substantial  lack  of  studies 
investigating its mechanisms of action. This combined with the evidence that implicates the 
commensal microbiota in disease pathogenesis led the researcher to postulate a mechanism 
of EEN action mediated through modulation of intestinal microbiota diversity and/or metabolic 
activity. In 2004 when this PhD started there was no published evidence, which explored this 
although  leading  reviews  on  the  topic  often  cited  this  as  a  mechanism  of  action.  More 
evidence was therefore needed to address these anecdotal speculations. The two studies 
that  followed  were  of  small  number  of  patients  and  were  restricted  only  to  changes  in 
bacterial  diversity.  None  of  these  explored  changed  in  the  metabolic  activity  of  the 
commensal microbiota. A study that assessed changes in metabolic activity and bacterial 
diversity is presented in Chapter 7. 
  As was described in Section 1.5, nutritional therapy has a double role in paediatric 
CD. This is mainly to induce clinical remission, and in parallel, to improve nutritional status in 
active  paediatric  CD.  Although  changes  in  basic  anthropometry  have  been  described  in 
almost all of the studies, changes in body composition and micronutrient status have not 
been reported extensively. New methods of body composition are now available which allow 
measurements at bedside.  These are explored in Chapter 4. 
Micronutrients  play  an  important  role  in  health,  and  in  IBD,  there  is  evidence  to 
suggest  an  additional  role  in  disease  pathogenesis,  and  intestinal  injury.  Consensus   125 
guidelines from  North  America  suggest  that  all  patients  should  be  screened  regularly  for 
micronutrient deficiencies. However any speculation on micronutrient deficiencies in IBD is 
based on studies from adult studies, case reports and studies of individual micronutrients. 
Moreover low levels observed in many of the and their association with disease activity has 
to be revisited as recent evidence suggests that disease activity and acute phase response 
can spuriously change the serum levels of micronutrients and any association with activity 
markers may actually be artefactual.  This is investigated in Chapter 5. 
On  the  other  hand  the  role  of  other  unconventional  nutritional  therapies,  such  as 
probiotics, and special diets are increasing in the general population but the evidence from 
paediatric IBD studies is limited. As many of these therapies, have a good record of efficacy, 
increase in their use, by IBD patients should be anticipated. Moreover avoidance of specific 
food groups, as part of adherence on exclusion diets, can impact on the micronutrient status 
of the patients and affect their health negatively. The use of nutritional therapies, special 
diets and alternative medicine is explored in Chapter 2.  
The aim of this doctorate therefore was to study the use of unconventional nutritional 
therapies by paediatric IBD patients and the effect of EEN on the intestinal microbiota and 
nutritional status, by measuring body composition, micronutrient status and disease activity.   126 
 
 
 
 
 
 
CHAPTER TWO 
 
 
 
 
 
Dietary modifications, nutritional supplements 
and alternative medicine in paediatric patients 
with IBD.   127 
 
OUTLINE 
This chapter describes a questionnaire survey to assess the use of special diets, nutritional 
supplements and alternative medicine in a paediatric population of Scottish children with IBD. 
Predictors  and  reasons  of  use  are  discussed.  This  study  has  already  been  published. 
Alimentary Pharmacology and Therapeutics. 2008 15;27(2):155-65 
 
2.1. Introduction 
The aetiology of IBD remains unknown and the most effective medications commonly have 
side  effects  that  limit  patients’  acceptance  and  long-term  compliance.  In  children,  the 
additional  issues  of  growth,  maturity  and  body  image  make  disease  management  more 
complicated  and  troublesome  for  health  professionals,  the  patients  themselves  and  their 
guardians (34). Although most patients rely on conventional medicine, some may combine or 
replace this with unconventional-alternative remedies for the management of their condition 
(60;68). 
Complementary  an  alternative  medicine  (CAM)  use  by  the  general  population  is 
widespread  around  the  world  (48)  and  increasing  over  time  (Section  1.2.2).  CAM  use  is 
reported  as  high  in  chronic  illness  and  gastrointestinal  patients  (47;50;51;56;60-
62;66;69;70;535). In particular, the prevalence of CAM use in IBD patients has been reported 
to be higher than in healthy people (61) and although early studies estimated that 4% of 
patients use CAM (62), recent surveys reported a sharp increase to 72% (69). However no 
definite figures can be drawn. The use of CAM varies widely between studies and this could 
reflect differences in study design, responding populations (68;536), cultural specificities or 
preferences  (46),  but  most  of  all  the  different  definitions  of  CAM  (48).  There  is  no  clear 
definition of which specific methods and remedies comprise CAM and which do not. Some 
studies  included  therapies  like  prayer  (46;537)  and  exercise  in  the  definition  and  others 
excluded  the  use  of multivitamins  purchased  over  the  counter (63). Therapies  with  good 
evidence  of  clinical  efficacy,  but  which  are  not  prescribed  as  conventional  medicine,  like 
probiotics, were included in only a few studies (64;66). In fact with more scientific evidence 
accumulating around the efficacy of such products (75;538) and their commercialization, it is 
anticipated that more patients will use them in the future. New branches of established CAM 
disciplines are continually being developed, taught in medical schools, used in hospital or in 
primary  healthcare  (54;56;539),  reimbursed  by  insurance  companies,  and  integrated  into 
conventional medicine (540). 
Although there have been some studies on the use of CAM in adult IBD patients 
(46;63;68;539)  the  prevalence  of  CAM  in  paediatric  populations  is  not  well  studied.   128 
Differences in disease management regimes between adult and paediatric patients (34), as 
well as the issues of growth, maturity and image make the extrapolation of the results from 
adult studies difficult. Indeed the use of CAM by paediatric patients reflects the choice of their 
guardians  and  not the patients’,  and  rather  how  the former  perceive and  cope  with  their 
child’s disease.   
Most paediatric surveys have been conducted in the US (64) and Australia (66) with 
only one multinational study which included only a small sample of UK patients from a single 
hospital in London, UK (65). Disease management protocols differ between countries (256) 
and  as  the  use  of  CAM  in  adults  was  associated  with  the  type  and  use  of  specific 
medications (68;541), different patterns of CAM use should be expected worldwide. 
The main purpose of the present study was the evaluation of current and past CAM 
use by a paediatric IBD population in the West of Scotland, including types of CAM with good 
records of clinical efficacy, the reasons of their choice, and parental attitudes on CAM use. A 
secondary  outcome  was  to  report  any  factors  associated  with  CAM  use  including  new 
predictors like growth and anthropometry and serial post diagnostic laboratory markers of 
disease activity.  
 
2.2. Materials and methods 
All paediatric (<18 y old) IBD patients, along with their guardians, who attended their follow 
up clinical appointments at Yorkhill Royal Hospital of Sick Children, Glasgow were eligible to 
participate.  This  is  the  biggest  tertiary  paediatric  IBD  referral  centre  in  Scotland,  serving 
approximately half of the Scottish paediatric population and is predominately in charge of the 
management of almost all children with IBD in the greater region of the West of Scotland. At 
the time of the study, there was no private paediatric clinic. This allowed inclusion of nearly 
all paediatric patients diagnosed with IBD and residing in the West of Scotland. 
Given  that  each  patient  visits  the  IBD  outpatients  clinic  at  least  once  a  year  for 
medical review (independent of disease activity), it was anticipated that all IBD patients, and 
their  guardians,  could  be  approached  within  a  year.  All  recently  diagnosed  patients  (<  3 
months) were excluded, as they would not have had much time to consider CAM treatment. 
Patients with other severe concomitant chronic illness were also excluded.  
The study protocol was approved by the Local Research Ethics Committee and the 
Research and Development Office at Yorkhill Hospitals. 
 
2.2.1. Recruitment 
An  independent  clinical  researcher  explained  the  research  to  the  patients  and  their 
guardians. An information leaflet was given to the guardians and an age adapted version to   129 
the patients themselves. If both agreed to participate, a blank questionnaire was provided 
with a post-paid, pre-addressed envelope and the method of completion was demonstrated 
on a template questionnaire by the researcher. Participants could ask questions on clarity. 
The  guardian  filled  in  the  questionnaire  at  home  and  returned  it  by  post.  A  second 
questionnaire was posted to all participants that had not responded within 15 days.  
 
2.2.2. Questionnaire 
The  instrument  consisted  of  40  questions  and  took  approximately  15  min  to  complete 
(Appendix).  A  preliminary  questionnaire  was  compiled  using  two  existing  questionnaires 
(64;66). The questionnaires were then modified with the inclusion and exclusion of questions 
to reflect the use, and types of CAM commonly used in the UK. CAM was defined as those 
unconventional remedies and treatments that are not normally taught in UK medical schools, 
as  established  approaches  to  IBD  management,  are  not  reimbursed  by  the  NHS  nor 
recommended by our medical staff. Exercise and prayers were not included. 
The face validity of the questionnaire was checked by several health professionals 
and the first 10 participants were asked anonymously to comment on questionnaire clarity 
and ease of use. Appropriate amendments were made to the questions and the structure of 
the instrument. 
The first section of the questionnaire described the patient’s socio-demographic and 
disease characteristics. The following section focused on the use of CAM and listed four 
groups  of  therapies  namely  Dietary  modifications,  Herbals,  Nutritional  Supplements,  and 
Alternative Therapists. The guardians answered whether the child used, or had recently used 
any  of  these  especially  for  the  management  of  IBD.    The  time  from  symptoms  onset  to 
diagnosis is quite variable and patients may have had the opportunity to use CAM before 
diagnosis, however to ensure all patients had significant time to try CAM after diagnosis this 
survey asked carers to document any type of CAM used three months post-diagnosis. 
In total, 35 different types of CAM were described and there was an open question at 
the  end  of  each  group  for  any  CAM  not  on  the  list.  Although  multivitamins  and  dietary 
modifications were included, it was made clear to participants to report only those that were 
purchased over the counter or not recommended by their hospital medical staff.  
The next section, applied only to those patients that had used CAM. Participants were 
asked  to  report  sources  of  information  on  CAM,  reasons  they  had  chosen  these,  their 
effectiveness, cost and doctor’s awareness of their CAM use. The last section, directed to all 
the respondents consisted of five questions addressing parental attitudes about CAM, and 
the use of CAM by other members of their family or the patients themselves for other health 
reason.    130 
To ensure anonymity, confidentiality and undistorted responses the questionnaires 
were not numbered and parents asked not to add any identifiers. An invisible number was 
located on each questionnaire to identify non-respondents for subsequent mailing.  
On a supplementary form, detached from the main questionnaire, but with the same 
invisible  number,  the  researchers  recorded  information  on  disease  characteristics,  post 
diagnostic laboratory data, conventional treatments, growth and anthropometry (Appendix). 
This form  was  reattached  to  the main questionnaire  when  the  latter was  returned  to the 
researchers by the participants.  
 
2.2.3. Statistical analysis 
The prevalence of CAM use was estimated as the total number of patients reporting CAM 
use  of  any  type  divided  by  the  total  number  of  respondents.  Categorical  variables  were 
presented  as  frequencies  and  means  with  standard  deviations  and  medians  with  inter-
quartile range for parametric and non parametric variables respectively.  
Binary  and  nominal  logistic  regression  analyses  (Minitab  13)  were  undertaken   to 
determine potential predictors of CAM use. Candidate predictors were suggested a priori. 
These included age, sex, disease type, phenotype and duration, total number and types of 
medication  since  diagnosis,  serial  post  diagnostic  laboratory  data  on  CRP  (C-Reactive 
Protein), haemoglobin, albumin, ESR (Erythrocyte Sedimentation Rate), IBD operation, BMI 
(Body Mass Index), height and height velocity z-score at recruitment, six and 12 months 
before, parental use of CAM, CAM use for other reason, social deprivation score (Scottish 
Index  of  Multiple  Deprivation;  http://www.scotland.gov.uk/Topics/Statistics/SIMD/Overview), 
parental  education  and  age.  For  purposes  of  analysis,  patients  were  grouped  into  “Self-
prescribed CAM Users” (including dietary modifications, nutritional and herbal supplement 
users)  and  “CAM  Therapist  Users”  (those  who  consulted  an  alternative  therapist)  as 
proposed  by  Harris  and  Rees  (48)  to  permit  comparison  with  other  studies  (537).  The 
strength of association between use of CAM and associated factors was measured by odds 
ratio and 95% CI.  
The  process  of  selection  and  inclusion  of  variables  in  the  multivariate  model  was 
based on univariate logistic regression analysis. Associated predictors with p-values < 0.1 
were  entered  in  a  multivariate  model  and  their  independent  association  tested  using 
backward stepwise regression. The final model included only those predictors with p-value 
less than 0.05 as independent predictors of CAM use for the binary analysis, whereas for the 
nominal regression analysis the final model considered only predictors with p-value less than 
0.05 for at least one of the comparisons.  
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2.3. Results  
2.3.1. Recruitment 
Approximately  480,000  children  are  serviced  by  the  Yorkhill  hospitals,  and  159  patients 
visited the IBD outpatient clinic between June 2005 and July 2006 and this covers the IBD 
population serviced by the IBD clinic. Twenty four patients were not eligible to participate. 
From 135 eligible patients 104 were approached (77% of the eligible population) along with 
their  guardians  and  all  consented  to  participate.    Due  to  logistic  constraints  it  was  not 
possible to approach all patients and 31 who visited the clinic in the time of the study were 
not recruited. Eighty six including 40 female patients completed and returned the survey (83 
% response) and all were used in the analysis. All but one patient were of Caucasian origin. 
 
2.3.2. Respondents demographic characteristics 
The median age of patients at recruitment was 12.7 (4.8 – 17.5) y. There was almost equal 
distribution  of  the  family  social  deprivation  score  (Scottish  Index  of  Multiple  Deprivation) 
(Table 2.1). The majority of the responding parents were more than 31 y old and 56% had 
higher education (college and university combined) (Table 2.1).  
 
Table 2.1: Demographic characteristics of participants in a Scottish survey on the use of CAM 
by children with IBD 
Demographics    Parental age†  N (%) patients 
Gender (M/F)  46/40    18-30      5 (6) 
Age (y mean ± SD)  12.7 ± 2.8    31-45    58 (68) 
      46-60+    22 (26) 
 
Social deprivation* 
(quintiles) 
N (%) patients  Parental education†  N (%) patients 
  1    16 (20)  Standard Grade (year 11)    25 (33) 
  2    15 (18)  Highers (year 12)    8 ( 11) 
  3    13 (16)  Further Education/College    18 (24) 
  4    22 (27)  University    24 (32) 
  5    15 (19)     
*Scottish Index of Multiple Deprivation 2004; based on six individual domains of current income, employment, housing, health, 
education, skills and training and geographic access to services and telecommunications † responding parent 
 
2.3.3. Patients disease characteristics 
Crohn’s disease patients accounted for two thirds of participants, whereas 26% had UC, and 
9% were classified as IC according to standard endoscopy, histology and radiology criteria. 
The median age at diagnosis was 10.3 y (range: 1.9-14.5) with median disease duration of 
2.4  y  (0.4-7)  at  time  of  recruitment.  The  majority  of  patients  had  been  treated  with  5-
aminosalicylates, azathioprine, steroids and EEN (Table 2.2). The majority of them had a 
repeat course of EEN or oral steroids. 12% of patients had had a major operation for IBD that 
included resection of part of their gut.   132 
 
2.3.4. Patients anthropometry and growth data 
The mean BMI z-score of the respondents was 0.2 SD with 2.4% classified underweight (BMI 
z-score < 2 SD) and 3.6% obese (BMI z-score > 2 SD).  
 
Table 2.2: Disease characteristics and post diagnostic medication of participants in a Scottish 
survey on the use of CAM by children with IBD 
Disease type (n=86)  N (%) patients  Disease location   N (%) patients 
Crohn’s disease  56 (65)  Lower GI  33 (42) 
Ulcerative colitis  22 (26)  Upper & Lower  42 (53) 
Indeterminate colitis  8 (9)  Upper  4 (5) 
       
Total post-diagnostic 
medication No  N (%) of patients  Total post-diagnostic 
medication type 
N (%) of 
patients 
≤2  6 (7)  5-ASAS  16 (81) 
3  8 (10)  Azathioprine  58 (68) 
4  19 (23)  Steroids  55 (65) 
5  10 (12)  Vitamins / Minerals  55 (65) 
6  12 (14)  EEN  51 (60) 
7  8 (10)  Caloric Supplements  37 (43) 
8  10 (12)  Antibiotics  36 (42) 
≥9  10 (12)  Omeprazole  20 (24) 
Gut Resection  10 (12)  Methotrexate  15 (18) 
    Infliximab  8 (9) 
No of oral steroid 
courses  N (%) of patients  No of EEN courses  N (%) of 
patients 
0  36 (42)  0  36 (42) 
1  17 (20)  1  24 (28) 
2  15 (18)  2  15 (18) 
3  12 (14)  3  4 (5) 
>3  5 (6)  >3  6 (7) 
Biochemistry*  Median; (Range)  Hospitalization (last 2 y)  N (%) of 
patients 
Albumin (g/l)    39   (24-47)  0  34 (40) 
CRP (mg/l)    7   (7-100)  1  20 (24) 
Haemoglobin (g/dl)     11.8   (8.4-14.7)  2  14 (17) 
ESR (mm/hr)    20.7   (3-66)  >2        16 (19) 
* Median of all available post-diagnosis values 
 
The  mean  height  z-score  was  –0.4  SD  with  7.2%  presenting  values  less  than  -2  SD 
suggesting possible growth retardation. Their median height velocity at six and 12 months 
was 0.9 and 0.8 SD respectively. 
 
2.3.5. Use of CAM 
Fifty two of the eighty six respondents (61%) reported prior use of CAM for the management 
of IBD and 37% were using some form of CAM on recruitment. A quarter of the respondents 
(21/86) had consulted at least one alternative therapist whereas only three patients were 
using that kind of CAM on recruitment (Table 2.3). 
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Table 2.3 Past and recent users of CAM in a Scottish survey of children with IBD grouped into 
“self-prescribed CAM users” and “CAM therapist users” 
Type of CAM User  N (%) Ever used 
(n=86) 
N (%) Recently used 
(n=86) 
“Self-prescribed CAM users”  31 (37)  29 (34) 
“CAM therapist users”  21 (24)  3 (3) 
Overall CAM use  52 (61)  32 (37) 
 
Probiotics,  dairy  free  diet,  omega-3/fish  oils  and  aloe  were  the  most  common  therapies, 
followed  by  gluten  free  diet,  homeopathy,  massage  and  over  the  counter  multi  and 
megavitamins  (Table  2.4).  The  median  and  interquartile  range  of  total  number  of  CAM 
therapies ever used was three (range: 2-6) CAM and two (range: 1-2) in the recent users.  
 
Table  2.4:  Use  of  dietary  modifications,  nutritional  supplements,  herbals  and  alternative 
therapists in a Scottish survey on the use of CAM by children with IBD  
  N (%) Ever used 
(n=86) 
N (%) Recently used 
(n=86) 
Dietary modifications 
    Dairy free diet 
 
24 (28) 
 
12 (14) 
    Gluten free diet  13 (15)  2 (2) 
    Low residue diet  8 (9)  3 (3) 
    Low sugar diet  4 (5)  0 (0) 
   Vegeterian diet  4 (5)  0 (0) 
   Other diets  5 (6)  1 (1) 
     
Herbals 
    Aloe 
 
16 (19) 
 
2 (2) 
    Garlic  8 (9)  0 (0) 
    Echinacea  8 (9)  1 (1) 
    Evening primrose  7 (8)  0 (0) 
    Other herbals  19 (23)  1 (1) 
     
Nutritional supplements 
    Probiotics 
 
38 (44) 
 
17 (20) 
    Fish / Omega-3 Oils  25 (27)  7 (8) 
    Vitamins / Minerals  12 (14)  3 (3) 
    Prebiotics  8 (9)  1 (1) 
    ‘Active’ dairy products  8 (9)  2 (2) 
    Other nutritional supplements  11 (13)  3 (3) 
     
Alternative therapists 
    Homeopathy 
 
12 (14) 
 
1 (1) 
    Massage  11 (13)  1 (1) 
    Aromatherapy  8 (9)  0 (0) 
    Yoga  5 (6)  0 (0) 
    Relaxation  5 (6)  1 (1) 
    Chiropractic  4 (5)  0 (0) 
    Reflexology  4 (5)  0 (0) 
    Other alternative therapists  14 (16)  0 (0) 
 
Seventy three percent (38/52) of CAM users answered the relevant section on CAM use. Of 
14 respondents that skipped the section, only one was a “CAM Therapist User”. Of these 22 
revealed the use of CAM to their doctor. 50% reported that their doctor reacted positively, 
37% neutrally and 12% negatively to the use of CAM. Most participants that did not report   134 
the use of CAM to their doctor, thought that it was not important for their doctor to know or 
they  forgot  to  do  so.    Parents  reported  that  they  received  information  about  CAM  from 
personal recommendations, magazines, newspapers and the Internet (Table 2.5).  
 
Table 2.5: Reasons of use and sources of information on CAM in a Scottish survey on the use 
of CAM by children with IBD  
 
Reasons given for using CAM included an attempt to complement conventional treatment, 
personal experience with CAM use, frustration with conventional medication side effects and 
the belief that CAM is natural and harmless (Table 2.5).  
Approximately equal numbers (16 and 17 respectively) of CAM users judged CAM 
use effective and not effective. One patient reported deterioration of the disease condition 
and one mentioned side effects. More “CAM Therapist Users” (12/16) labelled CAM effective 
compared  to  “Self-prescribed  CAM  Users”  (p=0.022).  Fifteen  of  38  users  found  CAM 
expensive although most of these (10/15) had consulted an alternative therapist.  
Twenty seven percent of all respondents had discussed CAM with their doctors and 
most were “CAM Therapist Users” (p=0.003). 16% of the children had used a type of CAM 
for other reasons whereas 32 % of the patients’ relatives had used CAM.  
Most of the parents were positive about the use of CAM, but the majority (40/53) had 
already used CAM for their child’s IBD (Table 2.6). 89% of the respondents would give their 
child  CAM  if  they felt  it  to  be  useful  although 50  out  of  73  were  already  CAM  users.  In 
addition 52% of the respondents were not wary of using CAM, 57% of them would be happy 
for their child to use any type of CAM and 86% agreed with the statement that “doctors 
should  be  supportive  of  people  using  CAM”.  On  the  other  hand  the  majority  of  the 
respondents  had  no  opinion  about  CAM  safety  and  agreed  with  the  statement  that  “not 
enough is known about CAM” (Table 2.6).  
Reasons of CAM use  N (%)  Sources of information  N (%) 
Complement conventional treatment  21 (45)  Read about it  18 (47) 
Personal experience  16 (42)  Recommended by friends  18 (47) 
CAM is natural and harmless  12 (32)  Internet search  10  (26) 
Frustration with medication side effects   11 (29)  Recommended by health professional  7 (18) 
Dissatisfaction with medication  5 (13)  Other reason  7 (18) 
Other reason  7 (10)     
CAM is more effective  1 (3)     
Lack of confidence in medication  1 (3)       135 
 
Table 2.6: Attitude on CAM use by parents of children with IBD in a Scottish survey of the use 
of CAM 
  Disagree 
N (%) 
No opinion 
N (%) 
Agree  
N (%) 
Not a person that would use CAM  53 (74)  11 15)  8 (11) 
Doctors should be supportive of CAM  3 (4)  8 (10)  66 (86) 
Wary of using CAM  39 (52)  3 (4)  33 (44) 
CAM is very safe  16 (21)  36 (49)  22 (30) 
Not enough is known about CAM  8 (11)  15 (20)  51 (69) 
Would be happy my child to use any CAM  19 (25)  14 (18)  44 (57) 
Would give CAM only if doctor says so   31 (39)  9 (12)  39 (49) 
Would give CAM if I felt to be helpful  6 (7)  3 (4)  73 (89) 
 
2.3.6. Predictors of CAM use 
Parents under 46y and of high parental educational level were the strongest independent 
predictors that distinguished CAM users in the multivariate analysis (Table 2.7). Use of CAM 
for other health reason, and an increased number of oral steroid courses were additional 
variables  that  differentiated  “CAM  Therapist  Users”  from  non  users  although  a  positive 
association between disease duration and use of “CAM Therapist Users” revealed in the 
univariate analysis was lost in the multivariate model. 
 
2.4. Discussion 
Knowledge of CAM use by children with IBD is imperative. Some of these treatments have 
severe adverse effects with reports in the literature of death, anaphylaxis, renal failure and 
malignancies (77;542) whereas for those with good safety records in adults, the same doses 
used in adults, may not be safe in children with a smaller drug distribution volume. Moreover 
possible  unpredicted  interactions  with  conventional  medicine,  could  reduce  or  delay  the 
efficacy of the prescribed treatment with subsequent detrimental prognostic effects (543). 
Paediatric  data  on  CAM  use  by  IBD  patients  is  scarce  and  to  the  best  of  our 
knowledge this study is the biggest paediatric study so far in the UK and Europe. Unlike 
previous  surveys  (65)  only  patients  younger  than  18  y  were  recruited  to  ensure that  the 
measured CAM use was not confounded by “adult children”. 
In this study the number of non respondents was small and any difference between 
respondents  and  non  respondents  should  not  change  the  overall  findings  significantly. 
Response is of utmost importance in a study where a goal is to generalize the results to the 
entire  population.  Poor  response  rate  raise  concerns  that  existing  differences  between 
responders and non-responders would significantly change the results.  
Although three patients approached in this study were of Asian origin, none of them 
returned the questionnaire in agreement with an adult survey where significantly less Asians 
than  Europeans  responded  (47).  However  no  difference  in  the  use  of  CAM  was  found   136 
between Asians and Europeans in that study and therefore the children with Asian origin in 
this study would be unlikely to differ from the responders.  
The study design approached a geographically diverse sample, representative of half 
of  the  whole  Scottish  paediatric  IBD  population  in  contrast  to  other  surveys  with 
predominantly severely  ill patients from a single tertiary hospital (65). This was achieved 
because there was no other public or private paediatric clinics and the hospital management 
protocol ensured that each patient visits the hospital at least once a year independent of 
disease activity. Indeed the sample’s disease and demographic characteristics, mirrored the 
results of a Scottish national study (16) and a prospective epidemiological survey in the UK 
(11). This study surveyed only those patients who were diagnosed in a conventional clinic.     137 
Table 2.7: Predictors of CAM use by Scottish children with IBD based on univariate and multivariate logistic analysis with p-values, 95% CI and 
odds ratios. 
  All Users  “CAM Therapist Users”  “Self-Prescribed Users” 
Univariate analysis    P  OR  95%CI  P  OR  95%CI  P  OR  95%CI   
Diagnosis age    0.127  0.9  0.7  -  1.0    0.051  0.8  0.7  -  1.0    0.388  0.9   0.8  -  1.1 
Disease duration    0.517  1.1   0.9  -  1.4    0.048  1.3  1.0  -  1.8    0.541  0.9  0.7  -  1.2 
Parental age*    0.007  4.0  1.5  - 11.3    0.047  4.2  1.0  -  17.1    0.022  4.0  1.2  -  12.9 
Parental education†    0.001  5.8  2.0  - 16.2    0.001  12.7  2.9  -  55.9    0.017  3.9  1.3  -  11.9 
CAM for other reason    0.155;  2.7   0.7  - 10.5    0.028  5.4  1.2  -  24.2    0.659  1.4  0.3  -  7.0 
CAM use by family    0.360   1.6   0.6  -  4.1    0.061  3.1  0.9  -  10.0    0.951  1.0  0.3  -  2.9 
Steroid use    0.065;   2.3   0.9  -  5.8    0.144   2.5   0.7  -  8.5    0.116  2.3  0.8  -  6.3 
No of steroids courses    0.588   1.1   0.8  -  1.5    0.074   1.4   1.0  -  2.0    0.519  0.9  0.6  -  1.3 
Multivariate analysis   
Parental age*    0.005  6.6  1.8  - 24.3    0.012  21.4  2  -  232.6    0.021  5.5  1.3  - 23.8 
Parental education†    0.001  9.1  2.4  - 33.7    0.002  18.9  2.8 -  125.3    0.008  7.0  1.7  - 29.3 
CAM for other reason    0.128  4.5  0.6  - 30.8    0.009  25.3  2.3 -  283.7    0.434  2.3  0.3  - 18.8 
No of steroids courses    0.436  1.2  0.7  -  2.0    0.021  2.5  1.1 -  5.4    0.908  1.0  0.5  -  1.7 
* Age groups 18-30 and 31-45 unified 
† Unified into two groups (Standard Grade and Highers; College and University) 
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However, it is unlikely in the area surveyed that any child with IBD will never visit an 
NHS clinic and therefore very few who distrust conventional treatment will have been missed.  
Demonstration of the questionnaire and its completion at home ensured confidentiality and 
clarity of the questions. The anonymity of the questionnaire allowed undistorted responses 
and encouraged reliable answers and may have contributed to the high response rate.  
Consistent with previous paediatric studies (64-66;544), this study found that a large 
proportion of IBD children use CAM, to a similar or greater extent than adults (63;541). More 
than half of the children used some form of CAM and a quarter visited alternative therapists. 
This  is  much  higher  than  the  10%  use  of  alternative  therapists  reported  for  the  general 
population in the UK National Omnibus Survey. The estimated use of CAM in this study is 
lower than the 72% of the survey population in an Australian study, but higher than the 41% 
found  in  a  multinational  study  (65),  22%  and  51%  in  a  Canadian  (544)  and  American 
paediatric survey (64) respectively. It is possible that the increased use of CAM in this study 
reflects an increase over time, but this needs to be verified in a longitudinal study in the same 
population. A direct comparison between paediatric studies is hampered by differences in the 
study design, responding population, and definitions of CAM (48). Although this study did not 
compare the results with those from a healthy cohort, the questionnaire used in this study 
was  specific  for  the  past  and  current  use  of  CAM  for  IBD  management  and  also  asked 
participants whether they had used CAM for other medical reason than IBD management. 
The fact that different answers were given in the section on IBD CAM use and in the section 
of CAM use for other reasons or for parental use shows that the questionnaire used was 
clear and specific for CAM use for IBD management. 
In the current survey, probiotics, dairy free diet and fish oils were the most prevalent 
types of CAM, followed by aloe and homeopathy. This is consistent with previous paediatric 
studies in the USA (64) and Australia (66) which used similar questionnaires. In contrast the 
multicentre survey by Heuschkel and his colleagues (65) found only 6% of their participants 
used probiotics and only 2% in their centre in London compared to the 44% found in this 
Scottish survey. The higher use of probiotics in the current study parallels the increase in the 
number of studies suggesting a beneficial effect in IBD management (75;76) and increased 
availability and advertising. The belief that dairy products can exacerbate the disease and 
that patients restrict their consumption has already been well documented (545;546). The 
lower incidence of multi or megavitamin use than in other studies (65) could be attributed to 
the questionnaire being specific for vitamin supplements not prescribed by the medical team. 
It is noteworthy that three of the most commonly used CAM in this survey (probiotics, omega 
oils  and  aloe  vera)  already  have  controlled  trials  for  adults  published  in  the  literature 
(74;76;547),  are  suggested  through  support  groups  and  websites  and  which  could  have 
affected the choice of these treatments.  Although it would be interesting to know whether the   139 
patients  used  these  treatments  to  maintain  remission  or  to  suppress  a  relapse,  the 
questionnaire was not designed to address this.   
This  study  considered  a  wide  range  of  possible  predictors  for  CAM  use. 
Demographically  no  relation  to  age, gender,  or  disease  diagnosis  (UC  vs  CD)  has  been 
found in both adult (46;74;76;536;541;547-549) and paediatric surveys and the results are in 
accordance. Young parental age and higher education level were independently associated 
with CAM usage, a finding commonly reported in the general paediatric population (550). It 
may  be  that  young  educated  parents,  are  more  open  or  seek  information  on  innovative 
methods  of  disease  management,  or  do  not  trust  conventional  medicine.    It  has  been 
reported (12) previously that early onset CD is associated with affluence, however, in this 
study  the  spread  of  patients  between  deprivation  scores  based  on  (SIMD)  was  roughly 
equivalent and there was no higher number in the higher affluent scores.  Social deprivation 
was not found to be a predictor of CAM use.  
In contrast to other studies that assessed medication on recruitment, this study also 
considered  the  total  number  and  types  of  medication  that  each  patient  was  on  since 
diagnosis  as  a  better  depiction  of  disease  activity  history.  No  association  between  these 
indices and use of CAM was found confirming results from other paediatric (66;298) and 
adult studies (60;537). Although an association between CAM use and steroid use was not 
found, in contrast to findings in adults by Hilsden (541), an independent association between 
the number of steroid courses and the use of alternative therapists was evident. This has 
been previously reported in adults on high intravenous doses of steroids (68;541). No such 
association  was  found  between  repeated  courses  of  EEN  and  CAM  use.  Although  both 
repeated steroids and EEN courses reflect disease relapses, these findings suggest that the 
side effects of steroids and patients’ desire to terminate or avoid their use may be more 
important than disease activity. This was reported as a reason for using CAM in the current 
study and also by 63% of adults IBD patients in a German survey (68;541). 
As  EEN  is  the  standard  treatment  for  paediatric  CD  in  the  UK,  caloric 
supplementation was not a predictor of CAM use in this study unlike that of Markowitz in the 
USA (64) where different management protocols are followed (256).  
Reading about CAM, friends’ recommendation and internet searches were the main 
sources of information about CAM similar to previous adult (549) and paediatric surveys (66). 
The chronic nature of the disease and the lack of a definite cure are highlighted by the fact 
that most of the participants chose CAM to complement conventional medicine. Frustration 
with conventional medicine side effects has been continually reported as the main reason 
adult IBD patients used CAM (60;65;66;68;541;551) and this coincides with the observation 
that only 4% of patients with gastroesophageal reflux disease (for which effective medication 
with minimal side effects is available) tried to treat their condition with CAM (552). Moreover   140 
recently  medication  side  effects  have  been  documented  as  the  most  important  parental 
concern for their child with IBD (553) and could justify the need for alternative therapies with 
fewer or no side effects.  
Most  surveys  in  both  adults  and  paediatric  patients  have  shown  a  self-reported 
benefit of CAM use (65;66;539). In the present study half of the users considered CAM use 
effective,  although  any  possible  improvement  was  subjectively  assessed  by  the  patients 
themselves and it is impossible to distinguish whether this was attributed to the concomitant 
conventional medication, to the CAM use per se or to a spontaneous improvement due to a 
documented placebo effect (373). Only two patients reported an adverse effect in contrast 
with  adult  surveys  (549).  This  is  not  surprising  as  the  majority  of  therapies  used  by 
participants in the present study included nutritional remedies and exclusion diets generally 
characterised with good safety records.  
Fewer patients in this study told their doctor they were using CAM than in previous 
studies  (65). This  lack of  disclosure  is  undesirable  as  CAM  may  impact  on  conventional 
medicine or have side effects. The majority of the respondents wanted their doctor to be 
supportive  of  CAM.  Adult  IBD  patients  in  Germany  (68)  believed  that  a  combination  of 
methods  using  CAM  and  conventional  medicine  should  be  offered  within  one  integrative 
clinical institution.  
Most of the parents in the present study said “they would be happy for their child to 
use of CAM” but agreed that “not much is known about CAM safety”. The chronic nature of 
the condition and the desire to ensure the best possible outcome for their child is reflected in 
that almost 90% of the respondents stated they would choose CAM if they felt these were 
useful and some of them would do so even if medical advice was against it.  
Use of CAM is high in paediatric IBD patients in Scotland and paradoxically parallels 
the development of new and more effective medications and modes of disease management. 
With increasing use of CAM more quality studies and clinical trials are needed to shed light 
on their efficacy and better inform parents, patients and medical staff. So far the results of 
clinical trials are too limited and most too flawed to suggest use of CAM in clinical practice. 
Rather than actively discouraging or encouraging use, health professionals should 
encourage  IBD  patients  to  report  CAM  use  and  should  be  aware  of  all  the  alternative 
therapeutic  choices  that  are  available  to  their  patients.  Several  hospitals  worldwide  have 
published policies and guidelines on CAM use and the American Academy of Paediatrics 
published  a  relevant  article  on  counselling  families  who  choose  CAM  for  their  child  with 
chronic illness or disability (554).    141 
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OUTLINE 
This chapter describes a retrospective study of the prevalence of anaemia at diagnosis in 
paediatric patients with IBD and its progression over a one year follow up using case review 
analysis. Predictors of anaemia incidence at diagnosis and at follow up were explored.   
 
3.1. Introduction 
Anaemia is one of the extraintestinal co-morbidities in IBD. Overt or occult intestinal bleeding 
is  among  the  major  presenting  symptoms  of  the  new  IBD  patient  (33)  and  a  drop  in 
haemoglobin levels occurs with each flare up (246). In IBD two types of anaemia prevail, iron 
deficient  anaemia,  due  to  an  iron  poor  diet  and/or  haemoglobin  losses  through 
gastrointestinal bleeding, and the ACD with unspecified pathogenesis (236). This topic has 
been reviewed extensively in Section 1.4.  
Since all human cells, tissues and organs depend on an adequate oxygen supply, the 
onset of anaemia is accompanied by a variety of clinical manifestations for both the children 
and  adults  (Section  1.4.2).  Nonetheless  compared  to  the  average  awareness  of  other 
extraintestinal disease complications, such as arthritis and poor nutritional status, the issue 
of anaemia in IBD disease usually receives little attention from the clinician. While a possible 
explanation would be a low prevalence of anaemia in IBD, this is not supported by current 
evidence (229;236).  
Thus far the evidence of the prevalence of anaemia in IBD patients comes mainly 
from adult studies and relevant studies in children are scarce (Table 1.4.5). Moreover all but 
one of the paediatric studies (243) were undertaken in small (<100) patient groups (Table 
1.4.5). In most of these studies, anaemia prevalence was a secondary rather than a primary 
outcome  (228)  and  thus  may  have  included  selective  samples  that  do  not  allow  the 
extrapolation  and  generalization  of  the  findings  to  the  general  IBD  population.  Moreover 
studies that recruited children with longstanding IBD (242) may have underestimated the true 
anaemia  prevalence  at  diagnosis,  due  to  a  confounding  effect  of  concomitant  medical 
intervention.  Although most  of  the  authors  used  haemoglobin  concentration  thresholds  to 
define anaemia, the definition varied remarkably among the studies (Table 1.4.5). In fact 
most of the authors (252;253) failed to cite an appropriate reference source for the definition 
of anaemia. As normal levels of haemoglobin vary considerably with age and gender (205), it 
is essential to use appropriate and specific cut offs.  
Potential  predictors  of  anaemia  were  addressed  in  a  few  studies.  Mack  and 
colleagues  (243)  showed  that  increased  disease  activity  was  a  significant  predictor  of 
anaemia at diagnosis in paediatric IBD. Similarly Weinstein and colleagues (83), although 
they did not describe the prevalence of anaemia, found that haemoglobin was lower in CD   143 
than UC, a finding stronger in the oldest age group of patients (≥ 11 y). Only one study (247), 
published in abstract form, measured prevalence of anaemia in paediatric CD and attempted 
to link it with the nutritional status of the patients and disease characteristics at diagnosis. In 
this study, anaemic patients had higher values of PCDAI and ESR than their non-anaemic 
peers, and the presence of upper GI tract disease was significantly associated with anaemia 
incidence. Gender, duration of symptoms prior to diagnosis, body composition, or growth 
parameters were not predictors of anaemia at diagnosis (247).  
In summary the prevalence of anaemia in paediatric IBD is under-documented and 
not well assessed. Most of the evidence comes from small studies using variable definitions 
of anaemia and do not allow a direct comparison between studies or assessment of temporal 
changes of anaemia prevalence. Only one study has been published in the UK, the rest of 
Europe with a small sample of 32 UC children (252). Whether anaemia is more common in 
groups of patients, with specific disease characteristics has not been studied extensively in 
paediatric  studies.  In  light  of  new  consensus  guidelines  on  the  classification  of  disease 
location and behaviour (6) further studies should be conducted to address whether disease 
phenotype predisposes to anaemia. Undernutrition and growth parameters may also differ 
between anaemic and non-anaemic IBD patients and should be investigated further.  
To the best of our knowledge, no study has measured the outcome and prognosis of 
anaemia, during the natural history course of the disease. As early and better diagnosis is 
now available and new treatments are available that induce mucosal healing and tackle the 
inflammatory  cascade  at  the  initial  stages,  a  decrease  in  the  prevalence  of  anaemia  at 
presentation and at follow up should be expected.  
The aim of this study was to measure the prevalence of anaemia at diagnosis in a 
large representative population of children with IBD. Predictors of the incidence of anaemia 
at diagnosis and its progression at follow up were explored.  
 
3.2. Subjects and methods 
All paediatric patients that attended the IBD outpatient clinic between 2002 and 2007 were 
considered for analysis. Although no prospective IBD database existed at the time of the 
study, all the eligible patients were identified via their electronic attendance records of the 
IBD outpatient clinic. These were accessible through the hospital electronic patient database.  
For the purpose of this study two groups of patients were characterized. The first to 
describe the prevalence and predictors of anaemia at diagnosis, and a sub-group of this to 
look at the progress of anaemia over a 1y follow up.  
Patients’ demographics and disease characteristics were retrieved from the hospital 
internal electronic patient database (Table 3.1). Patients whose haemoglobin level was not   144 
available  at  diagnosis  and  those  with  concomitant  illness  that  could  potentially  affect 
haematological parameters, independently of IBD, were excluded.  
For  the sub-group  analysis,  the  case  notes  of  a  random  sample  of  patients  were 
reviewed and information on disease, medication, and anthropometry (Table 3.1) was culled 
at diagnosis and wherever available at approximately six and 12 month follow up. Although 
patients who received blood transfusion for acute management of severe anaemia or were 
on supplementation with oral iron at follow up were included, their results are presented and 
discussed appropriately.  
 
3.2.1. Statistical analysis 
All data were entered into an electronic database and the prevalence of anaemia calculated 
as  the  ratio  of  the  number  of  anaemic  patients  by  the  total  number  of  patients.  For  the 
definition of anaemia, gender and age specific haemoglobin cut offs were used (205) (Table 
1.4.1).  A  haemoglobin  concentration  less  than  10  mg/dl  was  characterized  as  severe 
anaemia  according  to  WHO  recommendations  (Table  1.4.1).  Patients  with  haemoglobin 
concentration lower than their age and gender defined cut offs, but above 10 mg/dl were 
classified as mildly anaemic. Differences between groups were assessed with 2-sample t-
test  and  analysis  of  variance  (ANOVA)  for  parametric  variables  and  Mann-Whitney  or 
Kruskal-Wallis  for  non-normally  distributed  data.  Difference  for  categorical  data  was 
assessed  with  chi-square  test  or  Fisher’s  exact  test  for  2x2  tables  with  small  counts. 
Potential predictors of anaemia were studied using univariate nominal and binary  logistic 
regression analysis. All predictors with p-value less than 0.1 were entered in a multivariate 
model and their independent association with the response was assessed using backward 
stepwise regression analysis. A model with p-values less than 0.05 for all predictors was 
considered the final model. Odd ratios and 95% confidence intervals were calculated. 
 
3.3. Results 
3.3.1. Prevalence and predictors of anaemia at diagnosis 
3.3.1.1. Patients demographics and disease characteristics 
Between April 2002 and December 2007, 272 IBD patients visited the outpatient clinic at 
Yorkhill RHSC. As the Yorkhill RHSC is the only tertiary paediatric referral centre for care of    145 
Table 3.1: Demographics, disease, medication, nutrition, biochemical and haematological, data 
collected for the study of anaemia in paediatric IBD at diagnosis (whole group) and at follow up 
(sub-group)  
Data    Whole group  Subgroup 
Demographics       
Gender  Ö  Ö 
Age(decimal y)  Ö  Ö 
 
Social deprivation score*  Ö   
Disease       
Age at diagnosis  Ö  Ö 
Diagnosis delay    Ö 
Type of disease  Ö  Ö 
Site of involvement  Ö  Ö 
Bowel motility at diagnosis    Ö 
 
Blood in stool at diagnosis    Ö 
Medication       
EEN; (No of courses)    Ö 
Oral steroids; (No of courses)    Ö 
IV steroids    Ö 
Aminosalicylates    Ö 
AZA    Ö 
Methotrexate    Ö 
Infliximab    Ö 
Antibiotics    Ö 
Vitamins-Minerals    Ö 
Oral iron    Ö 
Caloric supplements    Ö 
 
Gut resection    Ö 
Anthropometry       
Body weight     Ö 
Body height    Ö 
 
Weight loss at diagnosis    Ö 
Haematology       
Red blood cells count  Ö  Ö 
Haemoglobin concentration  Ö  Ö 
Haematocrit concentration  Ö  Ö 
MCV concentration  Ö  Ö 
 
MCH concentration  Ö  Ö 
Inflammatory markers       
ESR  Ö  Ö   
CRP  Ö  Ö 
       
Biochemistry  Albumin  Ö  Ö 
Folate (serum & RBC)  Ö   
B12  Ö   
 
Ferritin  Ö   
* Scottish Index of Multiple Deprivation 
 
all IBD children in the West of Scotland region, the identifiable sample of this corresponded 
roughly to the whole population of paediatric IBD patients.  
All  patients  had  been  diagnosed  according  to  standard  clinical,  endoscopic, 
histological  and  radiological  findings.  Those  patients  whose  haematology  profile  was  not 
available  close  to  the  date  of  diagnosis  (n=34)  or  were  suffering from  other  concomitant 
conditions  that  could  impact  on  their  haematological  profile  (cystic  fibrosis;  n=2)  were   146 
excluded. Overall 236 patients (87% of the population) had measurements of haematology at 
diagnosis and fulfilled the inclusion criteria.  
The majority of participants had CD whereas for 5.5% a diagnosis of IC was deemed 
appropriate (Table 3.2). There was a higher prevalence of males to females, due to more 
males than females being diagnosed with CD. No gender predominance was observed for 
UC  or  IC  patients.  The  mean  age  at  diagnosis  was  10.6  y  (SD;  3.1)  with  UC  patients 
diagnosed at an earlier age than CD (p<0.04). No gender effect was observed regarding the 
age at diagnosis (Table 3.2). 
The  majority  of  the  CD  patients  had  involvement  of  the  colon  (Table  3.2)  but 
involvement  of  the  upper  digestive  tract  and  ileum  were  also  common.  None  of  the  UC 
patients studied had isolated proctitis as opposed to the high prevalence of pancolitis, which 
was the commonest site of disease involvement. 
No  difference  in  the  social  deprivation  score  (SIMD  2004)  was  found  among  the 
different  types  of  disease.  Indeed  the  IBD  population  was  equally  distributed  in  the  five 
classes of social deprivation (Table 3.2). 
 
3.3.1.2. Basic haematology profile at diagnosis 
Full blood counts were available for 233 of the patients whereas three had only haemoglobin 
measurements  (Table  3.2).  All  these  three  patients  had  been  transferred  from  a  district 
general  hospital  and  no  local  haematology  report  was  available  close  to  the  time  of 
diagnosis.   
Approximately 50% of the patients had haemoglobin less than 10.8 g/dl (Fig 5) . As a 
group, girls had significantly lower RBC, haemoglobin and haematocrit values (all p<0.003) 
than boys. A disease dependent effect was found for RBC. Red blood count was higher in 
CD  than  UC  or  IC  patients  (p<0.0001)  but  no  similar  differences  were  observed  for 
haemoglobin  or  haematocrit  levels  (Table  3.3).  However  more  boys  than  girls  had  been 
diagnosed with CD which may explain these results. No difference was found between boys 
and girls for mean corpuscular volume and mean corpuscular haemoglobin.  
Similar  to  the  whole  group  analysis,  girls  with  CD  had  lower  RBC,  haemoglobin  and 
haematocrit concentration than boys. No gender effect was found for MCV and  MCH. In 
contrast,  none  of  the  haematological  parameters  assessed  (RBC,  Hb,  Hct,  MCV,  MCH) 
differed between boys and girls in UC and IBDU children.   
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Table 3.2: Demographics, social deprivation scores, and disease characteristics of paediatric IBD patients at diagnosis 
  CD  UC  IBDU  Total 
  M  F  M  F  M  F   
Gender (n)  93  58  33  37  7  8  236 
Age at diagnosis (mean± ± ± ±SD)  11.1 ± 2.9  11 ± 2.8  9.8 ± 3.5  9.9 ± 3.5  10.8 ± 1.8  8.5 ± 3.5  10.6 ± 3.1 
Deprivation Score (n)               
1  17 ; (18)  11 ; (19)  9 ; (27)  5 ; (13)  1 ; (14)  2 ; (25)  45 ; (19) 
2  15 ; (16)      8 ; (14)  9 ; (27)  5 ; (13)  0 ; (0)               4 ; (50)  41 ; (17) 
3  15 ; (16)  11 ; (19)  6 ; (18)  11 ; (30)  2 ; (29)  0 ; (0)  45 ; (19) 
4  21 ; (23)  14 ; (24)  6 ; (18)  9 ; (24)  0 ; (0)  2 ; (25)  52 ; (22) 
5  25 ; (27)  13 ; (22)  3 ; (9)  7 ; (19)                4 ; (57)  0 ; (0)  52 ; (22) 
               
Montreal classification (n)*               
L1  3 ; (3)  2 ; (3)          5 ; (2) 
L2  30 ; (32)  19 ; (33)          49 ; (21) 
L3  54 ; (58)  37 ; (64)          91 ; (39) 
L4  61 ; (66)  32 ; (55)          93 ; (39) 
B1  82 ; (88)  49 ; (84)          131 ; (55) 
B2  9 ; (10)  5 ; (9)          14 ; (6) 
B3  1 ; (1)  1 ; (2)          2 ; (1) 
E1      0 ; (0)  0 ; (0)      0 ; (0) 
E2      2 ; (7)  4 ; (12)      6 ; (2) 
E3      27 ; (93)  29 ; (88)      56 ; (24) 
* P denominator to characterize perianal disease was not available 
 
Table 3.3: Haematological characteristics of paediatric IBD patients at diagnosis (mean ± SD) 
  CD    UC    IBDU    Total 
  M  F    M  F    M  F     
RBC (x 10
12 )    4.6   ±   0.4    4.4   ±  0.5      4.3   ±   0.4    4.2   ±   0.5    4.5   ±   0.8    3.8   ±   0.6    4.4   ±   0.5 
Haemoglobin (g/dl)    11.1   ±   1.6   10.6   ±  1.5     10.9   ±   1.6    10.5   ±   2.3    12.2   ±   2.8     9.3   ±   2     10.8   ±   1.8 
Haematocrit (%)    35   ±   3.8   33.4   ±  4.0     33.7   ±   3.9   32.7   ±   5.9    35.5   ±   6.7   30.7   ±   4.9     34.0   ±   4.5 
MCV (fl)    75.8   ±   6.6   76.6   ±  6.5     78.3   ±   5.1   78.1   ±   8.4    70.4   ±   18.2   80.4   ±   7.5     76.7   ±   7.4 
MCH (pg)    24.2   ±   3.3   24.4   ±  3.1     25.2   ±   2.3   25   ±   3.7    26.6   ±   3.4   24.3   ±   3.4     24.6   ±   3.2 
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Figure  5: Distribution of haemoglobin concentration (mg/dl) in paediatric patients with CD at 
diagnosis 
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3.3.1.3. Systemic markers of disease activity at diagnosis in IBD patients 
ESR, CRP, albumin and platelets levels were available for 195, 205, 202 and 225 patients 
respectively (Table 3.4). Compared to UC children, CD patients had significantly higher CRP 
concentration  and  ESR  (p<0.0001  &  p=0.004  respectively)  and  lower  serum  levels  of 
albumin at diagnosis (p<0.0001). There was no difference for the same markers between UC 
and IBDU patients (Table 3.4). ESR and CRP were higher in CD than IBDU. No difference 
was found between boys and girls for any of the systemic markers of disease activity. The 
mean  platelet  concentration  was  higher  in  girls  than  boys  but  did  not  reach  statistical 
significance (p=0.057). 
Overall more than 70% of patients presented at diagnosis with raised ESR, whereas 
59%, 52%, and 48% had abnormal levels of CRP, albumin and platelets respectively (Table 
3.4).  There  was  no  difference  between  genders.  More  CD  patients  (38.5%)  had  all  the 
systemic markers of disease activity abnormal compared to UC (9.5%) and IBDU patients 
(0%).  Noteworthy  none  of  the  IBDU  patients  had  all  of  the  systemic  markers  of  disease 
activity abnormal. In fact the majority of these patients presented with normal markers of   149 
inflammation  at  diagnosis,  although  the  numbers  are  too  small  and  preclude  statistical 
analysis. Twenty nine percent of IBD children had all the systemic markers of disease activity 
abnormal  as  opposed  to  14%  of  the  cohort  with  respective  values  within  the  normal 
reference range.  
 
3.3.1.4. Prevalence of anaemia 
Defining anaemia with gender, and age specific haemoglobin concentration cut offs (205), 
73%  of  the  subjects  presented  with  anaemia  and  32%  suffered  from  severe  anaemia 
(haemoglobin concentration less than 10) (Fig 5). Severe anaemia was more common in 
girls than in boys (Fig 6). No difference in the prevalence of anaemia was found between the 
different types of disease (Fig 7).   
 
Figure  6: Prevalence of anaemia and degree of severity between IBD boys and girls at 
diagnosis 
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Figure  7: Prevalence of anaemia and degree of severity according to type of IBD in children 
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3.3.1.5. Correlation of haemoglobin concentration with systemic markers 
of disease activity 
Since ESR, CRP platelets and albumin concentration did not follow a normal distribution their 
concentrations were ranked and Spearman correlation calculated as the most appropriate 
measure of their association with haemoglobin. ESR, CRP and platelets counts were 
negatively correlated (r=-0.38, -0.30 and –0.52 respectively) (all p<0.0001) with haemoglobin 
concentration (Fig 8). Accordingly albumin was positively and strongly associated with 
haemoglobin levels (r=0.56 p<0.0001). 
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Table 3.4: Systemic markers of disease activity in paediatric patients with IBD at diagnosis 
  CD  UC  IBDU  Total 
  M  F  M  F  M  F   
ESR (mm/hr) (mean ± SD)    40.4   ±  23.9    46.8   ±  25.7    29.9   ±  23.3    35.6   ±  24.0    25.2   ±  33.4   26.3  ± 12    39.2  ±  24.8 
CRP (mg/l) (mean ± SD)    33.9   ±  39.7    45.9   ±  54.6    13.6   ±  26.2    28.7   ±  52.5    7.0   ±   0.0   20   ±  19    32.3  ±  44.6 
Albumin (g/l) (mean ± SD)    32.3   ±   6.1    31.6   ±   7.4    36.2   ±   4.8    36.2   ±   7.3    34.5   ±  11.8   31.1  ±   8.5    33.3  ±  6.9 
Platelets x 10
9 (mean ± SD)
     474.4   ± 145.1   528.5   ± 176.6   442.1   ± 179.4   489.6 ±  171.7   394   ± 158  459.1 ±164.4   482.4  ± 164.3 
               
Abnormal ESR n;(%)   60; (77)  44; (86)  14; (58)  20; (67)  2; (40)  4; (57)  144; (74) 
Adnormal CRP n;(%)  64; (74)  35; (70)  8; (29)      10; (33)  0; (0)  3; (60)  120; (59) 
Abnormal albumin n;(%)  55; (65)  29; (62)  10; (38)  7; (23)  1; (17)  3; (43)  105; (52) 
Abnormal platelets n;(%)  45; (51)  29; (55)  10; (34)  17; (46)  3; (43)  4; (50)  109; (48) 
               
Disease activity score n;(%)*               
0  7; (10)  5; (13)  4; 22  4; 17  2; 40  1; 25  23; (14) 
1  9; (12)  ;3 (8)  5; 28  9; 37  2; 40  0; 0  28; (17) 
2  9; (13)  6; (15)  1; 6  4; 17  0; 0  2; 50  22; (14) 
3  20; (29)  8; (21)  6; 33  5; 21  1; 20  1; 25  41; (26) 
4  25; (36)  17; (43)  2; 11  2; 8  0; 0  0; 0  46; (29) 
* Sum of abnormal systemic markers of disease activity [CRP>7 mg/L), ESR>20 mm/h, Albumin <35 g/L, Platelets>450 x 10
9 )]   152 
 
Figure  8: Rank correlation between haemoglobin concentration and systemic markers of disease activity in cildren with IBD 
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3.3.1.6. Predictors of anaemia incidence at diagnosis 
Potential predictors of anaemia were defined a priori. Disease type and anatomic location, 
age at diagnosis, gender, social deprivation, and systemic markers of disease activity were 
tested with nominal logistic regression to assess their independent association with anaemia 
prevalence and degree (moderate or severe) of severity.  
In the univariate analysis females were more likely to be severely anaemic than boys 
(p=0.005) (Table  3.5).  Increased  concentrations  of  ESR,  CRP,  platelets  and  low  albumin 
concentration were strongly associated with mild and severe anaemia (Table 3.5). Similarly 
abnormal levels of ESR (> 20 mm/h), CRP (>7 mg/l) platelets (> 450 x 10
9) and albumin (< 
35 g/l) were also associated with mild and severe anaemia (Table 3.5).  
In the multivariate analysis, disease activity score (sum of the number of abnormal 
systemic markers of disease activity) was the only independent predictor of mild and severe 
anaemia. Indeed the risk of being anaemic or severely anaemic was substantially higher with 
an increasing number of total abnormal systemic markers of disease activity. Any child with 
all systemic markers of disease activity abnormal at diagnosis (ESR, CRP, albumin) had 96 
times more chance to be severely anaemic compared with those IBD children who presented 
with normal serology. The odd ratios of being anaemic augmented proportionally with the 
total number of abnormal systemic markers of disease activity (Table 3.5). This effect was 
stronger  in  severe  than  mild  anaemia.  Gender  was  also  a  predictor  of  anaemia  and  its 
degree of severity with girls being more severely anaemic than boys (Table 3.5).   
Table  3.5:  Predictors  of  anaemia  incidence  at  diagnosis  in  paediatric  IBD  patients  with 
univariate and multivariate regression analysis   
Predictors  Mild anaemia  Severe anaemia 
  Univar p-value  OR   95%C   Univar p-value  OR  95%C 
Sex (male)    NS    0.017  0.43  0.22-0.86 
ESR (mm/hr)    0.0001  1.04   1.02-1.06    0.0001  1.05  1.03-1.07 
CRP (mg/l)    0.007  1.02   1.01-1.04    0.003  1.03   1.01-1.04 
Albumin (g/l)    0.0001  0.88  0.82-0.94    0.0001  0.78  0.72-0.84 
Platelet (x 10
9)    0.0001  1.01  1.00-1.01    0.0001  1.01  1.01-1.02 
Abnormal ESR*    0.001  3.78  1.74-8.21    0.0001  5.11   2.16-12.06 
Abnormal CRP*    0.005  2.79  1.37-5.68    0.0001  3.78  1.79-7.97 
Abnormal albumin*    0.007  2.73  1.31-5.69    0.0001  10.0   4.33-23.07 
Abnormal platelet*    0.0001  4.14   1.91-8.98    0.0001  14.42   6.22-33.43 
Disease activity score*     
One    NS    NS 
Two    NS    NS 
Three    0.01  5.83  1.52-22.41    0.0001  26.25   4.64-148.38 
Four    0.001  13.33  2.82-63.11    0.0001  65.50  10.12-450.08 
   
    Multivar p-value  OR  95% CI 
Gender (male)    0.322  0.64  0.26-1.56    0.003  0.20  0.07-0.58 
Disease activity score*     
One    0.139  2.5   0.74-8.61    0.870  1.2  0.14-10.17 
Two    0.141  2.8  0.71-10.63    0.128  4.38  0.65-29.42 
Three    0.007  6.5  1.65-25.65    0.0001  40.2   6.44-250.93 
Four    0.001  14.63 3.03-70.61    0.0001  96.27  13.26-699.12 
*Sum of abnormal systemic markers of disease activity [CRP>7 mg/L), ESR>20 mm/h, Albumin <35 g/L, Platelets>450 x 10
9 )]   154 
 
Age  at  diagnosis,  social  deprivation  score,  site  of  disease  involvement,  disease 
behaviour (inflammatory, stricturing, fistulising) checked independently for CD and UC did 
not predict anaemia.  
 
3.3.1.7. Temporal changes of anaemia prevalence at diagnosis 
No apparent trend in the prevalence or degree of anaemia severity was observed (Table 3.6) 
between 2001-2007. 
 
Table  3.6:  Temporal  trend  of  anaemia  prevalence  and  severity  at  diagnosis  in  paediatric 
patients with IBD diagnosed between 2001 and 2007 
Patients  2001  2002  2003  2004  2005  2006  2007 
All anaemic (n)  12  22  17  19  24  28  22 
All non-anaemic (n)  5  8  11  8  6  10  9 
Total diagnosed (n)  17  30  28  27  30  38  31 
Total anaemic (%)  70.6  73.3  60.7  70.4  80  73.7  71 
Mild anaemic (%)  23.5  46.7  32.1  44.4  66.7  36.8  25.8 
Severely anaemic (%)  47.1  26.7  28.6  25.9  13.3  36.8  45.2 
 
3.3.1.8. Classification of anaemia type 
Due to the retrospective design of this study it was difficult to differentiate among the different 
types of anaemia. A rough approach was attempted evaluating haematology parameters on 
the size (MCV) and colour of erythrocytes (MCH). No patient had features of macrocytic 
anaemia  (MCV  >  100).  Four  patients  had  MCV  values  greater  than  90  fl.  Of  these  four 
patients, one was severely anaemic (Hb; 7.7), one was mildly anaemic (Hb; 11.9) and two 
had normal levels of haemoglobin. Overall 41% of the patients had low MCV according to 
Dallman’s (205) reference range. Similarly setting 27 pg as the lower reference threshold of 
mean corpuscular haemoglobin, 76% of the subjects had suboptimal levels consistent with 
hypochromic anaemia. 
 
3.3.1.9. Ferritin, folate and B12 concentration 
For 122 children information on ferritin concentration was available  within four months of 
diagnosis. Ninety one of them were anaemic but 29 patients had normal levels of ferritin (> 
10   g/l)  and  normal  mean  corpuscular  volume  reflecting  normocytic  anaemia  possibly 
attributed  to  ACD.  Serum  ferritin  concentration  was  positively  associated  with  CRP 
(Spearman r: 0.33 p<0.001) and negatively with serum albumin (Spearman r: –0.21 p<0.03) 
and was significantly higher in CD than in UC patients. 
Twenty five and 26 patients had measurements of folate (serum & red blood cells) 
and  B12  respectively  within  four  months  of  diagnosis.  No  patient  had  suboptimal  levels   155 
compared  to  the  hospital  reference  range  [(B12:193-982  ng/l);  (RBC  folate:  93-641   g/l); 
(serum folate: 3-17  g/l)]. Erythrocyte folate concentration was significantly higher in CD than 
in  UC  patients  (Table  3.7).  Serum  but  not  RBC  concentration  of  folate  was  negatively 
associated with platelets concentration (Spearman r -0.50 p<0.02).  
 
Table 3.7: Systemic concentrations of serum ferritin, folate and vitamin B12 levels in paediatric 
patients with IBD at diagnosis 
Vitamin/Ferritin  CD 
(Median       Range) 
UC 
(Median      Range) 
P-value* 
Ferritin (ng/l)     23.0  2.0-  343.0   12.5  2.0-  226.0  0.02 
Serum folate ( g/l)    9.2  4.2-  15.8    7.5  2.7-  16.6  0.71 
RBC folate ( g/l)   517.0  237.0-1195.0   251.0 236.0- 752.0  0.02 
Serum B12 (ng/l)   621.0  246.0-1879.0  807  251.0-1611.0  0.75 
* Mann Whitney Test 
 
3.3.2 Prevalence and predictors of anaemia at follow up 
3.3.2.1. Patients characteristics 
The medical case notes were available for review in 179 children. Of these 12 were recently 
diagnosed and no follow up data were available at six months. One hundred and twenty-nine 
children had follow up measurements of haemoglobin at six and 12 months post-diagnosis. 
For the rest (38 patients) follow up measurements of haemoglobin were recorded either at 
six or 12 months (Fig 9). The disease and demographic characteristics of the patients are 
displayed  in  Table  3.8.  There  was  no  statistical  significant  difference  between  the  whole 
group presented above and the subgroup of the follow up analysis.  
The type of medical treatment and the total number of steroid and completed EEN 
courses  for  each  patient  were  collected  from  diagnosis  through  one  year  follow  up.  The 
proportion  of  patients  on  different treatments  is  presented  in Table  3.9.  As  expected the 
majority of CD and UC patients were treated with the two common mainstream first line 
treatments, EEN and steroids respectively. Aminosalicylates were the mainstream treatment 
to maintain disease remission in both diseases. Iron supplements had been used by 1/3 of 
the  CD  and  IBDU  patients  and  half  of the  UC  patients.  4%  of the  patients  had  a  major 
surgery  with  part  of  the  gut  resected.  Blood  transfusion  was  administered  in  8%  of  the 
patients during the follow up period.  
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Figure  9: Flow diagram of patients included in the study on the prevalence of anaemia in 
paediatric IBD patients 
 
 
 
Table 3.8: Demographics, age at diagnosis and diagnosis delay of paediatric IBD patiets who 
participated in a study on the prevalence of anaemia at follow up 
  CD  UC  IBDU  Total  
  M  F  M  F  M  F   
Gender (n)  68  45  26  31  4  5  179 
Diagnosis  
age (y) (mean 
± SD) 
11.0 ±  2.7  10.6 ±  2.8   9.9  ±  3.6   9.2 ±  3.3  11.3 ±   1.5   8  ±  4.6  10.3 ±  3.1 
Diagnosis 
delay (mth) 
(mean ± SD)  
11.7 ± 16.8   8.4  ± 10.9  10.8 ± 14.2   6.0 ±  4.9  15.2±  15.5   4.3 ±  3.4   9.6 ± 13.3 
 
Table 3.9: Total types of medical therapy used by paediatric IBD patients during one year of 
follow up post-diagnosis  
Percent of patients n;(%)  CD  UC  IBDU  All IBD 
EEN  80; (78)  2; (5)  2; (9)  84; (50) 
Oral steroids  43; (42)  33; (77)  13; (59)  89; (53) 
I.V. steroids  13; (13)  6; (14)  5; (23)  24; (14) 
5-ASAs  74; (72)  40; (93)  15; (68)  129; (77) 
Azathioprine  60; (59)  33; (33)  10; (45)  84; (50) 
Methotrexate  12; (12)  0; (0)  0; (0)  12; (7) 
Infliximab  6; (6)  1; (2)  1; (5)  8; (5) 
Antibiotics  46; (45)  11; (26)  7; (32)  64; (38) 
Vitamins  35; (34)  11; (26)  5; (23)  51; (30) 
Caloric supplements  47; (46)  2; (9)  4; (9)  53; (32) 
Iron supplements  36; (35)  24; (56)  7; (32)  67; (40) 
Surgery  3; (3)  2; (5)  1; (5)  6; (4)   157 
Omeprazole/Ranitidine  28; (27)  7; (16)  10; (45)  45; (27) 
Rectal steroids  9; (9)  9; (21)  6; (27)  24; (14) 
Laxatives  9; (9)  2; (5)  1; (5)  12; (7) 
Blood transfusion  6; (6)  5; (10)  3; (13)  14; (8) 
 
3.3.2.2.  Sub  group  anthropometric  characteristics  at  diagnosis  and 
follow up 
For  175  of  the  children  basic  anthropometric  measurements  were  collected  at  diagnosis 
(Table  3.10).  Standard  deviation  scores  (z-scores)  were  calculated  using  the  British 
normative data (94). A z-score of less than –2 SD for height and BMI were consistent with 
the definition of growth retardation and underweight respectively (Figs 10 & 11).  
BMI z-scores did not differ between boys and girls at diagnosis and 12 months follow 
up.  At  six  months girls had  significantly  higher BMI  z-scores than  boys  (p=0.028)  (Table 
3.11).  Children  with  CD  presented  with  significantly  lower  BMI  and  weight  z-score  than 
patients with UC or IBDU at diagnosis, and at all time points at follow up (p-values <0.0001). 
For  those  patients  with  follow  up  anthropometric  measurements  recorded  at  six  and  12 
months, changes since diagnosis were assessed with ANOVA of repeated measures and 
Bonferroni post-hoc pairwise comparisons. BMI z-scores increased at follow with a mean 
increase of 0.95 and 1 SD at six and 12 months (p<0.0001). No difference in BMI z-scores 
was observed between six and 12 months.  
At  diagnosis  29%  of  the  CD  patients  compared  to  4%  in  UC  and  11%  in  IBDU 
presented with BMI z-scores less than –2 SD (p<0.0001). At six and 12 months follow up 
fewer patients suffered from underweight. Five percent and 1% of the CD children as well as 
0% and 5% of UC patients respectively had BMI z-scores keeping in line with the definition of 
underweight (BMI z-score <-2 SD) at six and 12 months. Although none of the patients was 
obese (BMI z-score >2SD) at diagnosis, at six and 12 months follow up, over 12% of the UC 
patients had a BMI z-score above their age and gender defined obesity threshold  (BMI z-
score >2). On the contrary approximately 2% of CD children were defined as obese (BMI>2 
SD) at follow up. Weight loss prior to disease diagnosis was more frequently experienced in 
CD children than their peers with UC or IBDU (p=0.011).    158 
 
 
 
 
 
 
Table  3.10:  Anthropometric  characteristics  (mean  ±  SD),  and  prevalence  (%)  of  underweight,  obesity  and  short  stature  in  newly  diagnosed 
paediatric IBD patients  
  CD  UC  IBDU*  Total  
  M   F  M  F  M  F   
Diagnosis weight (kg)     31.3  ± 11.2    31.5  ±   11.5    32.7  ±   14.2    30.8  ±   12.4    33.1  ±  5.2    32.1  ± 20.6    31.5  ±   12.1 
Weight z-score    -1.2  ±   1.4    -0.9  ±   1.1    -0.3  ±   1.1    -0.4  ±   1.0    -0.5  ±  1.0    0.2  ±  2.0    -0.8  ±   1.3 
Diagnosis height (cm)   140   ±   17.6   137.5  ±   17.8   137   ±   21.9   133.6  ±   19.4   144.6  ±   7.1   127.6  ±   30.1   137.6  ±   18.8 
Height z-score    -0.6  ±   1.2    -0.6  ±   0.9    -0.3  ±   1.1    -0.2  ±   1.0    0  ±  0.6    0.5  ±   2.2    -0.5  ±  1.1 
BMI (kg/m
2)    15.6  ±   2.5    16.2  ±   3    17.1  ±   2.5    16.5  ±   2.5    15.7  ±   1.4    17.6  ±   3.7    16.2  ±  2.6 
BMI z-score    -1.2  ±   1.6    -0.9  ±  1.4    -0.2  ±   1.2    -0.4  ±   1.0    -0.9  ±   1.0    0   ±   1.5    -0.8  ±   1.4 
Height z-score<-2 n;(%)  11; (17)  2 ; (5)  1 ; (4)  0 ; (0)  0 ; (0)  1; (20)  15 ;(9) 
BMI z-score<-2 n;(%)  22 ;(33)  9 ;(21)  2 ;(8)   0 ;(0)  1 ;(25)  0; (0)  34; 20 
BMI z-score>2 n;(%)  0 ; (0)             0 ; (0)            0 ; (0)             0 ; (0)               0 ; (0)              0 ;(0)            0 ; (0) 
Weight loss n;(%)  43 ;(74)  32 ;(82)  58 ;(11)  61 ;(11)  25 ; (1)  50 ;(2)  70 ; (103) 
 
Table 3.11: Anthropometric characteristics (mean ± SD), and prevalence (%) of underweight, obesity and short stature of paediatric IBD patients at 
6 mth post-diagnosis (mean ± SD) 
  CD  UC  IBDU  Total 
  M  F  M  F  M  F   
Weight (kg) at 6 mth    36.0  ±  13.0    36.8  ±  11.6    37.5  ±  14.5    38.1  ±  18.0    36.2  ±  6.2  38.6   ±  27.2    36.8  ±  14.0 
Weight z-score (SD) at 6 mth    -0.6  ±   1.3    -0.4  ±   0.9    0.3  ±   1.0    0.5  ±   1.1    -0.3  ±  1.1    0.8  ±   1.7    -0.2  ±   1.2 
Height (cm) at 6 mth   140.7  ±  17.6   140.1  ±  17.1   137.3  ±  21.4   134.1  ±  20.8   143.7  ±  7.8   127.6  ±  29.9   138.6  ±  18.9 
Height z-score (SD) at 6 mth    -0.8  ±   1.2    -0.5 ± 0.9    -0.4  ±   0.7    -0.3  ±   1.1    -0.5  ±  0.5    -0.2  ±   1.5    -0.6  ±   1.1 
BMI (kg/m
2) at 6 mth    17.6 ±   3.0    18.0  ±   2.5    19.0  ±   3.1    19.8  ±   4.3    16.3  ±  1.5    20.7  ±   5.8    18.3  ±   3.4 
BMI z-score (SD) at 6 mth    -0.2  ±   1.3    0.0  ±   0.9    0.7  ±   1.0    0.8  ±   1    -0.6  ±  1.3    1.2  ±   1.1    0.2 ±   1.2 
Height z-score<-2 at 6 mth n;(%)    11; (17)  3; (8)  0; (0)  1; (4)  0; (0)  1; (20)  16; (10) 
BMI z-score<-2 at 6 mth n;(%)  5; (8)  0; (0)  0; (0)  0; (0)  0; (0)  0; (0)  5; (3) 
BMI z-score>2 at 6 mth n;(%)  3; (5)  0; (0)  2; (11)  4; (15)  0; (0)  2; (40)  11; (7) 
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Table 3.12: Anthropometric characteristics (mean ± SD), prevalence (%) of underweight, obesity and short stature of paediatric IBD patients at 12 
mth post-diagnosis (mean; SD) 
  CD  UC  IBDU  Total 
  M  F  M  F  M  F   
Weight (kg) at 12 mth   37.7  ±   12.7   37.5  ±   11.6   40   ±   18.3  40.1  ±  19.3   38.8  ±   11.1   38.4  ±  28.1   38.4   ±  14.5 
Weight z-score (SD) at 12 mth    -0.6  ±   1.1    -0.4  ±   0.9    0.4  ±   1.2   0.3  ±   1.6   -0.1  ±   0.3   -0.3  ±   2.0   -0.3   ±   1.2 
Height (cm) at 12 mth  144   ±   18.3  141.2 ±   16.5  140.9 ±   23.5  140  ±  18.7  147   ±   8.5  130.6   ±  27.7  142   ±  18.5 
Height z-score (SD) at 12 mth    -0.9  ±   1.2    -0.7  ±   0.9   -0.2  ±   1.0   0   ±   1.2   -0.2  ±   0.6   -1.7  ±   0.7   -0.6   ±   1.1 
BMI (kg/m
2) at 12 mth   17.6  ±   2.4   18.2  ±   2.6   19   ±   3.3  19.3  ±   5.6   17.8  ±   3.1   20.4  ±   7.6   18.3   ±   3.3 
BMI z-score (SD) at 12 mth     -0.2  ±   1.0    0.0  ±   0.9    0.7  ±   1.3   0.3  ±  1.7    0.0  ±   1.0    0.8  ±   1.7    0.1   ±   1.2 
Height z-score<-2 at 12 mth n;(%)     8; (14)  4; (11)      0; (0)      0; (0)      0; (0)     1; (50)      (9) 
BMI z-score<-2 at 12 mth n;(%)      1; (2)  0; (0)      1; (5)      1; (5)      0; (0)      0; (0)      3; (2) 
BMI z-score>2 at 12 mth n;(%)      2; (3)  0; (0)      1; (5)     4; (18)      0; (0)      0; (0)      7; (5) 
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Compared  to  UC  children,  CD  patients  had  significantly  lower  height  z-score  at 
diagnosis (p=0.025) and at 12 months follow up (p=0.002) (Table 3.12). Similar to BMI z-
score, no difference was found between boys and girls for height. Height z-score decreased 
by an average of 0.2 SD at six and 12 months follow up (p-<0.0001). No difference in the 
mean height z-scores change was found between six and 12 months.   
Thirteen  percent  of  the  CD  patients  had  suboptimal  height  consistent  with  the 
definition of short stature (height z-score <-2). No significant changes were presented at six 
and 12 months of follow up. Less than 2.5% of the UC patients had height z-score less than 
–2 SD at any time point over the follow up. Although no clear conclusions can be drawn, 
growth retardation tended to be more common in CD boys than girls at diagnosis (Fisher’s 
exact test p<0.075). At follow up no difference in the prevalence of growth retardation was 
observed between the two genders for any type of IBD. 
 
Figure  10: Distribution of height z-scores at diagnosis on IBD paediatric patients 
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Figure  11: Distribution of BMI z-scores at diagnosis on IBD paediatric patients 
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3.3.2.3. Changes in haematology at six and 12 months follow up 
Haemoglobin values and full blood counts were available for 179, 153, and 143 patients at 
diagnosis  and  at  six  and  12  months  follow  up  respectively  (Table  3.13).  The  mean 
haemoglobin concentration was less than 11 g/dl at diagnosis but significantly improved at 
follow up (p<0.0001). Mean values were 11.8 and 11.9 g/dl at six and 12 months follow up 
respectively.  The  same  trends  of  change  were  observed  for  the  other  haematological 
parameters of interest (Hct, MCV, MCH, RBC) (Table 3.13).   
  
3.2.4. Changes of anaemia prevalence and severity at follow up 
The progression of anaemia prevalence and degree of severity at follow up is shown in Fig 
12 and displayed per disease type in Table 3.14. The proportion of patients with severe 
anaemia decreased from 32% at baseline to 10% at six and 12 months follow up whereas 
the respective number of non-anaemic patients increased at follow up (Fig 12). Similar trends 
were observed for CD and UC. For IBDU no changes were observed compared to baseline 
values although definite conclusions are difficult to be drawn due to the small numbers of 
patients in this group (n=9)   162 
 
Figure  12: Prevalence and degree of anaemia in paediatric IBD at diagnosis and six and 12 
months of follow up 
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3.3.2.5. Individual changes in anaemia severity classification at follow up 
Patients were categorized into four groups according to the change of anaemia classification 
at six and 12 months follow up. Two groups included those patients who were anaemic at 
diagnosis and either improved to non anaemic or remained anaemic at follow up, and two 
other groups with those patients who were not anaemic at diagnosis and either remained so 
or deteriorated at follow up (Table 3.15). Approximately 30% of the anaemic patients became 
non anaemic at follow up and similarly around 8% who were not anaemic deteriorated at 
follow up (Table 3.15).      163 
 
Table 3.13: Haematological characteristics at diagnosis, six and 12 mth of follow up of paediatric IBD patients (mean ± SD) 
  Diagnosis  Follow up 6 mth  Follow up 12 mth 
  CD  UC  IBDU  CD  UC  IBDU  CD  UC  IBDU 
RBC (x 10
12 )   4.6   ±   0.4   4.2   ±  0.5   4.3   ±   0.5   4.6   ±  0.5   4.6   ±  0.4   4.4   ±   0.5   4.5   ±   0.4   4.5   ±   0.5   4.4   ±   0.6 
Haemoglobin (g/dl)  10.7   ±   1.4  10.5   ±  2.0  11.2  ±   2.1  11.9   ±  1.4  12.0   ±  1.3  11.6   ±   1.8  11.6   ±   1.4  12.3  ±   1.3  11.8   ±   1.8 
Haematocrit (%)  34.1   ±   3.8  32.6   ±  4.9  34   ±   5.1  36.6   ±  3.4  37.2   ±  3.3  35.8   ±   4.2  35.8   ±   3.3  36.9  ±   3.1  36.1   ±   4.7 
MCV (fl)  74.5   ±   6.3  77.8   ±  6.0  79.3  ±   7.2  79.4   ±  6.8  81.9   ±  7.9  80.3   ±   8.3  80.0   ±   6.9  82.8  ±   6.0  83.0   ±   6.6 
MCH (pg)  23.4   ±   2.8  24.8   ±  2.8  26.3  ±   3.9  25.8   ±  3.0  26.5   ±  2.9  26.0   ±   3.7  26.2   ±   4.1  27.5  ±   2.4  27.1   ±   3.0 
 
 
Table 3.14: Prevalence and degree of severity of anaemia at diagnosis six and 12 mth follow up in paediatric patients with IBD 
  CD  UC  IBDU 
  Non  
anaemic 
Mild 
anaemia 
Severe 
anaemia 
Non 
anaemic 
Mild 
anaemia 
Severe 
anaemia 
Non 
anaemic 
Mild 
anaemia 
Severe 
anaemia 
Baseline n;(%)  20; (19)  50; (46)  37; (35)  11; (22)  21; (43)  17; (35)  10; (43)  9; (39)  4; (18) 
Follow up 6 mth 
n;(%) 
42; (43)  46; (4)  10; (10)  25; (54)  15; (33)  6;(13)  5; (56)  4; (44)  0; (0) 
Follow up 12 mth 
n;(%) 
29; (32)  52; (57)  10; (11)  20; (51)  17; (44)  2; (5)  6; (46)  5; (39)  2; (15) 
 
 
Table 3.15: Change in -individual anaemia classification patterns in paediatric IBD patients between six and 12 mth post-diagnosis  
Follow up 6 mth  Follow up 12 mth 
Anaemia pattern 
change* 
AA n;(%)  NN n;(%)  AN n;(%)  NA n;(%)  Anaemia pattern 
change* 
AA n;(%)  NN n;(%)  AN n;(%)  NA n;(%) 
CD  (n=98)  47; (48)  16; (16)  27; (28)  8; (8)  CD   ( n=96)  58; (60)  9; (10)  22; (23)  7; (7) 
UC  (n=46)  17 ; (37)  7 ; (15)  18 ; (39)  4 ; (9)  UC    ( n=43)  18 ; (42)  9 ; (20)  14 ; (33)  2 ; (5) 
IBDU (n=9)  4 ; (44)  3 ; (34)  2 ; (22)  0 ; (0)  IBDU  (n=4)  3 ; (75)  1 ; (25)  0 ; (0)  0 ; (0) 
Total (n=153)   68; (44)  26; (17)  47; (31)  12; (8)  Total (n=143)  79; (55)  19; (13)  36; (25)  6; (7) 
* AA= Anaemic at diagnosis and at follow up; NN Non anaemic at diagnosis and at follow up 
* AN= Anaemic at diagnosis but Non anaemic at follow up; NA= Non anaemic at diagnosis but anaemic at follow up  
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3.3.2.6. Changes in haemoglobin concentration at six and 12 months   
Changes in the concentration of haemoglobin were calculated for each child separately as 
the numeric difference from diagnosis levels, at six and 12 months follow up. No difference in 
the mean  haemoglobin  change  was  found  between  the  diseases  (Table  3.16)  (p>0.200). 
Compared  to  baseline,  only  the  girls’  haemoglobin  levels  improved  at  12  but  not  at  six 
months follow up.  
For  analysis  purposes,  patients  were  grouped  into  two  categories  based  on  the 
direction of haemoglobin concentration change at six and 12 months follow up. Two groups 
were  assigned.  Those  patients  whose  haemoglobin  concentration  either  increased  or 
remained unchanged compared to diagnosis and those whose haemoglobin deteriorated at 
follow up. For approximately 67%-70% of the patients, haemoglobin concentration improved, 
compared  to  diagnosis,  at  six  and  12  months  follow  up.  No  significant  difference  in  the 
pattern of haemoglobin change was observed between the disease types (Table 3.16) 
 
Table  3.16:  Mean  changes  in  haemoglobin  concentration  (mean  ±  SD)  and  percent  of  IBD 
patients  whose  haemoglobin  concentration  improved  from  diagnosis  at  six  and  12  mth  of 
follow up  
  CD  UC  IBDU 
Mean Hb change (6 mth) (mg/dl)  1 ± 1.5 (n=98)  1.3 ± 2 (n=46)  1.4 ± 2.4 (n=9) 
Mean Hb change (12 mth) (mg/dl)  0.8 ± 1.5 (n=96)  1.7 ± 2.1 (n=43)  1.4 ± 3.3 (n=4) 
N;(%) patients whose Hb improved 
(6mth) 
68; (69)  31; (67)  6; (67) 
N;(%) patients whose Hb improved 
(12mth) 
68; (71)  29; (67)  3; (75) 
 
3.3.2.7. Predictors of improvement of haemoglobin concentration at six 
and 12 months  
Potential  predictors  were  chosen  a-priori  and  their  association  with  the  direction  of 
haemoglobin  change  (improvement  or  deterioration)  at  follow  up  was  examined  with 
univariate and multivariate logistic regression analysis as described above (Section 3.2.1).  
  Similar to the main cohort analysis, systemic markers of disease activity, and female 
gender were the most significant features that characterized anaemic patients at diagnosis. 
Weight  loss  prior  to  diagnosis,  low  BMI  and  delayed  diagnosis  were  the  most  important 
predictors of anaemia occurrence and degree severity at diagnosis in  univariate analysis 
(Table  3.17).  However  in  multivariate  analysis  only  the  level  of  serum  albumin  remained 
significant predictors (Table 3.17).   
In subgroup analysis (follow up data), abnormal systemic markers of disease activity 
and  low  haemoglobin  concentration  at  diagnosis  were  among  the  predictors  that 
differentiated those patients who improved from those that deteriorated at six and 12 months 
follow  up.  Improvement  of  disease  activity,  as  reflected  by  an  increase  in  albumin  and   165 
decrease of ESR levels at follow up, was also associated with improvement of haemoglobin 
levels (Table 3.18 & 3.19).  
 
Table 3.17: Predictors of anaemia incidence at diagnosis in paediatric IBD patients (group of 
patients with follow up data at six and/or 12 monts of follow up). Univariate and multivariate 
logistic regression analysis (p-value; OR; 95% CI) 
Predictors  Mild anaemia  Severe anaemia 
  Univariate 
 p-value  OR   95% CI     p-value  OR   95% CI 
Sex (male)        NS    0.038  0.42  0.19 -  0.95 
ESR (mm/hr)    0.009  1.03  1.01 -  1.05    0.001  1.04   1.01 -  1.06 
CRP (mg/l)    0.035  1.02   1.01 -  1.04    0.003  1.03  1.01 -  1.04 
Albumin (g/l)    0.000  1.83   0.76 -  0.91    0.001  0.75   0.67 -  0.83 
Diagnosis delay (mth)    0.058  0.97  0.95 -  1.00    0.022  0.96  0.93 -  0.99 
BMI z-score (SD)    0.001  0.59  0.43 -  0.81    0.003   0.60  0.43 -  0.84 
Weight loss (Yes)    0.042  2.47   1.03 -  5.93    0.004   4.44   1.63 -  12.10 
     
  Multivariate 
   p-value  OR   95% CI   p-value  OR   95% CI 
Albumin (g/l)    0.0001  0.83  0.76 -  0.91    0.0001  0.75   0.67 -  0.83 
 
Although  in  univariate  analysis  iron  supplementation  was  strongly  associated  with 
haemoglobin  improvement  at  12  months  for  both  diseases  in  multivariate  analysis  this 
association remained significant only for CD (Table 3.20). In UC patients, improvement of 
serum  albumin  and  low  haemoglobin  concentration  at  diagnosis  were  predictors  of 
haemoglobin  levels  improvement  at  follow  up  (Table  3.20).  On  the  other  hand  in  CD 
additional  characteristics  differentiated  patients  whose  haemoglobin  improved  from  those 
who  did  not.  In  particular  a  decrease  in  ESR  levels,  and  increase  in  BMI  and  growth 
acceleration  at  six  and  12  months  predicted  improvement  of  haemoglobin  concentration 
(Table 3.20).    166 
 
 
 
 
Table 3.18: Predictors of haemoglobin concentration increase (comparison with those who deteriorated) at six mth follow up in paediatric IBD 
patients (univariate logistic regression; p-value; OR; 95% CI) 
Predictors*    IBD  CD  UC 
      p-value  OR  95% CI    p-value  OR  95% CI    p-value  OR  95% CI 
Haematology  Haemoglobin concentration 
at diagnosis 
  0.0001  1.8  1.4 - 2.3    0.004  1.6  1.2 - 2.3    0.006  2.0  1.2 - 3.2 
Disease 
markers 
ESR concentration at 
diagnosis 
  0.036  1.0  0.9 - 1.0    0.087  1.0  0.9 – 1.0    0.521  1.0  0.9 – 1.0 
  ESR concentration decrease 
at follow up 
  0.008  1.0  1.0 - 1.1    0.008  1.0  1.0 - 1.1    0.700  1.0  1.0 - 1.1 
  CRP concentration decrease 
at follow up 
  0.033  1.0  1.0 - 1.1    0.030  1.0  1.0 - 1.1    0.612  1.0  0.9-1.0 
  Albumin concentration at 
diagnosis 
  0.0001  1.2  1.1 - 1.3    0.002  1.2  1.1 - 1.3    0.028  1.3  1.0 - 1.6 
  Albumin concentration 
increase at follow up 
  0.0001  0.8  0.8 - 0.9    0.003  0.9  0.8 -1.0    0.015  0.7  0.6 - 0.9 
Anthropometry  BMI z-score at diagnosis    0.015  1.4  1.1 - 1.9    0.028  1.4  1.0 -2.0    0.339  1.4  0.7 - 2.7 
  BMI z-score increase at 
follow up 
  0.006  0.5  0.3 - 0.8    0.028  0.6  0.3 - 0.9    0.290  0.6  0.2 - 1.6 
* Predictors studied but not significantly associated: age, type of disease, gender, CRP at diagnosis, height z-score at diagnosis, height z-score change at follow up, growth retardation (height z-
score<-2SD), weight loss prior to diagnosis, underweight (BMI <-2SD)   167 
 
 
 
 
 
 
Table 3.19: Predictors of haemoglobin concentration increase (comparison with those who deteriorated) at 12 mth follow up (univariate logistic 
regression; p-value; OR; 95% CI) 
Predictors    IBD  CD  UC 
      p-value  OR  95% CI    p-value  OR  95% CI    p-value  OR  95% CI 
Medication  Oral iron supplementation    0.001  0.2  0.1 - 0.6    0.012  0.2  0.1 - 0.7    0.009   0.1   0.0 - 0.6 
Haematics  Haemoglobin  concentration  at 
diagnosis 
  0.0001  2.3:   1.7 - 3.3    0.001  1.9:  1.3-2.9    0.002  5.6:  2 .0- 17.9 
Disease markers  ESR concentration at diagnosis    0.106  1.0  0.9 – 1.0    0.819  1.0  0.9 – 1.0    0.038  0.9  0.9 – 1.0 
  ESR  concentration  decrease  at 
follow up 
  0.010  1.0  1.0 - 1.1    0.107  1.0  0.9 – 1.0    0.055  1.1  1.0 - 1.2 
  CRP concentration diagnosis    0.094    1.0  0.9 – 1.0    0.112   1.0  0.9 – 1 0    0.418  1.0  0.9 – 1.0 
  CRP  concentration  decrease  at 
follow up 
  0.068  1.0  1.0 - 1.1    0.079  1.0  1.0 - 1.1    0.508  1.0  1.0 - 1.1 
  Albumin  concentration  at 
diagnosis 
  0.0001  1.2  1.1 - 1.3    0.001  1.2:  1.1 - 1.3    0.040   1.3  1.0 - 1.6 
  Albumin  concentration  increase 
at Follow up 
  0.0001  0.8:  0.8 - 0.9    0.002  0.9  0.8 - 0.9    0.038  0.8  0.0 –.6-1 
Anthropometry  BMI z-score at diagnosis    0.056  1.3:  1.0 - 1.7    0.157  1.3:  0.9 - 1.8    0.148  1.7  0.8 - 3.5 
  BMI z-score increase at follow up    0.008  0.6:  0.4 - 0.9    0.005  0.4  0.3 - 0.8    0.818  0.9  0.5 - 1.7 
  Height z-score increase at follow 
up 
  0.101  0.5:  0.3 - 1.1    0.013  0.2  0.1 - 0.7    0.825  0.9  0.4 – 2.0] 
 
  Weight loss at diagnosis    0.002  0.3:  0.1 - 0.6    0.018  0.3  0.1 - 0.8    0.101  0.3  0.1 - 1.3 
 
Predictors studied but not significantly associated: age, type of disease, gender, CRP at diagnosis, height z-score at diagnosis, growth retardation (height z-score<-2SD), underweight (BMI <-2SD), 
all types of medication used, number if oral steroid courses, number of EEN courses,   
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Table 3.20: Predictors of haemoglobin concentration increase (comparison with those who deteriorated) at six and 12 mth follow up in paediatric 
IBD patients (multivariate logistic regression ; p-value; OR; 95% CI) 
Predictors  IBD  CD  UC 
6 mth Follow up     p-Value   OR   95%CI    p-Value   OR   95%CI   p-Value   OR   95%CI 
Haemoglobin  concentration  at 
diagnosis  
  0.020  1.7  1.1 - 2.5    0.018  2.4  1.2 - 4.9   
ESR concentration at diagnosis    0.042  1.0  1.1 - 1.1    0.023  1.1  1.0 - 1.1   
Decrease in ESR concentration at 
6 mth  
  0.025  1.0  1.0 - 1.1    0.034  1.1  1.0 - 1.1   
Increase in albumin concentration 
at 6 mth 
  0.003  0.8  0.7 - 0.9    0.006  0.7  0.5 - 0.9    0.015  0.7  0.6 - 0.9 
BMI z-score at diagnosis    0.032  1.8  1.1 - 2.9    0.008  2.9  1.3 - 6.4   
Increase in BMI z-score at 6 mth    0.025  2.9  1.1 - 7.5    0.002  15.4  2.7 - 86.8   
12 mth Follow up        
Haemoglobin  concentration  at 
diagnosis  
  0.0001  2.6  1.6 - 4.3    0.029  1.7  1.1 - 2.8    0.002  6.0:   2.0 - 17.9 
ESR concentration at diagnosis    .037  1.0  1.0 -1.1     
Decrease in ESR concentration at 
12 mth  
  0.017  1.1  1.0 - 1.1     
Increase in albumin concentration 
at 12 mth 
  0.027  0.9  0.8 – 1.0    0.006    0.9 :  0.8 –1.0    
Oral iron supplementation      0.043    0.2:   0.1 - 0.9   
Height z-score increase at 12 mth      0.008  0.1  0.0 - 0.5   
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3.4. Discussion 
Anaemia  is  one  of  the  extra-intestinal  complications  of  IBD  affecting  body  homeostasis, 
quality  of  life  and,  in  children,  may  impair  cognitive  development  (Section  1.4.2).  The 
prevalence of anaemia in adult IBD is well reported but similar evidence in children is scarce 
(229).  
Poor  study  design,  with  small  sample  size  (213;242;252;253)  and  the  use  of 
inappropriate generic criteria to define anaemia were some of the drawbacks of previous 
paediatric reports. As it is well accepted that haemoglobin normal levels vary considerably 
with age and gender (205) the use of relevant cut offs is essential. In previous studies, both 
children with long-standing disease and newly diagnosed patients were recruited which may 
have induced selection bias to the estimation of anaemia prevalence at diagnosis (Table 
1.4.5).  In  contrast  this  current  study  included  only  patients  on  disease  presentation  and 
before medical therapy was applied. 
The Yorkhill Royal Hospital of Sick Children is the only paediatric referral hospital 
exclusively in charge of the care of all the children with IBD at the geographical area of the 
West of Scotland. This allowed to define a representative sample of the general Scottish IBD 
population  and  avoid  selection  bias  that  may  have  occurred  in  previous  studies,  which 
included  only  patients  with  active  disease  (242).  In  fact  the  demographic  and  disease 
characteristics of the population of the current study are in strong accordance with previous 
British epidemiological surveys (16;33) allowing the extrapolation of the results to the general 
Scottish paediatric IBD population.     
In  this  big  retrospective  study,  the  prevalence  of  anaemia  was  high  with 
approximately three quarters of the patients presenting with some degree of anaemia, and 
one third suffering from severe anaemia at diagnosis. Severe anaemia was more common in 
females with no difference observed between CD and UC. Blood loss from menstruation may 
explain this predisposition to girls despite the use of gender and age specific haemoglobin 
cut offs to define anaemia.    
Red blood cell counts were significantly higher in UC than CD despite no significant 
differences in haemoglobin levels or other haematological markers. Although it is difficult to 
elucidate the exact reason of this difference, a possible explanation would be the different 
causes of anaemia in the two diseases. Overt gastrointestinal bleeding with RBC loss is 
more common in UC than CD (33) and may be an additional major contributor to the origin of 
anaemia beyond any other causes like reduced iron intake and the disease affect. 
Gastrointestinal bleeding and poor dietary intake are typical clinical manifestations of 
the newly diagnosed IBD patient and may explain the strong association found in this study 
between systemic markers of disease activity and haemoglobin concentration. In fact the   170 
total  number  of  abnormal  systemic  markers  of  disease  activity  was  the  strongest 
independent  predictor  of  anaemia  occurrence  and  degree  of  its  severity.  A  patient  with 
abnormal  CRP,  ESR,  serum  albumin  and  increased  number  of  platelet  counts  had  an 
approximately 100 fold chance of severe anaemia.  
Disease location with involvement of the upper digestive tract, where dietary iron is 
absorbed, has been associated with anaemia occurrence in previous reports (244;247) but 
the results of this current study are not in accordance. New guidelines were used to define 
the anatomic location of the disease and failed to find any difference in anaemia prevalence 
between patients with upper and lower gastrointestinal involvement or between patients with 
extensive  or  disease  of  limited  extent.  Indeed  the  absence  of  difference  in  anaemia 
occurrence  between  CD  and  UC  advocates  that  iron  malabsorption  is  not  the  sole 
determinant of anaemia onset. Other factors such as intestinal bleeding, and a diet low in 
iron  (223)  could  equally  contribute  to  anaemia  aetiology.  Unfortunately,  due  to  the 
retrospective  design  of  this  study  no  dietary  assessment  was  available  to  address  this 
possibility.  On  the  other  hand  no  association  was  found  between  overt  self-reported 
gastrointestinal bleeding and anaemia although faecal occult blood cannot be excluded.    
Similar to disease location, disease behaviour was not significantly associated with 
anaemia  incidence.  Inflammatory,  penetrating  and  stricture  disease  behaviour  did  not 
differentiate anaemic from non-anaemic patients. However perianal disease involvement was 
not included in the disease phenotypic characterization and consequently this study cannot 
answer whether there are differences in the prevalence of anaemia in patients with perianal 
abscesses. The lack of relevant information was due to the retrospective nature of the study 
and  under-documentation  of  perianal  disease  in  the  electronic  pathology  reports  used  to 
assess the disease location. 
A high risk of undernutrition, as reflected by prior weight loss and low  at disease 
diagnosis,  differentiated  anaemic  from  non  anaemic  patients.  However  this  association 
disappeared when serum albumin levels were added in the multivariate model suggesting 
that  disease  activity  may  be  a  more  significant  predictor  of  anaemia  occurrence. 
Nevertheless albumin levels can be influenced by both inflammation and under-nutrition and 
a dependency with BMI may have confounded the results. Indeed when albumin substituted 
with  ESR  in  the  multivariate  model,  BMI  remained  a  statistically  significant  independent 
predictor of anaemia.   
The prevalence of anaemia varied between 2001 and 2007 but no overall temporal 
trends can be drawn. There was no decrease in the prevalence of anaemia over time despite 
our expectations. Temporal changes may have happened due to a shorter interval between 
symptoms onset and disease diagnosis nowadays. This would prevent the onset or allow 
timely  correction  of  anaemia  at  early  stages.  However  there  was  no  difference  in  the   171 
diagnosis delay within the short period assessed. Instead a significant association was found 
between  anaemia  occurrence  and  prompt  diagnosis.  This  could  be  due  to  an  inverse 
association between anaemia and diagnosis delay. It is possible that early onset of anaemia 
onset accelerates clinical investigations and hence prompt disease diagnosis, rather than a 
diagnosis delay predisposing to anaemia.  
This study aimed to assess the prevalence of anaemia and its progression at follow 
up. Due to the retrospective design of this study it was not possible to measure additional 
haematological parameters to differentiate between the types of anaemia. Based on the size 
of RBC, no patient suffered from megalocytic anaemia and this suggests that the primary 
cause of anaemia in IBD is IDA or ACD. Ferritin levels were available in a few patients and a 
significant positive correlation was found with CRP and a negative association with serum 
albumin concentration. Although at first sight this seems paradoxical and may suggest that 
iron  stores  are  improved  with  active  systemic  disease  or  undernutrition,  strong  evidence 
suggests that ferritin is a positive acute phase respondent that increases independently of 
the actual body iron stores in inflammatory conditions, infection and cancer (555). This study 
among others suggests that ferritin is an unreliable marker of body iron stores in patients with 
active IBD where systemic inflammation is present. The acute phase response and ACD 
could also explain why some anaemic patients had normal MCV and ferritin levels. Other 
surrogate  markers  should  be  used  with  better  diagnostic  value  in  order  to  differentiate 
between the different types of anaemia in IBD. Soluble serum receptor of transferrin is a 
potent marker but its use is limited to research only scale (228).  
Although there are a few case reports of nutritional anaemias caused by folate and 
vitamin B12 deficiency, none of the 26 patients studied had suboptimal levels of vitamin B12 or 
folate. Indeed there was no association between ileal defined disease and low levels of B12. 
This discrepancy with previous adult studies (236) may be ascribed to differences in subject 
characteristics and recruitment of patients with longstanding disease rather than the newly 
diagnosed  patients  this  study  included.  It  is  likely  that  vitamin  B12  body  stores,  although 
small,  are  adequate  to  sustain  serum  levels  and  prevent  B12  deficient  anaemia  in  newly 
presented  patients.  Conversely,  this  may  be  more  common  in  patients  with  longstanding 
disease and depleted vitamin stores.   
Changes in the pattern of anaemia prevalence over the natural history of the disease 
have not been described in adult or paediatric studies. This is the first study which assessed 
anaemia prevalence at follow up. Although anaemia prevalence remained high at follow up, a 
significant  decline  was  observed  which  coincided  with  a  significant  increase  in  mean 
haemoglobin concentration by approximately 1 g/dl at follow up.  Nevertheless more than 
half of the patients were anaemic at six months and 12 months post-diagnosis showing that a 
considerable number of patients remain anaemic within a year of diagnosis.   172 
With regard to changes in the severity of anaemia, one third of the children presented 
at diagnosis haemoglobin levels less than 10 g/dl, but only 10% were severely anaemic at 
follow up. On an individual basis approximately 50% of the patients anaemic at diagnosis 
remained so at follow up, and 31% improved to normal haemoglobin levels. Eight percent of 
the  patients  with  normal  levels  of  haemoglobin  at  diagnosis  deteriorated  and  became 
anaemic at follow up. Although subgroup analysis might reveal any disease or demographic 
differences compared to the rest of the groups, the sample sizes are too small and preclude 
reliable statistical analysis 
Several predictors of haemoglobin concentration improvement or deterioration were 
evaluated at follow up. Improvement of baseline serum albumin level at follow up was among 
the  strongest  predictors  in  univariate  and  multivariate  analysis  which  differentiated  those 
patients whose haemoglobin improved at follow up from those who did not. On the contrary 
CRP and ESR changes were not strong predictors of haemoglobin improvement particularly 
in UC patients. This discrepancy could show that other factors beyond changes in disease 
activity determine haemoglobin improvement or deterioration. In particular serum albumin, a 
negative acute phase respondent can be further decreased by poor nutritional status and 
subsequently increase of haemoglobin levels in response to improvement of serum albumin 
may  coincide  not  only  with  amelioration  of  disease  activity  but  also  with  nutritional 
rehabilitation. In support of this is that a BMI increase and linear growth acceleration in CD 
patients were strongly associated with improvement of haemoglobin levels, an effect that 
was independent of any improvement in the systemic markers of disease activity.  
Despite no difference in the prevalence of anaemia between CD and UC patients at 
any  point  of  follow  up,  disease  specific  differences  were  found  in  the  predictors  of 
haemoglobin change. A low haemoglobin at diagnosis and improvement of albumin at follow 
up were the strongest predictors of haemoglobin improvement at follow up in UC children. In 
contrast,  improvement  of  fundamental  anthropometry  and  ESR  were  additional  factors 
independently associated with increase of haemoglobin at follow up only in CD patients.   
As might be expected oral iron supplementation was independently associated with 
improvement  of  haemoglobin  levels  in  patients  with  CD.  This  effect  was  independent  of 
changes  in  systemic  markers  of  disease  activity  or  improvement  of  nutritional  status. 
Although  some  patients  who  received  blood  transfusion  were  included,  this  was  not  a 
significant predictor of haemoglobin anaemia improvement at follow up. It is possible that any 
favourable  effect  of  blood  transfusion  on  haemoglobin  levels  is  either  short  term  and 
counteracted by the increased disease severity and gross intestinal bleeding that is usually 
seen in this group of patients. In contrast to expectations, use of nutritional support did not 
differentiate those patients with improved haemoglobin levels at follow up from those who 
deteriorated. This study speculated that nutritional therapy and in particularly the number of   173 
EEN  courses  would  be  strongly  associated  with  haemoglobin  improvement.  However, 
frequent use of EEN nutrition also denotes increased disease activity and the number of 
courses  corresponds  to  clinical  relapses.  As  disease  activity  was  found  to  be  inversely 
associated with reduced haemoglobin levels in this study, any beneficial effect of nutritional 
support is counterbalanced by the negative effect of disease activity.  
Although it was not among the primary aims, this study provided useful information on 
the nutritional status body composition and disease characteristics of children with IBD at 
diagnosis  and  over  a  year  follow  up.  Disease  specific  differences  in  anthropometric 
characteristics  were found  between  children  with  CD  and  UC  as  reported  by  others.  CD 
children presented with significantly lower BMI z-scores than children with UC at diagnosis 
and at all time points of follow up. As a result the prevalence of underweight and growth 
retarded  children  was  significantly  higher  in  CD  than  UC  children.  Although  this  may  be 
attributed  to  the  involvement  of  upper  digestive  tract,  and  subsequent  nutrient  loss  from 
malabsorption  in  CD,  other  factors  could  be  implicated  too.  Crohn’s  disease  and  UC, 
although part of the same disease constellation, have different mechanisms of pathogenesis, 
and immunological responses that may affect nutritional status in a different way. As the 
findings of this study suggest, patients with CD have more abnormal systemic markers of 
disease activity compared to UC children, and it is perhaps due to the increased production 
of  inflammatory  markers  and  pro-inflammatory  cytokines  that  CD  children  more  often 
experience growth retardation and suboptimal nutritional status. This coincides with evidence 
that suggests that pro-inflammatory cytokines are partially responsible for growth retardation 
and suboptimal nutritional status (111). Future studies in this area should address this and 
whether  different  cytokines  exert  a  different  role  on  growth  and  nutritional  status.  It  was 
exciting to find that the majority of the children with suboptimal weight at diagnosis caught up 
within six months of follow up. The proportion of patients who presented BMI lower than -2 
SD at 12 months did not differ significantly from the normal distribution seen in the general 
healthy population.  Although no IBD patient was obese at diagnosis, more than 10% percent 
of the UC children could be classified obese at follow up. This reverse in nutritional status 
could be a combination, of disease improvement, nutritional support and the side effects of 
the use of steroid treatment.  
In the biggest study in Europe and the UK, the prevalence of anaemia is high in 
paediatric  IBD  at  diagnosis.  Disease  activity  and  nutritional  status  at  diagnosis  and  their 
change  at  follow  up  are  the  most  important  predictors  of  anaemia  occurrence  and  its 
evolution during the course of disease. Future research should be focused on the part of 
patients  who  deteriorated  at follow  up.  This study  just  explored  any  potential  association 
between the use of medication and prevalence of haemoglobin at follow up and therefore it is 
difficult  to  conclude  on  any  causative  association.  Further  well  controlled  trials  should   174 
investigate the collateral therapeutic effects of new anti-inflammatory agents and nutritional 
therapies  to  correct  anaemia.  This  is  particular  important  in  the  case  of  ACD  whose 
pathogenesis  is  predominantly  attributed  to  the  excessive  production  of  pro-inflammatory 
cytokines  (231).  It  was  noteworthy  to  find  that  there  is  a  lack  of  studies  on  the  dietary 
assessment of paediatric patients of IBD. A diet poor in iron unable to compensate with the 
excessive gastrointestinal losses may equally contribute to the onset of anaemia in IBD. Iron 
balance studies could be designed where the equilibrium of iron balance is monitored to 
accurately assess intake, use, and gastrointestinal losses. In any case a diet rich in iron 
containing foods should be encouraged. Oral iron supplementation, although supported by 
the findings of the current retrospective study, should be used cautiously in the light of animal 
studies  and  in-vitro  models  suggesting  that  excessive  production  of  free  radicals  and 
oxidative stress at the site of tissue lesion may have possible implications for increased risk 
of colonic carcinogenesis (236).   175 
 
 
 
 
 
 
CHAPTER FOUR 
 
 
Comparison of body composition assessment 
in healthy children with leg to leg bioelectrical 
impedance and DXA analysis   176 
OUTLINE 
This  chapter  describes  a  study  that  assessed  the  validity  of  a  simple  body  composition 
method,  based  on  bioimpedance,  to  measure  accurately  body  composition  in  healthy 
children.  The  secondary  aim  of  this  study  was  to  measure  the  body  composition  of  a 
representative  cohort  of  healthy  Scottish  children  and  to  compare  it  with  the  body 
composition of CD children who participated in the studies of this thesis. The results of the 
second part of this study are presented in Chapter 5. 
 
4.1. Introduction 
Assessment of body composition is important in health and disease. Measurement of body 
fat stores is important in obesity and calorie restricting diets, as is measurement of muscle 
mass in chronic catabolic disorders.  
Measuring body composition has been a constant challenge and at the moment no 
standard  method  is  universally  accepted  to  measure  body  compartments  accurately  and 
precisely (92). Chemical analysis of human cadavers is the only way body composition can 
be determined accurately but imaging techniques and the multi-compartment model (556) 
are considered the best approaches, usually cited as “gold standard” methods (557). Other 
techniques  like  stable  isotope  dilution,  underwater  weighing,  total  body  dual  x-ray 
absorptiometry (DEXA) known as “reference methods” rather than “gold standards”, are good 
alternatives  with  minimal  error,  but  are  mainly  laboratory  based  methods,  and  hence 
impractical in large scale community studies or for routine clinical use.  
Practical, cheap, safe and patient friendly methods of body composition assessment 
for  clinical  bedside  use  are  needed.  Fundamental  anthropometry  and  growth  charts, 
calculation of BMI, or use of prediction equations based on height and weight are not able to 
differentiate between fatness and lean mass (558). Although in healthy adults and children 
BMI, originally an index of morbidity risk, correlates well with fatness (93), their diagnostic 
value  to  differentiate  fat  from  lean  mass  is  questionable,  particularly  in  disease.  Multiple 
clinical conditions like oedema or dehydration, and use of steroids can affect body weight 
irrespective of changes in the actual muscle and fat stores. Hence the use of anthropometry 
can be inaccurate and misleading.  
Skinfold thickness measurements have been the only method used for surveillance of 
body stores in routine clinical practice. However they are prone to inter-observer error, need 
well trained personnel and may cause discomfort in young children.  Although reliable in the 
assessment of groups or populations, skinfold thickness measurements are not reliable in 
estimating the body composition of individuals. (559).    177 
The advent of bioelectrical impedance analysis (BIA) was welcomed as a potential 
alternative at the beginning of the 80’s. The equipment is non-invasive, portable, quick to 
use,  provides  direct  results  and  needs  less  subject  cooperation  than  any  other  method 
making it viable for field and routine use.    
The fundamental principle behind BIA is the measurement of the resistance of the 
human  body  to  an  insensible  electric  current  circulating  through  the  body  (560).  The 
measured resistance/impedance or more correctly the impedance index (Height
2/Resistance) 
is  proportionally  related  to  total  body  water  volume  and  consequently  total fat free mass 
(FFM), assuming a constant hydration of FFM containing virtually all the body’s conducting 
electrolytes (560). Nevertheless the relationship between total body water and impedance 
must be established empirically and there is evidence that this differs between populations, 
races, sexes and ages (561). The National Institute of Health published a consensus article 
that  highlights  the  importance  of  comparing  the  impedance  instruments  with  reference 
methods and that predictive equations are useful only for subjects who closely match the 
reference population from which they were derived (562;563). 
The traditional method is based on the measurement of impedance between the hand 
and foot. A new alternative has recently been introduced that measures the impedance from 
an electrical circuit between the legs (564). This adapted technique resembles a household 
bathroom scales with the subject required to stand briefly on two metallic footplates. Unlike 
the  conventional  technique  there  is  no  need  for  the  attachment  of  electrodes  at  precise 
anatomical sites and weight is simultaneously measured avoiding any transcription errors.  
Many studies have compared and validated or compared the traditional hand to foot 
technique with other “reference methods” both in adult (565-568) and paediatric populations 
(569;570) but the derived equations cannot be applied to the foot to foot appliance due to 
difference  in  the  measuring  segments  of  the  body  (hand  to  foot  vs  foot  to  foot)  (571). 
Relevant  studies  for  the  foot  to  foot  method  are  scarce  (572)  particularly  in  paediatric 
populations  (573;574)  and  so  the  validity  of  the  new  foot  to  foot  system  with  its  inbuilt 
manufacturer’s equations needed to be tested.  
The primary purpose of this study was to compare the foot to foot technique of body 
composition with respective DXA measurements in a healthy cohort of Scottish children. This 
would allow to consider its appropriateness for use in the assessment of body composition in 
paediatric  patients  with  CD.  The  second  aim  of  this  study  was  to  compare  the  body 
composition  of  this  healthy  control  cohort  with  a  cohort  of  children  with  CD  which  is 
presented in a following chapter (Chapter 5).   178 
 
4.2. Subjects and methods 
4.2.1. Subjects 
A  subgroup  of  children  from  a  larger  study  on  bone  health  and  body  composition,  in 
mainstream  and  specialist  sport  schools,  was  recruited  for  the  purpose  of  this  study. 
Potential participants were approached by posted invitation letters to lists of patients kindly 
supplied by their general practitioners. Exclusion criteria were acute or chronic illness and 
concomitant medication use known to induce changes in body composition. The volunteers 
were from mainstream schools in the area of Glasgow. Children were selected to provide an 
equal distribution of ages, genders, and BMIs. Written informed consent was obtained from 
all children and their parents. The study protocol was approved by the local research ethics 
committee and the research and development office.  
 
4.2.2. Basic anthropometry 
Anthropometric measurements were conducted according to standard procedures. A trained 
dietitian  and  a  paediatric  endocrinologist  performed  all  measurements.  Each  investigator 
performed a single type of measurement. Weight was measured to the nearest 100 g using a 
calibrated  digital  beam  scale  (SECA,  Birmingham,  UK).  Subjects  were  weighed  in  light 
clothing or wearing a hospital gown. Height was measured to the nearest 1 mm using a wall-
mounted stadiometer according to the Frankfurt plane position. BMI was computed as the 
fraction of weight to the squared height and corresponding z-scores were calculated using 
British national reference data (575).  
 
4.2.3. Body composition 
4.2.3.1. Foot to foot impedance measurements 
Bioelectrical impedance analysis (BIA) was performed with the foot to foot technique using a 
TANITA  body  fat  analyser  (TBF-300,  Tokyo,  Japan)  which  provides  a  print  out  of  the 
measured  weight,  impedance,  and  two  compartment  body  composition  analysis.  Gender, 
age and height to the nearest centimetre were entered manually into the keypad interface. 
Subjects stood on the two metal sole-pad electrodes embedded on the platform scales. The 
electrode for each foot was subdivided into anterior and posterior electrodes. A current was 
applied  through  the  anterior  portion  of  the  footpad  electrodes  and  the  voltage  drop  was 
measured in the posterior portion. The impedance measurement used a 50 kHz, 500  A 
insensible current. Subjects were asked to have only a light meal at least one hour before 
their  measurements  and  were  asked  to  void  their  bladder  before  the  start  of  the   179 
measurements. All the measurements were done after a period of at least 10 min standing 
upright to minimize potential errors from acute shifts in fluid distribution. Body composition for 
all  subjects  was  estimated  using  the  standard  inbuilt  prediction  equations  of  the 
manufacturer,  as  no  other  appropriate  equation  is  available  in  the  literature.  Every 
measurement was taken in duplicate and averaged unless the difference in two impedance 
measurements was greater than 10 Ohms.  
 
4.2.3.2. DXA measurements 
Whole body DXA scans were performed with a narrow fan beam Lunar Prodigy densitometer 
(GE Healthcare) and phantoms analysed using the Encore software (Version 8.80.001). The 
DXA technique is based on the attenuation properties of bone, lean and fat tissues at two 
different  x-rays  energies  and  it  measures directly  the  bone  mineral  content,  lean  and fat 
mass (FM) (576;577).  
Whole body composition was analyzed for bone mass and soft tissue and the latter 
was subdivided into lean and FM. Bone mass content added to lean mass corresponded to 
FFM in accordance with the two-compartment model. Each scan took approximately five min 
to  complete.  The  DXA  scans  were  carried  out  randomly  prior  to  or  after  the  BIA 
measurements. 
 
4.2.4. Statistical analysis 
The  difference  between  paired  data  was  tested  with  one  sample  t-test  and  one  sample 
Wilcoxon Sign Rank test, for normally and non-parametric distributed values. Normality of the 
data was checked with  the Darling-Anderson test. Spearman rank correlation coefficients 
were  calculated  for  BIA  and  DXA  for  all  body  composition  measures.  Linear  regression 
analysis with best fitting line was used to predict DXA FFM measurements by the respective 
TANITA values. The agreement between the two methods, was evaluated with Bland-Altman 
plots, by plotting the individual differences of a measure, between the two methods, against 
their mean (578). The bias of the method is equal to the mean difference of the methods. 
Limits of agreement between BIA and DXA were calculated as the mean difference of the 
two methods ± 1.96 times the standard deviation of the mean difference. The effect of size of 
the measurement on the agreement of the methods was assessed by calculating the R
2 co-
efficient of the linear regression model of the differences of the measures against their mean 
value. Statistical significance was set at p< 0.05. Standard deviation scores (z-scores) for % 
FM were calculated using British reference data (579) kindly provided by Professor Tim Cole. 
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4.3. Results 
4.3.1. Sample characteristics and basic anthropometry 
117  children  aged  (6.8-18.9)  agreed  to  participate.    All  participants  completed  all 
measurements  successfully.    Most  of  the  children  were  of  Caucasian  origin  (n=107). 
Demographics, anthropometry and body composition data grouped by sex are presented in 
Table  4.1.  No  difference  was  found  between  boys  and  girls  for  age  and  fundamental 
anthropometry. Height z-scores did not differ significantly from zero (p-value=0.540) but BMI 
z-scores were slightly higher than the British reference population (575) (p <0.0001).  
 
4.3.2. Body composition analysis 
For both methods the mean FM, expressed as absolute values (kg) or as percentage of body 
weight, was lower in boys than girls despite no significant mean differences in BMI, body 
weight  and  height  (Table  4.1).  Likewise  the  percentage  FFM  but  not  absolute  FFM  was 
higher in boys than girls. No gender-associated difference was found for the %FM z-scores. 
Females had significantly higher measurements of impedance than boys as expected.   
 
4.3.3. Comparison between DXA and TANITA 
4.3.3.1. Correlation of the methods 
As expected all body composition compartments (FM, FFM, %FM and %FFM) estimates by 
BIA were positively and highly correlated with those by DXA (Table 4.2). The Spearman rank 
correlations coefficient between DXA and BIA measures of FFM, FM, %FFM and %FM were 
high for both genders (Table 4.2 Fig 14-16). Fat free mass calculated by DXA was linearly 
regressed  against  FFM  predicted  by  TANITA.  A  FFM  prediction  line  was  drawn  that 
explained 96% of the measurements variance (Fig 13). 
 
4.3.3.2. Biases and limits of agreement between the methods 
4.3.3.2.1. Crude measurements of body composition 
The  differences  in  body  composition  measures  between  the  two  methods  were  normally 
distributed (Anderson-Darling normality test) and the use of Bland-Altman plot was deemed 
valid  and  no  log  transformation  of  the  data  was  required.  Mean  absolute  values  and 
percentages of FM and FFM were statistically different between DXA and TANITA (all p-
values <0.0001). Defining DXA as the “reference method”, TANITA overestimated %FFM by 
a mean of 4.5% and underestimated FM by -2.1 kg of fat (Table 4.3). Nonetheless, in all   181 
cases, the limits of agreement between the methods were wide and therefore the methods 
were not interchangeable at an individual level (Table 4.3). Biases and limits of agreement 
for absolute measures and % FM and FFM are displayed in Figs 16-18 and summarized in 
Table 4.3 for the whole group and separately for boys and girls. Taking body fat as a prime 
example, TANITA may underestimate or overestimate %FM as much as -13.3% and 4.3% 
respectively. The mean bias between the two methods was higher in girls than boys but in 
both cases the limits of agreement for all body composition measurements were wide (Table 
4.3). 
A  weak  but  statistically  significant  effect  of  the  size  of  measurement  on  the 
agreement of the methods was observed that partially justifies the broad limits of agreement 
(Table 4.4). However when the data were analyzed separately for boys and girls, a size of 
measurement effect was observed in males but not in females (Table 4.4). With increasing 
body  fatness  the  measurement  bias  between  TANITA  and  DXA  became  progressively 
negative in boys. In particular TANITA consistently underestimated %FM in boys with body 
fat more than 20% whereas the measurement error was variable in males with lower %FM. 
No similar patterns were observed for females (Fig 18).   
 
4.3.3.2.2. Z-scores of body composition measurements  
Percent FM values by both methods were converted to z-scores using the British reference 
range (579). The age and gender adjusted bias of foot to foot BIA for %FM was -1.3 SD with 
wide limits of agreement (Table 4.3; Fig 19). In contrast to %FM crude values, increase of 
%FM  z-scores  influenced  the  bias  between  the  two  methods  in  a  similar  way  for  both 
genders (Figs 20-21). For children with normal or high %FM z-score, the bias for foot to foot 
BIA was small and lay close to the line of method agreement. On the other hand the limits of 
agreement were wide and varied considerably for children with very low %FM z-score (Table 
4.3; Figs 20-21).           182 
 
Table 4.1: Demographics, anthropometry and body composition characteristics (mean; SD) of 
healthy Scottish children (mean ± SD)  
Measurement  F (n=63)  M (n=57)  Total (n=117) 
Age (decimal y)    12.6   ±   3.2    12.4   ±   3.7    12.5   ±   3.4 
Height (cm)   149.2   ±   14.0   152.0   ±   20.0   150.5   ±   17.0 
Weight (kg)    46.4   ±   17.7    47.8   ±   19.1    47.0   ±   18.3 
Height z-score    0.0   ±   1.0    0.1   ±   1.0    0.06   ±   1.0 
Weight z-score    0.3   ±   1.2    0.5   ±   1.1    0.4   ±   1.1 
BMI    20.2   ±   4.8    19.7   ±   3.9    20.0   ±   4.4 
BMI z-score    0.4   ±   1.2    0.6  ±   1.1    0.5   ±   1.1 
       
TANITA       
Impedance (Ohms)   601.0  ±   71.0*   564.0  ±   72.0   584.0   ±   74 
FFM (%)    77.3   ±   9.5*    83.4   ±   7.4    80.1   ±   9.1 
FFM (kg)    34.0  ±   8.9    39.1   ±   15.5    36.4   ±   12.6 
FM (%)    22.7   ±   9.5*    16.6   ±   7.4    19.9   ±   9.1 
FM (kg)    11.7   ±   10.1*    8.1   ±   5.8    10.0   ±   8.5 
FM (%) z-score    -1.1   ±   4.0    -0.7   ±   2.4    -0.9   ±   3.3 
Total body water    24.9   ±   6.5    28.6   ±   11.4    26.6   ±   9.2 
       
DXA       
Total body mass (kg)    45.5   ±   17.5    47.4   ±   19.1    46.4   ±   18.2 
FFM (kg)    31.6   ±   8.6    37.3   ±   14.4    34.2   ±   11.9 
FFM (%)    72.0   ±   9.2*    79.9   ±   9.3    75.7   ±   10.0 
FM (%)    28.0   ±   9.2*    20.1   ±   9.3    24.3   ±   10.0 
FM (kg)    13.9   ±   10.1*    10.1   ±   7.6    12.2   ±   9.2 
FM (%) z-score    0.6   ±   1.7    0.1   ±   1.9    0.3   ±   1.8 
       
* Difference between genders p< 0.05 (two sample t-test or Mann-Whitney test) 
 
 
 
Figure  13: Linear regression with best fitting line for FFM (kg) between TANITA and DXA 
measurements of body composition 
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Table 4.2: Spearman rank correlation (r coefficient and p-values) for body composition variables between DXA and TANITA in healthy Scottish 
boys and girls  
 
  Males    Females    Whole group   
  R coefficient  p-value  R coefficient  p-value  R coefficient  p-value 
FFM (Kg)  0.99  0.001  0.96  0.001  0.98  0.001 
FFM (%)  0.79  0.001  0.85  0.001  0.86  0.001 
FM (Kg)  0.92  0.001  0.95  0.001  0.94  0.001 
FM (%)  0.79  0.001  0.85  0.001  0.86  0.001 
 
 
Table 4.3: Measurement bias with 95% limits of agreement for body composition measurement between DXA and TANITA in healthy Scottish boys 
and girls  
  Males  Females  Whole group 
  Bias  Limits of agreement  Bias  Limits of agreement  Bias  Limits of agreement 
FFM (Kg)  1.8    -3.6:  7.3  2.4    -2.0:  6.9  2.2    -2.8:  7.1 
FFM (%)  3.5    -4.8:  11.8  5.3    -3.6:  14.2  4.5    -4.3:  13.3 
FM (Kg)  -2    -7.2:  3.2  -2.2    -6.4:  6.9  -2.1    -6.8:  2.5 
FM (%)  -3.5    -11.8:  4.8  -5.3    -14.2:  3.6  -4.5    -13.3:  4.3 
FM (%) z-score  -0.8    -4.0:  2.3  -1.2    -3.7:  1.2  -1.3    -6.0  5:4 
 
 
Table 4.4: Effect of the size of the measurement on the agreement of the methods in healthy Scottish boys and girls. R coefficient, slope (β 
coefficient), and p-values 
  Males  Females  Whole group 
  R  Slope  p-value  R  Slope  p-value  R  Slope  p-value 
FFM (Kg)  15.8  0.1  0.003  2.4  0.04  0.223  6.6  0.1  0.003 
FFM (%)  20.3  -0.2  0.001  0.5  0.03  0.592  4.4  -0.1  0.023 
FM (Kg)  44.5  -0.3  0.001  0.0  0  0.997  7.0  -0.1  0.004 
FM (%)  20.3  -0.2  0.001  0.5  0.03  0.592  4.4  -0.1  0.023 
FM (%) z-score  8.3  0.26  0.019  27.3  0.35  0.001  15.5  0.29  0.001 
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Figure  14: Spearman rank correlation for body composition measures between TANITA and DXA in healthy children (whole group) 
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Figure  15: Spearman rank correlation for body composition measures between TANITA and DXA in healthy children (males) 
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Figure  16 : Spearman rank correlation for body composition measures between TANITA and DXA in healthy children (females) 
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Figure 17: Bland Altman plots with 95% limits of agreement and regression line for body composition measures between TANITA and DXA in 
healthy children (whole group) 
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Figure  18: Bland Altman plots with 95% limits of agreement and regression line for body composition measures between TANITA and DXA in 
healthy children (females) 
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Figure  19: Bland Altman plots with 95% limits of agreement and regression line for body composition measures between TANITA and DXA in 
healthy children (males) 
 
30 20 10 0
5
0
-5
-10
Average (Tanita:DXA) FM (Kg) (Males)
D
i
f
f
e
r
e
n
c
e
 
(
T
a
n
i
t
a
:
D
X
A
)
 
F
M
 
(
K
g
)
 
(
M
a
l
e
s
)
40 30 20 10
5
0
-5
-10
-15
Average (Tanita:DXA) FM (%) (Males)
D
i
f
f
e
r
e
n
c
e
 
(
T
a
n
i
t
a
:
D
X
A
)
 
F
M
 
(
%
)
 
(
M
a
l
e
s
)
60 50 40 30 20
10
5
0
-5
Average (Tanita:DXA) FFM (kg) (Males)
D
i
f
f
e
r
e
n
c
e
 
(
T
a
n
i
t
a
:
D
X
A
)
 
F
F
M
 
(
k
g
)
 
(
M
a
l
e
s
)
90 80 70 60
15
10
5
0
-5
Average (Tanita:DXA) FFM (%) (Males)
D
i
f
f
e
r
e
n
c
e
 
(
T
a
n
i
t
a
:
D
X
A
)
 
F
F
M
 
(
%
)
 
(
M
a
l
e
s
)
Bland Altman plot of FM (kg) (Males) Bland Altman plot of FM (%) (Males)
Bland Altman plot of FFM (kg) (Males) Bland Altman plot of FFM (%) (Males)
   190 
 
Figure  20: Bland Altman plots with 95% limits of agreement and regression line for %FM z-scores between TANITA and DXA imn healthy children 
(whole group) 
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Figure  21: Bland Altman plots with 95% limits of agreement and regression line for body composition measures between TANITA and DXA in 
healthy children (analysis by gender) 
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4.4. Discussion 
Body composition assessment is important in disease where changes of body weight do not 
always parallel alterations in body muscle and fat stores. A prime example is the chronic use 
of steroids, where body fat stores increase in parallel to fluid retention and muscle wasting.  
There are several methods to assess body composition but at the moment none is 
able  to  assess  accurately  the  body  composition  in  the  living  human.  Some  of  the  most 
precise methods are impractical in clinical use or in large public health surveys whereas the 
accuracy of the more practical bedside methods is questionable and should always be tested 
against reference methods to the population intended for use. Indeed that was the primary 
aim  of  this  study.  To  test  the  validity  of  a  foot  to  foot  BIA  appliance  against  a  body 
composition reference method.  
In  the  current  study,  measurements  of  body  composition  carried  out  by  the  two 
different methods were highly correlated. This is not surprising as body composition in BIA is 
predicted  by  mathematical  models,  where  body  weight  contributes  substantially  to  the 
estimation  of  FM  or  muscle  stores.  On  the  other  hand  correlation  does  not  parallel  the 
agreement between the methods and whether these are inter-changeable at individual level 
(578). Thus the agreement of the two body composition methods was assessed using Bland-
Altman plots. The overall bias of BIA was estimated to approximately +2.2 kg of FFM or -
4.5% of FM and the limits of agreement were wide for all the body composition parameters. 
In practice this corresponds to underestimation or overestimation of real %FM by an extra 
13.3%  to  -4.3%  fat  respectively.  In  a  35  kg  child  with  actual  body  fat  of  15%  the  BIA 
predicted %FM can be between 1.7% to 19.3%. Measurements of body composition with 
TANITA tended to underestimate FM and, accordingly overestimate FFM in a higher degree 
in girls than boys. However in both cases the bias was large and the limits of agreement 
wide.  
The findings of this study are in accordance with previous work (573) where the same 
model of TANITA underestimated FM and overestimated FFM in a cohort of British eight y 
old children and, by Lazzer et al (580) in overweight/obese adolescents (Table 4.5). Opposite 
results and overestimation of FM by TANITA were also reported (581) and this may be due 
to  the  different  devices  and  prediction  algorithms  used  to  calculate  FM  in  the  studies  or 
different  sample  characteristics  and  the  physiological  changes  that  occur  in  body 
composition with age and gender (582). 
In  this  study  a  gender  specific  effect  of  the  size  of  the  measurement  on  the 
agreement of the methods was found and should be considered when interpreting results 
with TANITA. In boys with increasing percentage fat, TANITA tended to underestimate fat 
more.  Lazzer  et  colleagues  (580)  showed  that  two  different  foot  to  foot  BIA  appliances   193 
underestimated low %FM but overestimated high %FM in overweight/obese children when 
compared  with  DXA  body  composition  assessments.  Both  these  findings  are  particularly 
important when assessing or monitoring body composition changes in overweight and obese 
children. On the other hand one should always bear in mind that DXA is a reference method 
rather than an actual “gold standard” (556;558;583) and its accuracy may be influenced by 
the size of the measurement (584), the location of FM (585) and the hydration of the FFM 
(586).  
In this study it is presented for first time a new way of analyzing the agreement of 
body composition methods by converting %FM in z-scores using recent British normative 
data (579). In this way any age and gender confounding effect on the assessment of the 
effect of the size of the measurement on the agreement of the two methods was eliminated. 
Indeed similar patterns were observed for boys and girls in contrast to the crude values of 
%FM. A better agreement was found between the methods for children with %FM around or 
above the mean of the reference population. In contrast the limits of agreement were wide for 
negative %FM z-scores and thus TANITA consistently underestimated %FM is children with 
extremely  low  body  fat.  Poor  validity  of  body  composition  methods  is  common  at  the 
extremes of body composition (573). This can be attributed to small/inadequate sample sizes 
recruited in order to validate body composition at the two edges of the body composition 
spectrum or to the invalidation of the theoretical body composition constants in obese and 
underweight subjects.  
In this study body composition presented poor agreement with DXA to assess body 
composition  in  healthy  Scottish  children  and  therefore  the  two  methods  are  not 
interchangeable. However the estimation error of BIA techniques is inherent to the error that 
the prediction equations cause when they are used in populations different from those for 
which they have been validated. Manipulation of body impedance values in a way that would 
be independent of such prediction equations, may be a better and most reliable method to 
use BIA. Recently Professor Wright and colleagues, University of Glasgow, developed a new 
method to use bioimpedance measurements and classify children as having relatively high, 
average or low fatness and leanness independently (587).     
Although BIA may not be accurate to precisely assess body composition its use to 
assess longitudinal changes in follow up studies may be more useful. Its sensitivity to detect 
changes in body composition should be addressed with follow up studies measuring body 
composition at intervals with BIA and other reference methods (588;589).  
This  study  was  carried  out  to  evaluate  the  validity  of  TANITA  to  assess  body 
composition in patients with CD. However this study recruited only healthy children as this 
was a more convenient sample of a pre-existing ongoing study and therefore the validity of 
the method may be different in disease where the theoretical assumptions and constants that   194 
each method considers in the estimation of body composition may not be valid (590;591). 
Separate  validation  studies,  in  patients’  groups,  are  needed  to  check  the  validity  of  BIA 
(569;590). In paediatric IBD, Dung et al (592) tested the validity of several published hand to 
foot BIA prediction equations to assess FFM accurately compared to DXA measurements 
and proposed a new prediction equation for estimation of FFM in children with CD. In the 
same way validation of the foot to foot BIA appliance against reference methods of body 
composition, may offer a potential tool to easily, quickly and safely monitor body composition 
in paediatric patients with IBD.  
Although it was found that the foot to foot appliance is not accurate enough to assess 
body composition in children, this technique was still used in the studies of this thesis. This 
was because there is no other alternative method of body composition to use for routine 
clinical  and  research  investigations.  Methods  like  double-labelled  water,  and  DXA  scans 
although more reliable than the foot to for bioimpedance are difficult to be used in clinical 
settings,  are  expensive  and  need  much  co-operation from  the  participants.  Moreover  the 
results  of  this  study  give  more  insight  on  how  to  evaluate  and  interpret  the  findings  in 
following studies of this thesis where it was used the foot to foot bioimpedance.  
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Table 4.5: Paediatric studies comparing foot to foot BIA devices with DXA in the assessment of body composition in healthy Scottish children 
Study  Sample  BIA equipment  Age  Bias  Size and gender effect 
Hosking et 2006 
(573)  
203 (106 M); British  Tanita TBF-300M  8.3 ± 0.3  BIA underestimated FM & 
%FM and overestimated FFM 
& %FFM 
In  small  boys  %FM  was  overestimated 
whereas  in  big  boys  it  was 
underestimated; No similar effect in girls  
Lazzer et al 2003 
(580)  
53 (20 M); 
overweight/obese 
adolescents; French 
Tanita TBF-625 & 
Tefal Bodymaster 
Vision 
14.1 ± 1.4  Both devices underestimated 
%FM 
Bias higher in boys than girls; 
Both  devices  underestimated  low  %FM 
but overestimated high %FM particularly 
in boys 
Sung et al 2001 
(581) 
49;17 obese; 
Chinese 
Tanita TBF-401  13 ± 3.1  BIA significantly 
overestimated FM but not 
%FM 
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body composition and micronutrient status in 
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OUTLINE 
This  chapter  describes  a  prospective  observational  study  on  the  effect  of  EEN  on  body 
composition  and  micronutrient  status  in  paediatric  patients  with  active  CD.  Associations 
between systemic markers of disease activity, gut markers of disease activity and indices of 
nutritional status are explored. 
 
5.1. Introduction  
Exclusive enteral nutrition is the mainstream treatment of active paediatric CD in UK with 
double benefit. It induces clinical remission in more than 60% of the cases, and at the same 
time improves the nutritional status of the patient (297). This has been described extensively 
in Section 1.5. 
In  IBD  malnutrition  can  occur  with  all  its  different  facets.  Protein-energy 
undernutrition, low circulating levels of micronutrients and poor bone health are all seen in 
IBD patients (35) (Section 1.3). Vitamins, trace elements and minerals are key nutrients of 
the body’s harmonic function and homeostasis, and in IBD they play an additional role (Table 
1.3.2). Zinc, selenium and carotenoids are important components of the body’s antioxidant 
system  and  may  protect  biological  molecules  from  oxidative  damage  caused  by  the 
excessive production of reactive oxidative species from the activated immune system in IBD.  
Until now the mechanism of EEN action in inducing remission remains unexplained 
(Section 1.5.2). Early suggestions that nutritional replenishment is the main mechanism have 
been  revised  by  recent  evidence  that  EEN  has  direct  anti-inflammatory  effects,  which 
precede  nutritional  rehabilitation  (267).  On  the  other  hand  a  therapeutic  mode  of  action 
mediated  by  changes  in  micronutrient  status  is  possible  but  has  not  been  investigated 
thoroughly thus far. Two previous studies were limited to the effect of EEN on the body’s 
antioxidant systems and stores (148;336) and only one of these (148) made associations 
with concomitant changes in disease activity. The authors of this study (148) showed that CD 
children had reduced activity in enzymatic antioxidant systems in erythrocytes, which did not 
improve  with  eight  weeks  treatment  on  EEN  despite  parallel  improvement  of  the  clinical 
activity and systemic inflammatory markers (CRP and TNF-a). Although these results imply 
that  the  therapeutic  action  of  EEN  in  CD  is  independent  of  changes  in  the  antioxidant 
systems,  changes  in  other  micronutrient  status  during  EEN  and  their  association  with 
disease activity need to be clarified further. Likewise Akobeng and colleagues (336) did not 
find significant changes in antioxidant mechanisms or markers of oxidative stress in children 
with CD after a four week course with EEN. However they did not assess disease activity or   198 
changes  in  inflammatory  markers  levels  and  how  these  correlate  to  changes  in  the 
micronutrient status.  
There  are  other  valid  reasons  why  monitoring  micronutrient  status  during  EEN  is 
important in CD. Improvement of protein-energy status in CD children under treatment with 
EEN,  is  reflected  by  overt  changes  in  body  anthropometry  but  whether  these  changes 
coincide with replenishment or maintenance of micronutrient body stores is unknown and not 
easy  to  assess.  Although  most  commercially  available  feeds  provide  the  recommended 
micronutrient requirements for healthy children their corresponding adequacy in CD patients 
is uncertain. Malabsorption, increased consumption and increased needs in CD may require 
higher intakes than those established for healthy children. Abad-Lacruz et al (335), 20 years 
ago, failed to show improvement in the vitamin status of IBD adults on EEN despite provision 
of  micronutrients  in  doses  significantly  higher  than  the  recommended  dietary  allowance. 
Moreover nutritional supplements are “artificial composite food” made up of simple nutrients 
for which recommended allowances have been established and thus may be insufficient in 
non-nutrients that naturally occur in food but are rarely included in artificial feeds.  
Thus far no paediatric study has assessed changes in the status of a large number of 
vitamins and minerals in CD under treatment with EEN. The objective of this study was to 
measure the body composition and micronutrient status of children with CD and to assess 
their change under EEN. A second aim was to explore any association between systemic 
markers of disease activity, gut markers of disease activity and indices of nutritional status 
including body composition measures and micronutrient blood status. 
 
5.2. Subjects and methods 
5.2.1. Subjects 
Participants of this study were children CD who took part in a study on the effect of EEN on 
the  nutritional  status (Chapter  5),  disease  activity  markers (Chapter  6),  and  gut  bacterial 
metabolic activity and diversity (Chapter 7) of paediatric patients with CD (Fig 22).  
All the paediatric CD patients with active disease (<16 y old) who commenced an 
EEN  course,  as  part  of  their  standard  medical  management  were  eligible  to  participate. 
These patients were either newly diagnosed or patients with longstanding disease in clinical 
relapse. Newly diagnosed patients were approached within two days of colonoscopy or when 
the biopsy histology report was announced for patients with dubious endoscopic findings. 
The patients with longstanding disease in relapse were recruited at the end of their outpatient 
clinical appointment. An introductory letter and an information leaflet (Appendix) about the 
study  were posted to all patients with long standing disease to allow  them more time to 
consider the study in case they were eligible for recruitment.    199 
Figure  22: Study flowchart on the effect of EEN on inflammatory response, nutritional status and gut microbiota   200 
5.2.2. Exclusive enteral nutrition 
In all cases, the patients followed an eight weeks planned EEN course with a polymeric 
casein-based  liquid  supplement  enriched  with  Transforming  Growth  Factor-β  (Modulen®, 
Nestle). The feeds provided the recommended daily energy requirements for age and gender 
(COMA, 1990) favouring a higher intake of protein. A higher energy intake (200-500 kcals) 
was given to those children who presented underweight. The feeds were administered orally 
or  when  not  tolerable  via  a  fine  bore  nasogastric  tube  or  a  percutaneous  endoscopic 
gastrostomy. No other foodstuffs were allowed during the treatment with the exception of 
water,  tea  and  clear  mints.  At  the  end  of  treatment,  a  step-by-step  food  reintroduction 
program was followed before the patient returned to normal diet. Patients with suboptimal 
nutritional status were asked to continue supplementary feeds (500 kcals / d) in addition to 
their normal diet for one to two weeks after treatment completion.  
 
5.2.3. Blood sampling and initial manipulation 
For the purposes of this study, three blood samples were obtained from CD children before 
EEN initiation, on treatment cessation and whilst patients were on their normal diet. As it was 
deemed  unethical  to  venopuncture  children  for  research  only  purposes,  extra  blood  was 
taken when patients were due to give clinical monitoring samples. Eight ml of venous blood 
were  collected  for  research  purposes  in  NH  Trace  Elements  Sodium  Heparin  tubes 
(Vacuette, 456080, Austria). Six ml were centrifuged at 3500 g for 15 min at 4 
oC and the 
plasma  fraction  was  separated  from  the  rest  of  the  cellular  matrices.  Five  hundred   l  of 
plasma were stabilized with 6% metaphosphoric acid (Sigma Aldrich, 239275, UK) to prevent 
vitamin  C  oxidation.  The  samples  were  processed  within  an  hour  of  blood  sampling.  All 
bloods and serum specimens were stored at –70
oC covered in aluminium foil for a maximum 
of six months until further analysis.   
 
5.2.4. Micronutrient assays 
In  total,  19  micronutrients  were  measured  in  the  serum,  whole  blood  or  erythrocytes  of 
children with CD. Ferritin was measured as a marker of iron status and  total cholesterol to 
adjust vitamin E concentrations for total lipid concentration.  
Serum calcium and phosphate were available from the patients’ biochemical reports 
and had been analyzed according to standard hospital protocols. The remaining nutrients 
were measured in the Scottish Trace Element and Micronutrient Reference Laboratory, GRI.  
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Trace elements (Zn, Se, Cu) 
Briefly trace elements zinc, copper, and selenium were measured with an inductively coupled 
plasma mass spectrometer (ICP-MS) using germanium as an internal standard.  
 
Vitamin B1 
The method measures thiamine disphosphate (B1) in whole blood as an index of vitamin B1 
status. The thiamine disphosphate is oxidised using post column derivatisation with alkaline 
potassium ferriccyanide to form the fluorescent thiochrome derivative which is measured by 
reverse phase HPLC with fluorescent detection. The sensitivity of the method is down to 
5 g/L the intra and inter CV% are 6% and 7% respectively.  
 
Vitamin B2 
Packed red cells are precipitated with methanol, centrifuged and the supernatant is injected 
for  HPLC  analysis.  Flavin  adenine,  dinucleotide,  flavin  mononucleotide  and  riboflavin  are 
separated  on  an  isocratic  HPLC  system  with  a  reverse  phase  column  and  detected  by 
fluorescence  .  The  CV  of  the  method  is  3.6%  at  a  mean  whole  blood  flavin  adenine 
dinucleotide value of 135 nmol/L and 4.8% at a red cell flavin adenine dinucleotide mean 
value of 2.8 nmol/gHb.  
 
Vitamin A & E and carotenoids 
Serum  is  deproteinised  with  ethanol  containing  internal  standard.  After  centrifugation  the 
vitamins,  carotenoids  and  internal  standard  are  extracted  with  hexane.  The  hexane  is 
evaporated and the residue is dissolved in the developing solvent. An aliquot of this solution 
is  injected  onto  a  C18  reversed  phase  chromatographic  column  and  absorbance 
measurements at 325 nm and 295 nm for vitamin A and E respectively and 450 nm for 
carotenoids. Peak height ratios are used to quantify vitamins and carotenoids. Β-carotene is 
calculated by area. The intra and inter batch imprecision of the method is described in Table 
5.1.  
 
Table 5.1: Coefficient of variance for vitamin A, E and carotenoids assay 
Nutrient  Intra-batch imprecision  Inter-batch imprecision 
Retinol  5.4  7.8 
α-tocopherol  2.0  7.0 
Lutein  6.9  9.8 
Lycopene  9.0  14.0 
α-carotenoid  6.5  16.5 
β-carotenoid  7.6  15.0 
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Vitamin C 
Blood samples are stabilised to prevent oxidation and deproteinised with metaphosphoric 
acid. Following centrifugation and separation, an aliquot of the supernatant is injected on a 
C18 reverse chromatographic column and the ascorbic acid concentration assayed using an 
electrochemical detector. The within batch CV is 1.03% at a level of 31.66  mol/L and the 
between batch CV is 3.69% at a level of 38.16  mol/L.  
 
Vitamin B6  
The method measures pyridoxal-5-phosphate concentration in red blood cells as an index of 
vitamin  B6  status.  Pyridoxal-5-phosphate  and  pyridoxal  are  converted  to  their  semi-
carbazone  fluorescence  derivatives  which  are  measured  by  reverse  phase  HPLC  with 
fluorimetric detection. Pyridoxal is measured directly using its natural fluorescence. The intra 
assay CV for pyridoxal-5-phosphate is 5.2% at 367 pmol/gHb and 6.9% at 370 pmol/gHb.  
 
Vitamin D 
The  25-Hydroxy  vitamin  D  was  measured  with  a  IDS  25-Hydroxy  vitamin  D  EIA  kit 
(Immunodiagnostic  Systems  Ltd.,  Boldon,  UK)  is  an  enzyme  immunoassay  for  the 
quantitation of 25-OH D and other hydroxylated metabolites in serum or plasma. Calibrators, 
controls  and  samples  are  diluted  with  biotin  labelled  25-OH  D.  The  diluted  samples  are 
incubated in microtitre wells which are coated with a highly specific sheep 25-OH D antibody 
for  two  hours  at  room  temperature  before  aspiration  and  washing.  Enzyme  (horseradish 
peroxidase) labelled avidin, is added and binds selectively to complexed biotin and, following 
a  further  wash  step,  colour  is  developed  using  a  chromogenic  substrate  (TMB).  The 
absorbance of the stopped reaction mixtures are read in a microtitre plate reader, colour 
intensity developed being inversely proportional to the concentration of 25-OH D. The intra 
assay %CV of the method is 5.3, 5.6, 6.7 for mean concentrations of 39, 67.1, 165 nmol/L 
respectively. The inter assay %CV is 4.6, 6.4, 8.7 for mean concentrations of 40.3, 72.0, 132 
nmol/L respectively.   
    
5.2.5. Markers of disease activity 
Haemoglobin,  erythrocyte  sedimentation  rate,  serum  albumin  and  CRP  were  assayed 
according  to  standard  hospital  methods  and  were  readily  available  from  the  patients’ 
biochemical and haematological reports. Gut inflammation was assessed by measuring the 
faecal levels of calprotectin in stool samples collected close to the day of blood sampling. 
Faecal calprotectin was measured with a commercial available ELISA kit (Phical®, CALPRO, 
Lysaker,  Norway)  and  according  to  the  manufacturer’s  specifications.  The  outline  of  the   203 
assay is described in Chapter 6.2.5. Changes in the levels of disease activity markers during 
EEN are presented in Chapter 6. 
 
5.2.6. Anthropometry and body composition 
Changes of baseline anthropometric characteristics and body composition were assessed 
during  treatment  with  EEN.  Measurement  of  weight,  height  and  body  composition 
assessment by BIA, were performed before, after one month, at the end of treatment, and 
when patients returned to normal diet according to standard protocols as described in detail 
in Chapter 4. Measurements were obtained at the clinic, or when not possible, home visits 
were done. Triceps skinfold thickness and mid upper arm circumference were measured on 
the left arm midway between the acromion and olecranon according to standard procedures 
by a trained researcher. Measurements were performed at least twice and values averaged if 
the difference between the two measurements was minimal.  
 
5.2.7. Statistical analysis 
Descriptive statistics are presented as mean and standard deviation, or medians with ranges 
for  continuous  data,  and  with  counts  and  proportions  for  categorical  data.  Comparisons 
between  groups  were  done  using  2  sample  t-test  and  Mann-Whitney  test.  Changes  in 
micronutrient  concentration  during  EEN  were  assessed  with  Wilcoxon  signed-rank  test. 
Likewise the effect of EEN on body composition measures was evaluated using anova of 
repeated measures with Bonferroni post-hoc test. Anthropometry and %FM were converted 
to  z-scores  using  British  national  data  (579;593).  To  assess  the  adequacy  of  circulating 
micronutrients  in  house  laboratory  reference  range  was  used  (Appendix).  Association 
between micronutrient levels, body composition measures and disease activity markers were 
assessed with Spearman’s rank correlation coefficient.    
 
5.3. Results  
5.3.1. Recruitment 
Between October 2005 and August 2007 approximately 60 children started on EEN as part 
of  their  standard  clinical  management. Thirty  one  children  were  invited  to  participate,  six 
children  refused  participation,  and  two  withdrew  the  day  after  recruitment.  One  patient’s 
participation was terminated deliberately after a final biopsy histology report was consistent 
with UC diagnosis. One patient experienced a cerebral vascular accident while on treatment 
with EEN and stopped treatment within a  week of recruitment. For two patients, disease 
activity further deteriorated and both had to stop EEN and initiate a regime of steroids. Two   204 
other patients were recruited 15 days and 21 days after EEN initiation and their results are 
not  included  in  the  arm  of  the  study  on  the  effect  of  EEN  on  longitudinal  changes  in 
nutritional status.  
For  25  CD  children  at  least  one  blood  specimen  was  obtained  during  the 
observational period. For 13 of these patients, three serial samples were obtained before 
EEN  treatment,  close  to  the  time  of  EEN  cessation  and  on  normal  diet.  For  the rest  12 
patients  the  full  set  of  bloods  was  not  available  for  a  number  of  reasons  (e.g.  patients 
withdrew, patients were not due to have routine clinical bloods).  
Similarly basic anthropometry and body composition measures were obtained for 25 
CD  children.  For  16  of  these  children  serial  measurements  of  body  composition  were 
available over their nutritional therapy course. For the rest no serial follow up measurements 
were  available  or  obtained  due  to  a  variety  of  reason  (disease  exacerbation  and  EEN 
termination, withdrew, impractical to take measurements).    
 
5.3.2. Body composition and micronutrient status in children with 
CD. (Cross-sectional data) 
 
5.3.2.1.  Comparison  of  body  composition  between  CD  and  healthy 
controls 
Body composition measurements were obtained for 11 children close to the date of initiation 
of EEN, and for 14 children at their follow up clinical appointment, and whilst patients were 
on  normal  diet (Table  5.2).   The  majority  of  participants  had  abnormal  systemic  and gut 
specific inflammatory markers indicative of active disease (Table 5.2). Extensive disease with 
involvement of the upper and lower GI tract was the predominant site of disease location 
(Table 5.2). There was no significant difference in disease activity markers between boys 
and girls or between samples collected the day before the EEN initiation and those collected 
at follow up and whilst patients were on normal diet.    205 
 
Table  5.2:  Disease  location,  medical  treatment,  concentration  and  percent  of  patients  with 
abnormal systemic and gut disease activity markers of children with CD 
Characteristics  F (n=11)  M (n=14)  All (n=25) 
*Disease location (n)       
    Ileitis (L1)    1  1 
    Colitis (L2)  1  1  2 
    Upper colitis (L2L4)  3  5  8 
    Ileocolitis (L3)  2  0  2 
    Upper ileocolitis (L3L4)  5  7  12 
Concomitant treatment (n)       
    Steroids (tapering dose)  1  1  2 
    Aminosalicylates  2  2  4 
    Immunosuppresants  1  8  9 
    Antibiotics  1    1 
    Caloric supplements  1  1  2 
    None  8  5  13 
Disease activity markers       
Albumin (g/l) (mean ± SD)   30.8   ±   6.4   29.4   ±   7.3   30   ±   6.8 
$Abnormal albumin (n;%)      7     ;    64        8      ;       57      15      ;        83 
CRP (mg/l) (mean ± SD)   17.5  ±   13.2   31.5   ±   27.4   25.7   ±   23.3 
$Abnormal CRP  (n;%)     6      ;    55      11     ;        79   17        ;        68 
ESR (mm/h) (mean ± SD)   49.8   ±  34.7   39.5   ±   23.8   44.2   ±   29.1 
$Abnormal ESR (n;%)       9       ;    82      11      ;      85  20          ;  83 
Calprotectin (mg/l) (mean ± SD)  1965   ± 547  1903   ±   757  1934   ±   639 
$Abnormal calprotectin (n;%)  11         ;  100  15         ;  100  25         ;  100 
* Based on Montreal classification 
$ Abnormal to the laboratory or manufacturer reference range   
 
The mean body weight, BMI and % body fat z-scores of children with CD were negative and 
at least one SD lower than the national reference data indicating that the participants as 
group were substantially underweight and presented fat deficits (Table 5.3). There was no 
significant difference in height, weight, BMI and %FM z-scores between boys and girls. No 
statistics analysis was conducted for the raw data (before conversion to z-scores) as the 
results  would  be  misleading  due  to  normal  biological  differences  that  occur  in  body 
composition with gender, age and maturation.    206 
 
Table  5.3:  Basic  anthropometry  and  body  composition  characteristics  (mean  ±  SD)  with 
percent (%) of underweight, short stature in paediatric patients with CD  
Measurement  F  M  Total 
Patients (n)      11      14      25 
Age (y)    11.1  ±   2.9    12.5   ±   1.8    11.9   ±   2.4 
Weight (kg)    32.8   ±   13.4    36.3   ±   9.9    34.6   ±   11.6 
Weight z-score (SD)    -1.0   ±   1.4    -1.1   ±   1.3    -1.1   ±   1.3 
Height (cm)   142.5   ±   19.8   149.4   ±   11.1   146.1   ±   15.8 
Height z-score (SD)    -0.1   ±   1.4    -0.5   ±   0.9    -0.3   ±   1.2 
Height z-score < 2 SD (n;%)      1; 10%      1; 9%      2; 9.5% 
BMI (kg/m
2)    15.5   ±   2.3    16   ±   2.3    15.7   ±   2.3 
BMI z-score (SD)    -1.3   ±   1.1    -1.3   ±   1.3    -1.3   ±   1.2 
BMI z-score < 2 SD (n;%)      3; 30%      3; 27%      6; 29% 
% Fat mass     16.9   ±   9.2    11.7   ±   3.1    14   ±   6.9 
% Fat mass  z-score (SD)    -4.5   ±   9.4    -2.4   ±   2.1    -3.3  ± 6.4 
% Fat mass z-score < 2 SD (n;%)      5; 56%      5; 45%      10; 50% 
Fat free mass (kg)    26.7   ±   8.5    32   ±   8.4    29.6   ±   8.6 
Fat mass (kg)    6.6   ±   6.5    4.4   ±   2.1    5.4   ±   4.6 
Impedance (Ohms)   715   ±   70   665   ±  113   687   ±   97 
Total body water (kg)    19.6   ±   6.2    23.5   ±   6.6    21.8   ±   6.6 
MAC (cm)    20.4   ±   3.4    20.7   ±   3.1    20.6   ±   3.2 
TSF (mm)    12.3   ±   5.0    12.1   ±   4.8    12.2   ±   4.8 
TSF z-score (SD)    0.1   ±   1.6    1.8   ±   2.6    1.1   ±   2.3 
% TSF z-score < 2SD (n;%)      1; 11%      0; 0%      1; 5% 
MAMC (cm)    16.6   ±   2.1    16.9   ±   1.8    16.8   ±   1.9 
 
Compared to a cohort of healthy Glaswegian children (Table 5.4), CD children had 
significantly lower BMI and weight z-scores (p<0.0001). No significant difference was found 
between the two groups with regard to height z-score. Similar to BMI, %FM z-score was 
significantly lower in children with CD than in healthy controls (p=0.002). BMI and weight z-
scores  were  significantly  lower  in  CD  boys  and  girls  compared  with  their  same  gender 
healthy peers. However CD boys but not girls had significantly lower mean %FM z-score 
(p<0.01) compared to their healthy peers (Table 5.4). No differences between genders were 
found for CD patients or healthy children regarding BMI, height and weight z-score.  
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Table 5.4: Basic anthropometric and body composition characteristics (mean±SD) with percent of underweight, short stature in paediatric patients 
with CD and healthy Glaswegian children  
  CD    Healthy 
Measurement  F  M  Total    F  M  Total 
Patients (n)      11      14      25      63      57      117 
Age (y)    11.1   ±   2.9    12.5   ±   1.8    11.9   ±   2.4     12.6  ±   3.2    12.4   ±   3.7   12.5   ±   3.4 
Weight (kg)    32.8   ±   13.4    36.3   ±   9.9    34.6   ±   11.6     46.4  ±   17.7    47.8   ±   19.1   47   ±   18.3 
Weight z-score (SD)    -1.0   ±   1.4*    -1.1   ±   1.3*    -1.1   ±   1.3*      0.3  ±   1.2    0.5   ±   1.1    0.4   ±   1.1 
Height (cm)   142.5   ±   19.8   149.4   ±   11.1   146.1   ±   15.8    149.2 ±   14   152   ±   20  150.5   ±   17.0 
Height z-score (SD)    -0.1   ±   1.4    -0.5   ±   0.9    -0.3   ±   1.2      0.0  ±   1.0    0.1   ±   1.0    0.06   ±   1.0 
Height z-score < 2 SD (n;%)      1; 10%      1; 9%    2; 9%        2; 3%    1; 2%      3; 3% 
BMI (kg/m
2)    15.5   ±   2.3    16.0   ±   2.3    15.7   ±   2.3     20.2  ±   4.8    19.7   ±   3.9   20.0   ±   4.4 
BMI z-score (SD)    -1.3   ±   1.1*    -1.3   ±   1.3*    -1.3   ±   1.2*      0.4  ±   1.2    0.6   ±   1.1    0.5   ±   1.1 
BMI z-score < 2SD (n;%)      30%      27%      29%        1; 2%      0; 0%      1; 1% 
% Body fat z-score < 2 SD    16.9   ±   9.2    11.7   ±   3.1    14.0   ±   6.9     22.7  ±   9.5    16.6   ±   7.4   19.9   ±   9.1 
% Body fat z-score (SD)    -4.5   ±   9.4    -2.4   ±   2.1*    -3.3   ±   6.4*     -1.1   ±   4.0    -0.7   ±   2.4   -0.9   ±   3.3 
% Body fat  z-score < 2 SD 
(n;%) 
    5; 56%      5; 45%    10;   50%      17; 27%      12; 22%      29; 25% 
Fat free mass (kg)    26.7   ±   8.5    32.0   ±   8.4    29.6   ±   8.6     34.0  ±   8.9    39.1   ±   15.5   36.4   ±   12.6 
Fat mass (kg)    6.6   ±   6.5    4.4   ±   2.1    5.4   ±   4.6     11.7  ±   10.1    8.1   ±   5.8   10.0   ±   8.5 
Impedance (Ohms)   715   ±   70   665   ±   113   687   ±   97*    601   ±   71   564   ±   72  584   ±   74 
Total body water (kg)    19.6   ±   6.2    23.5   ±   6.6    21.8   ±   6.6     24.9  ±   6.5    28.6   ±   11.4   26.6   ±   9.2 
* Mann Whitney test, different from healthy (for same gender or total) p<0.002 
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5.3.2.2. Mean circulating concentration of micronutrients in CD children 
Systemic  levels  of  micronutrients  are  displayed  in  Table  5.5.  Females  had  higher 
concentrations of vitamin A (p<0.04), vitamin E (p<0.01), vitamin E / cholesterol (p<0.03), 
vitamin B6 in erythrocytes and plasma than boys (p<0.003) (Table 5.5).  
 
Table 5.5: Concentration of circulating micronutrient of CD children (mean ± SD) 
Micronutrient  Total  Female  Male 
Vitamin A ( mol/l)    1.1   ±   0.4    1.4   ±   0.5*    1.0   ±   0.3 
Lutein ( g/l)    69.7   ±   35.3    75.2   ±   35.9    65.4   ±   35.5 
Lycopene ( g/l)    85.4   ±   61.0    69.5   ±   55.2    98.0   ±   64.3 
A carotene ( g/l)    16.8   ±   12.8    15.6   ±   10.3    17.7   ±   14.8 
b-carotene ( g/l)    87.3   ±   84.3    93   ±   94.8    82.9   ±   78.5 
Vitamin E ( mol/l)    23.7   ±   5.7    27   ±   5.5*    21.1   ±   4.5 
Vitamin E/Chol ( mol/mmol)    7.2   ±   2.1    8.3   ±   2.3*    6.4   ±   1.5 
Vitamin D (nmol/l)    64.8   ±   38.7    54.5   ±   42.7    73.0   ±   34.6 
Vitamin B1 (wbl) (ng/g Hb)    576   ± 134     605   ±   95    552   ± 157 
Vitamin B2 (wbl) (nmol/l)    433   ±   49    448   ±   47    420   ±   49 
Vitamin B2 (rbc) (nmol/g Hb)    2.4   ±   0.5    2.6   ±   0.3    2.2   ±   0.6 
Vitamin B6 (nmol/l)     32.8   ±   39.3    53.3   ±   53.1*    16.6   ±   7.4 
Vitamin B6 (rbc) (pmol/g Hb)    560   ± 241    719   ± 220*    435   ± 178 
Vitamin B12 (pg/ml)    762   ± 482    915   ± 488    642   ± 459 
Folate (ng/ml)    4.2   ±   3.2    4.4   ±   2.9    4.1   ±   3.5 
Vitamin C ( mol/l)    35.4   ±   24.5    39.6   ±   29.9    31.8   ±   19.4 
Zn ( mol/l)    9.7   ±   2.5    10.4   ±   2.8    9.1   ±   2.1 
Cu ( mol/l)    21.7   ±   5.6    21.3   ±   3.8    22   ±   6.8 
Se ( mol/l)    0.6   ±   0.2    0.6   ±   0.2    0.6   ±   0.1 
Mg (mmol/l)    0.9   ±   0.1    0.9   ±   0.1    0.8   ±   0.1 
P (mmol/l)    1.3   ±   0.2    1.3   ±   0.1    1.3   ±   0.2 
Ca (mmol/l)    2.3   ±   0.1    2.3   ±   0.1    2.3   ±   0.1 
Ferritin (ng/ml)     48.4   ±   61    56.3   ±   84.7    42.1   ±   35.8 
Cholesterol (mmol/l)    3.4   ±   0.5    3.4   ±   0.7    3.4  ±   0.3 
* Different from male p< 0.05; whl: whole blood; rbc: red blood cells 
 
For  a  substantial  number  of  children  the  circulating  levels  of  micronutrients  were 
below  the  lower  threshold  of  the  laboratory  reference  range  (Appendix)  (Figs  23-25). 
Approximately three quarters of the participants had suboptimal levels for lutein, Zn, and Se 
whereas  two  thirds  had  low  levels  for  carotenoids,  lycopene,  α-carotene,  and  β-carotene 
(Table 5.6; Figs 23-25). Low circulating levels were found also for serum vitamin A, vitamin 
B6, folate, vitamin C, copper, ferritin and calcium. Although a few patients had low serum 
concentration  of  B6,  none  had  suboptimal  levels  when  the  latter  was  measured  in 
erythrocytes. No patient had suboptimal concentrations for vitamin D, thiamine, riboflavin, 
and B12. Suboptimal levels of serum B6 were seen more often in boys than girls (Table 5.6). 
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Table  5.6:  CD  children  (n;%)  with  suboptimal  concentrations  of  systemic  micronutrients 
compared with the laboratory reference range 
Micronutrient  F (n=11)  M (n=14)  Total (n=25) 
Vitamin A  1;  9  5;  36  6;  24 
Lutein  9;  82  11;  79  20;  80 
Lycopene  8;  73  9;  64  17;  68 
A carotene  7;  64  9;  64  16;  64 
b-carotene  7;  64  9;  64  16;  64 
Vitamin E  0;  0  1;  7  1;  4 
Vitamin E/Cholesterol  0;  0  1;  7  1;  4 
Vitamin D  0;  0  0;  0  0;  0 
Vitamin B1 (wbl)  0;  0  0;  0  0;  0 
Vitamin B2 (wbl)  0;  0  0;  0  0;  0 
Vitamin B2 (rbc)  0;  0  0;  0  0;  0 
Vitamin B6   2;  18  9;  64*  11;  44 
Vitamin B6 (rbc)  0;  0  0;  0  0;  0 
Vitamin B12  0;  0  0;  0  0;  0 
Folate  3;  27  6;  43  9;  36 
Vitamin C  3;  27  3;  23  6;  25 
Zn  8;  73  13;  93  21;  84 
Cu  0;  0  2;  14  2;  8 
Se  8;  73  10;  71  18;  72 
Mg  0;  0  0;  0  0;  0 
P  0;  0  0;  0  0;  0 
Ca  0;  0  4;  33  4;  21 
Ferritin  5;  45  3;  21  8;  32 
*Different between genders p<0.02 for chi square test; whl: whole blood; rbc: red blood cells 
 
 
 
Figure  23: : Percent of paediatric CD patients with suboptimal systemic levels of minerals & 
trace elements  
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Figure  24: Percent of paediatric CD patients with suboptimal levels of water soluble vitamins & 
ferritin 
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Figure  25: Percent of of paediatric CD patients with suboptimal levels of fat soluble vitamins 
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5.2.3. Correlation between disease activity markers, micronutrients 
and body composition in children with CD 
As  the  data  were  not  normally  distributed,  values  were  ranked  and  Spearman  rank 
correlations  performed.  The  circulating  levels  of  several  micronutrients  were  strongly   211 
associated  with  markers  of  disease  activity  (Table  5.7).  Serum  albumin  and  CRP  were 
significantly associated with β-carotene (Fig 26), plasma B6, vitamin C, zinc, ferritin (Fig 26), 
magnesium, calcium and folate, whereas faecal calprotectin levels were not associated with 
any micronutrient (Fig 26).  
 
Table  5.7:  Spearman  correlation  coefficients  between  systemic  and  gut  disease  activity 
markers and serum  micronutrient concentrations in paediatric  CD patients (r coefficient; p-
value) 
Micronutrient  CRP  ESR  Albumin  Calprotectin 
    R  p-value    R  p-value    R  p-value  R      p-value 
Lutein    -0.50  0.01       
A carotene        0.42   0.04   
Β-carotene    -0.55   0.01      0.40   0.05   
B6 plasma    -0.39  0.06      0.50   0.01   
Vitamin C    -0.47   0.02    -0.44   0.03    0.67  0.001   All p>0.05 
Zn    -0.44   0.03      0.58  0.002    
Ferritin    0.71   0.001       -0.42  0.04   
Mg    -0.46  0.03    -0.45  0.03    0.44  0.03   
P    -0.50  0.03        
Ca    -0.55  0.02      0.92  0.001   
Folate        0.62  0.001   
Haemoglobin        0.7  0.001   
 
Figure  26: Spearman correlation coefficients between disease activity markers and serum 
micronutrient concentrations in CD children 
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Faecal calprotectin and serum albumin concentrations were significantly associated with BMI 
and %FM z-scores (Table 5.8). With increasing gut inflammation, BMI and %FM were lower   212 
suggesting  that  increased  disease  activity  is  strongly  associated  with  thinness  and 
underweight (Fig 27). A similar positive association was observed with serum albumin levels. 
Low albumin levels were associated with low BMI and body fat stores. 
 
Table 5.8: Spearman correlation between systemic and gut disease activity markers and body 
composition measurements in paediatric CD patients (r coefficient; p-value) 
Disease activity marker  BMI z-score    %FM z-score 
    R  p-value      R  p-value 
Albumin    0.5   0.021      0.4   0.061 
CRP    -0.4    0.097      -0.2   0.315 
ESR    -0.5   0.037      -0.1   0.571 
Calprotectin    -0.6   0.021      -0.5   0.073 
 
Figure  27: Sprearman correlation between body composition measures and intestinal 
inflammation markers in paediatric CD patients 
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5.3.3.  Changes  in  body  composition  and  systemic  micronutrient 
levels in CD children during treatment with EEN (prospective follow 
up data) 
 
5.3.3.1. Patients characteristics 
For thirteen children, follow up measurements of body composition and micronutrient levels 
were obtained (Table 5.9). Extensive disease with involvement of the upper GI tract and ileo-
colon was the predominant site of disease (Table 5.9). Five children had other concomitant   213 
medical treatment during EEN (Table 5.9). For all but three this was their first course on 
EEN. Five children entered complete clinical remission at the end of treatment (PCDAI≤10).   
  
Table 5.9: Disease characteristics and concomitant medication of paediatric CD patients on 
treatment with EEN for eight weeks 
  F (n=7)  M (n=6)  All (n=13) 
Age  11.5 ± 3  12.9 ± 1.1  12.1 ± 2.3 
Disease location* (n)       
   Colitis ( L2)  1  0  1 
    Upper & colitis (L2L4)  1  2  3 
    Ileocolitis (L3)  1  0  1 
    Upper ileocolitis (L3L4)  4  4  8 
Concomitant treatment (n)       
     Aminosalicylates  3     
     Immunosuppresants  6     
     Corticosteroids  1     
     Antibiotics  1     
     None  5     
* Montreal classification 
5.3.3.2. Changes in systemic micronutrient status during EEN 
The serum levels of several micronutrients changed significantly during EEN (Table 5.10; 
Figs  28  &  29).  Compared  to  baseline,  vitamin  C,  folate,  thiamine,  B6  and  selenium 
significantly increased at the end of treatment (Table 5.10, Fig 29). In particular a three-fold 
increase  was  observed  for  serum  folate  as  opposed  to  a  dramatic  deterioration  of  all 
carotenoids levels at the end of EEN treatment (Table 5.10, Figs 28 & 29).  
As mean serum concentration changes do not reflect the adequacy of body store 
status, the percentage of patients with suboptimal levels was calculated at the different time 
points of follow up. At baseline the serum levels for several micronutrients were below the 
laboratory reference cut offs with the most pronounced being carotenoids, trace elements, 
vitamin C, serum B6 and folate (Table 10). Two thirds of the children had suboptimal levels 
for carotenoids whereas vitamin C, folate, and ferritin were at insufficient levels for more than 
25% of the patients (Figs 30-34).   
On treatment completion significantly fewer patients had suboptimal levels for most of 
the  micronutrients  apart  from  carotenoids,  copper  and  ferritin  which  further  deteriorated. 
Compared to 42% of the children at baseline, none of the children had suboptimal serum 
levels of folate at the end of treatment. Similar results were observed for selenium, which 
improved  significantly  over  the  treatment  period,  and  10  times  fewer  children  had  lower 
levels at the end of EEN. In contrast more than 90% of patients had carotenoid levels below 
the reference range on treatment cessation (Table 5.10). Indeed for many of the children, the 
latter were below the detection limits of the assay. 
Significant changes were observed when children returned to their normal diet. Those 
nutrients that had improved at the end of EEN reversed to pre-treatment levels  whereas   214 
serum  carotenoid  concentrations  increased  and  as  a  result  significantly  fewer  patients 
presented biochemically insufficient levels (Table 5.10 Fig 28).    215 
Table 5.10: Micronutrient concentrations (median) and percentage of patients with suboptimal levels before, at the end, and after treatment with 
EEN in paediatric CD patients   
Before EEN  After EEN  On normal diet 
Micronutrient‡  Median 
N; (%) with low 
levels§  Median 
N; (%) with low 
levels§  Median 
N; (%) with low 
levels§ 
Vitamin A ( mol/l)  1.2   1; (7)  1.7  0; (0)  1.2†  1; (8) 
Vitamin E ( mol/l)  27   0; (0)  24  0; (0)  25  0; (0) 
Vitamin E:cholesterol ( mol/mmol)  7.7  0; (0)  6.6  0; (0)  5.8  0; (0) 
Lutein ( g/l)  64  11; (79)  29.5*  11; (92)  108†  3; (25) 
Lycopene ( g/l)  76  9; (64)  12*  12; (100)  165†  4; (33) 
α-Carotenoid ( g/l)  10  9; (64)  10  12; (100)  14†  5; (42) 
β-Carotenoid ( g/l)  53  9; (64)  41*  11; (92)  99†  ;4 (33) 
Vitamin D (nmol/l)  64  0; (0)  102  0; (0)  59†  0; (0) 
Vitamin C ( mol/l)  29  3; (25)  51*  0; (0)  46  1; (8) 
Thiamin (whl; ng/g Hb)  559  0; (0)  669*  0; (0)  573  0; (0) 
Riboflavin (erythrocytes; nmol/g Hb )   2.5  0; (0)  2.5  0; (0)  2.1  0; (0) 
Riboflavin (whl; nmol/l)  461  0; (0)  477  0; (0)  435  0; (0) 
Vitamin B6 (nmol/l)   36  4; (29)  63*  0; (0)  21  5; (42) 
Vitamin B6 (erythrocytes; pmol/g Hb)  662  0; (0)  721  0; (0)  438  0; (0) 
Vitamin B12 (pg/ml)  662  0; (0)  843  0; (0)  505†  0; (0) 
Folate (ng/ml)  2.85  5; (42)  10.5*  0; (0)  7.3  2; (17) 
Zn ( mol/l)  8.5  9; (75)  11.5  7; (64)  10  11; (92) 
Cu ( mol/l)  21.2  1; (8)  26  2; (18)  24.5  1; (8) 
Se ( mol/l)  0.5  9; (69)  1*  1; (9)  0.7†  7; (58) 
Mg (mmol/l)  0.8  0; (0)  0.9  0; (0)  0.8  0; (0) 
Ferritin (ng/ml)  18.4  5; (42)  6.9*  7; (64)  15.7  2; (17) 
Haemoglobin (g/dl)  10.8    11.6    11.7   
Values were significantly different from those before EEN (Wilcoxon signed rank test): *P<0.05. Values were significantly different from those after EEN (Wilcoxon signed rank test): †P<0.05. 
‡Plasma, unless otherwise stated. §With reference to normal range; whole blood: wbl   216 
Figure  28: Concentrations of carotenoids and Se before, at the end, and after treatment with EEN in paediatric patients with CD 
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Figure  29: Concentrations of vitamin B1, B6, and folic acid before, at the end, and after treatment with EEN in paediatric patients with CD 
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Figure  30: Percent of patients with suboptimal circulating levels of trace elements before, after 
EEN and on normal diet in paediatric CD 
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Figure  31: Percent of patients with suboptimal circulating levels of fat soluble vitamin before, after 
EEN and on normal diet in paediatric CD 
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Figure  32: Percent of patients with suboptimal circulating levels of carotenoids before, after EEN 
and on normal diet in paediatric CD 
0
10
20
30
40
50
60
70
80
90
100
Lutein Lycop A car B car
(
%
)
 
S
u
b
o
p
t
i
m
a
l
 
l
e
v
e
l
s
Before EN After EN Normal Diet
 
 
Figure  33: Percent of patients with suboptimal circulating levels of Β complex vitamins before, 
after EEN and on normal diet in paediatric CD  
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Figure  34: Percent of patients with suboptimal circulating levels of vitamins (C, B12, folate) & 
ferritin before, after EEN and on normal diet in paediatric CD 
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5.3.3.3. Changes in body composition during EEN 
Body composition  was  assessed  in  16  children whose  measurements were available  before 
treatment initiation, 30 days on treatment, at the end of EEN and on normal diet (Table 5.11). 
Weight  (absolute  mass  and  z-scores)  and  accordingly  BMI  and  BMI  z-score  significantly 
increased within 30 days of treatment with an average increase of more than three kg. Weight 
increase plateaued and no further significant improvement was observed during the following 
month, and up till the end of treatment.  
Although body fat, expressed as absolute mass (kg) or expressed as percentage of body 
weight increased during EEN, the difference did not reach statistical significance. In contrast, 
FFM in absolute mass was significantly increased at follow up compared with baseline values 
and achieved its highest peak at the end of treatment (all p< 0.001). However, when expressed 
proportional to total body weight, no significant difference from baseline was observed.    221 
Similar to total body composition, all surrogate measurements of body composition (i.e. 
TSF, MAC, MAMC) significantly increased during EEN with a maximum increase observed at 
the end of eight weeks EEN. Changes in height were not assessed during EEN, due to the 
imprecision  of  the  height  measurements  in  short  observation  periods.  Although  body  weight 
increased in both the patients who entered into remission and those who failed treatment, the 
magnitude of change was smaller in the latter group. However, FFM increased significantly at all  
time points of follow up (p<0.006) only in those patients who had entered clinical remission at 
the end of treatment. On normal diet no significant changes in body composition were observed 
compared to the end of treatment.  
 
Table  5.11:  Anthropometry  and  body  composition  changes  during  treatment  with  EEN  and  on 
normal diet in paediatric CD patients (mean ± SD) 
Measurement  Before EEN  30 d on EEN  End of EEN  On normal diet 
Weight (kg)    33.6   ±  11.9    36.9   ±  10.1*    36.3   ±   9.7*    38.2   ±  12.2 
Weight z-score (SD)    -1.5   ±   1.6    -0.7   ±   1.2*    -0.9   ±   1.1*    -0.8   ±   1.3 
BMI (kg/m
2)     15.1   ±   2.8    16.7   ±   2.1*    16.7   ±   1.9*    16.8   ±   2.6 
BMI z-score (SD)    -2   ±   1.7    -0.7   ±   1.0*    -0.7   ±   1.0*    -0.8   ±   1.2 
FM (kg)    4.8   ±   5.5    5.8   ±   5.1    5.9 ± 4.7    6.9   ±   5.9 
FM (%)    12.0   ±   8.4    14.5  ±   8.4    15.1   ±   7.8    14.1   ±   7.6 
FM z-score (SD)    -5.5   ±   6.7    -2.5   ±   2.6    -2.6   ±   3.5    -2.5   ±   2.6 
FFM (kg)    29.1   ±   8.2    31.0   ±   7.0*    30.4   ±   6.7*    32.1   ±   8.0 
Impedance (Ohms)    719   ± 100    645.0   ±  99.0*    660.0   ± 105*    626.0   ±  57 
TBW (kg)    21.3   ±   6.0    21.1   ±   6.6    22.3   ±   4.9*    23.5   ±   5.8 
TSF (mm)    10.5   ±   5.6    13.3   ±   5.0*    13.8   ±   4.7*    12.7   ±   4.9 
TSF z-score    -0.32  ±   1.2    0.49  ±   0.9*    0.49  ±   0.25*    0.40  ±   0.95 
MAC (cm)    19.8   ±   3.3    21.3   ±   3.1*    21.3   ±   2.6*    21.4   ±   3.1 
MAMC (cm)    19.8   ±   3.3    21.3   ±   3.0*    21.3   ±   2.5*    21.3   ±   3.1 
         
* Statistical significant from “Before EEN” for a-nova of repeated measures and Bonferroni post-hoc test  All p<0.02 Mean + SEM 
 
5.4. Discussion 
Nutritional status is a composite term that grossly describes the state of energy/protein, and 
other micronutrient stores in the human body. Excessive consumption causes overnutrition and 
the  risk  of  toxicity  whereas  poor  intake  increases  the  risk  of  undernutrition.  Protein/energy 
undernutrition is important as it increases the risk of disease-associated complications, mortality, 
and impact negatively on length of hospital stay, and in children may impair linear growth and 
bone health.  
On the other hand micronutrients, including minerals, trace elements and vitamins are 
important nutrients in body homeostasis, function and metabolism. Suboptimal intake can cause 
nutrient-associated  anaemia,  osteoporosis,  neurological  disorders,  altered  taste,  depression,   222 
epithelial  defects,  and  it  is  only  when  the  body  stores  have  been  depleted  that  clinical 
manifestations occur.  
  Micronutrient deficiencies are uncommon in the general Westernised population, but their 
incidence can be high in chronic illness where an optimal balance is not achieved or maintained. 
With  regard  to  IBD,  poor  dietary  intake,  malabsorption  (190;199),  and  increased  needs 
substantially increase the risk of micronutrient deficiency (87;173;189).  
Earlier paediatric studies in IBD were restricted to assessing the energy stores and body 
composition (84;102) with negligible evidence existing on micronutrient status. As extrapolation 
of  results  from  adult  studies  is  inappropriate,  due  to  differences  in  requirements,  this  study 
aimed to assess the body composition and systemic micronutrient levels of CD children, and 
secondly to assess longitudinal changes under treatment with EEN.  
   This study confirmed the results from previous extensive research that underweight, and 
increased undernutrition risk is a common finding in CD children , and at the same time offered 
new evidence on the micronutrient status of CD children. Compared to the national reference 
range CD children were significantly thinner and had more store deficits with approximately 1/3 
of  them  having  BMI  values  consistent  with  the  definition  of  underweight  and  risk  of 
undernutrition. Likewise compared to a cohort of Glaswegian children, recruited at the same 
time, the CD children’s BMI was lower by a mean of approximately 2 SD.  
Body composition is a dynamic process in childhood, which varies considerably with age 
and gender, and this should be considered when attempting to compare groups with different 
demographic  characteristics.  As  national  reference  range  is  now  available  (579)  this  study 
compared differences in body composition between groups, by expressing %FM in respective z-
scores. In contrast to the nutritional status classification by BMI, 50% of the children had %FM 
less than 2 SD of the reference population, with a mean %FM z-score of –3.3. However 25% of 
the healthy children had depleted fat stores too despite the fact that only 1% of them were 
underweight based on BMI cut-offs. Lack of concordance between these two measurements of 
nutritional  status  may  denote  that  BMI is not  a suitable  surrogate  of  body  composition,  and 
moreover  that  the  healthy  cohort  recruited  was  significantly  slimmer  than  the  reference 
population.  Alternatively  these  results  should  be  interpreted  bearing  in  mind  differences  in 
socioeconomic  characteristics  of  the reference population  and  the healthy cohort as  well  as 
differences in the BIA equipment and the body composition prediction algorithm that the authors 
of the national reference data used to assess body composition.  
Weight loss, and underweight is among the major presenting symptoms of the newly 
diagnosed CD (33), which explains the increased prevalence of underweight in this sample,   223 
which consisted of approximately 50% of newly diagnosed children. None of the participants 
were on concomitant treatment EEN, which may have biased the results.  
Growth  faltering  is  common  in  children  with  CD  (109)  and  although  no  mean  height 
difference was found with the healthy Glaswegian children, four times more children with CD 
were classified as growth retarded than the healthy controls. Undernutrition, the action of pro-
inflammatory cytokines, delayed pubertal onset, and long-term use of steroids are all implicated 
in the slow linear development in CD (111).  
For sixteen CD children, serial measurements of body composition were obtained during 
their disease management course with EEN. Although previous studies assessed changes in 
fundamental  anthropometric  characteristics  during  EEN,  (Table  1.5.1)  only  a  few  studies 
measured parallel changes in body composition. As BMI is best seen as an index of nutritional 
status rather than a true measure of body composition (104;272), more comprehensive methods 
are needed to distinguish between changes in body fat and lean mass stores during therapy with 
EEN. Foot to foot BIA is a quick, easy to use, cost effective, patient friendly method of body 
composition assessment, suitable for monitoring body composition in a clinical setting. Although 
there  is  good  evidence  to  suggest  that  the  validity  of  BIA  equipment  is  poor  compared  to 
reference methods and that was also shown in a previous chapter of this thesis (Chapter 4), 
these studies have assessed only the ability of the manufacturer’s algorithm to predict body 
composition.  As  explained  elsewhere  in  this  thesis  (Section  4.4),  there  are  now  new  body 
composition  norms  which  manipulate  impedance  measurements  independently  of  the 
manufacturer’s  prediction  equations  (587),  and  classify  children  at  different  nutritional  status 
scores. As these norms have been established only recently, this study relied on the use of the 
BIA manufacturer’s equation and checked their validity against a reference method. On the other 
hand, use of BIA to longitudinally assess changes in body composition may be more useful than 
predicting accurate measurements of body composition.  
Faecal calprotectin a marker of gut inflammation correlated negatively with BMI z-scores, 
and  may  show  that  increased  intestinal  inflammation  and  hence  disease  activity  can  cause 
weight loss and increase underweight and malnutrition risk. On the contrary systemic markers of 
disease activity like CRP did not correlate strongly with BMI which indicates that in-situ intestinal 
inflammation  is  a  more  important  determinant  of  nutritional  status  than  the  acute  phase 
response. Serum albumin was equally associated with BMI and may represent both increased 
disease activity and undernutrition.  
In  this  study,  serial  measurements  of  anthropometry  and  body  composition  were 
assessed and showed that changes depended on the response of the patient to the treatment.   224 
Although body weight increased in patients who achieved clinical remission and those who did 
not, the mean increase was higher in the former group. The mean BMI increase in the group of 
children who achieved complete clinical remission was 1.5 SD compared to 1.2 SD for patients 
with active disease at the end of EEN. It is worth mentioning that increased FFM was observed 
only in those patients who entered clinical remission by the end of treatment. Absolute FFM 
increased sharply by 2.7 kg within one month of treatment and continued so to a lower extent 
over the following month. The increase in FM was marginal and less than 1kg by the end of 
treatment. On the contrary, only TSF thickness changed significantly in the group of patients 
who either failed treatment or had ongoing active disease at the end of EEN. Whether clinical 
remission is achieved only in those patients who restore muscle body stores, or the latter is the 
result  of  disease  remission  should  be  studied further. This is  supported  by  previous studies 
which  observed  lean  mass  accretion  during  EEN  (104)  and  recent  evidence  suggesting  an 
anabolic effect of EEN in children with CD with shift in the protein turnover (333). On the other 
hand these results should be considered with caution as the number of patients in each group 
was small and statistical results may be a random finding. 
An  increase  in  body  weight  and  favourable  changes  in  body  composition,  better 
represent  the  energy  and  macronutrient  adequacy  of  the  prescribed  EEN  regime.  However 
improvement  in  energy/protein  status may not  parallel  improvement  or  even  conservation  of 
body micronutrient balance.       
Although clinical presentation of micronutrient deficiencies in IBD is very rare (175;180) 
and  largely limited  to case  reports (176;594), suboptimal  circulating levels  for  virtually  every 
vitamin, mineral and trace element have been reported previously in adult IBD patients (99;157). 
In paediatric CD patients the few studies were limited to the assessment of a selective small 
number of antioxidant vitamins and minerals (Section 1.5.2.8.3) (145;177;181-183) and similar to 
adult  studies,  the serum levels  of  zinc,  selenium,  and  antioxidant  vitamins  were  significantly 
lower compared to healthy controls of the laboratory reference range.  
In  this  prospective  observational  study,  a  substantial  number  of  CD  children  had 
circulating  levels  of  a  large  number  of  micronutrients  below  the  laboratory  reference  range. 
Approximately  50%  of  the  participants  had  suboptimal  levels  for  serum  zinc,  selenium,  and 
carotenoids. Indeed the serum concentration of carotenoids was out of the detection limit of the 
assay for some children. Although suboptimal circulating levels of micronutrients may reflect 
depleted body stores, none of the subjects presented overt deficiency symptoms. On the other 
hand, low levels of antioxidants may represent suboptimal antioxidant defensive systems and 
increased risk of oxidative stress (80;146;173). Excessive production of reactive oxygen species   225 
by  the  activated  immune  system,  in  conjunction  with  low  dietary  intake  (87;190)  may 
compromise the body’s antioxidant status. Unfortunately this study did not measure markers of 
biological molecules oxidation (eg malondialdehyde) to confirm this hypothesis.  
Acute phase response in inflammatory conditions, infection and cancer can alter serum 
levels of many nutrients and biomolecules irrespective of actual body stores (178;595;596). Thus 
assessing them in serum may not represent body adequacy and results can be fallacious and 
misleading. There are proponents suggesting the measurement of the same nutrients in other 
body  tissues  or  blood  cell  types  (597).  In  this  study  erythrocyte  levels  of  some  B  complex 
vitamins  were  measured  and  different  results  were  found  compared  with  serum  levels. 
Approximately 50% of the participants were deemed to have insufficient serum concentrations of 
B6 but none had suboptimal levels in their erythrocytes which could more correctly reflect the 
adequacy  in  the  tissues.  Likewise  artefactual  changes  from  the  acute  phase  response  may 
explain the suboptimal levels observed for some vitamins and trace elements in a significant 
proportion of the subjects. Among them serum carotenoids, selenium, zinc, vitamin C, and B6 
are  negative  acute  phase  respondents,  whereas  Cu,  and  ferritin  are  increased  during 
inflammation  (178).  In  this  study,  serum  ferritin  was  strongly  correlated  with  inflammatory 
markers as shown in Chapter 3. Measurement of ferritin levels in patients with active disease is 
incorrect and can be misleading. However one third of patients had ferritin levels lower than the 
reference range, which clearly represents depleted iron stores independently of an acute phase 
response artefact. Although haemoglobin levels did not change significantly during treatment 
with EEN, they were strongly associated with albumin levels, a marker of disease activity and 
malnutrition and this is in accordance with the findings of a retrospective study described in a 
previous chapter (Chapter 3).     
Changes during the acute phase response may also explain the strong association found 
between  the  serum  levels  of  various  micronutrients  and  systemic  inflammatory  markers  like 
CRP. Previous studies explained this as a casual association between increase disease activity 
and  suboptimal  micronutrient  status  (99;175;177)  but  we  believe  that  these  results  are 
misleading  and  are  actually  an  epiphenomenon  of the acute  phase response  that  occurs in 
inflammation. Reduced serum levels of micronutrients are often used to define deficiency state, 
but these levels may correlate better with markers of disease activity and inflammation and do 
not always reflect body tissue stores or functional deficits (157;177;178). A prime example is that 
perturbation in trace elements and vitamin concentrations in patients with cancer of the colon 
can be partially reversed by anti-inflammatory treatment, without supplementation (179). In this 
study CRP was significantly correlated with serum (r=-0.39; p=0.06) but not erythrocyte (r=-0.21;   226 
p=0.32) vitamin B6. To further support of this and challenging a causative association between 
micronutrients  levels  and  disease  activity,  none  of  the  micronutrients  was  significantly 
associated with faecal calprotectin concentration, a gut specific marker of disease activity that 
better  represents  intestinal  inflammation.  Nevertheless  copper,  a  positive  acute  phase 
respondent  was  below  the  reference  levels  for  10%  of  the  patients  and  this  may  indeed 
represent insufficient body stores.  
For  half  of  the  participants,  measurements  of  micronutrients  were  available  before 
treatment initiation and at the end of EEN. Serum levels for many micronutrients improved but 
carotenoids  further  deteriorated.  Carotenoids  are  negative  phase  respondents  and  someone 
would  expect  them to  improve at  the  end of treatment  as  the  combined  effect of  nutritional 
hyperalimentation and improvement of disease activity. However, in contrast to expectations, 
these further deteriorated and more than 90% of the participants had depleted stores for all 
carotenoids on treatment completion. Indeed their concentrations were under the detection limit 
of the laboratory assay. These results provide strong evidence to suggest that carotenoids are 
severely depleted at the end of treatment with EEN. Increased consumption during the active 
course of the disease and inadequate replenishment through dietary intake (190) explains these 
findings. The nutritional supplement the participants used, is better characterised as an “artificial 
food” and is nutritionally complete and balanced for the basic nutrients for which recommended 
amounts  have  been  established  and  therefore  may  lack  the  “non-nutrient  compounds” 
micronutrients.  Indeed  Modulen®  Nestle  composition  tables  (Appendix)  do  not  outline 
carotenoids as part of their constituents and none of their ingredients is a carrier of them. This in 
conjunction with the increased utilisation of antioxidants during the active phase of the disease, 
and small body reserves, may explain the depleted body stores in the patients of this study.  
Within  a  short  period  of  time,  following  treatment  cessation,  the  majority  of  the 
micronutrients  reversed  to  pre-treatment  levels.  Carotenoids  increased  significantly  whereas 
selenium and vitamin A decreased. Although none of the participants had suboptimal levels for 
vitamin D and B12 at any time point of follow up, their median concentration was significantly 
decreased compared to the end of EEN treatment reflecting a gradual deterioration of body 
stores. Sentogo et al (136;136) reported that 16% of CD children and young adults presented 
low levels of vitamin D, in line with the definition of hypovitaminosis, compared to none of the 
participants  of  this  study.  Different  definitions  of  hypovitaminosis  between  the  two  studies 
explain this discrepancy. If like Sentogo, a threshold of 38nmol/L had been set for the definition 
of vitamin D hypovitaminosis in this study, 24% of participants would have been classified with 
suboptimal body stores.         227 
Among the main limitations of this study are the small sample size, missing data, and the 
lack of a healthy control group. As this study is supplementary to the main study on the effect 
EEN on gut microbiota, the collection of stool samples discouraged many children to participate, 
and subsequently increased the recruitment period by 1,5 years (planned one year). Similarly 
paediatric CD is an uncommon disease with approximately 20 new cases per year in the biggest 
paediatric  referral  center  in  Scotland.  This  in  conjunction  to  alternative  treatment  options 
(steroids, anti-TNFα agents) and the unpredictable course of the disease reduced substantially 
the eligible number of participants. Venupuncture for entirely research purposes was deemed 
unethical and this did not allow the recruitment of a healthy control group, or blood sampling 
when patient was not due to give monitoring clinical bloods.    
This study found that the protein/energy stores and micronutrient status of children with 
CD are suboptimal and significant changes occurred during treatment with EEN. The findings of 
this  study  advocate  the  use  of  EEN  as  a  nutritional  complete  regime  to  support  the 
protein/energy stores of CD with active disease but the formula may be insufficient to sustain 
carotenoid body stores. Suboptimal levels for many micronutrients were found but it is difficult to 
differentiate between true deficiencies or an artifact of the acute phase response. If these are 
true  deficiencies  these  could  be  attributed  to  suboptimal  dietary  intake  (87;190),  increased 
consumption by the activated immune system, malabsorption or increased enteric losses (199). 
On the other hand if these are an epiphenomenon of the acute phase response, measurement 
of the same micronutrients in other blood cells, which are unaffected by acute phase response, 
might be required to correctly assess body balance, and their causal association with disease 
activity, and intestinal injury. This needs to be studied further.   228 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER SIX 
 
 
Changes in systemic and gut markers of 
inflammation during treatment with EEN in 
paediatric patients with CD   229 
 
OUTLINE 
This study assessed changes in faecal markers of intestinal inflammation in paediatric patients 
with  CD  undergoing EEN  treatment.  Correlation  between  faecal  calprotectin  levels,  systemic 
inflammatory markers and clinical activity indices are explored. 
 
6.1. Introduction 
Mucosal  healing  rather  than  gastrointestinal  symptom  resolution  could  be  considered  the 
definitive target of contemporary drug therapy in IBD. However routine monitoring of intestinal 
inflammation  and  the  mucosa  healing  process  is  difficult  due  to  the  inaccessibility  of  the 
digestive  tract.  Assessing  mucosal  inflammation  and  healing  routinely  with  endoscopy  is 
impractical, expensive, not acceptable to patients and needs general anaesthesia in paediatric 
patients.  On  the  other  hand  surrogate  markers  of  systemic  inflammation  are  not  sensitive 
enough or sufficiently specific to reflect mucosal inflammation (598). 
The presence of active gut inflammation in patients with CD is associated with migration 
of leukocytes to the intestinal mucosa. This causes the production of several proteins, which can 
be detected in serum or stools (599).  Calprotectin, a 36K Da calcium and zinc binding protein, is 
a neutrophil derived protein present in faeces. It represents 60% of the cytosolic proteins in 
granulocytes  (599)  and  its  presence  in  faeces  is  directly  proportional  to  the  migration  of 
neutrophils and therefore gut inflammation (600).  
There is good evidence that faecal calprotectin correlates with histological activity, and 
mucosal healing in patients with UC and colonic CD (601-604). Thus measurement of faecal 
calprotectin may have good potential as a non-invasive way of assessing disease activity and 
treatment  response  at  the  site  of  inflammation  rather  than  relying  on  markers  of  systemic 
response.  
So far, one study of paediatric UC patients showed that faecal calprotectin remained high 
in  children  with  UC  despite  clinical  improvement  after  treatment  with  steroids  (312;601).  
Considering previous evidence, which showed that mucosal healing is achieved after treatment 
with  EEN  (Section  1.5.2.2),  significant  reduction  in  the  calprotectin  concentration  in  those 
patients whose disease activity improved at the end of treatment would be expected.   
  The aim of this study was to assess any changes of faecal calprotectin concentration in 
CD children on treatment with EEN and how these correlate with clinical activity indices.   
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6.2. Subjects and Methods 
6.2.1 Subjects 
As this study  was supplementary to the main study of the effect of EEN on gut microbiota, 
eligible  participants  and  overall  recruitment  is  presented  elsewhere  (Section  5.3.1).  Faecal 
calprotectin levels were also measured in a first-degree relative of the CD children and in healthy 
children with no family history of IBD.  
  
6.2.2. Study design 
Stool samples were collected from children with CD during their eight weeks course on EEN. A 
baseline sample was collected close to the date of EEN initiation, two during their course of 
treatment (15 & 30 d), and one close to the end of treatment (60 d). A final sample was collected 
whilst  patients  were  on  normal  diet  within  1-4  months  after  EEN  treatment  cessation.  The 
samples were collected within a maximum of four hours of defecation from the patient’s home, 
homogenized with mechanical kneading and stored at –70 
oC until further analysis. 
 
6.2.3. Systemic markers of disease activity 
Systemic markers of disease activity (CRP, ESR, albumin) were measured in plasma at the 
beginning of EEN, at the end of treatment and whilst on normal diet. These were available from 
the  routine  clinical  measurements  of  the  patients  and  were  assayed  according  to  standard 
hospital protocols. A serum albumin concentration less than 35 g/l, and CRP and ESR more 
than 7 mg/l, and 20 mm/h respectively were deemed “abnormal” according to the local hospital 
reference range. 
 
6.2.4. Clinical activity index 
Disease  activity  was  assessed  with  the  Paediatric  Crohn’s  Disease  Activity  Index  (PCDAI) 
(Appendix).  The  PCDAI  is  a  well  established  and  validated  clinical  activity  index  used 
extensively in research to assess disease activity in paediatric CD patients (332). An overall 
score  is  calculated  taking  into  consideration  a  week  history  recall  of  symptoms,  laboratory 
markers of disease and clinical examination. The index was completed by data collected by the 
paediatric gastrointestinal consultants at the beginning and the end of their treatment and on the   231 
same day as the collection of the last stool sample. An overall score more than 10 is suggestive 
of active disease.  
6.2.5. Faecal calprotectin 
Calprotectin  concentration  in  faecal  samples  was  measured  with  a  commercial  ELISA  kit 
(Phical®, Norway) according to the manufacture’s protocol. A sample is tested by an enzyme 
immunoassay  specific  for  calprotectin.  Samples  and  standards  are  incubated  in  separate 
microtitre  wells  coated  with  polyclonal  antibodies  against  calprotectin.  After  incubation  and 
washing of the wells, bound calprotectin is allowed to react with immunoaffinity purified enzyme 
labeled  anti-calprotectin.  The  amount  of  enzyme  bound  is  proportional  to  the  amount  of 
calprotectin in the sample or standard. Microtitre plates were coated with rabbit anticalprotectin 
for  capture,  and  immunoaffinity-purified  rabbit  anti-calprotectin  conjugated  with  alkaline 
phosphatase was used for development.  
Approximately  100  mg  of  thawed  faeces  were  suspended  in  manufacturer’s  “extract 
buffer” (w/v; 1:50) and homogenized for 30 sec on a vortex mixer (Fisher Scientific, FB 15024) 
and for 30 min on an orbital shaker (IKA VIBRAX VXR BASIC) at 1200 rpm. The homogenates 
(approximately 1.5 ml) were transferred into Eppendorf tubes and centrifuged for 20 min at 10 
000 g at 4 ° C. The clear extract supernatant was diluted 1:50 in the manufacturer’s “dilution 
solution” and immediately analysed by ELISA.  
Fifty  l of each standard, control and diluted sample were added in duplicate in the wells 
of a 96 microtitre plate according to the manufacturer’s protocol. The plate was covered with 
sealing foil and incubated at room temperature on a horizontal shaker for 45+/- 5 min. At the end 
of  incubation,  the  wells  were  washed  out  six  times  with  ample  washing  buffer.  Fifty   l  of 
conjugate were added to each well with a multi-channel pipette and reverse technique. The plate 
was  covered  and incubated  as  above. Six  further  washings  were  performed as above.  One 
hundred  l of “substrate solution” were added to each well using a multi-channel pipette and 
reverse pippeting technique. The plate was incubated at room temperature for approximately 15-
20 min in the dark until the O.D. value of the 1000ng/ml standard reached at 2.0 absorbance 
units. One-hundred  l of stop solution (NaOH 1N) was added to each well. The O.D. values 
were read by means of an ELISA reader at 405nm (ThermoLab Systems Multiskan Spectrum). 
The concentration of calprotectin in stool samples was calculated with reference to the standard 
curve and expressed as mg/kg of wet and dry faecal material. Values above 50mg/kg were 
regarded as positive calprotectin level according to the manufacturer’s protocol.    232 
Samples were measured in duplicate. All serial samples from the same patient were 
measured in the same kit under the same conditions and calibration curve to avoid inter-assay 
variance.  
 
6.3. Results 
6.3.1. Participants 
Measurements of calprotectin measurements were carried out for 16 CD children with serial 
samples whilst on EEN (age 11.8±2.3 y, range 7.4-14.7 y) and their 14 first-degree relatives (13 
healthy parents, one sibling). Calprotectin concentration was also measured in stool samples of 
10 healthy children without family history of IBD. This assured the validity of the assay and also 
offered a group for comparison with the results of children with CD.   
Nine children were on no other medication apart from EEN. The rest had other parallel 
medical treatments (Table 6.1). All but one child finished at least six weeks on EEN. One child 
stopped  treatment  after  a  month  on  EEN  due  to  symptoms  exacerbation.  All  participants 
provided at least three serial stool samples whilst on EEN. A final stool sample was collected on 
normal diet in all apart from one patient who had surgical removal of part of the large bowel. 
Twelve children were newly diagnosed with CD and this was their first course of EEN while for 
the remaining four this was a subsequent course following disease relapse. Seven children were 
girls. Thirteen children had extensive disease involving parts of both the small intestine and large 
bowel (Table 6.1). 
 
Table 6.1: Disease location and concomitant medical treatment of CD children on EEN treatment 
Disease location  N  Concomitant medication  N 
Colitis (L2)  2  None  9 
Ileocolitis (L3)  1  5-ASAs  4 
Upper GI & Ileocolitis (L3L4)  9  Immunomodulators  5 
Upper & Colitis (L2L4)  4  Steroids  2 
    Antibiotics  1 
 
6.3.2. Changes in disease activity markers 
All participants had active disease as depicted by the calculation of the clinical activity index and 
the systemic inflammatory markers (Table 6.2). As expected the median value of the disease 
activity markers decreased at the end of treatment (Table 6.2). Individually, the majority of the 
children  experienced  improvement  in  clinical  activity  and  improvement  of  the  systemic 
inflammatory markers (Fig 35). For all apart from one patient, CRP and PCDAI were reduced 
compared with baseline values (Fig 35). PCDAI remained the same (PCDAI=10) for one patient.   233 
Although most of the children had improved PCDAI in only seven out of the 16 children was 
complete clinical remission (PCDAI<10) achieved. There was no statistical significant difference 
in the baseline markers of disease activity between patients who achieved remission and those 
who did not. 
 
Table 6.2: Mean changes in PCDAI and systemic markers of disease activity before, after EEN and 
on normal diet in paediatric patients with CD 
  Baseline 
(mean ± SD) 
End of EEN 
(mean ± SD) 
Normal Diet 
(mean ± SD) 
PCDAI    40   ±   17    16   ±   16
$    18   ±   14 
CRP (mg/L)    47   ±   70    14   ±   17*    23   ±   36 
ESR (mm/h)    39   ±   27    22   ±   26*    28   ±   19 
Albumin (g/dl)    29   ±   7    35   ±   5
$    34   ±   6 
* p< 0.05; 
$ p<0.01   Wilcoxon Singed Rank Test;  
 
6.3.3.  Correlation  between  systemic  and  gut  specific  markers  of 
disease activity 
Correlation  between  systemic  and  gut  specific  markers  of  inflammation  was  assessed  after 
pooling the results of all CD patients who participated in the EEN study. As anticipated there 
were significant associations with all systemic markers of disease activity and faecal calprotectin 
(Fig 36). Albumin was negatively and strongly associated with calprotectin whereas ESR, CRP 
and PCDAI were positively (Table 6.3).  
 
6.3.4. Changes in faecal calprotectin concentrations 
All participants had faecal calprotectin concentrations significantly higher than the upper normal 
reference range of the manufacturer’s reference range (50 mg/kg) at most of the time points of 
the observational period (Table 6.4). Inter-individual calprotectin concentration changes varied 
considerably during treatment (Fig 37).  
   234 
Figure  35: Individual changes of clinical activity and systemic markers of disease activity before and at the end of treatment with EEN in 
paediatric patients with CD     235 
Figure  36: Spearman correlation (r coefficient and p-values) between systemic markers of 
disease activity, PCDAI and faecal calprotectin in paediatric patients with CD 
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Table 6.3: Spearman correlation between systemic markers of disease activity and PCDAI with 
faecal calprotectin in paediatric patients with CD (R coefficient, p-value) 
Disease marker  R coefficient  p-value 
ESR  0.56  0.001 
Albumin  -0.62  0.001 
CRP  0.48  0.002 
PCDAI  0.49  0.001 
  
Table 6.4: Individual changes of faecal calprotectin (mg/kg) levels during EEN and on normal 
diet in paediatric patients with CD 
Subject  Before EEN  15 d  30 d  60 d  Normal diet 
A  1130.4  47.7  5.8  88.4  2054.6 
B  1701.4  1241.4  1846.6  1894.8  145.6 
C  2076.3  1704.8  1459.5  39.1  1712.1 
D  2585.3  2390.1  2324.6  2563.7  2431.8 
E  2262.3  1808  1797.6  2055.8  2470.2 
F  2102.2  1999.9  1535.8  718.1  1632.2 
G  1170.1  224.4  2191.6  2163.7  245.4 
H  2272.3  1841.6  1673.7  1685.8  2085.3 
I  2581.7  2341.1  2394.3  2460.9  2495 
J  2187.9  2056.2  2076.7  2298.3  2169.5 
K  2438.7  2221.6  2000.5  1723.5  2327.7 
L  2389.7  3148.7  2717    1681.5 
M  2086.8  2026.6  2338  2437.7  1511.9 
N  2088.51    296.39  77.12  2418.17 
O  2474  2347  1864.9     
P  3114.22  2216.35  1803.81  106.12  2355.18 
           
Mean ± SD  2166 ± 503  1841 ± 807  1770 ± 717  1451 ± 1009*  1849 ± 748 
* Significant different from “Before EEN” for ANOVA of repeated and Bonferroni post-hoc test   236 
Only one of the fourteen children that completed the course of EEN had a calprotectin level 
within the normal range (<50mg/kg) at the end of EEN and three children had values of 
approximately  100mg/kg.  The  rest  remained  at  much  higher  than  normal  levels  and  the 
extent of the change during treatment varied considerably (Fig 37) and (Table 6.4). Using 
analysis  of  variance  of  repeated  measures  and  Bonferroni  post-hoc  adjustment,  mean 
calprotectin  was  significantly  reduced  at  the  end  of  treatment  compared  to  baseline 
measurements (p=0.01).  
 
Figure  37: Individual changes of faecal calprotectin in CD children during EEN (with red line 
patients who achieved clinical remission and with blue line patients with active disease at the 
end of EEN)  
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  The  group  of  patients  was  divided  into  those  children  who  entered  in  clinical 
remission (n=7) and those who did not or the treatment failed (n=9). In those patients who 
entered clinical remission (PCDAI <10) faecal calprotectin concentration reduced significantly 
(Fig 38). Faecal calprotectin was reduced during EEN treatment and was significantly lower 
than  baseline  at  30  (p<0.01)  and  60  day  of  treatment  (P<0.0001).  Mean  calprotectin 
concentration was reduced by 921 mg/kg (95%CI: -1568 to -274) and 1541 mg/kg (95%CI: -
2187 to -894) after 30 and 60 days of treatment respectively. Two of these children relapsed 
within six months of treatment cessation, judged by the introduction of a subsequent EEN, 
steroid course or anti-TNFα treatment.     
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Figure  38: Calprotectin levels in paediatric patients with CD who achieved clinical remission 
(PCDAI≤10) on treatment with EEN 
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*p<0.0001
*a-nova of repeated measures and Bonferroni pot-hoc test.
All follow up points significantly different from "BeforeEEN"
 
In contrast, in those patients who presented clinical symptoms of disease activity disease at 
the  end  of  treatment  (PCDAI≥10)  of  discontinued  treatment,  calprotectin  levels  did  not 
change significantly from baseline (Fig 39).  
     
Figure  39: Calprotectin levels in paediatric patients with CD who did not achieve clinical 
remission (PCDAI>10) on treatment with EEN 
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*p=0.205
*a-nova of repeated measures and Bonferroni pot-hoc test    238 
 
6.3.5. Changes of faecal calprotectin on normal diet 
None of the patients had calprotectin levels within the normal reference range (<50 mg/kg) 
up to four months of EEN completion and whilst on normal diet. Calprotectin increased by 
approximately 10 times in those patients (n=4) who achieved calprotectin levels close to the 
normal range at the end of EEN (Table 6.4). Compared to the values at the end of EEN, 
faecal calprotectin dropped in five children and increased to nine children whilst on normal 
diet (Table 6.4).  
 
6.3.6.  Comparison  of  faecal  calprotectin  levels  of  CD  patients  on 
normal diet, their first degree relatives and healthy children  
For ten healthy children, with no family history of IBD, and for 14 healthy first degree relatives 
of the CD children (13 parents, one sibling) faecal calprotectin was measured in a single 
stool sample. As expected none of the healthy children had calprotectin above the normal 
range (<50 mg/kg). On the contrary the majority of the healthy relatives of CD children (9/14) 
had abnormal calprotectin levels (Fig 40). 
Figure  40: Faecal calprotectin levels in CD patients, their healthy first degree relatives and 
healthy children with no familial history of IBD (with blue cross the median) 
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6.4. Discussion 
Calprotectin is a marker of intestinal inflammatory activity with increasing use in research and 
clinical gastroenterology. It has good diagnostic validity to discriminate between organic and 
functional  disorders  (605;606).  In  this  study  most  of  the  patients  (14/16)  were  newly 
diagnosed or had undergone recent repeat endoscopy that confirmed histological findings of 
active intestinal inflammation. In all of these patients faecal calprotectin concentration was 
significantly higher than the normal reference range, as opposed to 86%, 69%, and 73% of 
the same patients who presented with abnormal CRP, ESR and serum albumin respectively 
(data  not  shown).  This  is  in  accordance  with  substantial  evidence,  which  suggests  that 
calprotectin  levels  have  excellent  negative  predictive  value,  better  sensitivity  and  equal 
specificity  compared  to  serological  inflammatory  markers  to  reflect  gut  inflammation 
(311;603;604;607;608).  Moreover  faecal  calprotectin  concentration  correlates  well  with 
endoscopic  and  histological  activity  scores  (311)  that  makes  it  a  useful  tool  to  monitor 
treatment efficacy at the site of the disease onset. So far only a few studies have assessed 
the effect of IBD treatments on faecal calprotectin levels (312;609), and to the best of our 
knowledge this is the first study in paediatric patients on treatment with EEN.  
Similar  to  previous  research  (604;606;610)  this  study  found  a  strong  association 
between  clinical  activity  indices,  CRP,  ESR,  serum  albumin  and  faecal  calprotectin  and 
moreover showed that calprotectin levels are decreased only in those patients who achieved 
clinical remission at the end of EEN treatment.  Calprotectin did not change significantly in 
the patients where treatment failed or had ongoing clinically active disease (PCDAI>10) at 
the end of treatment. These results suggest that in only those patients who enter clinical 
remission is mucosal healing achieved. However it is noteworthy that for only one of the 
patients who achieved clinical remission, calprotectin levels decreased to within the normal 
reference range at the end of treatment. This may indicate that either there is still ongoing 
subclinical  intestinal  inflammation,  despite  apparent  full  clinical  remission,  or  that 
improvement  of  clinical  disease  activity  occurs  more  quickly  than  resolution  of  intestinal 
inflammation.  
It was not within the scope of this research to explore whether increased calprotectin 
levels at the end of EEN predict an earlier clinical relapse and this must be addressed in a 
future prospective study. Nevertheless there is evidence to suggest that calprotectin levels 
can predict disease relapse in IBD (311;611;612) and if this is the case then calprotectin 
levels should be monitored along with clinical activity.  
Apart from its growth promoting effects, the impact on the patient’s nutritional status 
and lack of side effects, EEN is superior to steroids due to its gut mucosal healing effects   240 
(90;261). This is in agreement with the findings of this study and a previous report in Finland, 
which failed to find any effect of oral steroid treatment on faecal calprotectin levels of IBD 
patients (312;604).  
Some patients were on concomitant medical treatment that may have confounded the 
net effect of EEN on faecal calprotectin levels. This was unavoidable as it is unethical to 
withhold medical treatment for research purposes when there are clinical indications for use. 
Nevertheless  none  of  the  patients  on  parallel  medical  treatment  experienced  statistically 
significant  reduction  of  calprotectin  levels  or  entered  clinical  remission,  which  may  have 
confounded the results of this study. Indeed all apart from one of the patients whose faecal 
calprotectin  was  reduced  at  follow  up,  were  solely  on  treatment  with  EEN  or  on  stable 
treatment  on  5-aminosalicylates  (n=1)  prior  to  EEN  introduction.  Moreover  there  was  no 
difference  in  the  baseline  disease  activity  characteristics  between  those  patients  whose 
faecal calprotectin improved and those did not change or increased. 
Increased  gut  mucosal  permeability  and  increased  levels  of  calprotectin  in  CD 
relatives have been described before (489;490;613;614) and the findings of this study are in 
agreement.  The  majority  of  the  healthy  parents  recruited  had  faecal  calprotectin  levels 
significantly higher than the normal reference range and this may denote that genetic and 
common environmental factors may predispose to intestinal inflammation. On the other hand 
this may be the result of lack of faecal calprotectin specificity or other unknown underlying 
gastrointestinal comorbidities that can affect calprotectin levels (606). Only a follow up of 
these  subjects  will  address  whether  relatives  of  CD  relatives  with  high  faecal  levels  of 
calprotectin are more susceptible to develop IBD or other digestive inflammatory disorders.  
For  ten  healthy  children  with  no  family  history  of  IBD,  faecal  calprotectin  was 
measured. These were significantly lower compared to any time point of the follow up in CD 
children and within the normal reference range of the kit. This ensured the validity of the 
assay and precluded any methodological errors. In fact the study design and the method of 
sample  analysis  are  among  the  strongest  points  of  this  study.  All  of  the  samples  were 
collected within four hours of defaecation, were homogenized, and all the follow up samples 
of the same participant were assayed in duplicate, with the same ELISA kit using the same 
calibration curve. Homogenization of faecal samples prior to measurement, and intra and 
inter  assay  variance  are  methodological  issues  that  can  affect  the  validity  of  the  current 
assay to measure accurately calprotectin levels particularly when changes between follow up 
measurements  are  to  be  considered.  In  this  study  faecal  calprotectin  levels  were  also 
converted to per dry kg faecal material to balance for differences in the water content of the 
stool samples particularly between the active and inactive phase of the disease. No different 
results were found (data not shown) compared to the “fresh” stool” samples.    241 
In conclusion this study found that induction of clinical remission in paediatric CD 
undergoing treatment with EEN is accompanied by a reduction in faecal calprotectin levels. 
However most patients had still high levels of calprotectin at the end of treatment and future 
studies should address whether these predict an earlier relapse. If this is the case then, 
monitoring  faecal  calprotectin  along  with  changes  in  clinical  activity  will  be  a  more 
appropriate indication of treatment termination or prolongation.    242 
 
 
 
 
 
 
 
CHAPTER SEVEN 
 
 
 
Nutritional therapy and gut microbiota in 
paediatric CD    243 
7.1. Introduction 
There is now vast clinical experience supported by a substantial number of clinical studies to 
advocate the use of nutritional therapy in the management of active paediatric CD. Exclusive 
enteral nutrition attenuates disease activity and induces clinical remission in the majority of 
CD children with active disease and gut mucosal healing is achieved in the majority of the 
cases (90;261) (Section 1.5.1.2).  
  As with many popular medications, the mode of action and ideal formulation of EEN 
remain  unknown  (530;615).  There  is  still  much  discussion  and  debate  about  putative 
mechanisms of action, mainly because the gut is a difficult organ to study directly. Gut rest, 
direct  anti-inflammatory  effects,  and  nutritional  rehabilitation  have  all  been  implicated 
(327;533) (Section 1.5.2) but at present there is no robust evidence to consistently support 
any of them in particular.  
Substantial  evidence  over  the  last  10-15  years  has  suggested  that  the  gut 
endogenous microbiota, rather than a specific microbial pathogen, plays an important role in 
the pathogenesis and propagation of intestinal inflammation and tissue injury, in CD (Section 
1.7.2)  (30).  Although  it  remains  unclear  whether  perturbation  of  the  intestinal  microbiota 
balance is a trigger of inflammation rather than the result of IBD, an unstable gut microbiota 
consisting  of uncommon  bacterial  species  (512;513),  with  mucosa  invasive  and  adherent 
properties has been described in several studies (504;523) (Section 1.7.2).  
Moreover studies in the early nineties described differences in the metabolic activity 
and production of bacterial metabolites between IBD patients and healthy controls (Section 
1.7.1) which subsequently triggered the experimental use of SCFA, mainly butyrate enemas, 
in a number of clinical trials (439;440) and animal models of colitis (428) (Section 1.7.1.1). 
Recently a number of clinical and animal studies (75;538) have tested food grade bacteria 
(probiotics) and prebiotics to induce, or maintain remission in both CD and UC by switching a 
putative “dysbiotic” gut microbiota (498) towards one more “normal”. 
Thus  modulation  of  the  intestinal  microbiota  could  be  an  attractive  potential 
mechanism for the action of EEN. Despite this being reported among the potential modes of 
EEN action in many relevant review articles (530;615) until recently no primary evidence had 
been cited. This was highlighted recently by an expert in paediatric CD and nutrition, Dr Anne 
Griffiths,  who  called  for  more  research  to  be  conducted  on  the  effect  of  EEN  on  gut 
microbiota (327).  
Thus far, two recent studies have described changes in the diversity of the dominant 
microbiota of children with CD on treatment with EEN. In the first of these studies, Lionetti et 
al (531) analyzed stool samples of nine CD children with TGGE and compared them with five 
healthy  controls.  A  greater  stability  of  the  gut  microbiota  diversity  was  observed  in  the   244 
healthy group, compared with the CD patients on EEN treatment, although no analysis of the 
electrophoresis gels  was  undertaken  by  the  authors,  who  evaluated  the  TGGE gels  only 
visually.  The  authors  concluded  that  EEN  may  exert  its  therapeutic  properties  through  a 
prebiotic effect on the large bowel microbiota of children with CD. 
In the second study, Leach et al (532) collected serial stools samples from six CD 
children during EEN, and at four weeks and at four months after treatment, and compared 
their bacterial composition patterns and diversity with seven healthy children. The bacterial 
diversity was assessed with DGGE and changes in the global bacterial and group specific 
diversity and similarity patterns were measured. Although bacterial diversity (bacterial band 
count) did not differ significantly between healthy and CD children at treatment initiation, a 
lower diversity was found at the end of treatment in the CD group compared with the healthy 
controls. Bacteroides-prevotella and Clostridium coccoides bacteria were significantly less in 
the CD group compared with the healthy controls at the end of EEN treatment. Moreover the 
similarity index of the bacterial diversity was low during treatment for all bacterial groups 
studied, and significantly lower than in healthy subjects. However no comparison of changes 
in bacterial diversity and similarity patterns were reported during EEN to investigate changes 
during treatment.     
Both  these  studies  assessed  changes  in  the  bacterial  diversity  and  composition 
stability  of  CD  children  on  EEN.  To  the  best  of  our  knowledge  no  previous  study  has 
explored whether EEN affects the metabolism of the microbiota in paediatric CD patients.  
To increase knowledge of the role of the microbiota in the action of EEN, the primary 
purpose of the study, described in this chapter, was to assess the effect of EEN on the gut 
microbiota metabolism and diversity in children with active CD. The secondary purpose was 
to compare the diversity of the gut microbiota and bacterial metabolism of the same children 
with their healthy first degree relatives and with healthy children with no family history of IBD.   
 
7.2. Subjects and methods 
 
7.2.1. Subjects 
For the purpose of this study three groups of subjects were recruited.  
i)  Paediatric CD patients with active disease on EEN 
ii)  First degree relatives of the above (CD) children 
iii)  Healthy children with no family history of IBD   245 
 
Crohn’s disease patients on EEN 
The characteristics of the eligible patients have been presented in Chapter 5. Briefly these 
included all the paediatric CD patients with active disease (<16 y old) who commenced an 
EEN course, as part of their standard medical management.  
 
First degree relatives of patients with CD on EEN 
A  single  stool  sample  was  requested  from  one  of  the  patients’  first  degree  relatives  for 
comparison purposes. This should allow a comparison between the gut microbiota diversity 
and metabolism of CD patients and their healthy relatives controlling partially for factors, 
which are known modifiers of the composition and metabolic activity of human gut microbiota 
(i.e. genes, diet, and environment). 
 
Healthy children with no family history of CD 
Stool samples were collected from 21 healthy children with no family history of IBD. Two 
stool samples were collected with at least a month gap between collections, to assess the 
temporal stability of bacterial diversity, composition, and metabolic activity, and to compare 
with the gut microbiota of CD patients under treatment with EEN.  
 
Exclusion criteria 
All  participants  were  asked  to  declare  recent  use  of  antibiotics  (last  three  months)  or 
systematic use of probiotic products or supplements. Healthy children or family members of 
CD patients that had been on a recent course of antibiotics were excluded. Although CD 
patients  with  recent  use  of  antibiotics  were  not  excluded  their  results  are  presented  and 
discussed with caution and, where differences were found, separately.  
 
7.2.2. Study design 
Serial stool samples were collected from CD children during their course of treatment on 
EEN. In total, five faecal samples were collected over a period of three to six months. A first 
stool sample was collected before or within five days of therapy initiation. For those patients 
who  started  treatment  on  the  same  day  as  endoscopy,  a  two  day  wash  out  period  was 
allowed to “balance” perturbation of bacterial population and metabolism owing to the bowel 
preparation  procedure.  For  these  patients  bowel  preparation  was  performed  with  sodium 
picosulfate (Picolax ®) and sennosides (Senna ®) liquid preparations. Collection of stool at 
this time was not ideal but unavoidable.  Serial stool samples were collected at 15, 30 days   246 
on treatment and close to the last day of EEN (day 60). A final stool sample was collected at 
least one month after treatment cessation whilst patients were on normal diet.   
 
7.2.3. Exclusive enteral nutrition regime 
In all cases, the patients followed an eight weeks planned EEN course with a polymeric 
casein-based  liquid  supplement  enriched  with  Transforming  Growth  Factor-β  (Modulen®, 
Nestle). The details of the composition of the dietary regime is described elsewhere (Section 
5.2.2). 
 
7.2.4. Methods & materials 
7.2.4.1. Samples collection and initial manipulation 
Fresh stool samples were provided by all participants (CD, relatives, healthy) at home or 
during their routine visit to the hospital. To facilitate the collection of the stool samples a 
special kit was supplied to all participants. The patient passed the entire bowel movement 
into  a  plastic  single  use  container  supported  on  the  toilet  seat  through  a  paper  bedpan. 
Immediately after defecation the patients or their parents put the container inside a gas proof 
bag  along  with  a  special  anaerobic  kit  (Anaerocult®  A,  Merck,  Germany)  to  reduce  the 
oxygen  concentration  in  the  sample  and  induce  anaerobic  conditions. A  special  indicator 
(Anaerotest®, Merck) was used to check the development of anaerobic conditions. The stool 
sample  was  kept  inside  an  insulated  bag  along  with  frozen  ice  blocks  to  retard  ongoing 
bacterial metabolism (Appendix).  
Typically stool samples were transferred to the laboratory within a maximum of four 
hours of defaecation and were processed within an hour. The protocol for the initial handling 
of the samples ensured that the biomarkers of interest most susceptible to the effect of time 
would be tested first. The initial handling of the sample included mechanical blending of the 
whole faecal sample with a domestic hand blender (Braun, MR4050HC, Germany). Samples 
were blended until complete homogenization (2-3 min, depending on consistency) inside a 
biological flow cabinet ((MSC 12, BS 5726, Juan).    
 
7.2.4.2. Determination of faecal pH 
Measurement of faecal pH was performed on 1:3 w/v aqueous faecal slurries.  Approximately 
0.8-1.2  g  of  homogenized  faecal  sample  was  measured  accurately  and  suspended  in 
threefold volume of distilled water. The slurry was agitated by vortex at full power for 1 min or 
until the sample was completely dispersed. In the case of hard samples, a thin stick or small 
glass beads were used to break the lumps. The measurement of the pH was performed with 
an autocalibrated portable digital pH meter (Hanna HI 98140, Portugal).   247 
 
7.2.4.3. Determination of SCFA and BCFA  
Short chain fatty acids (C2-C8) and  branched chain acids isobutyrate, isopentanoic, and 
isocaproic were measured with gas chromatography in ether extracts and according to the 
method by Laurentin & Edwards (616). 
 
Stabilization of faecal specimens for SCFA analysis 
Short chain fatty acids are particularly volatile and susceptible to oxidation. Substitution of 
their free carboxylic hydroxyl group, by divalent ions and conversion to their salt form in 
strong alkaline milieu preserves them from oxidation and decreases volatility and prevents 
the ongoing metabolic activity of the bacteria. Depending on the stool sample size (small 
samples)  and  its  consistency  (diarrhoeal  samples)  0.8-1.5  g  of  specimens  were  fully 
dispersed in a small (7 ml) bijoux tube with an equal volume of NaOH 1M. Each tube was 
agitated vigorously on a vortex mixer for approximately one min or until the sample was fully 
dispersed. In the case of hard samples pre-weighed small beads or magnetic stirrer were 
used  for  more  efficient  homogenization.  The  procedure  was  repeated  in  triplicate.  The 
samples were subsequently stored in –20 
oC until further use. 
 
Moisture and volatile matter determination 
Moisture content was determined the day before SCFA analysis based on the freeze drying 
method. The pre-weighted NaOH-stabilized stool samples, were freeze dried for 24 hours in 
a Edwards apparatus (Freezer Dryer Micro Modulyo). The sample dry weight was measured 
and the moisture content was expressed as percentage of water per mass of stool sample.  
 
Gas chromatographic determination of SCFA 
Short chain fatty acids were estimated by gas liquid chromatography using a TRACE 2000 
gas chromatograph (ThermoQuest Ltd, Manchester, UK) equipped with a flame ionisation 
detector (250 
oC) and using a Zebron ZB-Wax capillary column (15 m x 0.53 mm id x 1  m 
film  thickness),  made  of  polyethylene  glycol  (catalogue  No.  7EK-G007,  Phenomenex, 
Cheshire, UK). Nitrogen (30 ml/min) was used as the carrier gas.  
One hundred  l of internal standard solution (86.1 mmol/l 2-Ethylbutyric acid) and 100 
 ls of concentrated orthophosphoric acid were added to 800  ls of distilled water containing 
50   g  freeze  dried  faeces  previously  stabilized  with  1:1  NaOH  1  N.  The  mixture  was 
homogenized by vortex for 15 sec and was extracted immediately three consecutive times 
with 3 ml of diethyl ether, vortexed for 1 min each time, recovering and pooling the ether 
phase  (supernatant)  each  time  in  a  clean  tube.  Pooled  extract  (1ul)  was  automatically   248 
injected (injector temp 230 
oC, splitless) onto the column. The column temp was held at 80 
oC for 1 min, increasing by 15 
oC per min to a final oven temp of 210 
oC. 
The chromatograph and the peak integrals were analysed using Chrom-Card 32-bit 
version  2.2  (April  2003)  (Thermofinnigan,  Milan,  Italy).  For  the  calibration  an  external 
standard of (166.5  mol/l acetic, 135  mol/l propionic, 113.5  mol/l isobutyric, 113  mol/l 
butyric,  97.9   mol/l  isovaleric,  97.9   mol/l  valeric,  86.1   mol/l  hexanoic,  76.8   mol/l 
heptanoic and 69.3  mol/l octanoic, pH 8) was used. The external standard was run five 
times at the start of each run and the response factor for each standard averaged and the 
coefficient of variance calculated. The external standard was run again and the coefficient of 
covariance calculated after every 12 samples. All reagents used were Analytical Reagent 
Grade and supplied by Sigma-Aldrich Company Ltd (Dorset, UK), except acetic acid (glacial) 
which was supplied by Fisher Scientific (Loughborough, UK). All serial samples from each 
patient  were  analyzed  at  the  same  run  to  minimize  inter-assay  error.  Each  sample  was 
extracted  and  analysed  in  duplicate  (two  different  extractions)  and  in  reverse  order,  to 
account for any time effect (due to evaporation of the very volatile SCFA) on the accuracy of 
the results. The results from the two extracts were averaged unless their variance was wide. 
A quality control sample (well homogenized freeze dried stock faecal material) was included 
at the beginning and the end of each run to assure repeatability of the assay and intra-assay 
comparison of the results between different runs.  
 
7.2.4.4. Determination of faecal lactate 
D- and L- Lactate were measured in freeze dried faecal samples using a modified enzymatic 
spectrophotometric commercial assay (D, L Lactic Acid, UV Method, Boehringer Mannheim, 
Roche,  Cat  No;  11112821035).  In  the  presence  of  lactate  dehydrogenase,  lactic  acid  is 
oxidized to pyruvate by NAD according to the reaction:  
Lactate + NAD Û Pyruvate + NADH + H 
The  equilibrium  of  these  reactions  lies  on  the  side  of  lactate.  By  trapping  pyruvate  in  a 
subsequent  one-way  reaction  catalyzed  by  the  enzyme  glutamate-pyruvate  transaminase 
(GPT) in the presence of L-glutamate, the equilibrium can be displaced in favour of pyruvate 
and NADH according to the reaction. 
Pyruvate + L-glutamate ⇒ L-alanine + 2-oxoglutarate 
The amount of NADH formed in the above reactions is stoichiometric to the amount of D-
lactic and L-lactic acid respectively. The concentration of NADH is determined by means of 
its ultraviolet absorbance at 340 nm and equals to the expended lactate. 
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Modification and optimization of the commercial Kit 
The initial protocol of the assay was based on a commercially available kit of measuring D 
and L lactate in foodstuffs (D, L Lactic Acid, UV Method, Boehringer Mannheim, Roche, Cat 
No;  11112821035).  Several  modification  steps  were  applied  to  scale  down  the  original 
method  to  a  microtitre  calibre,  and  additional  steps  were  added  for  the  purification  and 
extraction of faecal lactate. In a two months optimization phase, different lactate extraction 
and enzymatic reaction conditions and protocols were tested and optimal conditions were 
selected. The description of the optimization steps is beyond scope of this thesis.  
The final optimized protocol for the measurement of faecal lactate in stool sample had 
two major stages.  
a.  Lactate extraction and removal of impurities  
b.  Spectrophotometric Determination of D and L lactate  
 
Table 7.1: Preparation method and reagents for the assay of the determination of faecal lactate 
NAD working solution 
(0.003097 mg/ l) 
Dissolve 232 mgs of NAD (Fluka 43407) in 5 ml of distilled water. 
The solution is stable at 4 
oC for one week. 
 
GPT solution (0.0139 Unit/ l)  Dilute  0.8  ml  of  well-shaken  stock  solution  of  GPT  (Glutamic 
Pyruvic Transaminase from porcine heart 90 Unit / mg protein, 
14.4  mg  /  ml.  SAFC  G9980  15UN)  suspension  in  4.2  ml  of 
distilled water. Shake well before use.  
 
D-lactase  dehydrogenase 
(0.048 Unit/ l) 
Dissolve 4.63 mg of lyophilised enzyme (SAFC 59023, D Lactate 
from  Lactobacillus  species,  1165  U  /  mg)  in  5  ml  of  distilled 
water. The solution is  stable at 4 
oC for one week 
L-lactase  dehydrogenase 
(0.048 Unit/ l) 
Dissolve  38  mg  of  lyophilised  enzyme  (Biochemika:  L-lactate 
Dehydrogenase from rabbit muscles 142 U/mg 61305) in 5 ml 
distilled water. The solution is stable at 4 
oC for one week. 
 
Carrez  I  and  II  clarification 
system 
Bioquant Carrez clarification 5-fold concentrated (Merck. 10537) 
(D, L Lactic Acid, UV Method, Boehringer Mannheim, Roche, Cat 
No; 11112821035) 
Quality standards  Standard  solutions  of  D  and  L  lactate  were  available  from  the 
manufacturer’s kit. 
  
Buffer glycylglycine  Dissolve 1.321 g of Glycylglycine (Argos Chemicals) in 100 ml of 
water. Add 1.4667 g L-glutamic acid (Fisher) in 100 ml. Stir with 
magnetic  stirrer  and  adjust  pH  with  concentrated  KOH  (5M). 
Bring solution to room temperature before use. 
 
Reagents 
All  reagents  (Table  7.1)  were  kept  in  dark  bottles  or  in  universal  tubes  wrapped  with 
aluminium foil and brought to room temperature before use.  
 
Lactate extraction and removal of impurities  
Freeze-dried stool samples (30-50 mg; same sample as for SCFA determination; fixed with 
1:1 NaOH 1M) were suspended in 800  l of distilled H2O in a 2 ml secure lock eppendorf   250 
tube. The suspension was agitated vigorously by vortex (1 min) and incubated in a water 
bath  at  65 
oC  for  20  min.  The  suspension  was  agitated  for  further  45  sec  and  faecal 
impurities removed with the Carrez clarification system (Merck, UN 3082). Typically 100  l of 
Carrez I were added followed by short agitation and addition of 100  l of Carrez II. The 
suspension was vortexed for further 10 sec before being spun at 14000 g for 8 min. 500  l of 
the supernatant were transferred into a clean secure lock eppendorf tube and 50  l of Carrez 
I and Carrez II were added as above. The suspension was centrifuged at 14000g for 6 min 
and  the  clear  supernatant  was  transferred  into  a  clean  eppendorf  tube.  The  extract  was 
centrifuged for a further 4 min without addition of Carrez clarification system and the final 
supernatant analysed immediately for the determination of the D and L lactate.  
 
Spectrophotometric determination of D and L lactate  
Each sample was analyzed twice (two separate extractions) and each extract in duplicate. 
The values of the two replicates and extracts from the same sample were averaged unless 
variance was wide. Two standard samples of D and L lactate were run each time to check 
completion  of  the  reaction.  A  quality  control  faecal  sample  identical  that  used  for  the 
determination of SCFA was analysed in each run to ensure intra-assay repeatability.  
In  a  96  microtitre  well  plate  (Costar  9017,  US),  the  reactants  and  the  under 
determination samples, quality controls and standards were added according to Table 7.2. 
The plate was covered with membrane sealer and mixed on an orbital shaker for 10 min to 
mix  up  the  reagents.  Absorbance  was  measured  at  340  nm  and  corresponds  to  the 
background absorption. D-lactate dehydrogenase (10ul) was added, and the plate incubated 
on a shaker for 60 min followed by measurement of absorbance at 340 nm. Finally, 10  l L-
lactate  dehydrogenase  was  added  and  the  plate  incubated  as  above  for  two  hours  and 
absorbance measured at 340 nm.  
 
Table 7.2: Composition table of the faecal lactate assay 
  GPT  Buffer  NAD  Water  Sample  QC  D-lactase  L-lactase 
Blank ( l)  15  100  15  75  0  0  10  10 
Control ( l)  15  100  15  65  0  10  10  10 
Sample ( l)  15  100  15  45  30  0  10  10 
 
 
 
Calculation of lactate concentration 
The concentration of lactate is given by the general formula:  
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V= Total volume of reactants in the well, v= Sample volume, MW= Molecular weight of substance to 
be assayed (g/mol), d= Well effective light path (cm), ε= Extinction coefficient of NADH at 340 nm = 
6.3 (l x mmol
-1 x cm
-1), DA=the difference between absorbance: For D-lactate this was A1 – A0, and for 
L-lactate  A2 – A1 
 
A0: Background Absorbance 
A1: Background Absorbance plus Absorbance due to D-lactate conversion 
A2: Background Absorbance plus Absorbance due to D-lactate and L-lactate conversion 
 
Concentration of ) / (
1000 020 . 0 64 . 0 3 . 6
1 . 90 215 . 0
l g DA lactate D ´ 





´ ´ ´
´
= -  
 
 
Concentration of  ) / (
1000 020 . 0 67 . 0 3 . 6
1 . 90 225 . 0
l g DA lactate L ´ 





´ ´ ´
´
= -  
 
Lactate concentration of initial slurry (g/l): 
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Lactate concentration in dry stools (g/100g) =  100 ´
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Lactate concentration was expressed per g of dry or wet stool sample.  
 
7.2.4.5. Determination of free and total sulphide in faecal samples 
Free and total sulphide were measured in stool samples with a spectrophotometric assay in 
accordance to an in-house modified method reported by Strocchi (617). This is based on the 
principle of the methylene blue reaction first described by Cline (618) measuring sulphide in 
environmental  specimens.  Typically  sulphide  reacts  with  a  diamine  reagent  in  an  acidic 
environment under the oxidative effect of ferric chloride. The absorbance is measured at 670 
nm and its intensity is proportional to the concentration of sulphide.  
 
Optimization of previous assays 
Several methods have been reported in the literature for determination of faecal sulphide. 
Most are based on the principle of the methylene blue reaction (457;617;619) and one (620)   252 
is  based  on  microdistillation  and  ion  chromatography.  A  number  of  spectrophotometric 
assays  were  tested  to  select  the  most  appropriate  for  this  research  and  optimized  them 
where appropriate. The protocols described by Florin (619) and Moore (457) were initially 
chosen  as  they  seemed  easier  and  more  practical  but  our  results  were  not  encouraging 
particularly regarding the recovery of the assays and the sensitivity of the methods. To select 
the  best  concentrations  of  reactants,  samples,  and  reaction  conditions  (incubation  times, 
temperatures and reaction pH) an optimization phase of four months was undertaken. The 
detailed experimental description of these optimization steps and their results are out of the 
scope of this thesis and will not be reported in detail.  
 
Interference of assay by formula feed ingredients and sulphate salts.  
In a short experiment the influence of the ingredients of a nutritional supplement (Modulen), 
and particularly sulphur containing compounds (eg sulphate salts) was tested on the assay 
performance and mainly specificity. The free and total sulphide concentration of Modulen 
feeds (20%), a commercial infant milk powder (Cow & Gate), and three inorganic sulphate 
salts (magnesium sulphate, sodium sulphate, ferrous sulphate) were measured.  
None  of  the  inorganic  salts  tested  presented  substantial  amounts  of  total  or  free 
sulphide  and  therefore  interference  from  sulphate  salts  (not  bacterial  produced  sulphide) 
should be negligible. Surprisingly in both Modulen and baby feed free sulphide was detected 
but not total sulphide.  In theory this could be attributed to release of sulphide during the free 
sulphide stabilization step with NaOH and a possible unspecific reaction between the latter 
and sulphur containing ingredients in Modulen (sulphur containing amino acids). 
The main assay protocol consists of two main stages:  
a.  Trapping and stabilization of free and bound sulphide 
b.  Spectrophotometric determination of sulphide 
 
Reagents  
All the reagents (Table 7.3) were of Analytical Reagents Grade and supplied from Sigma 
Aldrich and Fisher Scientific (Loughborough). 
 
Trapping and stabilization of free and bound sulphide step 
Sulphide occurs in stool samples in two chemical forms, typically as hydrogen sulphide or 
bound to divalent minerals like zinc and copper. Although bound sulphide is relatively stable, 
hydrogen  sulphide  is  extremely  volatile  and  susceptible  to  oxidation.  Stabilization  of  free 
sulphide  by  converting  it  to  the  relevant  salt  is  necessary  for  accurate  measurements  of 
sulphide  in  faecal  material.  A  rule  of  thumb  is  to  trap  total  (free  and  bound)  sulphide  in   253 
insoluble zinc sulphide with zinc acetate or to increase solubility and decrease oxidation of 
free sulphide in an oxygen-free alkaline solution.  
 
Table 7.3: Preparation method and reagents for assay of the determination of faecal sulphide 
NaOH 1.25 M 
 
Oxygen free NaOH 1.25 M prepared to solubilise free H
2S and to prevent 
oxidation.  Aliquots  of  1.25  N  NaOH  stored  in  28  ml  McCartney  tubes 
(rubber sealed) and degassed by sonication (15 min) in warm water-bath 
(Sonomatic 375H, Jencons Scientific ltd, Bedfordshire, England).  
 
Zn-acetate 0.11 M 
 
Zinc  acetate  trapping  solution  prepared  to  preserve  and  stabilize  both 
free and bound sulphide.  Zinc displaces the H atoms and other divalent 
minerals attached to sulphide forming stable insoluble zinc sulphide salt.  
Zinc acetate 0.11 M (Fisher 2/0700/50) prepared by mixing zinc acetate 
dihydrate with distilled water and degassing by sonication as above.  
 
Colour forming reagent 
(reaction reagent) 
 
Reaction  reagent  (concentrated)  prepared  by  dissolving  2g  of  n,n-
dimethyl-p-phenylenediamine  (DPD;  Fluka  07750)  and  3g  of  FeCl3 
(Sigma Aldrich, 23648) in 500 ml of ice cold HCl 6M. Solution prepared 
fresh (weekly) and kept in dark bottle at -20 
oC. Diluted reagent prepared 
by mixing equal volumes of the concentrated reagent with ice cold HCl 
6N. Both dilute and concentrated reaction reagents used ice cold.  
 
Sulphide standard 
stock solution (2 mM): 
 
Sulphide  standard  stock  solution  prepared  with  sodium  sulphide 
nonahydrate  (Na2S  •  9H2O)  (Sigma  Aldrich,  20804-3).  A  crystal  of 
sodium sulphide nonahydrate (Na2S • 9H2O) washed out with distilled 
water discarding washings, wiped dry with cellulose tissue and weighed 
accurately.  2mmol/l solution made up with zinc-acetate 0.11 M in a gas 
proof glass container with rubber seal and flushed with nitrogen for 10 
min  to  displace  oxygen.  Slight  nitrogen  over-pressure  applied. 
Concentration of sulphide calculated from amount of sulphide dissolved 
(after washings) or iodometrically. Stock solution kept in 4 
oC for 15 d and 
working  aliquots  drawn  prior  to  assay  with  syringe  after  shaking 
vigorously.  
 
Sulphide spike solution 
(0.5 mM) 
 
Spikes of standard sulphide (0.5 mM) prepared fresh prior to assay to 
measure the recovery of faecal sulphide in the assayed samples. 0.5 mM 
spike was prepared by mixing 200  l of standard (2mM) solution with 600 
 l of zinc acetate 0.11 M.  
 
Typically  1-1.5  g  of  weighed  faecal  sample  was  dispersed  in  a  50  ml  pre-weighed 
polypropylene centrifuge tube containing 10 ml oxygen free NaOH 1,25M (free sulphide) or 
oxygen free zinc acetate 0,11 M (total sulphide). The sample was dispersed completely in 
the liquid phase by vortex. The zinc acetate faecal slurry was kept at –20 
oC until further 
handling  whereas  the  alkaline  slurry  was  centrifuged  at  15000g for  30 min  to  precipitate 
insoluble sulphide salts and recover the supernatant that contained the soluble free sulphide. 
The supernatant was transferred carefully in new eppendorfs and was stored at –20 
oC.    254 
 
Dilution step 
Prior  to  analysis,  frozen  faecal  extracts  (free  sulphide)  and  slurries  (total  sulphide)  were 
thawed  and  brought  to  room  temperature.  The  determination  of  sulphide  was  performed 
immediately  after  thawing  and  the  time  of  the  assay  was  kept  minimal  to  avoid  loss  of 
sulphide due to oxidation. The alkaline faecal extract (free sulphide) was centrifuged for five 
min at 14000 g whereas the faecal slurry (total sulphide) was resuspended thoroughly before 
use. 1.5 ml of faecal extract (free sulphide) was diluted with 6 ml of distilled water in a dilution 
ratio 1:5. Similarly 0.5 ml of well-dispersed total sulphide faecal slurry were diluted to 1:20 
with 9.5 ml of zinc acetate trapping solution.  
 
Spectrophotometric determination of free and total sulphide 
Samples (faecal extracts or slurries) were run in duplicate and their results averaged unless 
the variance between replicates was large. All serial samples from the same participant were 
run on the same assay using the same calibration curve to minimize intra-assay variance.  
Ice cold concentrated (80  l; blank samples) or 160  l of diluted reaction reagent 
(sample and spiked sample) were added in polypropylene eppendorfs containing 900  l of 
faecal slurry or extract (Table 7.4). Tubes were capped immediately to trap released sulphide 
and inverted gently approximately 5-10 times. Tubes were vortexed for 5 sec and incubated 
in the dark for 15 min at room temperature and then for 30 min at 37 
oC to allow full colour 
development. Eppendorfs were centrifuged (6 min, 14000 g) and the supernatant transferred 
into  disposable  cuvettes.  Absorbance  was  measured  at  670  nm  in  a  conventional 
spectrophotometer (Biomate® 3,Thermo, UK).  
For  each  sample  a  blank  replicate  was  prepared  to  correct  for  background 
absorbance  of  the  faecal  particulate  and  any  interference  due  to  a  non  specific  reaction 
between the latter and the reaction reagent. The blank sample had identical composition to 
the unknown sample apart from all intrinsic sulphide being driven off, achieved by adding 80 
 l of HCl 6N (Table 7.4) before development of the methylene blue color and vigorously 
agitating the tube on an orbital shaker (VXR Basic IKA Vibrax® SHAKER) for 1 hour with the 
cap on.   
A spiked sample identical to the under determination sample, but spiked with 10  l of 
sulphide standard (0.5 mM), was assayed to measure the recovery of the assay for each 
individual sample and to correct the measured absorbance of the unknown sample (Table 
7.4).    255 
 
Standard Calibration Curve 
A standard calibration curve (Fig 41) was prepared at the beginning of each run. A working 
standard solution of 0.05M was prepared by mixing 200  l of 2mM sulphide standard and 7.8 
 l of zinc-acetate 0.11 M. Seven serial dilutions (0 – 37.4 M) were assayed with the same 
protocol for the determination of sulphide in faecal samples (Table 7.5). Absorbance of the 
standards was plotted against their concentrations and a linear curve was plotted. 
 
Table  7.4:  Composition  of  blank,  sample,  blank  spike,  spike  and  spiked  sample  in  the 
determination of sulfide in faecal samples (all volumes in ( l) 
  Blank  Sample  Spiked Sample  Spike Blank  Spike 
Sample
$  900  900  900     
Zinc acetate 0.11N  10  10    900  900 
Sulphide standard 0.5mM      10  10  10 
Reaction reagent  80*  80* 
HCl 6N  80 
 
160 
 
160 
80 
 
160 
Final volume 
1070  1070  1070  1070  1070 
* Concentrated reaction reagent; 
$ Faecal slurry or  extract 
 
Table 7.5: Composition of calibration curve for the determination of sulphide in faecal samples 
Sulphide 
( M)  Blank  0  1.4  2.3  4.7  9.3  18.7  28  37.4 
Zn-Acetate  810  910  880  860  810  710  510  310  110 
Standard   100  0  30  50  100  200  400  600  800 
Reagent  80* 
HCl  80 
160  160  160  160  160  160  160  160 
*Concentrated reaction reagent   256 
 
 
Figure  41: Calibration curve of spectrophotometric determination of sulphide 
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Calculation of sulphide concentration 
The  concentration  of  sulphide  in  samples  was  calculated  by  reference  to  the 
calibration  curve  equation  corrected  for  recovery.  The  recovery  of  the  assay  was 
calculated by the formula:  
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Where: Abs the absorbance of Spiked Sample (SSp), Sample Blank (BS), Sample (S), Spike (Sp), and 
Spike Blank (BSp). 
The corrected absorbance of the sample was calculated by the formula:  
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The concentrations of free and total sulphide per mass of stool sample are calculated by the formula:  
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Where: Cabs is the corrected absorbance, A and B the intercept and slope of the calibration curve, 
and W the weight of the stool sample.    257 
 
7.2.4.6. Determination of faecal ammonia 
Faecal  ammonia  was  measured  in  the  same  faecal  slurry  (1:3,  w/v)  used  for  pH 
determination. Faecal slurry (100-500  l) was diluted to a final volume of 40 ml with distilled 
water in a conical polypropylene centrifuge tube. The suspension was vortexed and filtered 
(0.22  m Millipore filter). Determination of ammonia in the clear supernatant was performed 
with an automated ammonia analyzer (Hanna, HI 93715). 
 
7.2.4.7.  Analysis  of  bacterial  diversity  and  composition  with  molecular 
bacteriology techniques 
The bacterial diversity of CD children and changes during EEN treatment were assessed 
with  molecular  microbiology  methods.  Temporal  temperature  gradient  gel  electrophoresis 
(TTGE) is a molecular fingerprinting method that separates polymerase chain reaction (PCR) 
generated DNA amplicons of the same size (340). During TTGE, PCR products encounter 
increasingly higher running buffer temperature as they migrate through a polyacrylamide gel. 
Upon reaching a threshold buffer temperature, the weaker melting domains of the double 
stranded PCR product will begin to denature at which time migration slows substantially. 
Different sequences of DNA (from different) bacteria will denature at different temperatures 
resulting  in  a  pattern  of  bands.  Each  band  theoretically  represents  a  different  bacterial 
species present in the community. TTGE uses a polyacrylamide gel containing a constant 
concentration of urea.  
DNA isolation from faecal samples 
Approximately 200-300 mg of homogenized faecal material were stored in 1.5 ml screw cap 
eppendorfs on sample collection and stored at –80 
oC until further analysis. Total DNA was 
extracted with the bead beating method according to Sokol et al (512) as originally described 
by Godon et al. (621) 200 mg (wet weight) of stool were suspended in 250  l buffer 4M 
guanidine  thiocyanate  (G-9277  Sigma),  0.1M  Tris  (pH  7.5)    and  40   l  of  10%  N-lauroyl 
sarcosine. After addition of 500  l 5% N-lauroyl sacrosine in 0.1 M buffer phosphate (pH 8) 
the eppendorf was incubated in 70 
oC for 1 hour. 375  l of 0.1 mm diameter zirconium beads 
(Cat. No 110791012, Biospec) previously sterilized by autoclaving were added, and the tube 
was  shaken  in  a  Fastprep®  homogenizer  (MP  FastPrep  24,  MP  Biomedicals,  California, 
USA)  5.5  speed  twice  for  5  min  to  lyse  bacterial  cells.  Polyvinylpolypyrrolidone  (P6755 
Sigma) (15 mg) was added to the tube, which was vortexed and centrifuged for 3 min at 
15,000 rpm. After recovery of the supernatant in a new eppendorf, the pellet was washed 
with  500  ml  TENP  (50  mM  Tris  [pH  8],  20  mM  EDTA  [pH  8],  100  mM  NaCl,  1%   258 
polyvinylpolypyrrolidone) and centrifuged for 3 min at 15,000 rpm. The new supernatant was 
added  to  the  first  supernatant.  The  washing  step  was  repeated  three  times.  The  pooled 
supernatants (about 2 ml) were centrifuged briefly to remove particles and then split into two 
2-ml tubes. 
Precipitation and purification of nucleic acids 
Nucleic acids were precipitated by the addition of 1 ml of isopropanol for 10 min at room 
temperature and centrifuged for 5 min at 15000 rpm. The supernatant was discarded and 
pellets resuspended and pooled in 450 ml 100 mM phosphate buffer, pH 8, and 50  l 5 M 
potassium acetate (P1190, Sigma). The tube was placed on ice for 90 min or left at 4 
oC 
overnight. Following centrifugation at 15,000 rpm for 30 min, the supernatant was transferred 
to a new tube and 2  l of RNAse (RNAase ONE, M426A, Promega) (1 unit/ l) added. The 
mixture was incubated in a dry bath at 37° C for 30  min. DNA was precipitated by the addition 
of 50  l of 3 M sodium acetate (S2889, Sigma) and 1 ml of ice cold absolute ethanol. The 
tube was left for 30 min at room temperature or overnight at -20C.  DNA was recovered with 
a sterile stick after centrifugation at 15000 rpm for 15 min. The DNA pellet was finally washed 
with 70% ice cold ethanol, dried, and resuspended in 30-300  l of TE buffer.  
Assessment of DNA concentration and integrity 
The amount and integrity of DNA were estimated visually by electrophoresis on agarose gel. 
Typically 2  l of DNA template were mixed with 3  l of loading buffer (Bromophenol 6 X 
(B0126,  Sigma)  and  loaded  onto  the  wells  of  an  agarose  gel  (0.8%  containing  ethidium 
bromide 5  l for 50 ml of agarose). The electrophoresis run in 1 X TBE (Tris Borate EDTA) 
for 30 min at 100 V. A 100 bp DNA ladder (G210A, 100 bp DNA Ladder, Promega) was run 
in parallel to quantify the base pair size of the DNA templates.   
Spectrophotometric determination of DNA concentration and purity 
The concentration of total DNA was determined by measuring the ratio of the absorbance of 
total DNA to protein. Typically 2  l of DNA extract were dissolved to a final volume of 50  l 
with distilled water and the absorbance measured in UV at 260 (DNA) and 280 (proteins) nm 
corrected for the background absorbance at 320 nm. A ratio greater than 1.8 represented 
DNA fraction of high purity. The initial concentration of the DNA template was calculated by 
multiplying with the dilution factor.  
Ribosomal DNA amplification 
Primers with GCclamp-U968 (5’ GCclamp- GAA CGC GAA GAA CCT TAC) and L1401 (5’ 
GCG TGT GTA CAA GAC CC) were used to amplify the V6 to V8 regions of bacterial 16S   259 
rDNA.  Polymerase  chain  reaction  (PCR)  was  performed  using  HotStar  Taq  Master  Mix 
(Qiagen). The PCR mix (50 ml) contained 25  l of the Hotstar mixture (HotStar Taq Master 
Mix Kit Cart. No 203443 QIAGEN) (1 x PCR buffer, 15 mM MgCl2, 200mM each dNTP, 2.5 
units  of  HotStar  Taq  DNA  polymerase),  20  pmol  of  primers  U968-GC  and  L1401,  and 
approximately 20 ng of DNA. Samples were amplified in a thermocycler (PT C-200, Peltier 
thermal Cycler, Massachusetts, USA) using the following programme: 95° C for 15 min, 35 
cycles of 97° C for 1 min, 58° C for 1 min, 72° C for  I.5min, and finally 72° C for 15 min. PCR 
products were identified by electrophoresis on 1% agarose gel (BPE 1356, Fisher) containing 
ethidium bromide to check their size (500 base pairs) and estimate their concentration.  
Temporal temperature gel electrophoresis (TTGE) 
The  DCode  Universal  Mutation  Detection  System  (Bio-Rad,  Paris,  France)  was  used  for 
sequence specific separation of PCR products. Electrophoresis was performed through a 
1mm  thick,  16x16  cm  polyacrylamide  gel  (8%  wt/vol  acrylamide/Bis  (A7168,  Sigma),  7M 
urea, 1.25XTAE, and, respectively, 60 l and 600 l of N,N,N',N'-Tetramethylethylenediamine 
(T9281, Sigma) and 10% ammonium persulfate (A3678, Sigma) using 7l of 1.25 XTAE as the 
electrophoresis buffer. Electrophoresis was run at a fixed voltage of 64 V for 16 hrs with an 
initial temperature of 66° C and a ramp rate of 0.3° C/h. For better resolution, the voltage was 
fixed at 20V for 20 min at the beginning of electrophoresis. Each well was loaded with 300–
400 ng of amplified DNA plus an equal volume of 2X gel loading dye (0.05% bromophenol 
blue,  0.05%  xylene  cyanol,  and  70%  glycerol).  A  DNA  ladder  and  a  mixture  of  PCR 
amplicons  of  known  bacteria  were  used  for  each  gel.  Gels  were  stained  in  the  dark  by 
immersion  for  30  min  in  a  solution  of  SYBR  Green  I  Nucleic  Acid  Gel  Stain  (Roche 
Diagnostics, GmbH, Mannheim, Germany) and read under UV light (Gel Doc EQ 170-8060, 
Paris, France). 
Calprotectin assay 
Faecal calprotectin, a marker of mucosal inflammation, was measured in the stool samples 
of children with CD and their relatives. The assay description is outlined in Section 6.2.5 . 
 
7.2.4.8. Statistical analysis 
The results of faecal metabolites were expressed both per g ‘dry’ and per g ‘wet’ faecal 
material to account for overall production (‘dry’ matter) and to demonstrate their approximate 
luminal concentration in the large bowel lumen that is ready available to the colonocytes 
(‘wet’). The relative ratio of each SCFA to the total amount of SCFA (% of total SCFA) was 
calculated to assess changes in the pattern of SCFA production. Likewise the ratio of D to L 
isomer lactate concentration was computed to assess changes in the production pattern.    260 
  Data are presented with means and SD or with medians and range for parametric 
and nonparametric variables respectively. To assess changes of faecal biomarkers during 
EEN one way analysis of variance (ANOVA) with repeated measures and Bonferroni post-
hoc test was applied. For between two group comparisons the Mann-Whitney test was used 
and for intra-individual changes one sample Wilcoxon signed rank was applied. Fisher exact 
test and chi-square test were applied for differences in categorical variables between groups. 
Correlations between faecal calprotectin levels and faecal metabolites were assessed with 
Spearman rank r correlation.  
TTGE gel images were captured with UV camera (Gel Doc 170-8060, Biorad, Paris, 
France) and analyzed with the Quantity One software version 4.5.0 (Biorad). A TTGE profile 
with more bands generally indicates a greater degree of bacterial species diversity compared 
with a TTGE profile with few bands. Therefore the number of bands that appeared on the 
TTGE was quantitated and used to estimate bacterial diversity in each sample. Comparison 
of  the TTGE  band  patterns  of  individual  samples  was  performed  by  Sorensen's pairwise 
similarity coefficient (Cs) using the similarity matrix function of the software. Cs is defined as 
(2j/a+b)*100, where a is the number of bands in lane one, b is the number of bands in lane 
two, and j is the number of common bands in both lanes. Two identical profiles result in a Cs 
value of 100%, whereas completely different profiles (no common band) result in a Cs value 
of 0%.  
 
7.2.4.9. Power calculation 
The statistical power of the study was calculated for an 80% probability of detecting a 5.5 
mM increase or decrease in the faecal concentration of butyrate at a 5% significance level. 
For a faecal butyrate concentration of 13.4 mM with a standard deviation of 12.7 (417) and 
for a minimum clinical significant increase or decrease of 5.5 mM concentration the required 
sample size is 44 subjects. 
 
7.3. Results 
7.3.1. Recruitment 
Between October 2005 and August 2007 approximately 60 children started on EEN as part 
of their standard clinical management. Thirty children were invited to participate in the “EEN 
and  gut microbiota  study”  and  three  patients  in  clinical  remission  were  approached  as  a 
control  group.  In  total,  six  children  refused  participation,  and  two  withdrew  the  day  after 
recruitment. Two collected less than two stool samples but did not formally withdraw from the 
study. One patient’s participation was terminated deliberately after a final biopsy histology 
report  was  consistent  with  UC  diagnosis.  One  patient  experienced  a  cerebral  vascular   261 
accident while on treatment with EEN and stopped treatment within a week of recruitment. 
For two patients, disease activity further deteriorated and both had to stop EEN and initiate a 
regime  of  steroids.  Two  other  patients  were  recruited  15  days  and  21  days  after  EEN 
initiation and their results are not included in the arm of the study on the effect of EEN on gut 
microbiota  diversity  and  metabolism.  Fourteen  children  completed  between  six  to  eight 
weeks of EEN course. Approximately 100 stool samples were collected from children with 
CD. Only eight stool samples were provided at hospital despite the expectations of the single 
researcher. The rest were collected from patients’ home by the researcher within four hours 
of defecation.  
Fresh  stool  samples  were  collected  from  eighteen  CD  children  (11  boys)  at  the 
different  time  points  of  the  follow  on  EEN  (Table  7.6).  Two  patients  provided  only  two 
samples (one discontinued treatment and the other withdrew within 2 weeks of treatment) 
and therefore were excluded from analysis. Three children gave in total three serial samples 
during treatment (one could not provide a sample-was on holiday, two stopped at week 5 and 
4 respectively due to symptoms deterioration). These patients were included in the analysis.  
A final stool sample was collected whilst patients were on normal diet. For one child a 
final sample was not collected due to subsequent operation and resection of a significant part 
of the ileocolon.  
From the 16 children whose data is presented (mean age: 11.8 ± 2.3 y) nine were 
boys, twelve were newly diagnosed and this was their first course on EEN. The remaining 
four patients were receiving their second course to manage a subsequent disease relapse. 
Nine  children  were  on  no  other  medication  apart  from  EEN.  The  rest  were  on  other 
concomitant treatments (Table 7.6). For the patients with longstanding disease, the type and 
dose  of  concurrent  treatment  did  not  change  during  EEN  course.  Thirteen  children  had 
extensive disease involving the upper and lower part of the GI tract (Table 7.6). 
 
Table 7.6: Disease location and medical treatment of CD children on EEN treatment 
Disease location (Montreal 
classification) 
N  Concomitant medication  N 
Colitis (L2)  2  None  9 
Ileocolitis (L3)  1  5-ASAs  4 
Upper GI & ileocolitis (L3L4)  9  Immunomodulators  5 
Upper & colitis (L2L4)  4  Steroids  2 
    Antibiotics  1 
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7.3.2. Changes of disease activity markers during EEN  
Changes in disease activity markers are described in detail in Chapter 6. All participants 
were undergoing the active phase of their disease as evident by the increased score of the 
clinical activity index (PCDAI) and elevated systemic inflammatory markers (Table 6.2).  
All disease activity markers improved significantly at the end of treatment as a group 
and  individually  in  the  majority  of  the  children  (Chapter  6,  Fig  35).  Regardless  of  any 
improvement  in  disease  activity  during  treatment,  seven  out  of  the  16  children  achieved 
complete clinical remission (PCDAI≤10). There was no statistically significant difference in 
the baseline markers of disease activity between patients who achieved remission and those 
who did not.  
 
7.3.3. Changes in bacterial metabolic activity during EEN  
7.3.3.1. Changes in faecal water content, pH and ammonia  
No significant changes in faecal water content were observed during treatment with EEN. In 
contrast, faecal pH rose significantly (p<0.0001) (Fig 42). Compared to baseline values, a 
mean increase of 0.5 pH units was observed within 15 days of treatment initiation (p<0.01). 
Faecal pH remained significantly elevated at all time points of follow up (p<0.02) (Fig 42) but 
returned to pre-treatment levels when children were eating their normal diet.  
  Different patterns of faecal pH change were observed between those patients who 
achieved  complete  clinical  remission  and  those  who  discontinued  treatment  or  presented 
with  still  active  disease  at  the  end  of  treatment.  In  those  patients  who  achieved  clinical 
remission (PCDAI≤10) faecal pH was significantly increased at all follow up points compared 
to baseline  values (p<0.0001; Fig 43) whereas, no significant changes  were observed in 
those patients who did not achieve clinical remission or discontinued treatment (Fig 44).    263 
 
Figure  42: Boxplots showing changes in faecal pH during EEN and on normal diet in 
children with CD (all patients) 
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Figure  43: Boxplots showing changes in faecal pH during EEN and on normal diet in children 
with CD (remission) 
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Figure  44: Boxplots showing changes in faecal pH during EEN and on normal diet in children 
with CD (No remission) 
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Treatment with EEN had no effect on faecal ammonia (expressed per litre of stool sample or 
per kg dry faecal material). No difference in pattern of change was found between patients 
who achieved clinical remission at the end of EEN treatment and those did not (Fig 45).  
 
Figure  45: Boxplots showing changes in faecal ammonia during EEN and on normal diet in 
children with CD  
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7.3.3.2. Changes in faecal SFCA and BCFA concentration  
Overall  there  were  no major  changes  in the  concentration  of  the  main  SCFA  and  BCFA 
during EEN treatment. Faecal butyrate concentration and its proportional fraction (% of total 
SCFA) were reduced during EEN treatment but this did not reach statistical significance.  
However, similar to the patterns of faecal pH change, significant SCFA alterations 
were observed for the patients who achieved clinical remission at the end of treatment (Table 
7.7). Butyrate concentration and its relative ratio (% of total SCFA) were significantly reduced 
within  15d  of  treatment  initiation  and  continued  to  decrease  during  follow  up  with  the 
maximum mean reduction observed at the end of treatment (60 d) (Table 7.7). At the end of 
EEN, faecal butyrate concentration was half that of baseline values, and its proportional ratio 
was reduced to one third of pre-treatment levels (Table 7.7). Whilst on normal diet, butyrate 
levels  reverted  to  pre-treatment  levels.    None  of  the  SCFA  or  BCFA measured  changed 
during  treatment  in  those  patients  who  did  not achieve  clinical  remission  or  discontinued 
treatment (Table 7.8).    266 
Table 7.7: Changes in faecal concentration and % of SCFA and BCFA in paediatric CD patients who achieved clinical remission with EEN treatment   
Subjects (n=7)  Before EEN  15 d  30 d  60 d  Normal diet 
  Mean  SD  Mean  SD  Mean  SD  Mean  SD  Mean  SD 
Dry faecal material                     
Acetate (µmol/g)  237.9  138.9  222.5  63.6  199.8  99.6  187.3  82.3  238.9  124.5 
Propionate (µmol/g)  37.0  23.4  41.2  23.6  34.4  21.5  29.7  15.1  53.2  19.6 
Butyrate (µmol/g)  63.0  38.9  31.7  19.0  26.3*  10.5  23.8*  11.7  59.8  32.3 
Valeric (µmol/g)  5.9  6.7  4.9  6.6  4.2  5.0  4.8  4.5  5.6  5.6 
Caproic (µmol/g)  0.8  0.5  2.0  1.4  1.3  0.9  0.8  0.5  1.7  0.7 
Heptanoic (µmol/g)  0.2  0.6  1.1  0.7  0.4  0.7  0.0  0.0  0.7  1.3 
Octanoic (µmol/g)  0.8  1.0  2.0  1.7  1.3  1.0  1.1  0.6  1.2  1.1 
Isobutyrate (µmol/g)  12.2  7.0  12.2  4.5  10.0  4.3  7.9  2.1  7.0  1.3 
Isovaleric (µmol/g)  17.4  8.9  17.4  7.3  14.6  6.5  11.4  2.5  11.7  3.0 
Isocaproic (µmol/g)  4.2  9.4  0.7  1.0  0.4  0.7  0.1  0.4  0.0  0.0 
Total SCFA (µmol/g)  379.4  160.8  335.7  91.3  292.6  119.8  266.9  98.4  379.9  174.5 
Stool sample                     
Acetate (µmol/g)  57.3  21.3  61.2  17.9  54.5  14.8  50.1  16.5  59.6  17.5 
Propionate (µmol/g)  9.4  5.4  11.6  7.7  9.5  5.0  7.9  3.5  13.8  3.5 
Butyrate (µmol/g)  15.4  7.4  9.1  6.3  7.8*  3.4  6.7**  2.9  14.8  5.6 
Valeric (µmol/g)  1.6  2.1  1.2  1.6  1.3  1.5  1.4  1.3  1.5  1.5 
Caproic (µmol/g)  0.2  0.1  0.5  0.3  0.4  0.3  0.2  0.1  0.5  0.2 
Heptanoic (µmol/g)  0.1  0.2  0.3  0.2  0.1  0.3  0.0  0.0  0.2  0.5 
Octanoic (µmol/g)  0.3  0.4  0.6  0.5  0.4  0.3  0.3  0.2  0.4  0.4 
Isobutyrate (µmol/g)  3.2  1.9  3.5  1.6  2.9  1.1  2.2  0.4  1.9  0.7 
Isovaleric (µmol/g)  4.9  3.7  5.0  2.6  4.3  1.8  3.1  0.6  3.2  1.2 
Isocaproic (µmol/g)  0.8  1.5  0.2  0.2  0.1  0.2  0.0  0.1  0.0  0.0 
Total SCFA (µmol/g)  93.1  27.6  93.2  30.5  81.3  18.3  72.0  18.3  96.0  25.9 
Proportional ratio                     
% Acetate  61.7  14.5  66.1  8.4  66.7  9.1  68.7  6.7  61.8  3.1 
% Propionate  9.4  4.3  12.3  5.6  11.4  4.8  11.5  5.6  14.7*  2.9 
% Butyrate  16.9  8.8  9.3*  3.8  9.8*  3.6  9.3**  3.5  15.2  3.1 
% Valeric  1.6  1.9  1.4  1.8  1.7  2.0  1.9  1.8  1.5  1.4 
% Caproic  0.3  0.2  0.6  0.4  0.4  0.4  0.3  0.2  0.5  0.3 
% Heptanoic  0.1  0.2  0.3  0.2  0.1  0.3  0.0  0.0  0.2  0.4 
% Octanoic  0.3  0.4  0.7  0.7  0.5  0.4  0.5  0.2  0.4  0.3 
% Isobutyrate  3.5  1.8  3.7  1.2  3.7  1.1  3.2  0.9  2.1**  0.8 
% Isovaleric  5.2  2.8  5.4  2.1  5.4  1.9  4.6  1.3  3.6  1.5 
% Isocaproic  1.1  2.3  0.2  0.3  0.2  0.3  0.0  0.1  0.0  0.0 
Values were significantly different from those “Before EEN” (repeated measures ANOVA and Bonferroni post-hoc test):  *P<0.05, **P<0.02.   267 
Table 7.8: Changes in faecal concentration and % total SCFA and BCFA in paeiatric CD patients who did not achieve clinical remission with EEN 
treatment   
Subjects (n=9)  Before EEN  15 d  30 d  60 d  Normal diet 
  Mean  SD  Mean  SD  Mean  SD  Mean  SD  Mean  SD 
Dry faecal material                     
Acetate (µmol/g)  230.5  126.9  240.7  126.6  254.9  130.1  271.1  149.3  276.8  183.4 
Propionate (µmol/g)  37.8  24.5  29.9  23.6  33.7  17.4  39.8  12.6  41.6  30.3 
Butyrate (µmol/g)  26.3  25.6  20.0  16.7  20.6  15.3  25.4  15.4  39.6  42.9 
Valeric (µmol/g)  5.0  7.8  3.3  4.3  4.4  5.5  4.3  4.2  3.3  4.5 
Caproic (µmol/g)  1.4  1.9  1.0  1.2  1.3  0.9  1.3  0.3  1.0  0.7 
Heptanoic (µmol/g)  0.5  0.6  0.4  0.7  0.7  1.1  0.1  0.4  0.3  0.5 
Octanoic (µmol/g)  1.1  1.3  0.6  0.9  0.7  1.2  0.5  0.7  1.0  1.3 
Isobutyrate (µmol/g)  7.8  6.9  6.1  3.9  6.0  4.3  9.3  9.0  5.7  2.1 
Isovaleric (µmol/g)  10.6  7.8  6.7  3.6  7.8  6.2  10.3  6.2  9.1  4.3 
Isocaproic (µmol/g)  1.1  1.4  1.8  3.0  1.3  2.1  3.9  7.0  0.0  0.1 
Total SCFA (µmol/g)  322.1  130.0  310.5  135.2  331.5  123.2  366.0  159.0  378.5  203.7 
Stool sample                     
Acetate (µmol/g)  44.5  17.6  43.5  14.6  44.9  20.7  46.8  11.3  63.4  32.5 
Propionate (µmol/g)  9.5  7.6  6.3  5.7  6.9  4.3  7.4  1.1  10.9  7.2 
Butyrate (µmol/g)  7.2  7.0  4.0  2.9  4.7  5.1  5.1  2.8  10.5  9.8 
Valeric (µmol/g)  1.4  2.1  0.7  0.8  1.2  1.6  1.0  1.0  0.9  1.4 
Caproic (µmol/g)  0.4  0.6  0.2  0.3  0.3  0.2  0.3  0.1  0.2  0.2 
Heptanoic (µmol/g)  0.1  0.2  0.1  0.2  0.2  0.2  0.0  0.1  0.1  0.1 
Octanoic (µmol/g)  0.3  0.3  0.1  0.2  0.2  0.4  0.1  0.2  0.3  0.4 
Isobutyrate (µmol/g)  2.1  1.9  1.3  0.7  1.4  1.2  1.8  1.4  1.6  0.9 
Isovaleric (µmol/g)  2.8  2.3  1.5  1.0  1.9  2.0  2.1  1.2  2.7  1.7 
Isocaproic (µmol/g)  0.3  0.3  0.3  0.4  0.2  0.3  0.6  1.1  0.0  0.0 
Total SCFA (µmol/g)  68.5  34.3  58.0  18.9  62.0  28.3  65.3  9.8  90.7  39.1 
Proportional ratio                     
% Acetate  70.9  18.2  75.5  12.1  73.5  13.9  71.3  10.2  69.6  15.2 
% Propionate  11.9  6.7  10.2  6.1  11.1  5.0  11.7  3.0  12.1  7.2 
% Butyrate  8.3  6.8  6.8  4.9  7.1  4.9  7.8  3.8  10.9  7.7 
% Valeric  1.6  2.3  1.3  1.6  2.0  2.8  1.6  1.6  1.2  1.8 
% Caproic  0.5  0.5  0.3  0.4  0.4  0.3  0.4  0.2  0.3  0.2 
% Heptanoic  0.2  0.4  0.2  0.3  0.3  0.4  0.0  0.1  0.1  0.2 
% Octanoic  0.4  0.4  0.2  0.3  0.3  0.4  0.2  0.3  0.4  0.5 
% Isobutyrate  2.4  1.8  2.2  1.3  2.1  1.5  2.7  1.9  2.0  1.2 
% Isovaleric  3.4  2.2  2.6  1.8  2.8  2.2  3.3  1.9  3.3  2.2 
% Isocaproic  0.3  0.4  0.6  0.9  0.4  0.6  0.9  1.5  0.0  0.1   268 
7.3.3.3. Changes in faecal sulphide concentration  
Total  but  not  free  faecal  sulphide  concentration  increased  significantly  during  EEN 
(p<0.0001)  (Fig  46).  A  three-fold  increase  in  total  sulphide  was  observed  within  15  d  of 
treatment initiation (p=0.02). This plateaued at 30 d of treatment (p<0.02). At 60 d the mean 
total  sulphide  concentration  was  higher  than  at  baseline  but  this  did  not  reach  statistical 
significance. Total sulphide reverted to pre-treatment levels on normal diet. 
  
Figure  46: Boxplots showing changes in faecal free & total sulphide during EEN and on normal 
diet in children with CD 
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When  sub-analysis  was  conducted  separately  for  patients  who  achieved  clinical 
remission at the end of treatment, and those did not or who discontinued treatment, different 
patterns of change were observed (Fig 47 & 48). A seven-fold increase for total sulphide was 
observed  after  15  days  of  treatment  introduction  in  the  patients  who  entered  clinical 
remission. From a pre-treatment concentration of 0.64  mol/g, total sulphide increased to 
4.74  mol/g after two weeks on EEN treatment introduction (p<0.001). At 30 and 60 d follow 
up measurements, total sulphide remained at the same high levels (p<0.03). Concentration 
of total sulphide returned to pre-treatment levels when patients went back to their normal diet 
(Fig 48). No significant changes were seen for total sulphide concentration in patients with 
active disease at end of treatment or those who discontinued treatment (Fig 48).   
Faecal free sulphide concentration did not change from baseline levels during EEN 
(Fig 47). No different patterns of change were seen between patients who achieved clinical   269 
remission and those did not (Fig 47 & 48). Same change patterns were found when sulphide 
concentrations expressed per g dry sample (data not presented). 
 
Figure  47: Boxplots showing changes in free faecal sulphide during EEN in CD children. 
Comparison between patients with active disease and in remission at the end of EEN 
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Figure  48: Boxplots showing changes in total faecal sulphide during EEN in children with CD. 
Comparison between patients with active disease and in remission at the end of EEN 
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7.3.3.4. Changes in faecal lactate concentration  
Neither D nor its isomer L-Lactate changed significantly during treatment with EEN. In sub-
group analysis D but not L-Lactate decreased after 15 and 30 d of treatment initiation in the 
group of children who achieved clinical remission (p<0.04; Table 7.9). At 60 d the mean 
decrease did not reach statistical significance (p=0.08). No change was found in the ratio of 
D and L lactate isomer concentration during the course of treatment. However children who 
achieved clinical remission had a higher D/L Lactate ratio on normal diet than pre-treatment. 
No significant changes in concentrations of D-Lactate, L-Lactate nor their ratio were 
found in children who did not achieve clinical remission or discontinued treatment (Table 
7.10).  
 
7.3.4. Gut inflammation and bacterial metabolic activity 
Patients were categorized into two groups based on the direction of calprotectin change at 
the  end  of  treatment.    The  first  group  included  those  patients  (n=11)  whose  calprotectin 
levels was reduced at the end of treatment, and the second group (n=5) those patients with 
calprotectin concentrations, at treatment cessation higher than at baseline. Four patients in 
the first group did not achieve complete clinical remission at the end of EEN (PCDAI>10) 
compared to all patients in the group in which calprotectin increased.  
 
7.3.4.1. Changes in water content, faecal pH and ammonia 
For both groups no significant changes in the faecal water content or ammonia were found 
during EEN (data not presented). Faecal pH increased only in the group of patients that 
calprotectin decreased at the end of treatment (Figs 49 & 50). In this group pH reversed to 
pre-treatment when patients were on normal diet. 
 
7.3.4.2. Changes in faecal sulphide concentration 
Similar to the pattern of change observed in the patients who achieved clinical remission at 
the end of EEN, faecal levels of total but not free sulphide increased significantly at 15 and 
30 d, only in the patients with lower than pre-treatment levels of calprotectin, at the end of 
EEN  (Fig  51).  Total  sulphide  returned  to  pre-treatment  levels  when  patients  returned  to 
normal diet. No change in total or free sulphide was found in the group of patients with higher 
than baseline levels of calprotectin at the end of treatment (Fig 52).   
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Table 7.9: Changes in faecal lactate concentration during treatment with EEN and on normal in patients who achieved clinical remission 
N=7  Before EEN  15 d  30 d  60 d  Normal diet 
  Mean  SD  Mean  SD  Mean  SD  Mean  SD  Mean  SD 
Dry faecal material                     
D-lactate (mg/100g)  51.9  47.4  18.4*  6.5  18.9*  8.9  22.4  10.8  40.3  24.8 
L-lactate (mg/100g)  160.4  262.6  29.8  10.6  29.7  11.5  32.5  15.6  49.9  31.0 
Total lactate (mg/100g)  213.0  294.0  49.2  17.3  49.2  19.3  55.7  25.8  91.2  53.3 
Stool sample 
                   
D-lactate (mg/100g)  10.3  6.2  4.9
$  1.1  5.2
$  1.3  6.0  2.2  10.0  4.0 
L-lactate (mg/100g)  28.9  41.0  8.1  2.2  8.4  2.3  8.6  3.2  12.2  4.8 
Total lactate (mg/100g)  39.4  44.6  13.3  3.4  13.9  3.0  14.9  5.1  22.5  7.1 
D/L-lactate  0.6  0.3  0.6  0.1  0.7  0.2  0.8  0.3  0.9*  0.7 
ANOVA of repeated measures and Bonferroni post-hoc test *P<0.04 
$  P<0.03 from “Before EEN” 
 
Table 7.10: Changes in faecal lactate concentration i during treatment with EEN and on normal in patients who did not achieve clinical remission 
after EEN 
N=9  Before EEN  15 d  30 d  60 d  Normal diet 
  Mean  SD  Mean  SD  Mean  SD  Mean  SD  Mean  SD 
Dry faecal material                     
D-lactate (mg/100g)  39.4  35.7  76.8  87.5  78  75.7  72.3  62.2  77.3  129.0 
L-lactate (mg/100g)  76.2  77.7  187.4  214.8  173.7  168.9  151.5  192.6  106.9  170.5 
Total lactate (mg/100g)  115.7  111.2  264.3  285  251.7  231.6  223.8  246.4  184.0  299.0 
Stool sample 
                   
D-lactate (mg/100g)  6.8  3.2  11.7  8.7  11.2  7.3  11.7  6.4  13.9  15.0 
L-lactate (mg/100g)  12.5  8.3  29.2  28.9  23.9  17.7  22.9  22.2  19.7  19.5 
Total lactate (mg/100g)  19.3  11.2  40.9  34.6  35.1  23.2  34.6  27.4  33.6  34.5 
D/L-lactate  0.6  0.2  0.5  0.2  0.6  0.2  0.6  0.2  0.7  0.1 
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Figure  49: Boxplots showing changes in faecal pH during EEN and on normal diet in children 
with CD (calprotectin decreased) 
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Figure  50: Boxplots showing changes in faecal pH during EEN and on normal diet in children 
with CD  (calprotectin increased) 
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Figure  51: Boxplots showing changes in faecal free & total sulphide during EEN in children 
with CD (calprotectin decreased at the end of EEN) 
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Figure  52: Boxplots showing changes in faecal free & total sulphide during EEN in children 
with CD (calprotectin increased at the end of treatment) 
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7.3.4.3. Changes in faecal SFCA and BCFA concentration 
Butyrate  concentration  decreased  by  50%  within  15d  on  EEN  only  in  patients  whose 
calprotectin  decreased  at  the  end  of  treatment  (Table  7.11).  From  a  baseline  mean 
concentration  of  47.9   mol/g,  butyrate  dropped  to  24.6   mol/g  at  15 d  and  continued  to 
decline further during follow up reaching the nadir mean concentration of 20.5  mol/g at the 
end of treatment. No significant changes were observed for the other SCFA or BCFA (Table 
7.11).  None  these  metabolites  changed  in  the  group  of  patients  with  increased  levels  of 
calprotectin  at  the  end  of  treatment  (Table  7.12).  On  normal  diet  butyrate  concentration 
returned to pre-treatment concentrations and BCFA proportional ratio were significantly lower 
than on treatment initiation.     
 
7.3.4.4. Changes in lactate 
Neither D or the L isomer of lactate changed significantly during EEN in any group of patients 
(Tables 7.13 & 7.14). On normal diet the D/L lactate concentration ratio was higher than pre-
treatment in patients with a calprotectin decrease at the end of EEN treatment (p<0.001).    275 
Table 7.11: Changes in faecal concentration and % of SCFA & BCFA in paediatric CD patients with decreased levels of calprotectin at end of EEN 
treatment   
Subjects (n=11)  Before EEN  15 d  30 d  60 d  Normal diet 
  Mean  SD  Mean  SD  Mean  SD  Mean  SD  Mean  SD 
Dry faecal material                     
Acetate (µmol/g)  245.6  150.7  224.5  125.8  227.7  137.7  219.4  133.4  285.9  175.5 
Propionate (µmol/g)  38.5  22.9  39.1  27.0  34.4  21.2  32.5  14  53.3  27.4 
Butyrate (µmol/g)  47.9  38.7  24.6  17.3  21.6*  11.3  20.5*  11.0  47.8  33.7 
Valeric (µmol/g)  5.8  6.7  3.9  5.4  4.5  5.1  4.0  4.2  5.0  5.5 
Caproic (µmol/g)  0.8  0.5  1.5  1.2  1.4  1.0  0.9  0.5  1.7  0.6 
Heptanoic (µmol/g)  0.4  0.7  0.8  0.7  0.7  1.0  0.1  0.3  0.7  1.1 
Octanoic (µmol/g)  1.0  1.2  1.4  1.5  1.0  0.9  0.8  0.7  0.9  1.0 
Isobutyrate (µmol/g)  10.4  6.9  9.7  5.0  8.4  4.7  7.9  1.8  6.3
$  2.1 
Isovaleric (µmol/g)  15.2  8.4  13.6  7.6  12  6.7  11.2  2.4  10.4  4.2 
Isocaproic (µmol/g)  2.9  7.6  0.4  0.8  0.2  0.6  0.7  1.3  0.0  0.0 
Total SCFA (µmol/g)  368.5  158.4  319.6  143.8  311.9  141.7  297.9  140.9  411.9  196.5 
Stool sample                     
Acetate (µmol/g)  53.8  20.1  55.2  18.1  53.4  19.2  49.4  15.9  64.7  28.7 
Propionate (µmol/g)  10.0  6.2  10.6  7.5  9  5  7.7  2.9  13.7  5.9 
Butyrate (µmol/g)  12.0  8.0  6.9  5.6  6.2**  3.7  5.5**  3.1  12.1  6.8 
Valeric (µmol/g)  1.6  1.9  1.0  1.3  1.3  1.5  1.2  1.2  1.4  1.6 
Caproic (µmol/g)  0.2  0.2  0.4  0.3  0.4  0.3  0.2  0.1  0.4  0.2 
Heptanoic (µmol/g)  0.1  0.2  0.2  0.2  0.2  0.3  0  0.1  0.2  0.4 
Octanoic (µmol/g)  0.3  0.4  0.4  0.4  0.3  0.3  0.2  0.2  0.3  0.4 
Isobutyrate (µmol/g)  2.8  1.8  2.7  1.6  2.4  1.3  2  0.5  1.7  0.8 
Isovaleric (µmol/g)  4.2  3.2  3.9  2.4  3.4  2.0  2.8  0.8  2.9  1.5 
Isocaproic (µmol/g)  0.5  1.2  0.1  0.2  0.1  0.2  0.1  0.2  0.0  0.0 
Total SCFA (µmol/g)  85.6  30.0  81.4  29.4  76.8  23  69.2  16.7  97.5  33.8 
Proportional ratio                     
% Acetate  64.1  15.6  68.5  10.3  69.1  12.7  70.4  8.5  65.9  13.6 
% Propionate  11  5.8  12.6  6.1  11.6  5.2  11.7  5.0  14.0  5.3 
% Butyrate  13.5  8.9  8*  3.9  8.2**  4.2  7.9**  4.0  12.4  6.2 
% Valeric  1.8  2.1  1.4  1.8  2.1  2.7  1.7  1.8  1.5  1.8 
% Caproic  0.3  0.3  0.5  0.4  0.5  0.4  0.3  0.2  0.5  0.3 
% Heptanoic  0.2  0.4  0.3  0.2  0.3  0.4  0.0  0.1  0.2  0.3 
% Octanoic  0.4  0.4  0.5  0.6  0.4  0.4  0.3  0.3  0.3  0.3 
% Isobutyrate  3.1  1.7  3.3  1.3  3.1  1.4  3.0  1.0  1.9**  1.1 
% Isovaleric  4.7  2.6  4.7  2.1  4.5  2.3  4.3  1.5  3.2**  1.9 
% Isocaproic  0.7  1.8  0.1  0.2  0.1  0.2  0.2  0.3  0.0  0.0 
Values were significantly different from those before EEN (repeated measures ANOVA and Bonferroni post-hoc test): 
$P<0.07, *P<0.05, **P<0.02. 
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Table 7.12: Changes in faecal concentration and % of SCFA and BCFA in paediatric CD patients with increased levels of calprotectin at end of EEN 
treatment   
Subjects (n=5)  Before EEN  15 d  30 d  60 d  Normal diet 
  Mean  SD  Mean  SD  Mean  SD  Mean  SD  Mean  SD 
Dry faecal material                     
Acetate (µmol/g)  207.6  56.4  251.3  35.0  237.8  65.3  253.7  108.8  205.6  93.4 
Propionate (µmol/g)  35.1  26.5  25.1  10.7  33.1  13.2  40.3  15.6  34.5  17.8 
Butyrate (µmol/g)  30.1  30.0  24.7  21.4  26.4  18.2  35.0  13.4  51.5  51.0 
Valeric (µmol/g)  4.4  8.8  4.1  5.3  3.9  5.6  6.0  4.3  3.1  4.1 
Caproic (µmol/g)  1.9  2.6  1.1  1.5  1.0  0.7  1.5  0.1  0.7  0.8 
Heptanoic (µmol/g)  0.3  0.4  0.6  0.9  0.3  0.7  0.0  0.0  0.1  0.2 
Octanoic (µmol/g)  0.9  1.1  0.6  1.1  0.8  1.6  0.8  0.8  1.5  1.5 
Isobutyrate (µmol/g)  8.1  7.9  6.2  4.8  6.4  4.9  10.4  12.4  6.3  1.6 
Isovaleric (µmol/g)  10.1  9.3  5.7  3.5  8.0  7.9  9.9  8.5  10.3  3.6 
Isocaproic (µmol/g)  1.7  1.7  3.2  3.4  2.4  2.4  5.2  9.4  0.1  0.2 
Total SCFA (µmol/g)  300.2  95.6  322.6  31.9  320.2  55.8  362.9  133.3  313.6  152.8 
Stool sample                     
Acetate (µmol/g)  42.0  18.4  41.3  14.7  39.6  13.9  46.0  6.4  55.5  19.8 
Propionate (µmol/g)  8.2  7.6  4.2  2.2  5.9  3.2  7.5  1.1  9.4  4.7 
Butyrate (µmol/g)  8.2  8.5  4.4  3.8  5.7  6.8  6.8  2.0  13.5  11.2 
Valeric (µmol/g)  1.2  2.5  0.6  0.7  1.1  1.6  1.4  1.0  0.7  1.0 
Caproic (µmol/g)  0.5  0.7  0.2  0.3  0.2  0.1  0.3  0.1  0.2  0.2 
Heptanoic (µmol/g)  0.1  0.1  0.1  0.2  0.0  0.1  0.0  0.0  0.0  0.1 
Octanoic (µmol/g)  0.2  0.3  0.1  0.2  0.2  0.5  0.2  0.3  0.4  0.5 
Isobutyrate (µmol/g)  2.1  2.3  1.0  0.6  1.4  1.5  2.0  1.9  1.8  0.7 
Isovaleric (µmol/g)  2.6  2.7  1.0  0.6  2.0  2.6  2.1  1.5  3.0  1.5 
Isocaproic (µmol/g)  0.3  0.4  0.5  0.5  0.4  0.3  0.9  1.4  0.0  0.1 
Total SCFA (µmol/g)  65.4  38.5  53.4  19.6  56.5  28.2  67.2  8.4  84.6  31.6 
Proportional ratio                     
% Acetate  73.0  19.5  78.3  11.8  73.6  11.6  68.8  9.3  66.1  7.8 
% Propionate  10.3  6.1  7.9  3.6  10.4  3.9  11.3  2.5  12.0  6.4 
% Butyrate  8.9  8.1  7.3  6.0  8.5  5.4  9.9  2.1  13.9  7.0 
% Valeric  1.1  2.1  1.2  1.5  1.3  1.8  2.0  1.5  1.0  1.4 
% Caproic  0.6  0.6  0.3  0.4  0.3  0.2  0.5  0.2  0.2  0.2 
% Heptanoic  0.1  0.1  0.2  0.3  0.1  0.2  0.0  0.0  0.0  0.1 
% Octanoic  0.3  0.3  0.2  0.3  0.2  0.5  0.3  0.4  0.6  0.6 
% Isobutyrate  2.3  2.0  1.9  1.4  2.1  1.7  2.9  2.6  2.4  1.0 
% Isovaleric  2.9  2.4  1.8  1.1  2.6  2.5  3.0  2.1  3.8  1.7 
% Isocaproic  0.5  0.4  1.0  1.1  0.8  0.7  1.2  1.9  0.0  0.1   277 
 
 
 
 
Table 7.13: Changes in faecal lactate concentration in paediatric CD patients whose calprotectin concentration decreased at the end of EEN 
N=11  Before EEN  15 d  30 d  60 d  Normal diet 
  Mean  SD  Mean  SD  Mean  SD  Mean  SD  Mean  SD 
Dry faecal material                     
D-lactate (mg.100g)  39.9  40.4  40.5  66.9  43.5  68.3  39.5  44.5  74.1  114.9 
L-lactate (mg/100g)  117.1  212.3  73.9  129.5  70.8  119.8  91.5  168.4  95.7  154.1 
Total lactate (mg/100g)  157.3  240.4  115.0  196.2  114.6  187.8  131.6  211.7  170.5  268.5 
Stool sample 
                   
D-lactate (mg/100g)  8.3  5.7  8.0  7.2  8.1  7.0  7.9  4.9  13.8  13.4 
L-lactate (mg/100g)  21.7  33.4  14.3  14.1  12.9  12.3  15.7  19.9  17.5  18.1 
Total lactate (mg/100g)  30.0  37.0  22.3  21.3  21.1  19.1  23.6  24.6  31.2  31.1 
D/L-lactate  0.6  0.3  0.6  0.1  0.7  0.2  0.7  0.3  0.9*  0.5 
* p<0.001 from “Before EEN "for ANOVA of repeated measures and Bonferroni post-hoc test 
 
 
Table 7.14: Changes in faecal lactate concentration in paediatric CD patients whose calprotectin concentration increased at the end of EEN 
N=5  Before EEN  15 d  30 d  60 d  Normal diet 
  Mean  SD  Mean  SD  Mean  SD  Mean  SD  Mean  SD 
Dry faecal material                     
D-lactate (mg/100g)  55.9  42.1  79.4  84.3  71.3  51.9  66.8  65.0  31.9  9.5 
L-lactate (mg/100g)  104.2  98.7  225.0  241.0  198.5  166.8  93.3  78.4  49.5  10.4 
Total lactate (mg/100g)  160.1  138.1  305.0  296.0  269.7  198.4  160.2  143.1  81.4  19.6 
Stool sample 
                   
D-lactate (mg/100g)  8.4  2.9  11.0  8.3  9.7  4.6  11.3  6.8  8.6  2.2 
L-lactate (mg/100g)  15.3  10.4  33.7  36.2  26.3  18.5  16.0  7.1  13.6  2.5 
Total lactate (mg/100g)  23.7  13.1  44.6  40.9  36.0  20.8  27.3  13.8  22.2  4.6 
D/L-lactate  0.6  0.2  0.5  0.2  0.5  0.2  0.7  0.2  0.6  0.1 
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7.3.5.  Changes  in  bacterial  metabolic  activity  of  healthy  children 
without family history of IBD  
The  stability  of  the  gut  bacterial  metabolic  activity  of  healthy  children  was  evaluated  by 
comparing  the  concentration  of  faecal  biomarkers  between  two  serial  stool  samples  of 
healthy children with no family history of IBD. 
 
7.3.5.1. Recruitment 
20 healthy children controls (12 boys; 9.6 y [4.5-16.9]) without known family history of IBD 
were  recruited  via  advertisement  and  word  of  mouth.  Eighteen  children  gave  two  serial 
samples at least one month apart. For two children follow up samples were not obtained 
(both withdrew) and these were excluded from this analysis.  
 
7.3.5.2. Changes in faecal water content, pH and ammonia  
Faecal pH did not differ significantly between the two faecal samples. The average water 
content  was  higher  in  the  second  sample  but  the  difference  did  not  reach  statistical 
significance (p=0.061). Faecal  ammonia  concentration  was  not  different  between  the  two 
samples  when  this  was  calculated  per  volume  of  stool  sample  but  it  was  marginally 
significant when it was expressed per kg of dry faecal material (Table 7.15). 
 
Table 7.15: Comparison of water content, faecal pH and ammonia concentration in two serial 
stool samples of healthy children (n=20) 
  First sample 
Median          Range 
Second sample 
Median       Range 
p-value* 
Water content (%)    66.3  59.6  - 84.8    69.8  65.2  - 76.4    0.061 
Faecal pH    6.8  6.0  -  8.0    6.8  5.7  -  7.4    0.538 
Ammonia (mg/lit stool)    1151  641  -5060    1073  447  -1806    0.050 
Ammonia (mg/kg dry stool)    3580  2526  -13130    3755  1797  -5569    0.276 
* One sample Wilcoxon signed rank 
 
7.3.5.3. Changes in faecal SFCA and BCFA concentration  
There  were  no  major  differences  in  the  concentration  of  the  individual  or  total  SCFA, 
between the two serial stool samples. Mean propionate concentration was slightly (p=0.05) 
higher in the second sample. Similarly the molar proportion of isopentanoic and octanoic 
acids were significantly lower in the second sample (Table 7.16).  
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Table 7.16: Comparison of faecal SCFA concentration and proportional ratio in two serial stool samples of healthy children 
  Dry faecal material ( mol/g) 
 
Relative ratio (%)  “Wet” stool sample ( mol/g) 
Subjects 
(n=18) 
First sample  Second sample  p  First sample  Second sample  p  First sample  Second sample  p 
  Median range  Median range    Median range  Median range    Median range  Median range   
Acetate   2312  68.4  - 464.3  248.8  90.3  - 451.7  0.163  65.2  54.2  -73.0  63.5  52.6  -76.9  0.459   73.1  26.9 -103.2   73.3  28.8 -110.4  0.542 
Propionate   41  11.8  -  86.4   58.4  8.7  - 116.5  0.050  11.6   9.3  -18.7  12.7  7.4  -23.0  0.055   14.8  4.6 - 24.3   16.7  2.8 - 36.4  0.055 
Isobutyrate     5.6  0.0  -  13.3    5.2  1.9  -  15.4  0.695   1.9  0.0  -  2.7   1.6  0.4  -  2.6  0.089    1.9  0.0 -  4.7    1.6  0.6 -  5.0  0.258 
Butyrate    51.3  10.9  - 135.5   59.6  8.6  - 130.8  0.223  15.0  7.4  -20.3  14.3  7.3  -27.6  0.862   16.6  3.8 - 30.6   16.6  2.7 - 37.6  0.360 
Isopentanoic     9.2  0.0  -  23.3    8.3  2.7  -  26.7  0.486   3.1  0.0  -  4.8   2.6  0.4  -  4.6  0.033    3.2  0.0-  8.2    2.6  0.6 -  8.6  0.139 
Pentanoic     7.6  0.0  -  17.0    7.7  0.0  -  19.2  0.636   2.4  0.0  -  3.8   2.1  0.0  -  3.3  0.130    2.5  0.0 -  5.9    2.3  0.0 -  6.2  1.000 
Isocaproic     0.0  0.0  -  0.56    0.0  0.0  -  3.4  1.000   0.0  0.0  -  0.2   0.0  0.0  -  0.7  1.000    0.0  0.0 -  0.2    0.0  0.0 -  0.9  1.000 
Caproic     1.6  0.0  -  12.9    1.5  0.5  -  14.8  0.760   0.6  0.0  -  2.4   0.44  0.1  -  2.5  0.794    0.5  0.0 -  3.8    0.5  0.1 -  4.1  0.931 
Eptanoic     0.1  0.0  -  1.6    0.0  0.0  -  2.4  0.563   0.03  0.0  -  0.7   0.0  0.0  -  7.0  0.351    0.04  0.0 -  0.58  0.0   0.0 -  0.8  0.398 
Octanoic     1.8  0.0  -  7.4    1.4  0.0  -  3.6  0.098   0.6  0.0  -  2.0   0.39  0.0  -  1.14  0.045    0.6  0.0 -  2.1    0.4  0.0 -  1.2  0.050 
Total SCFA   353.5 104.0  - 691.5  407.5 117.4  - 651.3  0.177  -  -    114.9 40.8 -171.0  116.3 37.5 -189.1  0.384 
* One sample Wilcoxon signed rank 
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7.3.5.4. Changes in faecal sulphide and lactate concentration 
Free sulphide and the dextrorotatory isomer of lactate differed significantly between the two 
serial samples (Table 7.17). Free sulphide was significantly higher and D-Lactate significant 
lower in the second sample.   
 
Table 7.17: Comparison of total and free faecal sulphide and lactate concentration in two serial 
stool samples of healthy children 
Subjects (n=18)  First sample  Second sample  p-value* 
 
Median Range  Median Range   
Dry faecal material 
     
Free sulphide ( mol/g)    0.38  0.11 -  1.91    0.62  0.19 -  2.3  0.005 
Total sulphide ( mol/g)    1.28  0.0  -  2.91    1.13  0.34 -  2.9  0.794 
D-lactate (mg/100g)    25.1  15.6  -393.6    26.2  14.9  - 54.3  0.965 
L-lactate (mg/100g)    25.2  17.6  -423.8    26.9  11.7  - 44.4  0.695 
Total lactate (mg/100g)    52.7  33.2  -817.4    56.0  32.5  - 80.2  0.794 
D/L-lactate    0.88  [0.8  -  2.6    0.84  0.7  -  2.1  0.055 
Stool sample 
     
D-lactate (mg/100g)    7.8  5.5  - 59.7    7.7  4.8  - 17.3  0.033 
L-lactate (mg/100g)    8.3  6.2  - 64.2    8.6  3.5  - 12.6  0.794 
Total lactate (mg/100g)    16.8  11.7  -123.9    16.7  10.5  - 25.5  0.207 
Free sulphide ( mol/g)    0.11  0.04 -  0.62    0.17  0.06 -  0.54  0.029 
Total sulphide ( mol/g)    0.46  0.0  -  0.98    0.36  0.11 -  0.92  0.408 
 * One sample Wilcoxon signed rank 
 
7.3.6.  Comparison  of  metabolic  activity  between  healthy  children 
and CD children on normal diet 
Faecal  metabolites  of  gut  microbiota  activity  were  compared  between  CD  children  and 
healthy children with no family history of IBD. Due to the substantial effect of EEN on the gut 
microbiota which  was observed in the previous section of this thesis (Section 7.3.3), the 
following study chose to compare only the gut microbiota of CD children whilst on normal diet 
to avoid any confounding effect from the concomitant use of EEN.  
 
7.3.6.1. Recruitment 
For this arm of the study 19 children with CD (13 boys/ 6 girls) and 20 healthy controls (12 
boys / 8 girls) were recruited. The healthy children (9.6; range [4.5-16.9]) were significantly 
younger than the patients with CD (13; range [7.6-15]). The majority of the CD children were 
also participated in the study of the effect of EEN on gut microbiota. Only those children who 
provided a stool sample whilst on normal diet were included. For healthy children the values 
of the faecal bacterial metabolites of two serial samples were averaged. All, apart from three   281 
children, were on concomitant treatment (Table 7.18). No patient was on antibiotics or EEN. 
The  majority  of  the  children  had  elevated  systemic  and  gut  inflammatory  markers  of 
inflammation (Table 7.18). Nevertheless six out of 19 were in clinical remission (PCDAI ≤10). 
 
Table 7.18: Disease activity markers and medical treatment in CD children on normal diet 
Disease markers  Median   Range  Medical treatment  N (%) 
PCDAI    15.0  0.0  -  55.0  Steroids  4 (21%) 
ESR (mm/h)    20.5  3.0  -  55.0  Azathioprine  11 (58%) 
CRP (mg/l)    7.0  7.0  -  69.0  5-ASAs  7 (37%) 
Albumin (g/l)    36.0  20.0  -  41.0  Infiximab  1 (5%) 
Calprotectin (mg/l)  2070  146  -2495  Nutrition supplements  2 (11%) 
    Omeprazole  3 (16%) 
    Methotrexate  2 (11%) 
    Vitamins/Minerals  4 (21%) 
    No Treatment  3 (16%) 
 
7.3.6.2. Differences in water content, faecal pH and ammonia 
No difference in faecal pH was found between CD children and their healthy peers. Faecal 
water and ammonia concentration were significantly lower in CD children (Table 7.19).  
 
Table 7.19: Comparison of water content, faecal pH and ammonia concentration between CD 
and healthy children 
  CD (n=19) 
Median Range 
Healthy (n=20) 
Median; Range 
p-value* 
Water content (%)    73.0  64.2  - 87.2    68.2  58.1  - 77.8  0.041 
Faecal pH    6.8  5.5  -  7.9    6.9  5.9  -  7.6  0.683 
Ammonia (mg/lit stool)     844.9  427.0  -1882.0]  1073.0  544.0  -3200  0.044 
Ammonia (mg/kg dry stool)  3169  1907  -14703  3336  2388  -8509  0.098 
* Mann-Whitney test 
 
7.3.6.3. Differences in faecal SFCA and BCFA concentration 
Compared to the healthy group, total SCFA concentration was significantly lower in the stool 
samples of CD patients. At the individual level butyrate, valeric, caproic and octanoic acid 
were at significantly higher concentrations in the stool samples of healthy children (Table 
7.20). Valeric and octanoic were proportionally higher in the faeces of healthy children but 
this difference did not receive statistical significance. In particular valeric and octanoic acid 
were detected in the stool samples of more healthy children than CD. Thirty seven and 47% 
of  the  CD  children  had  undetectable  amounts  of  octanoic  and  pentanoic  respectively  as 
opposed to 5% and 0% of the healthy children (p=0.003).  
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Table 7.20: Comparison of faecal SCFA concentration and proportional ratio between CD children and healthy children 
  Dry faecal material ( mol/g) 
 
Relative ratio (%)  “Wet” stool sample ( mol/g) 
Subjects  CD (n=20)  Healthy (n=20)  p  CD (n=20)  Healthy (n=20)  p  CD (n=20)  Healthy (n=20)  p 
  Median    Range  Median   Range    Median  Range  Median   Range    Median   Range  Median    range   
Acetate     210.7  106.9 -602.9    227.4  99.4 -458.0  0.789    62.6  48.8  -97.1    64.3  53.4 - 74.1  0.944  56  30.2-132.5  70.4 32.6-101.6  0.106 
Propionate    45.0  9.3 -103.3    49.2  11.5 - 90.8  0.423    13.4  1.9  -23.8    12.0  8.4 - 20.9  0.565  12.9  1.2  - 22.7   15.0  3.8  -  30.4  0.267 
Isobutyrate     5.9  1.6 -  8.6    4.7  2.9 - 14.4  0.148    1.93  0.0  - 3.3    1.75  0.43-  2.69  0.232   1.7  0.0  - 2.95  1.62  0.6  -  4.8  0.944 
Butyrate     29.8  0.0 -138.4    54.2  9.9 -125.3  0.182    11.7  0.0  -24    14.3  7.3 - 21.1  0.222  10.6  0.0  - 30.8   16.4  3.2  -  32.6  0.054 
Isopentanoic     9.1  1.6 - 15.9    8.4  3.4 - 25.0  0.292    2.9  0.0  - 5.9    2.9  0.5 -  4.7  0.279   2.7  0.2  -  5.0  2.7  0.74 -  8.41  0.855 
Pentanoic     0.3  0.6 - 13.9    7.7  0.0 - 18.1  0.023    0.1  0.0  - 4.8    2.41  0.0 -  3.39  0.068   0.16  0.0  -  4.0  2.5  0.0  -  6.1  0.009 
Isocaproic     0.0  0.0 -  0.35    0.0  0.0 -  1.7  0.811    0.0  0.0  - 0.19    0.0  0.0 -  0.38  0.811   0.0  0.0  -  0.1  0.0  0.0  -  0.4  0.789 
Caproic     1.2  0.0 -  2.6    1.6  0.36- 10.3  0.211    0.32  0.0  - 0.78    0.58  0.05-  2.18  0.089   0.32  0.0  - 0.76   0.47  0.09-3.02  0.062 
Eptanoic     0.09  0.0 -  3.56    0.3  0.0 -  1.9  0.684    0.04  0.0  - 0.99    0.06  0.0 -  0.61  0.877   0.02  0.0  - 1.27  0.09  0.0  -  0.67  0.684 
Octanoic     0.7  0.0 -  3.9    1.6  0.4 -  3.7  0.024    0.13  0.0  - 1.53    0.51  0.15-1.07  0.058   0.16  0.0  - 1.27   0.46  0.14 -  1.06  0.015 
Total SCFA     307.0  184.5. -749.8    365.0  134.8 -671.4  0.527  -  -    83.1  50.4-164.8   109.044.2  - 180.0  0.054 
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7.3.6.4. Difference in sulphide and lactate concentration 
Both D and particularly L-lactate in stool samples or dry faecal material of CD children were 
significantly higher than healthy children. Significant differences were found for the fractional 
production of the lactate isomers (Table 7.21). The D to L lactate ratio was significantly lower 
in  stool  samples  of  CD  children  denoting  differences  in  the  pattern  of  isomer  production 
between the two groups. No difference was found for free or total faecal sulphide between 
healthy and CD children (Table 7.21).     
Table 7.21: Comparison of total and free faecal sulphide and lactate concentration between CD 
children and healthy children 
 
CD (n=20) 
Median Range 
Healthy (n=20) 
Median Range  p-value* 
Stool sample 
     
Free sulphide ( mol/g)    0.08  0.02  -  0.64    0.14  0.03  -  0.58  0.099 
Total sulphide ( mol/g)    0.46  0.0  -  1.82    0.43  0.11  -  0.95  0.922 
D-lactate (mg/100g)    9.1  5.1  - 50.7    7.6  5.2  - 33.8  0.090 
L-lactate (mg/100g)   12.5  6.2  - 67.6    8.4  5.5  - 37.2  0.001 
Total lactate (mg/100g)   21.4  11.7  -118.3    16.2  11.1  - 98.0  0.003 
Dry faecal material 
     
Free sulphide ( mol/g)    0.33  0.0  -  1.78    0.46  0.08  -  2.11  0.182 
Total sulphide ( mol/g)    1.45  0.0  -  5.6     1.22  0.4  -  2.9  0.684 
D-lactate (mg/100g)   35.1  16.5  -395.9   24.6  15.2  -210.2  0.044 
L-lactate (mg/100g)   44.8  17.4  -528.3   27.5  17.6  -229.0  0.001 
Total lactate (mg/100g)   77.8  46.1  -924.2   51.9  32.9  -439.3  0.001 
D/L lactate    0.72  0.4  -  2.4    0.86  0.6  -  2.3  0.002 
* Mann and Whitney test 
7.3.6.5. Correlation of faecal bacterial metabolites with disease activity 
markers 
Significant correlations were found between systemic markers of disease activity and the 
faecal metabolites checked (Table 7.22). The BCFA, isobutyrate and isovaleric acid were 
positively  associated  with  CRP  and  ESR  but  no  association  was  found  with  faecal 
calprotectin  (Table  7.22).  A  strong  negative  association  was  found  for  ESR  with  faecal 
acetate  and  a  positive  with  propionate  (Table  7.22).  D  and  L  lactate  were  negatively 
associated with CRP levels and ESR positively with free and total sulphide.  
  Faecal calprotectin expressed per weight of dry faecal material was associated with 
acetate concentration as well as with D but not L Lactate (Table 7.22). A strong positive 
association was found between calprotectin in dry faecal material and faecal water content 
(Table 7.22).  
Only  the  percentage  butyrate  and  heptanoic  differed  significantly  between  the 
patients with active disease (PCDAI>10) and those in clinical remission (PCDAI≤10). Median 
butyrate in dry faecal material  was significantly higher (63 vs 28.3  mol/g; p=0.048) and   284 
heptanoic  significantly  lower  (0  vs  0.473   mol/g;  p=0.032)  in  the  group  of  patients  with 
quiescent disease compared with the children with clinically active disease.   
 
 
 
 
 
 
 
Table 7.22: Spearman rank correlation between gut and systemic inflammatory markers and 
faecal metabolites in dry faecal material in CD children 
Faecal 
metabolites 
CRP  ESR  Calprotectin* 
  R  P value  R  P value  R  P value 
Free sulphide 
(dry faecal  
material) 
0.45  0.081  0.57  0.027     
Total sulphide 
(dry faecal  
material) 
    0.56  0.029     
Acetate (dry 
faecal  
material)  
        0.56  0.020 
% Acetate      -0.71  0.006     
Propionate 
(dry faecal 
material) 
    0.63  0.014     
% Propionate      0.60  0.020     
Isobutyrate 
(dry faecal 
material)  
0.52  0.042  0.54  0.037     
% Isobutyrate       0.50  0.055     
Isovaleric (dry 
faecal  
material)  
0.56  0.031  0.52  0.046     
% Isovaleric      0.49  0.058     
D-Lactate (dry 
faecal 
material)  
-0.49  0.059      0.51  0.037 
L-Lactate (dry 
faecal 
material)  
-0.57  0.028         
Faecal water           0.62  0.010 
* Expressed per kg of dried faecal material 
 
7.3.7. Comparison of faecal metabolic activity between CD children 
and their healthy first degree relatives  
Stool samples were collected from the first-degree relatives of children with CD and were 
compared with samples of CD children on normal diet.   
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7.3.7.1. Recruitment  
For 14 CD children stool samples were collected from their respective first-degree relatives. 
For  the  remaining  CD  children  no  samples  were  provided  by  their  relatives  and  for  two 
children their parents were also sufferers of IBD. One child with CD was excluded due to 
parallel use of antibiotics.  
 
7.3.7.2. Comparison in faecal water content, Faecal pH and ammonia 
Similar to the results observed in healthy control children, the water content in the relatives of 
CD children was significantly lower. Faecal ammonia was significantly higher in the relatives 
of  CD  children.  Faecal pH  was  significantly  higher  in  the  relatives  of CD  children  (Table 
7.23).     
 
Table 7.23: Comparison of water content, faecal pH and ammonia concentration between CD 
children and their first degree relatives 
Variable  CD (n=14) 
Median         range 
Relatives (n=14) 
Median          range 
p-value* 
Water content (%)    72.0  64.2  -  87.2    63.6  51.0  -  74.1  0.001 
Faecal pH    7.0  6.0  -  7.9    7.3  6.6  -  7.7  0.046 
Ammonia (mg/lit stool)   864  427  -1882  1607  1063  -3807  0.001 
Ammonia (mg/kg dry stool)  2989  2179  -14703  4636  2181  -10111  0.016 
* Mann and Whitney test 
 
7.3.7.3. Difference in faecal SFCA and BCFA concentration 
No  substantial  difference  was  found  between  CD  children  and  their  healthy  relatives  for 
butyrate concentration (Table 7.24). In contrast acetate, propionate and isobutyrate and the 
total amount of SCFA, were significantly higher in the dry faecal material of CD children 
compared to their healthy relatives (Table 7.24). Although valeric and caproic acid in “fresh” 
stool  samples  or  dry  faecal  material  did  not  differ  significantly  between  the  groups  (CD 
children & healthy relatives), these were significantly higher in the healthy group when the 
results were expressed as the relative ratio to total quantity of SCFA (Table 7.24). Similar to 
the  patterns  observed  in  healthy  children,  valeric  and  octanoic  acid  were  detected  more 
frequently in the stool samples of the healthy relatives than CD children. Forty-three and 36% 
of the CD children had undetectable pentanoic and octanoic acid respectively as opposed to 
7% of their healthy relatives (relatives p=0.08 for octanoic and p=0.03 for pentanoic).  
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Table 7.24: Comparison of faecal SCFA concentration and proportional ratio between CD children and their healthy first degree relatives 
  Dry faecal material ( mol/g) 
 
Relative ratio (%)  “Wet” stool sample ( mol/g) 
Subjects   CD (n=14)  Relatives (n=14)  p  CD (n=14)  Relatives (n=14)  p  CD (n=14)  Relatives (n=14)  p 
  Median        Range   Median       Range    Median    Range  Median      Range    Median   Range  Median    Range    
Acetate   212.6  110.6  -491.6    124  74.4 -  352.2  0.006  61.2  57.7  - 97.1  66.4  53.7  - 79.3  0.800  58.5 30.2  - 82.3  49.3 27  - 91.4  0.175 
Propionate  43.4  9.3  -  94.8    27.7  6.3  -52.3  0.02  13.9  1.9  - 23.8  12.1  6.0  -17.1  0.260  13.6  1.2  - 22.5  10.4  2.38  - 18.76  0.113 
Isobutyrate    6.0  1.6  -  8.3    4.6  2.0  -  8.1  0.051    2.13  0  -  3.34    2.42  0.8  -  3.38  0.395   1.74  0.0  -  2.95   1.72  0.72  -  2.9  0.836 
Butyrate   38.7  0.0  -138.4    31.1  2.6  -92.3  0.206  12.7  0.0  - 24.0]  11.6  2.8  - 20.2  0.629  11.6  0.0  - 30.8  10.3  0.95  - 23.96  0.323 
Isopentanoic    9.7  1.6  -  14.6    8.0  4.2  -13.1  0.135    3.4  0.3  -  5.7    4.41  1.11-  6.0  0.280   2.7  0.2  -  5.0   2.9  1.45  -  4.9  0.765 
Pentanoic    0.64  0.0  -  13.9    6.3  0.0  -10.2  0.260    0.2  0.0  -  4.13    2.77  0.0  -  3.72  0.026   0.16  0.0  -  4.0   2.0  0.0  -  3.7  0.093 
Isocaproic    0.0  0.0  -  0.35    0.0  0.0   -0.0  1.000    0.0  0.0  -  0.19    0.0  0.0  -  0.0  1.000   0.0  0.0  -  0.1   0.0  0.0  -  0.0  1.000 
Caproic    1.18  0.0  -  2.65    1.64  0.0  -  5.2  0.206    0.31  0.0  -  0.76    1.1  0.0  -  2.77  0.032   0.30  0.0  -  0.76   0.69  0.0  -  1.98  0.103 
Eptanoic    0.0  0.0  -  3.6    0.0  0.0  -  0.68  0.765    0.0  0.0  -  0.99    0.0  0.0  -  0.53  0.800   0.0  0.0  -  1.27   0.0  0.0  -  0.19  0.765 
Octanoic    0.92  0.0  -  3.9    1.52  0.0  -  3.72  0.251    0.3  0.0  -  1.53    0.9  0.0  -  1.53  0.066   0.25  0.0  -  1.28   0.51  0.0  -  1.23  0.141 
Total SCFA   332.6  184.5  -728.3    208.1  94.7-  503.6  0.007  -  -  0.800  91.7 50.4  -128.3  79.4 34.0  -130.7  0.301   287 
 
7.3.7.4. Difference in sulphide and lactate concentration 
No difference between groups was found for free sulphide concentration expressed either 
per g of “fresh” stool sample or “dry” faecal material. Total sulphide in the stool samples of 
the  relatives  of  CD  patients  was  significantly  higher  than  their  offsprings.  However  the 
difference  disappeared  when  results  were  expressed  per  g  of  dry  faecal  material  (Table 
7.25).  
Total and L- lactate but not D-lactate was statistically higher in dry faecal material CD 
children  compared  with  their  healthy  relatives.  No  difference  was  found  when  the  same 
bacterial metabolites were expressed per g of “fresh” stool sample (Table 7.25).   
 
 
 
Table 7.25: Comparison of total and free faecal sulphide and lactate concentration between CD 
children and their healthy first-degree relatives 
Variable  CD (n=15) 
Median         Range 
Relatives (n=15) 
Median        Range 
p-value 
Dry faecal material 
     
Free sulphide ( mol/g)    0.46  0.0  -  1.8    0.33  0.0  -  0.71  0.408 
Total sulphide ( mol/g)    1.54  0.0  -  5.6    1.91  0.0  -  9.0  0.260 
D-lactate (mg/100g)    34.1  16.5  -395.9    22.5  8.5  - 41.7  0.077 
       L-lactate (mg/100g)    45.1*  17.4  -528.3    32.8  18.0  - 61.7  0.051 
Total lactate (mg/100g)    76.5*  46.1  -924.2    55.7  34.6  -103.4  0.020 
D/L lactate    0.69  0.4  -  2.4    0.68  0.3  -  2.1  0.597 
Stool sample 
   
 
Free sulphide ( mol/g)    0.16  0.02 -  0.64    0.11  0.02 -  0.32  0.918 
Total sulphide ( mol/g)    0.49  0.0  -  1.8    0.85  0.19 -  3.35  0.049 
D-lactate (mg/100g)    9.3  5.1  - 50.7    8.5  4.2  - 13.9  0.301 
L-lactate (mg/100g)    13.1  6.2  - 67.6    12.1  6.5  - 20.1  0.535 
Total lactate (mg/100g)    22.3  11.7  -118.3    19.7  14.3  - 33.7  0.241 
*P<0.02 Mann-Whitney compared to relatives 
 
 
7.3.8.  Bacterial  diversity  and  composition  in  children  with  CD  on 
EEN and healthy controls 
All stools collected from children with CD and control children and parents were subjected to 
DNA extraction and PCR-TGGE (Fig 53 & 54). Although a decreasing trend was observed 
there was no statistical significant difference in the total number of bacterial bands between 
samples collected on treatment initiation and those at any time point of the follow up (Fig 55). 
No different patterns were observed between those patients who achieved clinical remission 
and those who did not, nor when patients on antibiotic treatment were excluded. Similar to   288 
the CD children, no statistical significant difference was found in the faecal bacterial diversity 
between two samples collected with at least one-month gap in healthy children. However the 
total number of bacterial bands in the samples of CD children was significantly lower than 
healthy  children  at  all  times  of  follow  up  (Fig  55).  Likewise  stool  samples  from  healthy 
relatives of CD children had significantly less bacterial bands compared with healthy children. 
No such difference was found with their CD offsprings at any time point of the follow up. 
A higher degree of microbiota pattern similarity was observed between the two serial 
stool samples in the healthy children compared with the samples of CD children on EEN. 
Indeed compared with any time point of the observational period, the similarity index of the 
bacterial  pattern  of  the  faecal  microbiota  in  CD  children  was  significantly  lower  than  the 
healthy controls (Fig 56). The similarity index dropped by more than 40% within 15 days of 
start of treatment and remained low during follow up. In contrast, the similarity remained high 
and more than 70% in the healthy children (Fig 56). 
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Figure  53:TTGE bacterial profiles of serial stool samples of CD patients during EEN, on normal diet, and their healthy first degree relatives 
 
 
 
 
A-D: samples during EEN at  0, 15, 30, 60 d; E: 
sample on normal diet; R: relative’s sample; S: 
sibling’s  sample;  Black  R:  reference  bacterial 
scale; L: DNA ladder; Same color samples from   290 
 
 
 
        Figure  54: TTGE bacterial profiles of two serial stool samples of healthy children 
 
 
 
 
A & B: serial samples from the same 
subject; R: reference bacterial scale; 
L: DNA ladder; Neighbouring samples 
with same color: samples from same 
patient   291 
 
Figure  55: Number of gut bacterial bands of healthy children, healthy relatives of CD children. 
and CD children on EEN and normal diet (mean with 95% CI) 
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Figure  56: Percent similarity of gut bacterial composition of healthy children and CD children 
on EEN and on normal diet (mean with 95% CI) 
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7.4. Discussion 
The exact mechanism of the therapeutic action of EEN in paediatric CD remains unknown. 
This in conjunction with robust evidence suggesting an important role of the commensal gut 
microbiota in IBD pathogenesis prompted the researcher to undertake this study. 
Since the initiation of this work in 2004 there have been two studies which looked at 
changes in the bacterial microbiota diversity (531;532).  The study presented here in addition 
to studying micorbiota diversity explored changes in the bacterial metabolic activity of CD 
children during treatment with EEN.  
Taken  as  a  whole  the  findings  of  this  study  are  in  contrast  to  the  statement  by 
Lionnetti and his colleagues (531) for a therapeutic mechanism of EEN action mediated by a 
“prebiotic” effect of the nutritional supplement on the gut microbiota of children with active 
CD.  On  the  contrary,  this  study  reported  significant  deterioration  of  the  colonic  micro-
environment and a substantial increase in the faecal concentration of potentially “harmful”, 
for the colonic health, bacterial metabolites. Indeed these effects were seen solely in those 
patients  whose  intestinal  markers  of  gut  inflammation  decreased  and  achieved  complete 
clinical remission at the end of the treatment course.  
Changes in the metabolic dynamics of the gut microbiota, and mainly fermentation, 
are grossly reflected and assessed by changes in the colonic pH. In the current study faecal 
pH was significantly increased to the alkaline range within 15 days of EEN initiation and 
remained elevated during the entire course of treatment. This first observation pre-predicted 
the significant changes observed in the concentration of acidic, like SCFA, and alkaline, like 
ammonia and sulphide, bacterial metabolites.  
Within 15 days of treatment initiation, butyrate, the colonocytes’ preferred metabolic 
fuel decreased dramatically by 100% and further continued to decrease until the end of the 
treatment  course.  This  was  not  unexpected,  as  the  nutritional  supplement  that  all  
participants received, Modulen IBD, is of low residue content and hence lacks fermentable 
fibre  or  prebiotic  substrates  that  colonic  bacteria  would  ferment  to  SCFA.  This  lack  of 
fermentable substrate in the feeds may have reduced the metabolic activity of the butyrate 
producing bacteria and consequent production of butyric acid. This was also represented by 
the significant reduction in the relative molar concentration of butyrate to the total SCFA pool. 
On the other hand, reduced faecal concentration of butyrate may be an indication of a more 
efficient  absorption  and  utilization  of  butyrate  by  the  colonic  epithelium  following  disease 
improvement. Although the evidence is controversial (622) some studies have proposed that 
butyrate metabolism (426), oxidation (422), and uptake (427) is impaired in the colonocytes 
of  IBD  patients  particularly  during  the  active  phase  of  the  disease  (425).  Thus  a  better 
absorption  and  utilization  of  butyrate  by  the  colonocytes  may  explain  the  reduction  in   293 
butyrate  concentration  during  treatment  only  in  those  patients  who  achieved  clinical 
remission.  
Sulphide  in  its  free  form  as  hydrogen  sulphide  has  been  implicated  in  the 
pathogenesis  of  IBD  primarily  due  to  its  toxic  effect  to  the  colonocytes  and  inhibition  of 
butyrate oxidation (452). Previous research in this area reported a high number of sulphate 
reducing bacteria, increased faecal concentration and rate of hydrogen sulphide production 
in UC patients (458) but overall the results are contradictory (406;457). In contrast to that and 
expectations for a reduction in the faecal sulphide levels during treatment with EEN, this 
current  study  reports  a remarkable  increase  in the faecal  concentration  of total sulphide. 
Although the free fraction of faecal sulphide, hydrogen sulphide, did not change during the 
course of treatment, bound sulphide in the form of salts with divalent metals significantly 
increased  within  two  weeks  of  treatment.  A  seven-fold  increase  was  observed  despite 
improvement in the disease activity and colonic inflammation. This could be attributed to the 
increased  metabolic  activity  of  sulphate  reducing  bacteria  in  the  presence  of  abundant 
sulphur containing substrate (623) and an increase in the gut transit time (468). Modulen IBD 
is a nutritional supplement rich in protein and fortified with divalent metals in the form of 
sulphate  salts  (Appendix).  Ferrous  sulphate,  manganese  sulphate,  zinc  sulphate,  copper 
sulphate, are added in order to increase the nutritional value of the feeds and may actually 
offer  abundant  fermentative  substrate  for  the  sulphide  reducing  bacteria  (468).  Sulphate 
reducing  bacteria  may  utilize  sulphate  anions  and  subsequently  increase  faecal  sulphide 
concentration. 
It was a paradoxical finding that disease improvement coincided with the increase of 
total sulphide. This may imply that either sulphide is not implicated in the tissue injury in CD, 
as proposed by others (406;457) or that the biological importance of the bound compared to 
free sulphide is different. Moreover recent studies have now revised the role of sulphide in 
gut physiology (408) and current evidence suggests that it can be a potent, endogenous anti-
inflammatory substance, modulating leukocyte-endothelial adhesion and leukocyte migration 
in the gut (466). Fiorucci et al (466) recently found that a sulphide reducing derivative of 
mesalamine was more effective than standard mesalamine in reducing the severity of colitis 
in  an  animal  model  by  reducing granulocyte  infiltration  into  the  colonic  tissue  as  well  as 
reducing the expression of mRNA for several key proinflammatory cytokines. A new era for 
the role of sulphide in IBD may be emerging. 
No  significant  changes  were  observed  for  the  bacterial  metabolites  of  protein 
metabolism  like  BCFA,  ammonia  and  C5:C8  SCFA. We  anticipated  seeing  an  increased 
bacterial proteolytic activity in the absence of non-digestible carbohydrates in the feeds, and 
fermentation of amino acids that escaped absorption in the upper digestive tract. However no   294 
such change was observed and the results may indicate that absorption of amino acids is 
efficient in the upper digestive tract and no significant residual protein reaches the colon.  
Faecal lactate was relatively high on treatment initiation and significantly decreased 
during  treatment  in  the  group  of  patients  who  clinically  improved.  D  and  L  lactate  are 
metabolic  products  of  bacterial  fermentation  that  are  further  metabolized  to  butyrate  and 
acetate  (400)  and  they  occur  only  in  low  concentration  in  the  healthy  colon.  High 
concentration  of  lactate  may  denote  malabsorption  in  the  small  intestine  and  increased 
availability of carbohydrates in the ileum, which are further fermented to lactate by the lactic 
producing  bacteria.  Increased  L-lactate  levels  have  been  observed  in  inflamed  colonic 
mucosal (421;434) and have been implicated in disease activity previously (421;434) but we 
suggest that this is not of causative association but an epiphenomenon of malabsorption, 
reduced gut transit time and diarrhoea (434;624). Indeed in the current study faecal water 
content  was  strongly  associated  with  lactate  concentration  (data  not  shown)  and  was 
significantly higher in the patients with watery diarrhoea.  
The  use  of  molecular  biology  fingerprinting  techniques  in  this  study,  allowed 
characterization of changes of the intestinal microbiota during treatment with EEN, which 
was  independent  of  the  drawbacks  of  the  traditional  microbiology  culture  media.  No 
significant changes were observed in the diversity of the gut microbiota of CD children during 
treatment  on  EEN.  An  unstable  faecal  microbiota  was  found  during  treatment  and  the 
average similarity between any time points of the follow up was significantly lower than the 
similarity index in the healthy children. These findings are in accordance with the findings by 
Leach et al (532) and agree with adult IBD studies which found that commensal microbiota in 
IBD  is  unstable  over  time  and  is  characterized  by  low  bacterial  diversity  (504;523). 
Comparison of these findings with those by Leach et al (532) is difficult as the authors did not 
report pairwise changes in bacterial similarity and diversity changes during EEN treatment. 
This is surprising in a follow up study. On the other hand this study did not replicate the 
results  by  Leach  et  al  (532)  of  a  similar  bacterial  diversity  with  healthy  controls  at  the 
beginning of treatment. In fact it was observed that bacterial diversity was consistently lower 
than healthy controls at all time points of the observational period. This different result may 
be due to differences in methodology (DGGE vs TTGE, extraction DNA with spin column vs 
beat beater) or the small sample size and lack of statistical power. 
The molecular biology used to characterize the intestinal microbiota, although robust, 
can only assess changes in the composition and diversity of the intestinal microbiota without 
allowing for identification of changes in specific species. For this, other molecular techniques, 
such  as  cloning  and  sequencing,  are  required  for  group  specific  bacteria  (532).  This 
technique is laborious, expensive and no resources were available to conduct this during this 
PhD.  Alternatively  changes  in  selective  bacteria  can  be  assessed  using  other  molecular   295 
biology  techniques,  such  as  FISH  which  identify  bacteria  by  using  species  specific 
fluorescence probes (340). Although it was among the aims of this study to assess changes 
using FISH analysis, and hence samples were prepared for such analysis, lack of resources, 
and shortage of time did not allow it.  
On the other hand although significant changes in the diversity of microbiota were not 
observed during treatment with EEN, the method used in this study can characterize only the 
dominant microbiota of the digestive tract, which essentially occurs in  more than 10
6-10
7 
bacterial per g of faecal material. Therefore our knowledge for changes in the diversity of 
subdominant  species  remains  unknown.  Moreover  faecal  microbiota  is  at  the  best  an 
abstract  of  the  mucosal  associated  microbiota  (346)  and  different  changes  may  have 
occurred  at  the  bacteria  adherent  to  the  gut  lining.  However  a  study  with  multiple  serial 
mucosal biopsies within a short period of two months might be unfeasible and unethical.  
Although it was not a primary outcome, part of this project studied differences in the 
gut microbiota diversity and metabolic activity between CD children, their healthy first-degree 
relatives, and healthy children with no family history of IBD. Prior to the current study the 
faecal concentration of SCFA in CD children had been reported in a single study 15 years 
ago (417). In contrast to this previous report, which reported increased levels of butyrate in 
children  with  CD,  this  current  study  found  that  total  faecal  SCFA  and  butyric  acid  were 
significantly  lower  in  CD  children  compared  to  their  healthy  peers.  Nevertheless  this 
difference disappeared when results were expressed per mass of dry faecal material. This 
suggests that high faecal water content and diarrhoea in patients with CD may explain the 
different results with Treem et al (417). Alternatively, adherence to a diet low in fibre, which is 
commonly followed by IBD patients (545) and as in the IBD population this study recruited 
(625),  in  order  to  avoid  symptom  exacerbation,  might  explain  the  lower  concentration  of 
SCFA in CD patients.  
CD children had significantly lower levels of faecal pentanoic and octanoic acids than 
healthy controls and in fact a substantial proportion of them had undetectable levels. Little is 
known about the biological significance of SCFA longer length than butyrate such as valerate 
(C5) and caprylic (C8) acid, although antimicrobial properties against enteropathogenic E. 
coli bacteria have been described for some of them (626). On the other hand, increased 
production of these metabolites may be a random finding or in conjunction with the increased 
levels  of  ammonia  observed  in  healthy  children  may  denote  increased  proteolytic 
fermentation due to excessive consumption of dietary protein in modern healthy children. 
This, in parallel with an inadequate dietary intake in children with IBD, may explain these 
findings.  Moreover  carbohydrate  fermentation  and  SCFA  production  tend  to  occur  at  the 
ascending colon whereas protein fermentation and production of iso-carbonic acids and C5-
C8 carbon SCFA occurs in the descending colon (367). Fast transit time and diarrhoea in   296 
active CD may limit protein fermentation in the distal colon (367), and perhaps explain the 
significantly low  levels  of these bacterial metabolites compared with the healthy controls. 
Fast intestinal transit time and malabsorption may also explain the higher concentration of 
faecal lactate in CD children compared to the healthy cohort.  
In accordance to the findings by Treem (417) this study did not observe any major 
differences in SCFA with disease activity. The higher concentration of butyrate and a lower 
concentration  of  heptanoic  found  in  patients  with  quiescent,  compared  with  those  with 
clinically active disease, may be related to differences in water content and gut transit time 
between groups (627).  
To  the  best  of  our  knowledge  this  is  the  first  study  that  compared  the  intestinal 
microbiota of CD patients with that of their healthy first-degree relatives. Environment, diet 
and genes are strong determinants of the bacterial composition and metabolic activity and 
this  study  enrolled  healthy  relatives  of  CD  children  to  control  for  that.  Total  acetate, 
propionate,  isobutyrate  and  hence  total  SCFA  were  significantly  higher  in  the  dry  faecal 
matter  of  CD  patients.  Malabsorption  of  macronutrients  in  the  small  bowel  may  have 
increased  the  availability  of  fermentable  substrate  in  the  large  bowel  and  consequently 
increased the production of SCFA. On the other hand, age dependent differences in the 
bacterial metabolic activity (628) may explain some of the differences observed between CD 
children and their healthy relatives although these have been reported for subjects older than 
70 years old (628). To the best of our knowledge none of the healthy relatives were over 70 
years of age. Similar to healthy children a higher proportion of CD children had undetectable 
levels of pentanoic and octanoic. These may indicate differences in the metabolic activity of 
the bacterial microbiota or rapid transit time in CD patients which limits the fermentation of 
proteins at the distal colon (367).  
Another interesting finding of the current study was the low diversity of the faecal 
microbiota observed in the relatives of CD patients. Although no difference was found with 
the  CD  patients,  the  bacterial  diversity  was  significantly  lower  than  healthy  children. 
Differences in age between groups may not allow a straightforward comparison with healthy 
children.  However  there  is  very  limited  data  on  the  effect  of  age  on  bacterial  metabolic 
activity and diversity, and mostly relates to very young infants or toddlers. A comparison with 
a cohort of healthy adults will show whether bacterial diversity is reduced in family members 
of patients with CD.    
Although this study was initially powered to detect a 40% change in butyrate (417) a 
more than a 120% decrease was observed and therefore the study achieved significance 
even  with  a  smaller  number  of  patients.  However  it  may  lack  power to  detect  significant 
differences  in  other  parameters  this  study  assessed,  like  changes  in  the  diversity  and 
composition of the dominant microbiota. Lack of power is common in this type of research   297 
where long and large recruitment are required. With an intended recruitment sample size of 
40 children within 1½ years 21 children on CD were enrolled within approximately two years. 
Although more than 60 children started on treatment in the same period only half of them 
were  approached.  Recruitment  on  the  day  of  disease  diagnosis,  the  restrictive  type  of 
treatment  and  in  particular  the  type  of  collected  sample  significantly  decreased  out 
recruitment success, and increased significantly recruitment period. On the other hand due to 
the unpredictable course of the disease, many participants had either to stop treatment, or to 
introduce other treatments. This reduced the number of patients used in the final analysis.  
The type  of  the  analysis  conducted  and the  effect  of  the  time  on the metabolites 
measured did not allow to use ‘old’ samples. According to the protocol of this study it was 
expected that most of the samples would be collected during the routine hospital visits of the 
patients.  However  just  eight  out  of  the  approximately  187  samples  were  brought  to  or 
collected in the clinic. The remaining samples were collected within four hours of defaecation 
at any time (3 am earliest to 11:30 pm latest) and any place convenient to the participants 
(maximum distance 60 miles), 24 hours, seven days a week. Despite these difficulties and 
the discomfort this caused this study managed to recruit twice as many subjects than any 
similar previous report (531;532). Moreover using vigorous methods of sample collection and 
preservation samples were processed soon after collection ensuring rigorous and reliable 
findings. 
As  this  study  recruited  new  patients  along  with  children  in  clinical  relapse,  many 
patients had received recent bowel preparation. That was inevitable and although it may 
have imposed an important confounding factor in study results, no differences were observed 
between children who had a recent colonoscopy and those who did not. The exclusive nature 
of the treatment on the other hand is an advantage of this study as it assessed only the effect 
of the treatment and results were not confounded by other dietary intake.  
In conclusion the findings of this study oppose the speculation by Lionetti et al (531) 
for  a  mechanism  of  EEN  action  in  paediatric  CD  mediated  by  a  prebiotic  effect  of  the 
nutritional supplement. Indeed results show that in those patients achieved remission, EEN 
induced an “unfriendly” for the colon, luminal microenvironment, with reduced availability of 
metabolic fuels for the colonocytes, and increased production of potent harmful substances 
for the colonic health. Moreover in light of the remarkable effect on EEN on gut metabolism, 
future studies of bacterial metabolic activity in IBD, should consider carefully the recruitment 
of  patients  on  oral  artificial  nutritional  support,  in  the  same  way  as  with  the  usage  of 
antibiotics.  
Relating the effects of changes in the concentration of faecal metabolites to events in 
the colon is not straightforward. It is difficult to know whether these effects have a causative 
association  or  they  are  simply  epiphenomenon.  Many  factors  can  affect  the  luminal   298 
concentrations of faecal metabolites that are difficult to distinguish. Changes in production 
rate (458), gut mobility (468;627), malabsorption, luminal conditions (401) or impairment in 
metabolism and absorption  make interpretation of the results a difficult task.  
On the other hand it is not possible to be sure whether the changes observed were 
disease specific and do not happen in healthy children too. Comparison with a parallel cohort 
of  healthy  children  on  treatment  with  the  same  dietary  regime  will  better  answer  this. 
However  such  a  study  is  unethical  to  conduct  in  healthy  children.  Previous  studies 
summarized by Whelan et al (529) found a significant decrease in the concentration of total 
SCFA and butyrate in healthy human subjects.  
The current study offers substantial insight on the effect of EEN on the metabolic 
activity and gut microbiota of CD children. The initial scope of this project was to use this 
baseline data to conduct a RCT on the use of a prebiotic or synbiotic supplement in parallel 
with EEN. The findings of this study encourage such a trial although the anticipated outcome 
is ambiguous. If the observed effects are the inevitable result of a lack of non-digestible 
carbohydrate  in  the  EEN  feeds,  improvement  of  colonic  health  with  synbiotic  (pre  and 
probiotic) therapy (324) may improve the clinical efficacy of the treatment. On the other hand 
if  reduction  of  butyrate  and  a  high  colonic  pH  mediates  the  therapeutic  effect  of  EEN, 
addition of a synbiotic supplement could potentially be harmful. This has to be addressed 
with a clinical trial or in-vitro studies with colonic biopsies.      299 
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8.1. General discussion and conclusions 
Since  I  finished  my  first  degree  in  nutrition  and  dietetics  in  1999,  I  have  always  been 
interested in the importance of nutrition in diseases of the alimentary tract. Then it was the 
important role of the dietitian in the clinical management of the paediatric patient with IBD 
that motivated me to undertake this PhD. This is because nutrition is implicated in all aspects 
of the disease:  
a)  Disease pathogenesis with dietary risk factors predisposing disease onset. 
b)  Management  of  active  disease  with  nutritional  therapies;  EEN  being  the  primary 
treatment for paediatric CD patients. 
c)  Overall health, nutritional status, and growth of the patient.  
Although the primary aim of this thesis was to study the effect of EEN on the commensal 
microbiota composition and metabolic activity, for several reasons outlined below I had the 
opportunity to explore other aspects of the nutrition in paediatric IBD. Thus this thesis would 
be better presented as a compilation of research on nutritional aspects in paediatric IBD.  
Although  the  prevalence  of  juvenile  onset  of  CD  is  high  in  Scotland  (16),  it  still 
remains an uncommon GI disorder with a frequency of 20-25 new cases per year in a busy 
paediatric tertiary hospital like the one in which this PhD took place. This did not allow easy 
recruitment of a large number of patients and inevitably prolonged recruitment duration much 
beyond the initial expectations of this study. Moreover due to ethical constraints this study 
did not recruit newly presented patients before their disease diagnosis had been medically 
confirmed.  As  a  result  the  majority  of  patients  were  approached  on  the  same  day  of 
diagnosis, soon after the end of their endoscopy, and before the patients were discharged! 
This  resulted  in  many  patients  being  missed  or  not  being  appropriate  for  recruitment.  In 
addition, the incurable and chronic nature of the disease and the restrictive dietary regime 
was upsetting for the majority of families and patients, and resulted in many children refusing 
to participate. Finally the collection of stool samples was not pleasant. For all these reasons 
recruitment had to be extended from one year to 2 ½ years. This in conjunction with the 
uncertainly  of  recruitment  and  possible  patient  dropout  gave  time  for  the  researcher  to 
develop parallel projects. Four of these six projects were presented in this thesis. Two other 
projects, which were conducted at the same time, were not included. 
In summary the aims of the studies that comprise this PhD were: 
1.  To assess the prevalence and predictors of use of dietary modifications, nutritional 
supplements and alternative medicine in paediatric patients with IBD. 
2.  To investigate the prevalence and predictors of anaemia in paediatric IBD patients. 
3.  To investigate the effect of EEN on  
a.  Gut specific and systemic markers of disease activity   301 
b.  Gut microbiota diversity and metabolic activity 
c.  Body composition, and circulating micronutrients in children with CD 
4.  To compare  
a.  The  validity  of  the  body  composition  method  used  in  some  of  the  studies 
described in this thesis against a reference method 
b.  The  body  composition  of  CD  children  with  a  cohort  of  healthy  Scottish 
children. 
 
Prevalence  and  predictors  of  use of  dietary  modifications,  nutritional  supplements 
and alternative medicine in paediatric patients with IBD 
In agreement with previous studies in adult populations with IBD (63;68;70;536), this study 
described  a  high  use  of  dietary  modifications,  nutritional  supplements  and  alternative 
medicine in paediatric patients with IBD. Probiotic use was the most predominant form of 
unconventional treatment by both the current and past users.  
Although  the  majority  of  the  nutritional  therapies  that  the  respondents  of  the 
questionnaire used have good safety records, this study shows that patients supported and 
used  alternative  treatment  options,  which  they  did  not  declare  to  their  doctors.  This  has 
important  clinical  applications  as  some  of  them  may  present  adverse  effects  (77),  may 
interfere with the action of conventional treatment and the avoidance of specific food groups 
or adherence on special diets can compromise the long-term health and nutritional status of 
the patients. A prime example is the use of dairy free diets, which can negatively affect the 
already vulnerable bone health of IBD children. Similarly exclusion of high fibre/residue foods 
in order to avoid exacerbation of GI symptoms can reduce the production of butyrate from 
the colonic microbiota and simultaneously increase the action of proteolytic bacteria. This 
could possibly induce an unhealthy luminal environment and lack of energy substrate to the 
colonocytes. This may also explain the low faecal butyrate concentrations observed in this 
and other studies (419).  
Therefore  medical  and  health  professional  staff  responsible  for  the  care  of  these 
patients  should  ask  and  record  the  use  of  unconventional  therapies  and  this  must  be 
integrated in the standard clinical review of the patient.  
Although  the  sample  size  was  relatively  small  this  study  managed  to  recruit  the 
majority  of  patients  of  a  representative  IBD  population  and  to  achieve  an  excellent 
compliance rate. The stringent recruitment process this study followed ensured anonymity 
and perhaps undistorted responses. Although a limitation of this study would be the lack of a 
cohort of healthy children to compare with the results of the IBD children this was overcome 
this by asking parents of IBD children for details of their use of unconventional treatment   302 
prior to disease onset, and the questionnaire was specific to the use of remedies exclusively 
for the management of IBD.  
Among  the  main  reasons  this  study  was  carried  out  was  to  assess  the  use  of 
probiotic  supplements.  It  was  the  intention  of  the  researcher  to  use  this  information  to 
support the design of a clinical trial on the use of probiotic/prebiotic supplements in the same 
paediatric population. The findings of this study can now justify an intervention study with the 
systematic use of probiotic supplements in a population that is already receiving them and 
supports their use.  
Several studies have been conducted on the composition and diversity of the colonic 
microbiota in IBD patients (Section 1.7.2.3.4). Although most of these considered patients’ 
use of antibiotics, they rarely described or commented on the use of probiotic supplements. 
In  light  of  these  results,  and  the  established  effects  of  probiotic  organisms  on  the  gut 
microbiota and metabolism, future studies in this field should question eligible patients about 
probiotic use.  
It is difficult to compare the results of this study with previous reports and to assess 
temporal changes in the use of unconventional treatments as the definition unconventional 
medicine and the types of therapies used varies considerably among the studies. Only a 
study using the same questionnaire in the same population will allow assessment of temporal 
changes in the use of unconventional medicine by children with IBD.   
Moreover, with the increasing use of CAM reported in this and previous studies (see 
Section 1.2.2), and the positive attitude of parents and patients to them, more high quality 
and clinical trials are needed to establish their efficacy and to better inform parents, patients 
and medical staff.  
 
Prevalence and predictors of anaemia in paediatric IBD patients 
Anaemia is an extraintestinal manifestation in IBD. Although its prevalence is well described 
in adult IBD studies, in paediatrics the evidence comes from a limited number of reports with 
significant methodological flaws (see Section 1.4.4). 
Using  age  and  gender  appropriate  cut  offs  to  define  anaemia,  it  was  found  that  its 
occurrence was high in a large population of paediatric patients with IBD and higher than 
previous adult reports (229). Disease severity and underweight were the strongest predictors 
of anaemia incidence at diagnosis and their improvement at follow up, correlated with parallel 
improvement  in  the  concentration  of  haemoglobin.  Knowledge  of  predictors  of  anaemia 
incidence at diagnosis and at follow up may avert early onset and accelerate its resolution at 
follow up.  
This  study  failed  to  find  a  treatment  that  was  associated  with  improvement  or 
deterioration of haemoglobin levels at one year of follow up. In particular it was postulated   303 
that nutritional replenishment on treatment with EEN would be associated with improvement 
of haemoglobin levels at follow up but the results of this study failed to confirm this. It is 
possible that the retrospective design of the study, that correlated the use of EEN at any time 
point over a 12-month period with changes of haemoglobin levels at 12 months, was not an 
appropriate  method  to  detect  any  potential  short-term  effects  of  EEN  on  the  patient’s 
haematology profile. Nevertheless neither did haemoglobin levels improve significantly in the 
prospective longitudinal study in this thesis (Chapter 5), which assessed the effect of EEN on 
circulating micronutrient status. Unfortunately this study had a small number of participants 
and therefore may be underpowered. A larger prospective study is needed.  
A strong positive correlation was found between CRP and serum a ferritin level, which is 
consistent  with  the  evidence  that  suggests  that  serum  ferritin  is  a  positive  acute  phase 
respondent. This implies that the diagnostic value of serum ferritin to assess body iron stores 
can be misleading in the presence of a systemic inflammatory response and this should be 
considered  by  the  medical  staff  responsible  for  the  care  of  these  patients.  In  particular, 
discrimination between the different types of anaemia, and mainly between IDA and ACD, 
cannot rely solely on these markers, and other serological indices with better predictive value 
should be used.  
Despite the retrospective design of this study, it was found that iron therapy is indeed a 
valuable option in the treatment of anaemia in paediatric IBD, although it can exacerbate GI 
symptoms  in  patients  and  animal  studies  (236)  and  may  increase  the  risk  for  colonic 
carcinogenesis. For those patients who do not improve on treatment with oral iron, the use of 
alternative treatment options such as intravenous iron sucrose and erythropoetin are needed. 
As  ACD  pathogenesis  is  attributed  to  the  action  of  inflammatory  cytokines  (231),  future 
studies  should  address  whether  the  use  of  anti-inflammatory  agents,  which  avert  the 
activation  or  propagation  of  the  pro-inflammatory  cytokine  cascade,  can  improve 
haematological profiles. 
Although  a  proportion  of  the  patients  improved  at  follow  up,  some  deteriorated  and 
became anaemic. Future research should be focused on this patient group to find predictors 
and modifiable factors that could prevent anaemia onset with early intervention.  
Anaemia  in  IBD  can  be  attributed  to  many  factors  with  the  most  important  being  GI 
bleeding. Although a diet poor in iron should be considered too, there is not good evidence to 
support that in paediatric IBD patients. Future studies in an IBD population should assess the 
dietary iron intake of these patients. An iron balance study could be designed where the 
equilibrium of iron will be monitored to accurately assess intake, use, and GI losses. A study 
which assesses the dietary intake of IBD patients and patients with other GI disorders has 
been designed by the researcher of this PhD and is ongoing.  
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The effect of EEN on gut specific and systemic markers of disease activity 
Improvement in the clinical activity and systemic inflammatory markers occur within a few 
days  on  treatment  initiation  on  EEN  although  they  may  not  both  be  sensitive  or  specific 
enough  to  reflect  intestinal  inflammation  and  mucosal  healing.  New  faecal  markers  of 
intestinal inflammation are now available with good diagnostic value to discriminate between 
organic and functional GI disorders. Faecal calprotectin levels was measured in the majority 
of patients at the time of their colonoscopy and the results showed that this correlated well 
with serologic markers of inflammation and presented a 100% sensitivity to identify patients 
with mucosal inflammation. On the contrary CRP and ESR were within the normal range for 
a substantial proportion of patients despite evident endoscopic and histological inflammation. 
This study for first time measured changes in faecal calprotectin levels during treatment 
with  EEN  and  correlated  changes  with  clinical  response  to  the  treatment.  Although  the 
majority  of  the  patients  improved  clinically  and  their  systemic  inflammatory  markers 
decreased,  only  in  those  patients  who  achieved  complete  clinical  remission,  did  faecal 
calprotectin levels decrease. This may indicate that improvement in clinical activity does not 
parallel changes in intestinal inflammation unless full clinical remission is achieved. This may 
also imply that complete clinical remission is achieved only in those patients whose intestinal 
inflammation attenuated. Nevertheless even in the patients who entered clinical remission, 
calprotectin  decreased  to  within  the  manufacturer’s  normal  reference  values  in  only  one 
patient.  This  may  indicate  that  there  is  still  subclinical  intestinal  inflammation  despite 
induction  of  clinical  remission  or  that  improvement  in  clinical  symptoms  preceded 
improvement of intestinal inflammation. Perhaps there is a faecal calprotectin concentration 
cut off below which clinical symptoms of inflammation are quiescent. This should be explored 
in a future study.  
Although recent studies (612) have shown that calprotectin levels can predict disease 
exacerbation this study did not explore that, and in particular whether calprotectin levels at 
the end of treatment on EEN can predict a subsequent flare up. This has to be addressed in 
a future study. If this is the case then the decision to terminate or prolong EEN treatment 
duration may depend also on changes in markers of GI inflammation beyond improvement in 
clinical activity.  
A  secondary  outcome  of  this  study  was  that  a  high  number  of  healthy  first-degree 
relatives  with  CD  have  considerably  high  levels  of  calprotectin.  This  has  been  reported 
previously  in  the  literature  (614)  and  further  studies  should  monitor  these  individuals  to 
confirm whether they are at a high risk of developing GI inflammatory conditions.  
Strength of this study was the methodology followed to obtain stool samples and analyze 
faecal calprotectin. All samples were collected within four hours of defaecation, the whole 
bowel movement was homogenized, and all specimens from the same patient were analyzed   305 
in duplicate on the same ELISA plate to avoid inter-assay variability. A limitation was the 
small number of participants and thus the results should be interpreted cautiously.  
 
The effect of EEN on body composition and circulating micronutrient levels. 
Reduced dietary intake, malabsorption, increased energy requirements, and the action of 
pro-inflammatory  cytokines  have  all  been  implicated  in  the  undernutrition  and  growth 
retardation seen in paediatric IBD patients (Table 1.3.1).  
This  study  assessed  the  nutritional  status  of  CD  children,  using  body  composition 
assessment  and  circulating  micronutrient  levels  and  explored  how  these  changed  on 
treatment with EEN. The results of this study agreed with previously published evidence that 
anthropometry is negatively affected in paediatric patients with CD (33;82). Underweight and 
growth failure were proportionally higher in CD patients compared with a cohort of healthy 
children. An interesting outcome of this study, which highlights the importance of using body 
composition assessment, is that FFM but not FM increased during EEN treatment only in the 
group of patients who achieved clinical remission. In those patients who did not enter clinical 
remission no significant changes in total body composition were observed. Use of BIA as a 
body composition assessment method may lack of validity as was found in another study of 
this thesis (Chapter 4) and therefore the results of this study should be confirmed by more 
accurate body composition reference methods such as the four compartment model (556). If 
these  results  are  replicated  then  FFM  replenishment  should  be  further  explored  as  a 
potential  mechanism  mediating  induction  of  clinical  remission.  This  is  also  supported  by 
recent evidence that suggested suppressed proteolysis and increasing protein synthesis with 
nutritional therapy in children with inactive CD (333). 
Suboptimal levels of circulating micronutrients have been described in adult patients with 
IBD (100;180), and this paediatric study is in accordance with that. Most of the antioxidant 
vitamins  and  trace  elements  measured  were  lower  than  the  laboratory  reference  range. 
However none of the patients developed clinical symptoms of deficiency although this study 
did not specifically look at that. Some authors linked suboptimal antioxidant system with the 
aetiology of intestinal injury (141), but we suggest that this is an epiphenomenon of the acute 
phase  response.  Upon  increase  of  CRP,  in  inflammatory  conditions  and  infection, 
redistribution  of  many  micronutrients  takes  place  in  the  human  body  compartments,  and 
therefore  serum  measurements  are  not  reflective  of  the  actual  body  stores.  A  lack  of  a 
causative association between inflammation and micronutrient status is further supported by 
the  lack  of  association  found  between  the  serum  micronutrient  levels  and  gut  specific 
markers of inflammation (calprotectin). We suggest that other indices of body micronutrient 
status should be used in patients with acute phase response in order to assess the actual 
body stores. Measurements in red blood cells are a potential surrogate index, as they are not   306 
influenced  by  the  acute  phase  response.  Such  a  study,  measuring  micronutrients  in 
erythrocytes, is required to reliably answer the question whether body micronutrient stores 
are low in children with CD and whether this is associated with intestinal inflammation.  
An interesting finding of the second part of this study is that nutritional therapy with EEN 
improved  the  circulating  levels  of  several  micronutrients  but  the  serum  carotenoid 
concentrations deteriorated with more than 90% of the patients being biochemically depleted 
at  the  end  of  treatment.  This  is  a  surprising  result  contrary  to  expectations.  Carotenoid 
concentration was predicted to increase firstly due to nutritional replenishment, and secondly 
because of the resolution of the inflammation and reversal of the serum levels of carotenoids 
(which  are  negative  phase  respondents)  to  higher  levels.  Instead  carotenoids  further 
deteriorated at the end of treatment, which may indicate increased metabolism, due to the 
increased oxidative stress in patients with IBD, and/or poor replenishment from the nutritional 
supplement. Indeed the nutritional supplements that the patients received in all cases lacks 
of carotenoids. Considering the importance of an effective antioxidant system in health and in 
mucosal injury in IBD, these results may have implications in the industrial production of 
artificial feeds. Depletion of antioxidant micronutrients may compromise the body’s defensive 
mechanisms  and  increase  oxidative  stress  and  damage  of  biological  macromolecules. 
Unfortunately this study did not measure the serum levels of oxidative stress markers like 
malondialdehyde, and therefore it is not possible to comment whether treatment with EEN 
impaired the antioxidant defensive mechanisms. If this is the case supplementation or the 
feeds with antioxidants may be required and perhaps increase the clinical efficacy of the 
treatment given the important role of antioxidants in IBD.  
Similar to the cross-sectional data on the circulating micronutrient status of children with 
CD, the changes in the level of some of the micronutrients observed are difficult to interpret. 
Improvement in the levels of some of the micronutrients may be a combined effect of the 
nutritional replenishment, resolution of the acute phase response, and less consumption with 
improvement of disease activity. The use of other markers of micronutrient body stores may 
facilitate the interpretation of these results. The results of this study triggered the researcher 
to  continue  this  study  and  explore  changes  in  the  levels  of  the  same  micronutrient  in 
erythrocytes. 
A limitation of this study was the small number of participants, which is frequently seen in 
investigations  in  uncommon  diseases.  Moreover  collection  of  blood  samples for research 
purposes were only allowed as an extra amount collected during routine blood samples of 
the patient. It was deemed unethical to venupuncture children for research purposes only 
and therefore, some blood samples were missed from patients who were not due to give 
routine clinical bloods. As this study was supplementary to the main project of the effect of   307 
EEN on gut microbiota, recruitment was hampered by the fact that many patients did not 
want to participate in the arm of study, which involved the collection of stool samples. 
 
Comparison  of  body  composition  assessment  in  healthy  children  with  leg  to  leg 
bioelectrical impedance and DXA analysis 
An additional experimental chapter of this work compared two methods of body composition 
in healthy children (Chapter 4). One of them is a common reference method to assess bone 
mineral content and body composition and the other one a novel bedside body composition 
analyzer suitable for routine measurements. The overall results of this part of the thesis do 
not  suggest  that  the  validity  of  the  new  bedside  equipment,  using  the  manufacturer’s 
equation is as good as the reference method at individual level, and thus the results in the 
studies this used should be interpreted bearing that in mind. Manipulation of body impedance 
values in a way that would be independent of the manufacturer prediction equations may be 
better and the most reliable way to use BIA. Recently lean and fat index norms have been 
developed that use bioimpedance measurements and classify children as having relatively 
high, average or low fatness and leanness independently (587). On the other hand although 
BIA may not be accurate to precisely assess body composition its use to assess longitudinal 
changes in follow up studies, like those presented in this thesis, may be more reliable. Its 
sensitivity to detect changes in body composition should be addressed with follow up studies 
measuring  body  composition  with  BIA  at  different  intervals  and  comparing  it  with  other 
reference methods. 
Although  this  chapter  seems  to  be  unlinked  from  the  rest  of  the  thesis,  it  gave 
important  information  on  the  accuracy  of  a  quick  method  to  assess  body  composition  in 
healthy children. A subsequent study should be planned to check the accuracy of the same 
method in a paediatric cohort of IBD children. The results of a respective study will be useful 
in  clinical  practice  and  may  help  the  transition  from  recordings  of  anthropometric 
measurements to the actual evaluation of body composition stores. Furthermore this study 
offered the opportunity to compare the body composition of CD children with a large sample 
of contemporary healthy children of the same socio-demographic background.  
 
The effect of EEN on gut microbiota diversity and metabolic activity 
A substantial number of studies have compared EEN with other mainstream treatments in 
the induction of clinical remission in active paediatric CD (Section 1.5.1), but there is lack of 
evidence to suggest the actual mechanisms of action. On the other hand the strong evidence 
implicating  commensal  microbiota  in  disease  pathogenesis  challenged  the  researcher  to   308 
undertake a study on the effect of EEN on the gut microbiota metabolism and diversity of 
these patients.  
  To the best of our knowledge this is the first study that explored the effect of EEN on 
intestinal microbiota metabolic activity in patients with CD, and one of the few that explored 
changes  in  gut  bacterial  diversity.  A  prebiotic  effect  of  EEN  proposed  by  the  first  Italian 
research on the topic (531) is not supported by the findings of this study which observed an 
increase in the faecal pH, reduced concentration of butyrate, and significant increase in the 
total sulphide concentration. These conditions should be better described as an “unhealthy” 
colonic microenvironment where colonocytes are deprived by significant energy substrates. 
This  is  a  paradox finding,  as  the  patients  who  presented  these findings  were  those  who 
clinically  improved  and  their  gut  inflammation  ameliorated.  Similar  findings  were  not 
observed  in  the  patients  who  did  not  achieve  full  clinical  remission.  It  is  very  difficult  to 
interpret this discrepancy and whether this is a random finding resulting from differences in 
gut motility between the two patient groups or an actual phenomenon mediating the efficacy 
of EEN. Perhaps an impaired metabolism of butyrate, which has been described previously 
and in recent studies, is resolved on treatment with EEN although most of the evidence on 
an abnormal metabolism of butyrate in IBD, comes from studies on UC but not CD patients. 
Likewise the role of total sulphide should be further explored in the light of evidence that 
sulphide-releasing derivatives have better efficacy than standard mesalazine in animal model 
of colitis (466). An alternative explanation of these findings is that while on treatment with 
EEN, the growth, metabolic activity and microbial products of bacterial species, which may 
be involved in the pathogenesis or perpetuation of intestinal injury in IBD, are decreased, and 
the findings of this study are in fact a secondary epiphenomenon of these changes with the 
reduction of some as yet unidentified bacterial product which exacerbates the inflammation in 
the GI tract.  
Although  this  study  compared  the  changes  of  intestinal  microbiota  diversity  and 
metabolic  activity  in  CD  on  treatment  with  EEN  against  the  changes  observed  in  serial 
samples of healthy children on normal diet, a study on healthy children on EEN treatment 
would be more appropriate and would answer whether changes in bacterial metabolism and 
diversity are disease specific.  
  Apart from the effect of EEN on the bacterial metabolic activity this study explored 
parallel  changes  in  the  diversity  of  the  commensal  microbiota.  Although  the  commensal 
microbiota diversity was significantly lower than in healthy controls, no significant changes in 
the bacterial diversity were observed during treatment. Unfortunately the molecular biology 
method  used  does  not  allow  to  comment  on  strain  specific  changes  or  changes  in  the 
bacterial counts. Other methods like FISH should be used to explore that. That was among 
the  original  aims  of  this  study  and  samples  were  prepared  for  analysis  with  the  FISH   309 
technique combined with flow cytometry. However due to the lack of time, resources and 
essential equipment this analysis was not performed. The changes in bacterial metabolic 
activity  observed,  with  significant  increase  in  sulphide  concentrations  and  reductions  in 
butyrate  strongly  suggest  the  use  of  SRB  specific  probes  and  probes  specific  for  major 
butyrate producing species for FISH analysis. Further funding and collaboration is required to 
allow to analyze these samples and explore the changes in bacterial diversity, composition, 
and metabolic activity during treatment with EEN. On the other hand both the TTGE and 
FISH analysis can only assess the dominant microbiota that occur in a concentration of > 
10
6/g of colonic content. Thus any changes in the subdominant microbiota remain unknown 
and  are  difficult  to  study  with  current  techniques.  Changes  in  the  mucosal  bacterial 
microbiota may not coincide with changes in faecal material and this should be explored, 
although  serial  biopsies  over  a  short  period  of  time  may  be  judged  unethical  and 
inappropriate. 
  A limitation of this study is the small number of patients and the heterogeneity in 
disease characteristics between patients. Lack of statistical power is a common problem in 
these studies due to the feasibility of large numbers given the rarity of the disease. The need 
to  measure  metabolic  products  in  fresh  stool  samples,  within  four  hours  of  defaecation 
reduced recruitment rates, imposed a significant personal burden to the researcher who had 
to travel in a radius of 60 miles, at any time and day to collect the samples. However the 
rigorous methodology followed in this study ensured reliable results. Multicentre studies are 
essential to achieve better recruitment and acquire adequate sample sizes. However this 
study is by far the biggest study carried out so far having recruited at least a double number 
of participants than previous report. 
 
Conclusion 
The results of this work offer new insight into several aspects of the nutrition of paediatric 
IBD patients and comprise the foundation for further ongoing work. Although the efficacy of 
EEN  to  induce  clinical  remission  in  active  paediatric  CD  was  well  described  before  the 
initiation of this PhD, the mechanisms of action remained unknown. This PhD tried to assess 
potential modes of action, which involve changes in the gut microbiota and nutritional status 
of the patients.  
Considering the results of this study, the importance of the commensal microbiota in 
IBD  pathogenesis,  and  other  studies  showing  clinical  and  experimental  evidence  on  the 
therapeutic effect of probiotics, prebiotics and butyrate in IBD, future studies should look at 
the effect of dual nutritional therapies or improvement of the composition of the existing ones. 
Prebiotics or fibre can easily be added in nutritional feeds, whereas new vehicles of oral   310 
butyrate  derivatives  which  could  act  along  the  large  bowel  are  now  available.  Probiotic 
supplements could also be used and their use is supported by a few studies.  
Using  a  dual  nutritional  therapy  may  improve  the  colonic  microenvironment  and 
improve the efficacy of EEN. Such a speculation would be best addressed with well-designed 
clinical trials, animal models and in vitro studies using intestinal biopsies.  
In this study although treatment with EEN corrected the anthropometry and nutritional 
status, the circulating levels of certain micronutrients deteriorated due to lack of carotenoids 
in the feeds. As carotenoids are important micronutrients in the human antioxidant system, 
and the latter have been implicated in tissue injury in IBD, future studies should compare the 
efficacy of standard EEN with feeds supplemented with carotenoid antioxidants. A potential 
superior effect of the fortified supplement may have important implications for the producers 
of feed companies. On the other hand, measurement of systemic micronutrients in red blood 
cells  will  better  assess  the  actual  micronutrient  body  stores  and  would  better  address 
whether there is an actual aetiological association with inflammation, intestinal injury in IBD.  
 
“This is the END of a long journey to reach “My Ithaca”. Although I avoided the rage of 
Poseidon and did not fight with Cyclops, and Lestrygonians, like Ulysses in Homer Odyssey, 
I run my journey of over four years, where I fought patience, and persistence to reach “My 
Ithaca”. Unfortunately my Penelope was not still waiting for me…. and I had to be deceived 
by some Sirens!!!” 
 
As an overall review of these last four years 
 
·  6 studies were designed, and run of which four were presented in this thesis 
·  4 full ethical ethic applications (3 for clinical studies) and two substantial amendments were 
prepared 
·  Over 400 patients were actively recruited 
·  Over 180 stool samples were collected from the four points of the compass within four hours of 
defaecation, within a 2 ½ years of 24-hour daily recruitment. 
·  Four laboratory assays developed and established in the department 
·  Over 600 stool samples were analysed for SCFA 
·  Over 250 stool samples were analysed for calprotectin,  
·  Over 2500 stool samples were analysed for sulphide concentration 
·  Over 200 stool samples were analysed for TTGE analysis 
·  Over 200 stool were analyzed for ammonia and pH 
·  Over 400 stool samples were analysed for lactate   311 
·  Over 300 measurements of body composition were conducted 
·  Over 300 patient medical notes were scrutinized 
·  Hundred of hours of data analysis 
·  6 posters, 3 oral presentations and two full papers (one under review) 
·  2 prizes for best presentations won 
ALL by the same and only crazy Greek!!!!   312 
 
REFERENCES 
Reference List 
 
  1.   Farrell RJ, Peppercorn MA. Ulcerative colitis. Lancet 2002;359:331-40. 
  2.   Ghosh S, Shand A, Ferguson A. Ulcerative colitis. BMJ 2000;320:1119-23. 
  3.   Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002;347:417-29. 
  4.   Shanahan F. Crohn's disease. Lancet 2002;359:62-9. 
  5.   Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and 
established and evolving therapies. Lancet 2007;369:1641-57. 
  6.   Silverberg MS, Satsangi J, Ahmad T et al. Toward an integrated clinical, molecular 
and serological classification of inflammatory bowel disease: Report of a Working 
Party of the 2005 Montreal World Congress of Gastroenterology. Can J 
Gastroenterol 2005;19 Suppl A:5-36. 
  7.   Griffiths AM. Specificities of inflammatory bowel disease in childhood. Best Pract 
Res Clin Gastroenterol 2004;18:509-23. 
  8.   Binder V. Epidemiology of IBD during the twentieth century: an integrated view. 
Best Pract Res Clin Gastroenterol 2004;18:463-79. 
  9.   Loftus EV, Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, 
prevalence, and environmental influences. Gastroenterology 2004;126:1504-17. 
  10.   Rubin GP, Hungin AP, Kelly PJ, Ling J. Inflammatory bowel disease: epidemiology 
and management in an English general practice population. Aliment Pharmacol 
Ther 2000;14:1553-9. 
  11.   Sawczenko A, Sandhu BK, Logan RF et al. Prospective survey of childhood 
inflammatory bowel disease in the British Isles. Lancet 2001;357:1093-4. 
  12.   Armitage EL, Aldhous MC, Anderson N et al. Incidence of juvenile-onset Crohn's 
disease in Scotland: association with northern latitude and affluence. 
Gastroenterology 2004;127:1051-7. 
  13.   Askling J, Grahnquist L, Ekbom A, Finkel Y. Incidence of paediatric Crohn's disease 
in Stockholm, Sweden. Lancet 1999;354:1179. 
  14.   Hildebrand H, Finkel Y, Grahnquist L, Lindholm J, Ekbom A, Askling J. Changing 
pattern of paediatric inflammatory bowel disease in northern Stockholm 1990-2001. 
Gut 2003;52:1432-4. 
  15.   Watson AJ, Johnston AT, Barker PM, Youngson GG, Bisset WM, Mahomed AA. 
The presentation and management of juvenile-onset chronic inflammatory bowel 
disease in Northeastern Scotland. J Pediatr Surg 2002;37:83-6. 
  16.   Armitage E, Drummond HE, Wilson DC, Ghosh S. Increasing incidence of both 
juvenile-onset Crohn's disease and ulcerative colitis in Scotland. Eur J 
Gastroenterol Hepatol 2001;13:1439-47.   313 
  17.   Barton JR, Gillon S, Ferguson A. Incidence of inflammatory bowel disease in 
Scottish children between 1968 and 1983; marginal fall in ulcerative colitis, three-
fold rise in Crohn's disease. Gut 1989;30:618-22. 
  18.   Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel 
disease. Nature 2007;448:427-34. 
  19.   Heyman MB, Kirschner BS, Gold BD et al. Children with early-onset inflammatory 
bowel disease (IBD): analysis of a pediatric IBD consortium registry. J Pediatr 
2005;146:35-40. 
  20.   Kugathasan S, Judd RH, Hoffmann RG et al. Epidemiologic and clinical 
characteristics of children with newly diagnosed inflammatory bowel disease in 
Wisconsin: a statewide population-based study. J Pediatr 2003;143:525-31. 
  21.   Hampton T. Scientists explore pathogenesis of IBD. JAMA 2004;292:2708-13. 
  22.   Orholm M, Binder V, Sorensen TI, Rasmussen LP, Kyvik KO. Concordance of 
inflammatory bowel disease among Danish twins. Results of a nationwide study. 
Scand J Gastroenterol 2000;35:1075-81. 
  23.   Russell RK, Satsangi J. IBD: a family affair. Best Pract Res Clin Gastroenterol 
2004;18:525-39. 
  24.   Thompson NP, Driscoll R, Pounder RE, Wakefield AJ. Genetics versus environment 
in inflammatory bowel disease: results of a British twin study. BMJ 1996;312:95-6. 
  25.   Hugot JP, Laurent-Puig P, Gower-Rousseau C et al. Mapping of a susceptibility 
locus for Crohn's disease on chromosome 16. Nature 1996;379:821-3. 
  26.   Wehkamp J, Salzman NH, Porter E et al. Reduced Paneth cell alpha-defensins in 
ileal Crohn's disease. Proc Natl Acad Sci U S A 2005;102:18129-34. 
  27.   Hugot JP, Chamaillard M, Zouali H et al. Association of NOD2 leucine-rich repeat 
variants with susceptibility to Crohn's disease. Nature 2001;411:599-603. 
  28.   Ogura Y, Bonen DK, Inohara N et al. A frameshift mutation in NOD2 associated 
with susceptibility to Crohn's disease. Nature 2001;411:603-6. 
  29.   Van LJ, Russell RK, Nimmo ER, Satsangi J. The genetics of inflammatory bowel 
disease. Am J Gastroenterol 2007;102:2820-31. 
  30.   Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology 
2008;134:577-94. 
  31.   Jose FA, Heyman MB. Extraintestinal manifestations of inflammatory bowel 
disease. J Pediatr Gastroenterol Nutr 2008;46:124-33. 
  32.   Cohen RD. The quality of life in patients with Crohn's disease. Aliment Pharmacol 
Ther 2002;16:1603-9. 
  33.   Sawczenko A, Sandhu BK. Presenting features of inflammatory bowel disease in 
Great Britain and Ireland. Arch Dis Child 2003;88:995-1000. 
  34.   Kirschner BS. Differences in the management of inflammatory bowel disease in 
children and adolescents compared to adults. Neth J Med 1998;53:S13-S18.   314 
  35.   Kleinman RE, Baldassano RN, Caplan A et al. Nutrition support for pediatric 
patients with inflammatory bowel disease: a clinical report of the North American 
Society for Pediatric Gastroenterology, Hepatology And Nutrition. J Pediatr 
Gastroenterol Nutr 2004;39:15-27. 
  36.   Egan LJ, Sandborn WJ. Advances in the treatment of Crohn's disease. 
Gastroenterology 2004;126:1574-81. 
  37.   Buller H, Chin S, Kirschner B et al. Inflammatory bowel disease in children and 
adolescents: Working Group Report of the First World Congress of Pediatric 
Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr 2002;35 
Suppl 2:S151-S158. 
  38.   Escher JC, Taminiau JA, Nieuwenhuis EE, Buller HA, Grand RJ. Treatment of 
inflammatory bowel disease in childhood: best available evidence. Inflamm Bowel 
Dis 2003;9:34-58. 
  39.   Friedman S. General principles of medical therapy of inflammatory bowel disease. 
Gastroenterol Clin North Am 2004;33:191-208, viii. 
  40.   Markowitz J. Current treatment of inflammatory bowel disease in children. Dig Liver 
Dis 2008;40:16-21. 
  41.   Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory 
bowel disease in adults. Gut 2004;53 Suppl 5:V1-16. 
  42.   Hanauer SB. Medical therapy for ulcerative colitis 2004. Gastroenterology 
2004;126:1582-92. 
  43.   Harrison J, Hanauer SB. Medical treatment of Crohn's disease. Gastroenterol Clin 
North Am 2002;31:167-84, x. 
  44.   Jani N, Regueiro MD. Medical therapy for ulcerative colitis. Gastroenterol Clin North 
Am 2002;31:147-66. 
  45.   Larson DW, Pemberton JH. Current concepts and controversies in surgery for IBD. 
Gastroenterology 2004;126:1611-9. 
  46.   Rawsthorne P, Shanahan F, Cronin NC et al. An international survey of the use and 
attitudes regarding alternative medicine by patients with inflammatory bowel 
disease. Am J Gastroenterol 1999;94:1298-303. 
  47.   Moody GA, Eaden JA, Bhakta P, Sher K, Mayberry JF. The role of complementary 
medicine in European and Asian patients with inflammatory bowel disease. Public 
Health 1998;112:269-71. 
  48.   Harris P, Rees R. The prevalence of complementary and alternative medicine use 
among the general population: a systematic review of the literature. Complement 
Ther Med 2000;8:88-96. 
  49.   MacLennan AH, Wilson DH, Taylor AW. Prevalence and cost of alternative 
medicine in Australia. Lancet 1996;347:569-73. 
  50.   Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delbanco TL. 
Unconventional medicine in the United States. Prevalence, costs, and patterns of 
use. N Engl J Med 1993;328:246-52.   315 
  51.   Eisenberg DM, Davis RB, Ettner SL et al. Trends in alternative medicine use in the 
United States, 1990-1997: results of a follow-up national survey. JAMA 
1998;280:1569-75. 
  52.   Barnes PM, Powell-Griner E, McFann K, Nahin RL. Complementary and alternative 
medicine use among adults: United States, 2002. Adv Data 2004;1-19. 
  53.   Simpson N, Roman K. Complementary medicine use in children: extent and 
reasons. A population-based study. Br J Gen Pract 2001;51:914-6. 
  54.   Thomas KJ, Nicholl JP, Coleman P. Use and expenditure on complementary 
medicine in England: a population based survey. Complement Ther Med 2001;9:2-
11. 
  55.   Thomas K, Coleman P. Use of complementary or alternative medicine in a general 
population in Great Britain. Results from the National Omnibus survey. J Public 
Health (Oxf) 2004;26:152-7. 
  56.   Thomas KJ, Coleman P, Nicholl JP. Trends in access to complementary or 
alternative medicines via primary care in England: 1995-2001 results from a follow-
up national survey. Fam Pract 2003;20:575-7. 
  57.   Ong CK, Petersen S, Bodeker GC, Stewart-Brown S. Health status of people using 
complementary and alternative medical practitioner services in 4 English counties. 
Am J Public Health 2002;92:1653-6. 
  58.   Tas F, Ustuner Z, Can G et al. The prevalence and determinants of the use of 
complementary and alternative medicine in adult Turkish cancer patients. Acta 
Oncol 2005;44:161-7. 
  59.   Furler MD, Einarson TR, Walmsley S, Millson M, Bendayan R. Use of 
complementary and alternative medicine by HIV-infected outpatients in Ontario, 
Canada. AIDS Patient Care STDS 2003;17:155-68. 
  60.   Ganguli SC, Cawdron R, Irvine EJ. Alternative medicine use by Canadian 
ambulatory gastroenterology patients: secular trend or epidemic? Am J 
Gastroenterol 2004;99:319-26. 
  61.   Kong SC, Hurlstone DP, Pocock CY et al. The Incidence of self-prescribed oral 
complementary and alternative medicine use by patients with gastrointestinal 
diseases. J Clin Gastroenterol 2005;39:138-41. 
  62.   Smart HL, Mayberry JF, Atkinson M. Alternative medicine consultations and 
remedies in patients with the irritable bowel syndrome. Gut 1986;27:826-8. 
  63.   Hilsden RJ, Verhoef MJ, Best A, Pocobelli G. Complementary and alternative 
medicine use by Canadian patients with inflammatory bowel disease: results from a 
national survey. Am J Gastroenterol 2003;98:1563-8. 
  64.   Markowitz JE, Mamula P, delRosario JF et al. Patterns of complementary and 
alternative medicine use in a population of pediatric patients with inflammatory 
bowel disease. Inflamm Bowel Dis 2004;10:599-605. 
  65.   Heuschkel R, Afzal N, Wuerth A et al. Complementary medicine use in children and 
young adults with inflammatory bowel disease. Am J Gastroenterol 2002;97:382-8.   316 
  66.   Day AS, Whitten KE, Bohane TD. Use of complementary and alternative medicines 
by children and adolescents with inflammatory bowel disease. J Paediatr Child 
Health 2004;40:681-4. 
  67.   McCann LJ, Newell SJ. Survey of paediatric complementary and alternative 
medicine use in health and chronic illness. Arch Dis Child 2006;91:173-4. 
  68.   Langhorst J, Anthonisen IB, Steder-Neukamm U et al. Amount of systemic steroid 
medication is a strong predictor for the use of complementary and alternative 
medicine in patients with inflammatory bowel disease: results from a German 
national survey. Inflamm Bowel Dis 2005;11:287-95. 
  69.   Day AS. Use of complementary and alternative therapies and probiotic agents by 
children attending gastroenterology outpatient clinics. J Paediatr Child Health 
2002;38:343-6. 
  70.   Langmead L, Chitnis M, Rampton DS. Use of complementary therapies by patients 
with IBD may indicate psychosocial distress. Inflamm Bowel Dis 2002;8:174-9. 
  71.   Kemper KJ. Complementary and alternative medicine for children: does it work? 
Arch Dis Child 2001;84:6-9. 
  72.   Ben-Arye E, Goldin E, Wengrower D, Stamper A, Kohn R, Berry E. Wheat grass 
juice in the treatment of active distal ulcerative colitis: a randomized double-blind 
placebo-controlled trial. Scand J Gastroenterol 2002;37:444-9. 
  73.   Joos S, Brinkhaus B, Maluche C et al. Acupuncture and moxibustion in the 
treatment of active Crohn's disease: a randomized controlled study. Digestion 
2004;69:131-9. 
  74.   Langmead L, Feakins RM, Goldthorpe S et al. Randomized, double-blind, placebo-
controlled trial of oral aloe vera gel for active ulcerative colitis. Aliment Pharmacol 
Ther 2004;19:739-47. 
  75.   Kruis W, Fric P, Pokrotnieks J et al. Maintaining remission of ulcerative colitis with 
the probiotic Escherichia coli Nissle 1917 is as effective as with standard 
mesalazine. Gut 2004;53:1617-23. 
  76.   Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-
pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: 
a randomised trial. Lancet 1999;354:635-9. 
  77.   Ernst E. Serious adverse effects of unconventional therapies for children and 
adolescents: a systematic review of recent evidence. Eur J Pediatr 2003;162:72-80. 
  78.   Kappelman MD, Bousvaros A. Nutritional concerns in pediatric inflammatory bowel 
disease patients. Mol Nutr Food Res 2008;52:867-74. 
  79.   Reynolds JV, O'Farrelly C, Feighery C et al. Impaired gut barrier function in 
malnourished patients. Br J Surg 1996;83:1288-91. 
  80.   Hengstermann S, Valentini L, Schaper L et al. Altered status of antioxidant vitamins 
and fatty acids in patients with inactive inflammatory bowel disease. Clin Nutr 
2008;27:571-8.   317 
  81.   Razack R, Seidner DL. Nutrition in inflammatory bowel disease. Curr Opin 
Gastroenterol 2007;23:400-5. 
  82.   Kugathasan S, Nebel J, Skelton JA et al. Body mass index in children with newly 
diagnosed inflammatory bowel disease: observations from two multicenter North 
American inception cohorts. J Pediatr 2007;151:523-7. 
  83.   Weinstein TA, Levine M, Pettei MJ, Gold DM, Kessler BH, Levine JJ. Age and 
family history at presentation of pediatric inflammatory bowel disease. J Pediatr 
Gastroenterol Nutr 2003;37:609-13. 
  84.   Burnham JM, Shults J, Semeao E et al. Body-composition alterations consistent 
with cachexia in children and young adults with Crohn disease. Am J Clin Nutr 
2005;82:413-20. 
  85.   Jahnsen J, Falch JA, Mowinckel P, Aadland E. Body composition in patients with 
inflammatory bowel disease: a population-based study. Am J Gastroenterol 
2003;98:1556-62. 
  86.   Paerregaard A, Uldall UF. Anthropometry at the time of diagnosis in Danish children 
with inflammatory bowel disease. Acta Paediatr 2005;94:1682-3. 
  87.   Sousa GC, Cravo M, Costa AR et al. A comprehensive approach to evaluate 
nutritional status in Crohn's patients in the era of biologic therapy: a case-control 
study. Am J Gastroenterol 2007;102:2551-6. 
  88.   Thayu M, Shults J, Burnham JM, Zemel BS, Baldassano RN, Leonard MB. Gender 
differences in body composition deficits at diagnosis in children and adolescents 
with Crohn's disease. Inflamm Bowel Dis 2007;13:1121-8. 
  89.   D'haens G, Van DS, Van HR et al. Endoscopic and histological healing with 
infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European 
multicenter trial. Gastroenterology 1999;116:1029-34. 
  90.   Fell JM, Paintin M, rnaud-Battandier F et al. Mucosal healing and a fall in mucosal 
pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in 
paediatric Crohn's disease. Aliment Pharmacol Ther 2000;14:281-9. 
  91.   Capristo E, Mingrone G, Addolorato G, Greco AV, Gasbarrini G. Metabolic features 
of inflammatory bowel disease in a remission phase of the disease activity. J Intern 
Med 1998;243:339-47. 
  92.   Wells JC, Fewtrell MS. Measuring body composition. Arch Dis Child 2006;91:612-7. 
  93.   Reilly JJ. Diagnostic accuracy of the BMI for age in paediatrics. Int J Obes (Lond) 
2006;30:595-7. 
  94.   Cole TJ, Freeman JV, Preece MA. Body mass index reference curves for the UK, 
1990. Arch Dis Child 1995;73:25-9. 
  95.   Ma K, Mallidis C, Bhasin S et al. Glucocorticoid-induced skeletal muscle atrophy is 
associated with upregulation of myostatin gene expression. Am J Physiol 
Endocrinol Metab 2003;285:E363-E371.   318 
  96.   Tjellesen L, Nielsen PK, Staun M. Body composition by dual-energy X-ray 
absorptiometry in patients with Crohn's disease. Scand J Gastroenterol 
1998;33:956-60. 
  97.   Filippi J, Al-Jaouni R, Wiroth JB, Hebuterne X, Schneider SM. Nutritional 
deficiencies in patients with Crohn's disease in remission. Inflamm Bowel Dis 
2006;12:185-91. 
  98.   Mingrone G, Capristo E, Greco AV et al. Elevated diet-induced thermogenesis and 
lipid oxidation rate in Crohn disease. Am J Clin Nutr 1999;69:325-30. 
  99.   Geerling BJ, Badart-Smook A, Stockbrugger RW, Brummer RJ. Comprehensive 
nutritional status in recently diagnosed patients with inflammatory bowel disease 
compared with population controls. Eur J Clin Nutr 2000;54:514-21. 
  100.   Geerling BJ, Badart-Smook A, Stockbrugger RW, Brummer RJ. Comprehensive 
nutritional status in patients with long-standing Crohn disease currently in 
remission. Am J Clin Nutr 1998;67:919-26. 
  101.   Geerling BJ, Lichtenbelt WD, Stockbrugger RW, Brummer RJ. Gender specific 
alterations of body composition in patients with inflammatory bowel disease 
compared with controls. Eur J Clin Nutr 1999;53:479-85. 
  102.   Boot AM, Bouquet J, Krenning EP, de Muinck Keizer-Schrama SM. Bone mineral 
density and nutritional status in children with chronic inflammatory bowel disease. 
Gut 1998;42:188-94. 
  103.   Sentongo TA, Semeao EJ, Piccoli DA, Stallings VA, Zemel BS. Growth, body 
composition, and nutritional status in children and adolescents with Crohn's 
disease. J Pediatr Gastroenterol Nutr 2000;31:33-40. 
  104.   Azcue M, Rashid M, Griffiths A, Pencharz PB. Energy expenditure and body 
composition in children with Crohn's disease: effect of enteral nutrition and 
treatment with prednisolone. Gut 1997;41:203-8. 
  105.   Kanof ME, Lake AM, Bayless TM. Decreased height velocity in children and 
adolescents before the diagnosis of Crohn's disease. Gastroenterology 
1988;95:1523-7. 
  106.   Markowitz J, Grancher K, Rosa J, Aiges H, Daum F. Growth failure in pediatric 
inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1993;16:373-80. 
  107.   Markowitz J, Daum F. Growth impairment in pediatric inflammatory bowel disease. 
Am J Gastroenterol 1994;89:319-26. 
  108.   Ferguson A, Sedgwick DM. Juvenile onset inflammatory bowel disease: height and 
body mass index in adult life. BMJ 1994;308:1259-63. 
  109.   Griffiths AM, Nguyen P, Smith C, MacMillan JH, Sherman PM. Growth and clinical 
course of children with Crohn's disease. Gut 1993;34:939-43. 
  110.   Sawczenko A, Ballinger AB, Savage MO, Sanderson IR. Clinical features affecting 
final adult height in patients with pediatric-onset Crohn's disease. Pediatrics 
2006;118:124-9.   319 
  111.   Wong SC, Macrae VE, McGrogan P, Ahmed SF. The role of pro-inflammatory 
cytokines in inflammatory bowel disease growth retardation. J Pediatr Gastroenterol 
Nutr 2006;43:144-55. 
  112.   Alemzadeh N, Rekers-Mombarg LT, Mearin ML, Wit JM, Lamers CB, van 
Hogezand RA. Adult height in patients with early onset of Crohn's disease. Gut 
2002;51:26-9. 
  113.   Burnham JM, Shults J, Semeao E et al. Whole body BMC in pediatric Crohn 
disease: independent effects of altered growth, maturation, and body composition. J 
Bone Miner Res 2004;19:1961-8. 
  114.   Russell RK, Drummond HE, Nimmo ER et al. Analysis of the influence of OCTN1/2 
variants within the IBD5 locus on disease susceptibility and growth indices in early 
onset inflammatory bowel disease. Gut 2006;55:1114-23. 
  115.   Ballinger AB, Azooz O, El-Haj T, Poole S, Farthing MJ. Growth failure occurs 
through a decrease in insulin-like growth factor 1 which is independent of 
undernutrition in a rat model of colitis. Gut 2000;46:694-700. 
  116.   Mauro M, Armstrong D. Juvenile onset of Crohn's disease: a risk factor for reduced 
lumbar bone mass in premenopausal women. Bone 2007;40:1290-3. 
  117.   Sylvester FA, Wyzga N, Hyams JS et al. Natural history of bone metabolism and 
bone mineral density in children with inflammatory bowel disease. Inflamm Bowel 
Dis 2007;13:42-50. 
  118.   Card T, West J, Hubbard R, Logan RF. Hip fractures in patients with inflammatory 
bowel disease and their relationship to corticosteroid use: a population based 
cohort study. Gut 2004;53:251-5. 
  119.   Klaus J, Armbrecht G, Steinkamp M et al. High prevalence of osteoporotic vertebral 
fractures in patients with Crohn's disease. Gut 2002;51:654-8. 
  120.   van Staa TP, Cooper C, Brusse LS, Leufkens H, Javaid MK, Arden NK. 
Inflammatory bowel disease and the risk of fracture. Gastroenterology 
2003;125:1591-7. 
  121.   Semeao EJ, Stallings VA, Peck SN, Piccoli DA. Vertebral compression fractures in 
pediatric patients with Crohn's disease. Gastroenterology 1997;112:1710-3. 
  122.   Persad R, Jaffer I, Issenman RM. The prevalence of long bone fractures in pediatric 
inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2006;43:597-602. 
  123.   Compston JE, Judd D, Crawley EO et al. Osteoporosis in patients with inflammatory 
bowel disease. Gut 1987;28:410-5. 
  124.   Schoon EJ, van Nunen AB, Wouters RS, Stockbrugger RW, Russel MG. 
Osteopenia and osteoporosis in Crohn's disease: prevalence in a Dutch population-
based cohort. Scand J Gastroenterol Suppl 2000;43-7. 
  125.   Schoon EJ, Blok BM, Geerling BJ, Russel MG, Stockbrugger RW, Brummer RJ. 
Bone mineral density in patients with recently diagnosed inflammatory bowel 
disease. Gastroenterology 2000;119:1203-8.   320 
  126.   Semeao EJ, Jawad AF, Zemel BS, Neiswender KM, Piccoli DA, Stallings VA. Bone 
mineral density in children and young adults with Crohn's disease. Inflamm Bowel 
Dis 1999;5:161-6. 
  127.   Walther F, Fusch C, Radke M, Beckert S, Findeisen A. Osteoporosis in pediatric 
patients suffering from chronic inflammatory bowel disease with and without steroid 
treatment. J Pediatr Gastroenterol Nutr 2006;43:42-51. 
  128.   van Hogezand RA, Banffer D, Zwinderman AH, McCloskey EV, Griffioen G, Hamdy 
NA. Ileum resection is the most predictive factor for osteoporosis in patients with 
Crohn's disease. Osteoporos Int 2006;17:535-42. 
  129.   Ardizzone S, Bollani S, Bettica P, Bevilacqua M, Molteni P, Bianchi PG. Altered 
bone metabolism in inflammatory bowel disease: there is a difference between 
Crohn's disease and ulcerative colitis. J Intern Med 2000;247:63-70. 
  130.   Gokhale R, Favus MJ, Karrison T, Sutton MM, Rich B, Kirschner BS. Bone mineral 
density assessment in children with inflammatory bowel disease. Gastroenterology 
1998;114:902-11. 
  131.   Habtezion A, Silverberg MS, Parkes R, Mikolainis S, Steinhart AH. Risk factors for 
low bone density in Crohn's disease. Inflamm Bowel Dis 2002;8:87-92. 
  132.   Semeao EJ, Jawad AF, Stouffer NO, Zemel BS, Piccoli DA, Stallings VA. Risk 
factors for low bone mineral density in children and young adults with Crohn's 
disease. J Pediatr 1999;135:593-600. 
  133.   Siffledeen JS, Fedorak RN, Siminoski K et al. Bones and Crohn's: risk factors 
associated with low bone mineral density in patients with Crohn's disease. Inflamm 
Bowel Dis 2004;10:220-8. 
  134.   Lopes LH, Sdepanian VL, Szejnfeld VL, de Morais MB, Fagundes-Neto U. Risk 
factors for low bone mineral density in children and adolescents with inflammatory 
bowel disease. Dig Dis Sci 2008;53:2746-53. 
  135.   Paganelli M, Albanese C, Borrelli O et al. Inflammation is the main determinant of 
low bone mineral density in pediatric inflammatory bowel disease. Inflamm Bowel 
Dis 2007;13:416-23. 
  136.   Sentongo TA, Semaeo EJ, Stettler N, Piccoli DA, Stallings VA, Zemel BS. Vitamin 
D status in children, adolescents, and young adults with Crohn disease. Am J Clin 
Nutr 2002;76:1077-81. 
  137.   Sylvester FA. IBD and skeletal health: children are not small adults! Inflamm Bowel 
Dis 2005;11:1020-3. 
  138.   Tobias JH, Sasi MR, Greenwood R, Probert CS. Rapid hip bone loss in active 
Crohn's disease patients receiving short-term corticosteroid therapy. Aliment 
Pharmacol Ther 2004;20:951-7. 
  139.   Trebble TM, Wootton SA, Stroud MA et al. Laboratory markers predict bone loss in 
Crohn's disease: relationship to blood mononuclear cell function and nutritional 
status. Aliment Pharmacol Ther 2004;19:1063-71. 
  140.   Ballinger AB, Savage MO, Sanderson IR. Delayed puberty associated with 
inflammatory bowel disease. Pediatr Res 2003;53:205-10.   321 
  141.   Grisham MB. Oxidants and free radicals in inflammatory bowel disease. Lancet 
1994;344:859-61. 
  142.   Rezaie A, Parker RD, Abdollahi M. Oxidative stress and pathogenesis of 
inflammatory bowel disease: an epiphenomenon or the cause? Dig Dis Sci 
2007;52:2015-21. 
  143.   Lih-Brody L, Powell SR, Collier KP et al. Increased oxidative stress and decreased 
antioxidant defenses in mucosa of inflammatory bowel disease. Dig Dis Sci 
1996;41:2078-86. 
  144.   Sturniolo GC, Mestriner C, Lecis PE et al. Altered plasma and mucosal 
concentrations of trace elements and antioxidants in active ulcerative colitis. Scand 
J Gastroenterol 1998;33:644-9. 
  145.   Levy E, Rizwan Y, Thibault L et al. Altered lipid profile, lipoprotein composition, and 
oxidant and antioxidant status in pediatric Crohn disease. Am J Clin Nutr 
2000;71:807-15. 
  146.   Wendland BE, Aghdassi E, Tam C et al. Lipid peroxidation and plasma antioxidant 
micronutrients in Crohn disease. Am J Clin Nutr 2001;74:259-64. 
  147.   D'Odorico A, Bortolan S, Cardin R et al. Reduced plasma antioxidant 
concentrations and increased oxidative DNA damage in inflammatory bowel 
disease. Scand J Gastroenterol 2001;36:1289-94. 
  148.   Phylactos AC, Fasoula IN, rnaud-Battandier F, Walker-Smith JA, Fell JM. Effect of 
enteral nutrition on antioxidant enzyme systems and inflammation in paediatric 
Crohn's disease. Acta Paediatr 2001;90:883-8. 
  149.   Miles AM, Grisham MB. Antioxidant properties of aminosalicylates. Methods 
Enzymol 1994;234:555-72. 
  150.   Reifen R, Nur T, Ghebermeskel K, Zaiger G, Urizky R, Pines M. Vitamin A 
deficiency exacerbates inflammation in a rat model of colitis through activation of 
nuclear factor-kappaB and collagen formation. J Nutr 2002;132:2743-7. 
  151.   Abreu MT, Kantorovich V, Vasiliauskas EA et al. Measurement of vitamin D levels 
in inflammatory bowel disease patients reveals a subset of Crohn's disease patients 
with elevated 1,25-dihydroxyvitamin D and low bone mineral density. Gut 
2004;53:1129-36. 
  152.   Pappa HM, Gordon CM, Saslowsky TM et al. Vitamin D status in children and 
young adults with inflammatory bowel disease. Pediatrics 2006;118:1950-61. 
  153.   Lim WC, Hanauer SB, Li YC. Mechanisms of disease: vitamin D and inflammatory 
bowel disease. Nat Clin Pract Gastroenterol Hepatol 2005;2:308-15. 
  154.   Ademoglu E, Erbil Y, Tam B et al. Do vitamin E and selenium have beneficial 
effects on trinitrobenzenesulfonic acid-induced experimental colitis. Dig Dis Sci 
2004;49:102-8. 
  155.   Duggan P, O'Brien M, Kiely M, McCarthy J, Shanahan F, Cashman KD. Vitamin K 
status in patients with Crohn's disease and relationship to bone turnover. Am J 
Gastroenterol 2004;99:2178-85.   322 
  156.   Schoon EJ, Muller MC, Vermeer C, Schurgers LJ, Brummer RJ, Stockbrugger RW. 
Low serum and bone vitamin K status in patients with longstanding Crohn's 
disease: another pathogenetic factor of osteoporosis in Crohn's disease? Gut 
2001;48:473-7. 
  157.   Saibeni S, Cattaneo M, Vecchi M et al. Low vitamin B(6) plasma levels, a risk factor 
for thrombosis, in inflammatory bowel disease: role of inflammation and correlation 
with acute phase reactants. Am J Gastroenterol 2003;98:112-7. 
  158.   Erzin Y, Uzun H, Celik AF, Aydin S, Dirican A, Uzunismail H. 
Hyperhomocysteinemia in inflammatory bowel disease patients without past 
intestinal resections: correlations with cobalamin, pyridoxine, folate concentrations, 
acute phase reactants, disease activity, and prior thromboembolic complications. J 
Clin Gastroenterol 2008;42:481-6. 
  159.   Carrier J, Medline A, Sohn KJ et al. Effects of dietary folate on ulcerative colitis-
associated colorectal carcinogenesis in the interleukin 2- and beta(2)-microglobulin-
deficient mice. Cancer Epidemiol Biomarkers Prev 2003;12:1262-7. 
  160.   Lashner BA, Provencher KS, Seidner DL, Knesebeck A, Brzezinski A. The effect of 
folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis. 
Gastroenterology 1997;112:29-32. 
  161.   Phelip JM, Ducros V, Faucheron JL, Flourie B, Roblin X. Association of 
hyperhomocysteinemia and folate deficiency with colon tumors in patients with 
inflammatory bowel disease. Inflamm Bowel Dis 2008;14:242-8. 
  162.   Chowers Y, Sela BA, Holland R, Fidder H, Simoni FB, Bar-Meir S. Increased levels 
of homocysteine in patients with Crohn's disease are related to folate levels. Am J 
Gastroenterol 2000;95:3498-502. 
  163.   Barton R. Macrocytic anaemias. Three fifths of patients with Crohn's disease that 
has not been operated on have vitamin B12 malabsorption. BMJ 1997;314:1552. 
  164.   Romagnuolo J, Fedorak RN, Dias VC, Bamforth F, Teltscher M. 
Hyperhomocysteinemia and inflammatory bowel disease: prevalence and predictors 
in a cross-sectional study. Am J Gastroenterol 2001;96:2143-9. 
  165.   Rumi G, Jr., Szabo I, Vincze A, Matus Z, Toth G, Mozsik G. Decrease of serum 
carotenoids in Crohn's disease. J Physiol Paris 2000;94:159-61. 
  166.   Bartram SA, Peaston RT, Rawlings DJ, Francis RM, Thompson NP. A randomized 
controlled trial of calcium with vitamin D, alone or in combination with intravenous 
pamidronate, for the treatment of low bone mineral density associated with Crohn's 
disease. Aliment Pharmacol Ther 2003;18:1121-7. 
  167.   Semrin G, Fishman DS, Bousvaros A et al. Impaired intestinal iron absorption in 
Crohn's disease correlates with disease activity and markers of inflammation. 
Inflamm Bowel Dis 2006;12:1101-6. 
  168.   Griffin IJ, Kim SC, Hicks PD, Liang LK, Abrams SA. Zinc metabolism in adolescents 
with Crohn's disease. Pediatr Res 2004;56:235-9. 
  169.   Sturniolo GC, Di L, V, Ferronato A, D'Odorico A, D'Inca R. Zinc supplementation 
tightens "leaky gut" in Crohn's disease. Inflamm Bowel Dis 2001;7:94-8.   323 
  170.   Chen JH, Xu L, Hu AL et al. [Prevalence of low vision and blindness in defined 
populations in rural and urban areas in Beijing]. Zhonghua Yi Xue Za Zhi 
2003;83:1413-8. 
  171.   Hinks LJ, Inwards KD, Lloyd B, Clayton B. Reduced concentrations of selenium in 
mild Crohn's disease. J Clin Pathol 1988;41:198-201. 
  172.   Rannem T, Ladefoged K, Hylander E, Hegnhoj J, Jarnum S. Selenium status in 
patients with Crohn's disease. Am J Clin Nutr 1992;56:933-7. 
  173.   Aghdassi E, Wendland BE, Steinhart AH, Wolman SL, Jeejeebhoy K, Allard JP. 
Antioxidant vitamin supplementation in Crohn's disease decreases oxidative stress. 
a randomized controlled trial. Am J Gastroenterol 2003;98:348-53. 
  174.   Geerling BJ, Badart-Smook A, van DC et al. Nutritional supplementation with N-3 
fatty acids and antioxidants in patients with Crohn's disease in remission: effects on 
antioxidant status and fatty acid profile. Inflamm Bowel Dis 2000;6:77-84. 
  175.   Kuroki F, Iida M, Tominaga M et al. Multiple vitamin status in Crohn's disease. 
Correlation with disease activity. Dig Dis Sci 1993;38:1614-8. 
  176.   Myung SJ, Yang SK, Jung HY et al. Zinc deficiency manifested by dermatitis and 
visual dysfunction in a patient with Crohn's disease. J Gastroenterol 1998;33:876-9. 
  177.   Bousvaros A, Zurakowski D, Duggan C et al. Vitamins A and E serum levels in 
children and young adults with inflammatory bowel disease: effect of disease 
activity. J Pediatr Gastroenterol Nutr 1998;26:129-35. 
  178.   Galloway P, McMillan DC, Sattar N. Effect of the inflammatory response on trace 
element and vitamin status. Ann Clin Biochem 2000;37 ( Pt 3):289-97. 
  179.   McMillan DC, Sattar N, Talwar D, O'Reilly DS, McArdle CS. Changes in 
micronutrient concentrations following anti-inflammatory treatment in patients with 
gastrointestinal cancer. Nutrition 2000;16:425-8. 
  180.   Fernandez-Banares F, bad-Lacruz A, Xiol X et al. Vitamin status in patients with 
inflammatory bowel disease. Am J Gastroenterol 1989;84:744-8. 
  181.   Ojuawo A, Keith L. The serum concentrations of zinc, copper and selenium in 
children with inflammatory bowel disease. Cent Afr J Med 2002;48:116-9. 
  182.   Hoffenberg EJ, Deutsch J, Smith S, Sokol RJ. Circulating antioxidant 
concentrations in children with inflammatory bowel disease. Am J Clin Nutr 
1997;65:1482-8. 
  183.   Thomas AG, Miller V, Shenkin A, Fell GS, Taylor F. Selenium and glutathione 
peroxidase status in paediatric health and gastrointestinal disease. J Pediatr 
Gastroenterol Nutr 1994;19:213-9. 
  184.   Rigaud D, Angel LA, Cerf M et al. Mechanisms of decreased food intake during 
weight loss in adult Crohn's disease patients without obvious malabsorption. Am J 
Clin Nutr 1994;60:775-81. 
  185.   Ates Y, Degertekin B, Erdil A, Yaman H, Dagalp K. Serum ghrelin levels in 
inflammatory bowel disease with relation to disease activity and nutritional status. 
Dig Dis Sci 2008;53:2215-21.   324 
  186.   Barbier M, Cherbut C, Aube AC, Blottiere HM, Galmiche JP. Elevated plasma leptin 
concentrations in early stages of experimental intestinal inflammation in rats. Gut 
1998;43:783-90. 
  187.   Karmiris K, Koutroubakis IE, Xidakis C, Polychronaki M, Voudouri T, Kouroumalis 
EA. Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory 
bowel disease. Inflamm Bowel Dis 2006;12:100-5. 
  188.   Bannerman E, Davidson I, Conway C, Culley D, Aldhous MC, Ghosh S. Altered 
subjective appetite parameters in Crohn's disease patients. Clin Nutr 2001;20:399-
405. 
  189.   Aghdassi E, Wendland BE, Stapleton M, Raman M, Allard JP. Adequacy of 
nutritional intake in a Canadian population of patients with Crohn's disease. J Am 
Diet Assoc 2007;107:1575-80. 
  190.   Thomas AG, Taylor F, Miller V. Dietary intake and nutritional treatment in childhood 
Crohn's disease. J Pediatr Gastroenterol Nutr 1993;17:75-81. 
  191.   Mingrone G, Greco AV, Benedetti G et al. Increased resting lipid oxidation in 
Crohn's disease. Dig Dis Sci 1996;41:72-6. 
  192.   Mingrone G, Benedetti G, Capristo E et al. Twenty-four-hour energy balance in 
Crohn disease patients: metabolic implications of steroid treatment. Am J Clin Nutr 
1998;67:118-23. 
  193.   Al-Jaouni R, Hebuterne X, Pouget I, Rampal P. Energy metabolism and substrate 
oxidation in patients with Crohn's disease. Nutrition 2000;16:173-8. 
  194.   Filipsson S, Hulten L, Lindstedt G. Malabsorption of fat and vitamin B12 before and 
after intestinal resection for Crohn's disease. Scand J Gastroenterol 1978;13:529-
36. 
  195.   Fujisawa T, Kimura A, Ushijima K et al. Intestinal absorption of ursodeoxycholic 
acid in children and adolescents with inflammatory bowel disease. J Pediatr 
Gastroenterol Nutr 1998;26:279-85. 
  196.   Leichtmann GA, Bengoa JM, Bolt MJ, Sitrin MD. Intestinal absorption of 
cholecalciferol and 25-hydroxycholecalciferol in patients with both Crohn's disease 
and intestinal resection. Am J Clin Nutr 1991;54:548-52. 
  197.   Papazian A, Minaire Y, Descos L, Andre C, Melange M, Vignal J. Relationships 
between the extent of ileal lesion of resection and vitamin B12, bile salt and fat 
absorption. Hepatogastroenterology 1981;28:106-9. 
  198.   Davie RJ, Hosie KB, Grobler SP, Newbury-Ecob RA, Keighley MR, Birch NJ. Ileal 
bile acid malabsorption in colonic Crohn's disease. Br J Surg 1994;81:289-90. 
  199.   Vaisman N, Dotan I, Halack A, Niv E. Malabsorption is a major contributor to 
underweight in Crohn's disease patients in remission. Nutrition 2006;22:855-9. 
  200.   Winter TA, O'keefe SJ, Callanan M, Marks T. Impaired gastric acid and pancreatic 
enzyme secretion in patients with Crohn's disease may be a consequenece of a 
poor nutritional state. Inflamm Bowel Dis 2004;10:618-25.   325 
  201.   Duerksen DR, Fallows G, Bernstein CN. Vitamin B12 malabsorption in patients with 
limited ileal resection. Nutrition 2006;22:1210-3. 
  202.   Ferguson A, Glen M, Ghosh S. Crohn's disease: nutrition and nutritional therapy. 
Baillieres Clin Gastroenterol 1998;12:93-114. 
  203.   Beutler E, Waalen J. The definition of anemia: what is the lower limit of normal of 
the blood hemoglobin concentration? Blood 2006;107:1747-50. 
  204.   World Health Organization. Iron deficient anaemia. Assessment prevention and 
control. A guide for programme managers. WHO. WHO/NHD/01.3. 1-1-2001.  
Ref Type: Report 
  205.   Dallman PR, Siimes MA. Percentile curves for hemoglobin and red cell volume in 
infancy and childhood. J Pediatr 1979;94:26-31. 
  206.   Hermiston ML, Mentzer WC. A practical approach to the evaluation of the anemic 
child. Pediatr Clin North Am 2002;49:877-91. 
  207.   Hodges VM, Rainey S, Lappin TR, Maxwell AP. Pathophysiology of anemia and 
erythrocytosis. Crit Rev Oncol Hematol 2007;64:139-58. 
  208.   Frewin R, Henson A, Provan D. ABC of clinical haematology. Iron deficiency 
anaemia. BMJ 1997;314:360-3. 
  209.   Maherzi A, Galan P, Cezard JP, Cherouvrier F, Hercberg S, Navarro J. Assessment 
of iron status in children and adolescents with Crohn's disease: value of basic red 
cell ferritin. Ann Nutr Metab 1996;40:331-5. 
  210.   Cucino C, Sonnenberg A. Cause of death in patients with inflammatory bowel 
disease. Inflamm Bowel Dis 2001;7:250-5. 
  211.   Khan K, Schwarzenberg SJ, Sharp H, Greenwood D, Weisdorf-Schindele S. Role of 
serology and routine laboratory tests in childhood inflammatory bowel disease. 
Inflamm Bowel Dis 2002;8:325-9. 
  212.   Sabery N, Bass D. Use of serologic markers as a screening tool in inflammatory 
bowel disease compared with elevated erythrocyte sedimentation rate and anemia. 
Pediatrics 2007;119:e193-e199. 
  213.   Burbige EJ, Huang SH, Bayless TM. Clinical manifestations of Crohn's disease in 
children and adolescents. Pediatrics 1975;55:866-71. 
  214.   Dyer NH, Child JA, Mollin DL, Dawson AM. Anaemia in Crohn's disease. Q J Med 
1972;41:419-36. 
  215.   Gasche C, Berstad A, Befrits R et al. Guidelines on the diagnosis and management 
of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis 
2007;13:1545-53. 
  216.   Fitzsimons EJ, Brock JH. The anaemia of chronic disease. BMJ 2001;322:811-2. 
  217.   Gasche C. Anemia in IBD: the overlooked villain. Inflamm Bowel Dis 2000;6:142-50. 
  218.   Dallman PR, Siimes MA, Stekel A. Iron deficiency in infancy and childhood. Am J 
Clin Nutr 1980;33:86-118.   326 
  219.   Panagiotou JP, Douros K. Clinicolaboratory findings and treatment of iron-
deficiency anemia in childhood. Pediatr Hematol Oncol 2004;21:521-34. 
  220.   Cronin CC, Shanahan F. Anemia in patients with chronic inflammatory bowel 
disease. Am J Gastroenterol 2001;96:2296-8. 
  221.   Yip R, Johnson C, Dallman PR. Age-related changes in laboratory values used in 
the diagnosis of anemia and iron deficiency. Am J Clin Nutr 1984;39:427-36. 
  222.   Schreiber S, Wedel S. Diagnosis and treatment of anemia in inflammatory bowel 
disease. Inflammatory Bowel Diseases 1997;3:204-16. 
  223.   Lomer MC, Kodjabashia K, Hutchinson C, Greenfield SM, Thompson RP, Powell 
JJ. Intake of dietary iron is low in patients with Crohn's disease: a case-control 
study. Br J Nutr 2004;91:141-8. 
  224.   Barnich N, Carvalho FA, Glasser AL et al. CEACAM6 acts as a receptor for 
adherent-invasive E. coli, supporting ileal mucosa colonization in Crohn disease. J 
Clin Invest 2007;117:1566-74. 
  225.   Thomson AB, Brust R, Ali MA, Mant MJ, Valberg LS. Iron deficiency in inflammatory 
bowel disease. Diagnostic efficacy of serum ferritin. Am J Dig Dis 1978;23:705-9. 
  226.   Guagnozzi D, Severi C, Ialongo P et al. Ferritin as a simple indicator of iron 
deficiency in anemic IBD patients. Inflamm Bowel Dis 2006;12:150-1. 
  227.   Kohgo Y, Nishisato T, Kondo H, Tsushima N, Niitsu Y, Urushizaki I. Circulating 
transferrin receptor in human serum. Br J Haematol 1986;64:277-81. 
  228.   Revel-Vilk S, Tamary H, Broide E et al. Serum transferrin receptor in children and 
adolescents with inflammatory bowel disease. Eur J Pediatr 2000;159:585-9. 
  229.   Wilson A, Reyes E, Ofman J. Prevalence and outcomes of anemia in inflammatory 
bowel disease: a systematic review of the literature. Am J Med 2004;116 Suppl 
7A:44S-9S. 
  230.   Beguin Y. Soluble transferrin receptor for the evaluation of erythropoiesis and iron 
status. Clin Chim Acta 2003;329:9-22. 
  231.   Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005;352:1011-
23. 
  232.   Weiss G. Modification of iron regulation by the inflammatory response. Best Pract 
Res Clin Haematol 2005;18:183-201. 
  233.   Dohil R, Hassall E, Wadsworth LD, Israel DM. Recombinant human erythropoietin 
for treatment of anemia of chronic disease in children with Crohn's disease. J 
Pediatr 1998;132:155-9. 
  234.   Gasche C, Dejaco C, Reinisch W et al. Sequential treatment of anemia in ulcerative 
colitis with intravenous iron and erythropoietin. Digestion 1999;60:262-7. 
  235.   Schreiber S, Howaldt S, Schnoor M et al. Recombinant erythropoietin for the 
treatment of anemia in inflammatory bowel disease. N Engl J Med 1996;334:619-
23.   327 
  236.   Kulnigg S, Gasche C. Systematic review: managing anaemia in Crohn's disease. 
Aliment Pharmacol Ther 2006;24:1507-23. 
  237.   Hoffbrand V, Provan D. ABC of clinical haematology. Macrocytic anaemias. BMJ 
1997;314:430-3. 
  238.   Decaux G, Prospert F, Horsmans Y, Desager JP. Relationship between red cell 
mean corpuscular volume and 6-thioguanine nucleotides in patients treated with 
azathioprine. J Lab Clin Med 2000;135:256-62. 
  239.   Pizzi LT, Weston CM, Goldfarb NI et al. Impact of chronic conditions on quality of 
life in patients with inflammatory bowel disease. Inflamm Bowel Dis 2006;12:47-52. 
  240.   Wells CW, Lewis S, Barton JR, Corbett S. Effects of changes in hemoglobin level 
on quality of life and cognitive function in inflammatory bowel disease patients. 
Inflamm Bowel Dis 2006;12:123-30. 
  241.   Beeken WL. Absorptive defects in young people with regional enteritis. Pediatrics 
1973;52:69-74. 
  242.   Werlin SL, Grand RJ. Severe colitis in children and adolescents: diagnosis. Course, 
and treatment. Gastroenterology 1977;73:828-32. 
  243.   Mack DR, Langton C, Markowitz J et al. Laboratory values for children with newly 
diagnosed inflammatory bowel disease. Pediatrics 2007;119:1113-9. 
  244.   Gryboski JD. Crohn's disease in children 10 years old and younger: comparison 
with ulcerative colitis. J Pediatr Gastroenterol Nutr 1994;18:174-82. 
  245.   Mackerras D, Singh G. The prevalence of anaemia depends on the definition: an 
example from the Aboriginal Birth Cohort Study. Eur J Clin Nutr 2007;61:135-9. 
  246.   Hyams JS, Mandel F, Ferry GD et al. Relationship of common laboratory 
parameters to the activity of Crohn's disease in children. J Pediatr Gastroenterol 
Nutr 1992;14:216-22. 
  247.   Thayu M, Leonard M, Baldassano R, Mamula P. Prevalence of anaemia in incident 
paediatric Crohn's disease. J.Pediatr.Gastroenterol.Nutr. 2005;41:493-563 (abstr). 
  248.   Niv Y, Torten D, Tamir A, Epstein L. Incidence and prevalence of ulcerative colitis in 
the upper Galilee, Northern Israel, 1967-1986. Am J Gastroenterol 1990;85:1580-3. 
  249.   Reilly J, Ryan JA, Strole W, Fischer JE. Hyperalimentation in inflammatory bowel 
disease. Am J Surg 1976;131:192-200. 
  250.   Okada M, Yao T, Fuchigami T, Iida M, Date H. Anatomical involvement and clinical 
features in 91 Japanese patients with Crohn's disease. J Clin Gastroenterol 
1987;9:165-71. 
  251.   Harries AD, Fitzsimons E, Dew MJ, Heatley RV, Rhodes J. Association between 
iron deficiency anaemia and mid-arm circumference in Crohn's disease. Hum Nutr 
Clin Nutr 1984;38:47-53. 
  252.   Howarth LJ, Wiskin AE, Griffiths DM, Afzal NA, Beattie RM. Outcome of childhood 
ulcerative colitis at 2 years. Acta Paediatr 2007;96:1790-3.   328 
  253.   Thomas DW, Sinatra FR. Screening laboratory tests for Crohn's disease. West J 
Med 1989;150:163-4. 
  254.   Beeken WL, Sessions JT, Jr., Bozymski EM. Correlations between clinical, blood 
leukocyte, and skin test data in the National Cooperative Crohn's Disease Study. 
Gastroenterology 1979;77:921-4. 
  255.   Rodrigues AF, Johnson T, Davies P, Murphy MS. Does polymeric formula improve 
adherence to liquid diet therapy in children with active Crohn's disease? Arch Dis 
Child 2007;92:767-70. 
  256.   Levine A, Milo T, Buller H, Markowitz J. Consensus and controversy in the 
management of pediatric Crohn disease: an international survey. J Pediatr 
Gastroenterol Nutr 2003;36:464-9. 
  257.   Hyams JS, Markowitz JF. Can we alter the natural history of Crohn disease in 
children? J Pediatr Gastroenterol Nutr 2005;40:262-72. 
  258.   Day AS, Whitten KE, Lemberg DA et al. Exclusive enteral feeding as primary 
therapy for Crohn's disease in Australian children and adolescents: a feasible and 
effective approach. J Gastroenterol Hepatol 2006;21:1609-14. 
  259.   Borrelli O, Cordischi L, Cirulli M et al. Polymeric diet alone versus corticosteroids in 
the treatment of active pediatric Crohn's disease: a randomized controlled open-
label trial. Clin Gastroenterol Hepatol 2006;4:744-53. 
  260.   Johnson T, Macdonald S, Hill SM, Thomas A, Murphy MS. Treatment of active 
Crohn's disease in children using partial enteral nutrition with liquid formula: a 
randomised controlled trial. Gut 2006;55:356-61. 
  261.   Berni CR, Terrin G, Borrelli O et al. Short- and long-term therapeutic efficacy of 
nutritional therapy and corticosteroids in paediatric Crohn's disease. Dig Liver Dis 
2006;38:381-7. 
  262.   Gavin J, Anderson CE, Bremner AR, Beattie RM. Energy intakes of children with 
Crohn's disease treated with enteral nutrition as primary therapy. J Hum Nutr Diet 
2005;18:337-42. 
  263.   Knight C, El-Matary W, Spray C, Sandhu BK. Long-term outcome of nutritional 
therapy in paediatric Crohn's disease. Clin Nutr 2005;24:775-9. 
  264.   Afzal NA, Davies S, Paintin M et al. Colonic Crohn's disease in children does not 
respond well to treatment with enteral nutrition if the ileum is not involved. Dig Dis 
Sci 2005;50:1471-5. 
  265.   Afzal NA, Van Der Zaag-Loonen HJ, rnaud-Battandier F et al. Improvement in 
quality of life of children with acute Crohn's disease does not parallel mucosal 
healing after treatment with exclusive enteral nutrition. Aliment Pharmacol Ther 
2004;20:167-72. 
  266.   Ludvigsson JF, Krantz M, Bodin L, Stenhammar L, Lindquist B. Elemental versus 
polymeric enteral nutrition in paediatric Crohn's disease: a multicentre randomized 
controlled trial. Acta Paediatr 2004;93:327-35.   329 
  267.   Bannerjee K, Camacho-Hubner C, Babinska K et al. Anti-inflammatory and growth-
stimulating effects precede nutritional restitution during enteral feeding in Crohn 
disease. J Pediatr Gastroenterol Nutr 2004;38:270-5. 
  268.   Cameron EA, Middleton SJ. Elemental diet in the treatment of orofacial Crohn's 
disease. Gut 2003;52:143. 
  269.   Akobeng AK. Enteral nutritional supplementation and the maintenance of 
permission in Crohn's disease. J Pediatr Gastroenterol Nutr 2002;34:572-3. 
  270.   Akobeng AK, Miller V, Stanton J, Elbadri AM, Thomas AG. Double-blind 
randomized controlled trial of glutamine-enriched polymeric diet in the treatment of 
active Crohn's disease. J Pediatr Gastroenterol Nutr 2000;30:78-84. 
  271.   Beattie RM, Camacho-Hubner C, Wacharasindhu S, Cotterill AM, Walker-Smith JA, 
Savage MO. Responsiveness of IGF-I and IGFBP-3 to therapeutic intervention in 
children and adolescents with Crohn's disease. Clin Endocrinol (Oxf) 1998;49:483-
9. 
  272.   Khoshoo V, Reifen R, Neuman MG, Griffiths A, Pencharz PB. Effect of low- and 
high-fat, peptide-based diets on body composition and disease activity in 
adolescents with active Crohn's disease. JPEN J Parenter Enteral Nutr 
1996;20:401-5. 
  273.   Wilschanski M, Sherman P, Pencharz P, Davis L, Corey M, Griffiths A. 
Supplementary enteral nutrition maintains remission in paediatric Crohn's disease. 
Gut 1996;38:543-8. 
  274.   Papadopoulou A, Rawashdeh MO, Brown GA, McNeish AS, Booth IW. Remission 
following an elemental diet or prednisolone in Crohn's disease. Acta Paediatr 
1995;84:79-83. 
  275.   Breese EJ, Michie CA, Nicholls SW et al. The effect of treatment on lymphokine-
secreting cells in the intestinal mucosa of children with Crohn's disease. Aliment 
Pharmacol Ther 1995;9:547-52. 
  276.   Beattie RM, Schiffrin EJ, Donnet-Hughes A et al. Polymeric nutrition as the primary 
therapy in children with small bowel Crohn's disease. Aliment Pharmacol Ther 
1994;8:609-15. 
  277.   Ruuska T, Savilahti E, Maki M, Ormala T, Visakorpi JK. Exclusive whole protein 
enteral diet versus prednisolone in the treatment of acute Crohn's disease in 
children. J Pediatr Gastroenterol Nutr 1994;19:175-80. 
  278.   Thomas AG, Holly JM, Taylor F, Miller V. Insulin like growth factor-I, insulin like 
growth factor binding protein-1, and insulin in childhood Crohn's disease. Gut 
1993;34:944-7. 
  279.   Polk DB, Hattner JA, Kerner JA, Jr. Improved growth and disease activity after 
intermittent administration of a defined formula diet in children with Crohn's disease. 
JPEN J Parenter Enteral Nutr 1992;16:499-504. 
  280.   Aiges H, Markowitz J, Rosa J, Daum F. Home nocturnal supplemental nasogastric 
feedings in growth-retarded adolescents with Crohn's disease. Gastroenterology 
1989;97:905-10.   330 
  281.   Belli DC, Seidman E, Bouthillier L et al. Chronic intermittent elemental diet improves 
growth failure in children with Crohn's disease. Gastroenterology 1988;94:603-10. 
  282.   Sanderson IR, Udeen S, Davies PS, Savage MO, Walker-Smith JA. Remission 
induced by an elemental diet in small bowel Crohn's disease. Arch Dis Child 
1987;62:123-7. 
  283.   Sanderson IR, Boulton P, Menzies I, Walker-Smith JA. Improvement of abnormal 
lactulose/rhamnose permeability in active Crohn's disease of the small bowel by an 
elemental diet. Gut 1987;28:1073-6. 
  284.   Blair GK, Yaman M, Wesson DE. Preoperative home elemental enteral nutrition in 
complicated Crohn's disease. J Pediatr Surg 1986;21:769-71. 
  285.   O'Morain C, Segal AM, Levi AJ, Valman HB. Elemental diet in acute Crohn's 
disease. Arch Dis Child 1983;58:44-7. 
  286.   Navarro J, Vargas J, Cezard JP, Charritat JL, Polonovski C. Prolonged constant 
rate elemental enteral nutrition in Crohn's disease. J Pediatr Gastroenterol Nutr 
1982;1:541-6. 
  287.   Morin CL, Roulet M, Roy CC, Weber A, Lapointe N. Continuous elemental enteral 
alimentation in the treatment of children and adolescents with Crohn's disease. 
JPEN J Parenter Enteral Nutr 1982;6:194-9. 
  288.   Morin CL, Roulet M, Roy CC, Weber A. Continuous elemental enteral alimentation 
in children with Crohn's disease and growth failure. Gastroenterology 
1980;79:1205-10. 
  289.   Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for induction of 
remission in Crohn's disease. Cochrane Database Syst Rev 2007;CD000542. 
  290.   Voitk AJ, Echave V, Feller JH, Brown RA, Gurd FN. Experience with elemental diet 
in the treatment of inflammatory bowel disease. Is this primary therapy? Arch Surg 
1973;107:329-33. 
  291.   Gonzalez-Huix F, de LR, Fernandez-Banares F et al. Polymeric enteral diets as 
primary treatment of active Crohn's disease: a prospective steroid controlled trial. 
Gut 1993;34:778-82. 
  292.   Zoli G, Care M, Parazza M et al. A randomized controlled study comparing 
elemental diet and steroid treatment in Crohn's disease. Aliment Pharmacol Ther 
1997;11:735-40. 
  293.   Lochs H, Steinhardt HJ, Klaus-Wentz B et al. Comparison of enteral nutrition and 
drug treatment in active Crohn's disease. Results of the European Cooperative 
Crohn's Disease Study. IV. Gastroenterology 1991;101:881-8. 
  294.   Fernandez-Banares F, Mingorance MD, Esteve M et al. Serum zinc, copper, and 
selenium levels in inflammatory bowel disease: effect of total enteral nutrition on 
trace element status. Am J Gastroenterol 1990;85:1584-9. 
  295.   Griffiths AM, Ohlsson A, Sherman PM, Sutherland LR. Meta-analysis of enteral 
nutrition as a primary treatment of active Crohn's disease. Gastroenterology 
1995;108:1056-67.   331 
  296.   Messori A, Trallori G, d'Albasio G, Milla M, Vannozzi G, Pacini F. Defined-formula 
diets versus steroids in the treatment of active Crohn's disease: a meta-analysis. 
Scand J Gastroenterol 1996;31:267-72. 
  297.   Dziechciarz P, Horvath A, Shamir R, Szajewska H. Meta-analysis: enteral nutrition 
in active Crohn's disease in children. Aliment Pharmacol Ther 2007;26:795-806. 
  298.   Heuschkel RB, Menache CC, Megerian JT, Baird AE. Enteral nutrition and 
corticosteroids in the treatment of acute Crohn's disease in children. J Pediatr 
Gastroenterol Nutr 2000;31:8-15. 
  299.   Terrin G, Berni CR, Ambrosini A. A semielemental diet (Pregomin) as primary 
therapy for inducing remission in children with active Crohn's disease. Italian 
Journal of Pediatrics 2002;28:401-5. 
  300.   Rigaud D, Cosnes J, Le QY, Rene E, Gendre JP, Mignon M. Controlled trial 
comparing two types of enteral nutrition in treatment of active Crohn's disease: 
elemental versus polymeric diet. Gut 1991;32:1492-7. 
  301.   Royall D, Allard JP, Baker JP, Jeejeebhoy KN, Greenberg GR. Consequences of 
enteral nutrition therapy on body composition changes in acute Crohn's disease. 
Basic Life Sci 1993;60:225-8. 
  302.   Raouf AH, Hildrey V, Daniel J et al. Enteral feeding as sole treatment for Crohn's 
disease: controlled trial of whole protein v amino acid based feed and a case study 
of dietary challenge. Gut 1991;32:702-7. 
  303.   Teahon K, Bjarnason I, Pearson M, Levi AJ. Ten years' experience with an 
elemental diet in the management of Crohn's disease. Gut 1990;31:1133-7. 
  304.   Takagi S, Utsunomiya K, Kuriyama S et al. Effectiveness of an 'half elemental diet' 
as maintenance therapy for Crohn's disease: A randomized-controlled trial. Aliment 
Pharmacol Ther 2006;24:1333-40. 
  305.   Yamamoto T, Nakahigashi M, Umegae S, Kitagawa T, Matsumoto K. Impact of 
long-term enteral nutrition on clinical and endoscopic recurrence after resection for 
Crohn's disease: A prospective, non-randomized, parallel, controlled study. Aliment 
Pharmacol Ther 2007;25:67-72. 
  306.   Yamamoto T, Nakahigashi M, Saniabadi AR et al. Impacts of long-term enteral 
nutrition on clinical and endoscopic disease activities and mucosal cytokines during 
remission in patients with Crohn's disease: a prospective study. Inflamm Bowel Dis 
2007;13:1493-501. 
  307.   Verma S, Kirkwood B, Brown S, Giaffer MH. Oral nutritional supplementation is 
effective in the maintenance of remission in Crohn's disease. Dig Liver Dis 
2000;32:769-74. 
  308.   Verma S, Holdsworth CD, Giaffer MH. Does adjuvant nutritional support diminish 
steroid dependency in Crohn disease? Scand J Gastroenterol 2001;36:383-8. 
  309.   Yamamoto T, Nakahigashi M, Umegae S, Kitagawa T, Matsumoto K. Impact of 
elemental diet on mucosal inflammation in patients with active Crohn's disease: 
cytokine production and endoscopic and histological findings. Inflamm Bowel Dis 
2005;11:580-8.   332 
  310.   Meister D, Bode J, Shand A, Ghosh S. Anti-inflammatory effects of enteral diet 
components on Crohn's disease-affected tissues in vitro. Dig Liver Dis 
2002;34:430-8. 
  311.   Konikoff MR, Denson LA. Role of fecal calprotectin as a biomarker of intestinal 
inflammation in inflammatory bowel disease. Inflamm Bowel Dis 2006;12:524-34. 
  312.   Kolho KL, Raivio T, Lindahl H, Savilahti E. Fecal calprotectin remains high during 
glucocorticoid therapy in children with inflammatory bowel disease. Scand J 
Gastroenterol 2006;41:720-5. 
  313.   Landi B, Anh TN, Cortot A et al. Endoscopic monitoring of Crohn's disease 
treatment: a prospective, randomized clinical trial. The Groupe d'Etudes 
Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology 
1992;102:1647-53. 
  314.   Modigliani R, Mary JY, Simon JF et al. Clinical, biological, and endoscopic picture of 
attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude 
Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 
1990;98:811-8. 
  315.   Miki K, Moore DJ, Butler RN, Southcott E, Couper RT, Davidson GP. The sugar 
permeability test reflects disease activity in children and adolescents with 
inflammatory bowel disease. J Pediatr 1998;133:750-4. 
  316.   Wyatt J, Vogelsang H, Hubl W, Waldhoer T, Lochs H. Intestinal permeability and 
the prediction of relapse in Crohn's disease. Lancet 1993;341:1437-9. 
  317.   Teahon K, Smethurst P, Pearson M, Levi AJ, Bjarnason I. The effect of elemental 
diet on intestinal permeability and inflammation in Crohn's disease. 
Gastroenterology 1991;101:84-9. 
  318.   Zoetendal EG, Akkermans ADL, Vliet WMA, Arjan J, de Visser GM, de Vos WM. 
The Host Genotype Affects the Bacterial Community in the Human 
Gastronintestinal Tract. Microbial Ecology in Health and Disease 2001;13:129-34. 
  319.   Mansfield JC, Giaffer MH, Holdsworth CD. Controlled trial of oligopeptide versus 
amino acid diet in treatment of active Crohn's disease. Gut 1995;36:60-6. 
  320.   Royall D, Jeejeebhoy KN, Baker JP et al. Comparison of amino acid v peptide 
based enteral diets in active Crohn's disease: clinical and nutritional outcome. Gut 
1994;35:783-7. 
  321.   Cravo M, Camilo ME, Correia JP. Nutritional support in Crohn's disease: which 
route? Am J Gastroenterol 1991;86:317-21. 
  322.   Wright RA, Adler EC. Peripheral parenteral nutrition is no better than enteral 
nutrition in acute exacerbation of Crohn's disease: a prospective trial. J Clin 
Gastroenterol 1990;12:396-9. 
  323.   Greenberg GR, Fleming CR, Jeejeebhoy KN, Rosenberg IH, Sales D, Tremaine 
WJ. Controlled trial of bowel rest and nutritional support in the management of 
Crohn's disease. Gut 1988;29:1309-15. 
  324.   Whelan K, Judd PA, Preedy VR, Simmering R, Jann A, Taylor MA. 
Fructooligosaccharides and fiber partially prevent the alterations in fecal microbiota   333 
and short-chain fatty acid concentrations caused by standard enteral formula in 
healthy humans. J Nutr 2005;135:1896-902. 
  325.   Suzuki H, Hanyou N, Sonaka I, Minami H. An elemental diet controls inflammation 
in indomethacin-induced small bowel disease in rats: the role of low dietary fat and 
the elimination of dietary proteins. Dig Dis Sci 2005;50:1951-8. 
  326.   Leiper K, Woolner J, Mullan MM et al. A randomised controlled trial of high versus 
low long chain triglyceride whole protein feed in active Crohn's disease. Gut 
2001;49:790-4. 
  327.   Griffiths AM. Enteral feeding in inflammatory bowel disease. Curr Opin Clin Nutr 
Metab Care 2006;9:314-8. 
  328.   Gassull MA, Fernandez-Banares F, Cabre E et al. Fat composition may be a clue to 
explain the primary therapeutic effect of enteral nutrition in Crohn's disease: results 
of a double blind randomised multicentre European trial. Gut 2002;51:164-8. 
  329.   Matsui T, Ueki M, Yamada M, Sakurai T, Yao T. Indications and options of 
nutritional treatment for Crohn's disease. A comparison of elemental and polymeric 
diets. J Gastroenterol 1995;30 Suppl 8:95-7. 
  330.   Gorard DA, Hunt JB, Payne-James JJ et al. Initial response and subsequent course 
of Crohn's disease treated with elemental diet or prednisolone. Gut 1993;34:1198-
202. 
  331.   Teahon K, Pearson M, Smith T, Bjarnason I. Alterations in nutritional status and 
disease activity during treatment of Crohn's disease with elemental diet. Scand J 
Gastroenterol 1995;30:54-60. 
  332.   Hyams JS, Ferry GD, Mandel FS et al. Development and validation of a pediatric 
Crohn's disease activity index. J Pediatr Gastroenterol Nutr 1991;12:439-47. 
  333.   Hannon TS, Dimeglio LA, Pfefferkorn MD, Denne SC. Acute effects of enteral 
nutrition on protein turnover in adolescents with Crohn disease. Pediatr Res 
2007;61:356-60. 
  334.   Ballinger A. Fundamental mechanisms of growth failure in inflammatory bowel 
disease. Horm Res 2002;58 Suppl 1:7-10. 
  335.   Abad-Lacruz A, Fernandez-Banares F, Cabre E et al. The effect of total enteral tube 
feeding on the vitamin status of malnourished patients with inflammatory bowel 
disease. Int J Vitam Nutr Res 1988;58:428-35. 
  336.   Akobeng AK, Richmond K, Miller V, Thomas AG. Effect of exclusive enteral 
nutritional treatment on plasma antioxidant concentrations in childhood Crohn's 
disease. Clin Nutr 2007;26:51-6. 
  337.   Johtatsu T, Andoh A, Kurihara M et al. Serum concentrations of trace elements in 
patients with Crohn's disease receiving enteral nutrition. J Clin Biochem Nutr 
2007;41:197-201. 
  338.   Tannock GW. New perceptions of the gut microbiota: implications for future 
research. Gastroenterol Clin North Am 2005;34:361-82, vii. 
  339.   Guarner F, Malagelada JR. Gut flora in health and disease. Lancet 2003;361:512-9.   334 
  340.   Macfarlane S, Macfarlane GT. Bacterial diversity in the human gut. Adv Appl 
Microbiol 2004;54:261-89. 
  341.   Zoetendal EG, Akkermans AD, de Vos WM. Temperature gradient gel 
electrophoresis analysis of 16S rRNA from human fecal samples reveals stable and 
host-specific communities of active bacteria. Appl Environ Microbiol 1998;64:3854-
9. 
  342.   Edwards CA, Parrett AM. Intestinal flora during the first months of life: new 
perspectives. Br J Nutr 2002;88 Suppl 1:S11-S18. 
  343.   Hopkins MJ, Sharp R, Macfarlane GT. Variation in human intestinal microbiota with 
age. Dig Liver Dis 2002;34 Suppl 2:S12-S18. 
  344.   McCracken VJ, Simpson JM, Mackie RI, Gaskins HR. Molecular ecological analysis 
of dietary and antibiotic-induced alterations of the mouse intestinal microbiota. J 
Nutr 2001;131:1862-70. 
  345.   Rochet V, Rigottier-Gois L, Levenez F et al. Modulation of Lactobacillus casei in 
ileal and fecal samples from healthy volunteers after consumption of a fermented 
milk containing Lactobacillus casei DN-114 001Rif. Can J Microbiol 2008;54:660-7. 
  346.   Marteau P, Pochart P, Dore J, Bera-Maillet C, Bernalier A, Corthier G. Comparative 
study of bacterial groups within the human cecal and fecal microbiota. Appl Environ 
Microbiol 2001;67:4939-42. 
  347.   Zoetendal EG, von WA, Vilpponen-Salmela T, Ben-Amor K, Akkermans AD, de Vos 
WM. Mucosa-associated bacteria in the human gastrointestinal tract are uniformly 
distributed along the colon and differ from the community recovered from feces. 
Appl Environ Microbiol 2002;68:3401-7. 
  348.   Clavel T, Haller D. Molecular interactions between bacteria, the epithelium, and the 
mucosal immune system in the intestinal tract: implications for chronic inflammation. 
Curr Issues Intest Microbiol 2007;8:25-43. 
  349.   Rajilic-Stojanovic M, Smidt H, de Vos WM. Diversity of the human gastrointestinal 
tract microbiota revisited. Environ Microbiol 2007;9:2125-36. 
  350.   Cummings, J. H. The large intestine in nutrition and disease. Danone, Institute.  1-
1-1997.  
Ref Type: Serial (Book,Monograph) 
  351.   Tannock GW. Molecular methods for exploring the intestinal ecosystem. Br J Nutr 
2002;87 Suppl 2:S199-S201. 
  352.   Muyzer G, Smalla K. Application of denaturing gradient gel electrophoresis (DGGE) 
and temperature gradient gel electrophoresis (TGGE) in microbial ecology. Antonie 
Van Leeuwenhoek 1998;73:127-41. 
  353.   Muyzer G. DGGE/TGGE a method for identifying genes from natural ecosystems. 
Curr Opin Microbiol 1999;2:317-22. 
  354.   Fallani M, Rigottier-Gois L, Aguilera M et al. Clostridium difficile and Clostridium 
perfringens species detected in infant faecal microbiota using 16S rRNA targeted 
probes. J Microbiol Methods 2006;67:150-61.   335 
  355.   Blaut M, Collins MD, Welling GW, Dore J, van LJ, de VW. Molecular biological 
methods for studying the gut microbiota: the EU human gut flora project. Br J Nutr 
2002;87 Suppl 2:S203-S211. 
  356.   McCartney AL. Application of molecular biological methods for studying probiotics 
and the gut flora. Br J Nutr 2002;88 Suppl 1:S29-S37. 
  357.   Haller D, Jobin C. Interaction between resident luminal bacteria and the host: can a 
healthy relationship turn sour? J Pediatr Gastroenterol Nutr 2004;38:123-36. 
  358.   Mahida YR, Rolfe VE. Host-bacterial interactions in inflammatory bowel disease. 
Clin Sci (Lond) 2004;107:331-41. 
  359.   Gursoy S, Guven K, Arikan T et al. Clostridium difficile infection frequency in 
patients with nosocomial infections or using antibiotics. Hepatogastroenterology 
2007;54:1720-4. 
  360.   O'Hara AM, Shanahan F. The gut flora as a forgotten organ. EMBO Rep 
2006;7:688-93. 
  361.   Cario E. Bacterial interactions with cells of the intestinal mucosa: Toll-like receptors 
and NOD2. Gut 2005;54:1182-93. 
  362.   Shanahan F. Gut flora in gastrointestinal disease. Eur J Surg Suppl 2002;47-52. 
  363.   Wong JM, de SR, Kendall CW, Emam A, Jenkins DJ. Colonic health: fermentation 
and short chain fatty acids. J Clin Gastroenterol 2006;40:235-43. 
  364.   Cummings JH, Macfarlane GT. Role of intestinal bacteria in nutrient metabolism. 
JPEN J Parenter Enteral Nutr 1997;21:357-65. 
  365.   Macfarlane GT, Gibson GR, Cummings JH. Comparison of fermentation reactions 
in different regions of the human colon. J Appl Bacteriol 1992;72:57-64. 
  366.   Cummings JH, Englyst HN. Fermentation in the human large intestine and the 
available substrates. Am J Clin Nutr 1987;45:1243-55. 
  367.   Macfarlane S, Macfarlane GT. Regulation of short-chain fatty acid production. Proc 
Nutr Soc 2003;62:67-72. 
  368.   Topping DL, Clifton PM. Short-chain fatty acids and human colonic function: roles of 
resistant starch and nonstarch polysaccharides. Physiol Rev 2001;81:1031-64. 
  369.   Cummings JH, Pomare EW, Branch WJ, Naylor CP, Macfarlane GT. Short chain 
fatty acids in human large intestine, portal, hepatic and venous blood. Gut 
1987;28:1221-7. 
  370.   Pomare EW, Branch WJ, Cummings JH. Carbohydrate fermentation in the human 
colon and its relation to acetate concentrations in venous blood. J Clin Invest 
1985;75:1448-54. 
  371.   Cummings JH, Macfarlane GT. Colonic microflora: nutrition and health. Nutrition 
1997;13:476-8. 
  372.   Venter CS, Vorster HH. Possible metabolic consequences of fermentation in the 
colon for humans. Med Hypotheses 1989;29:161-6.   336 
  373.   Illman RJ, Topping DL, McIntosh GH et al. Hypocholesterolaemic effects of dietary 
propionate: studies in whole animals and perfused rat liver. Ann Nutr Metab 
1988;32:95-107. 
  374.   Chapman MA, Grahn MF, Hutton M, Williams NS. Butyrate metabolism in the 
terminal ileal mucosa of patients with ulcerative colitis. Br J Surg 1995;82:36-8. 
  375.   Roediger WE. Role of anaerobic bacteria in the metabolic welfare of the colonic 
mucosa in man. Gut 1980;21:793-8. 
  376.   Roediger WE. Utilization of nutrients by isolated epithelial cells of the rat colon. 
Gastroenterology 1982;83:424-9. 
  377.   Augeron C, Laboisse CL. Emergence of permanently differentiated cell clones in a 
human colonic cancer cell line in culture after treatment with sodium butyrate. 
Cancer Res 1984;44:3961-9. 
  378.   Hague A, Manning AM, Hanlon KA, Huschtscha LI, Hart D, Paraskeva C. Sodium 
butyrate induces apoptosis in human colonic tumour cell lines in a p53-independent 
pathway: implications for the possible role of dietary fibre in the prevention of large-
bowel cancer. Int J Cancer 1993;55:498-505. 
  379.   Hague A, Paraskeva C. The short-chain fatty acid butyrate induces apoptosis in 
colorectal tumour cell lines. Eur J Cancer Prev 1995;4:359-64. 
  380.   Trinidad TP, Wolever TM, Thompson LU. Effect of acetate and propionate on 
calcium absorption from the rectum and distal colon of humans. Am J Clin Nutr 
1996;63:574-8. 
  381.   Cherbut C. Motor effects of short-chain fatty acids and lactate in the gastrointestinal 
tract. Proc Nutr Soc 2003;62:95-9. 
  382.   Ropert A, Cherbut C, Roze C et al. Colonic fermentation and proximal gastric tone 
in humans. Gastroenterology 1996;111:289-96. 
  383.   Squires PE, Rumsey RD, Edwards CA, Read NW. Effect of short-chain fatty acids 
on contractile activity and fluid flow in rat colon in vitro. Am J Physiol 
1992;262:G813-G817. 
  384.   Mortensen FV, Nielsen H, Mulvany MJ, Hessov I. Short chain fatty acids dilate 
isolated human colonic resistance arteries. Gut 1990;31:1391-4. 
  385.   Mortensen FV, Hessov I, Birke H, Korsgaard N, Nielsen H. Microcirculatory and 
trophic effects of short chain fatty acids in the human rectum after Hartmann's 
procedure. Br J Surg 1991;78:1208-11. 
  386.   Sakata T, Yajima T. Influence of short chain fatty acids on the epithelial cell division 
of digestive tract. Q J Exp Physiol 1984;69:639-48. 
  387.   Siavoshian S, Segain JP, Kornprobst M et al. Butyrate and trichostatin A effects on 
the proliferation/differentiation of human intestinal epithelial cells: induction of cyclin 
D3 and p21 expression. Gut 2000;46:507-14. 
  388.   Koruda MJ, Rolandelli RH, Bliss DZ, Hastings J, Rombeau JL, Settle RG. 
Parenteral nutrition supplemented with short-chain fatty acids: effect on the small-
bowel mucosa in normal rats. Am J Clin Nutr 1990;51:685-9.   337 
  389.   Kripke SA, Fox AD, Berman JM, Settle RG, Rombeau JL. Stimulation of intestinal 
mucosal growth with intracolonic infusion of short-chain fatty acids. JPEN J 
Parenter Enteral Nutr 1989;13:109-16. 
  390.   Segain JP, Raingeard de la BD, Bourreille A et al. Butyrate inhibits inflammatory 
responses through NFkappaB inhibition: implications for Crohn's disease. Gut 
2000;47:397-403. 
  391.   Harig JM, Soergel KH, Komorowski RA, Wood CM. Treatment of diversion colitis 
with short-chain-fatty acid irrigation. N Engl J Med 1989;320:23-8. 
  392.   McIntyre A, Gibson PR, Young GP. Butyrate production from dietary fibre and 
protection against large bowel cancer in a rat model. Gut 1993;34:386-91. 
  393.   Lin J, Nafday SM, Chauvin SN et al. Variable effects of short chain fatty acids and 
lactic acid in inducing intestinal mucosal injury in newborn rats. J Pediatr 
Gastroenterol Nutr 2002;35:545-50. 
  394.   Nafday SM, Chen W, Peng L, Babyatsky MW, Holzman IR, Lin J. Short-chain fatty 
acids induce colonic mucosal injury in rats with various postnatal ages. Pediatr Res 
2005;57:201-4. 
  395.   Szylit O, Maurage C, Gasqui P et al. Fecal short-chain fatty acids predict digestive 
disorders in premature infants. JPEN J Parenter Enteral Nutr 1998;22:136-41. 
  396.   Edwards CA, Parrett AM, Balmer SE, Wharton BA. Faecal short chain fatty acids in 
breast-fed and formula-fed babies. Acta Paediatr 1994;83:459-62. 
  397.   Peng L, He Z, Chen W, Holzman IR, Lin J. Effects of butyrate on intestinal barrier 
function in a Caco-2 cell monolayer model of intestinal barrier. Pediatr Res 
2007;61:37-41. 
  398.   Ewaschuk JB, Naylor JM, Zello GA. D-lactate in human and ruminant metabolism. J 
Nutr 2005;135:1619-25. 
  399.   Bourriaud C, Robins RJ, Martin L et al. Lactate is mainly fermented to butyrate by 
human intestinal microfloras but inter-individual variation is evident. J Appl Microbiol 
2005;99:201-12. 
  400.   Morrison DJ, Mackay WG, Edwards CA, Preston T, Dodson B, Weaver LT. Butyrate 
production from oligofructose fermentation by the human faecal flora: what is the 
contribution of extracellular acetate and lactate? Br J Nutr 2006;96:570-7. 
  401.   Belenguer A, Duncan SH, Holtrop G, Anderson SE, Lobley GE, Flint HJ. Impact of 
pH on lactate formation and utilization by human fecal microbial communities. Appl 
Environ Microbiol 2007;73:6526-33. 
  402.   Gibson GR, Macfarlane GT, Cummings JH. Sulphate reducing bacteria and 
hydrogen metabolism in the human large intestine. Gut 1993;34:437-9. 
  403.   Pitcher MC, Cummings JH. Hydrogen sulphide: a bacterial toxin in ulcerative 
colitis? Gut 1996;39:1-4. 
  404.   Magee EA, Richardson CJ, Hughes R, Cummings JH. Contribution of dietary 
protein to sulfide production in the large intestine: an in vitro and a controlled 
feeding study in humans. Am J Clin Nutr 2000;72:1488-94.   338 
  405.   Levitt MD, Springfield J, Furne J, Koenig T, Suarez FL. Physiology of sulfide in the 
rat colon: use of bismuth to assess colonic sulfide production. J Appl Physiol 
2002;92:1655-60. 
  406.   Jorgensen J, Mortensen PB. Hydrogen sulfide and colonic epithelial metabolism: 
implications for ulcerative colitis. Dig Dis Sci 2001;46:1722-32. 
  407.   Roediger WE, Duncan A, Kapaniris O, Millard S. Sulphide impairment of substrate 
oxidation in rat colonocytes: a biochemical basis for ulcerative colitis? Clin Sci 
(Lond) 1993;85:623-7. 
  408.   Fiorucci S, Distrutti E, Cirino G, Wallace JL. The emerging roles of hydrogen sulfide 
in the gastrointestinal tract and liver. Gastroenterology 2006;131:259-71. 
  409.   Gibson JA, Sladen GE, Dawson AM. Protein absorption and ammonia production: 
the effects of dietary protein and removal of the colon. Br J Nutr 1976;35:61-5. 
  410.   Nugent SG, Kumar D, Rampton DS, Evans DF. Intestinal luminal pH in 
inflammatory bowel disease: possible determinants and implications for therapy 
with aminosalicylates and other drugs. Gut 2001;48:571-7. 
  411.   Sasaki Y, Hada R, Nakajima H, Fukuda S, Munakata A. Improved localizing method 
of radiopill in measurement of entire gastrointestinal pH profiles: colonic luminal pH 
in normal subjects and patients with Crohn's disease. Am J Gastroenterol 
1997;92:114-8. 
  412.   Evans DF, Pye G, Bramley R, Clark AG, Dyson TJ, Hardcastle JD. Measurement of 
gastrointestinal pH profiles in normal ambulant human subjects. Gut 1988;29:1035-
41. 
  413.   Inan MS, Rasoulpour RJ, Yin L, Hubbard AK, Rosenberg DW, Giardina C. The 
luminal short-chain fatty acid butyrate modulates NF-kappaB activity in a human 
colonic epithelial cell line. Gastroenterology 2000;118:724-34. 
  414.   Luhrs H, Gerke T, Muller JG et al. Butyrate inhibits NF-kappaB activation in lamina 
propria macrophages of patients with ulcerative colitis. Scand J Gastroenterol 
2002;37:458-66. 
  415.   Venkatraman A, Ramakrishna BS, Shaji RV, Kumar NS, Pulimood A, Patra S. 
Amelioration of dextran sulfate colitis by butyrate: role of heat shock protein 70 and 
NF-kappaB. Am J Physiol Gastrointest Liver Physiol 2003;285:G177-G184. 
  416.   Weng M, Walker WA, Sanderson IR. Butyrate regulates the expression of 
pathogen-triggered IL-8 in intestinal epithelia. Pediatr Res 2007;62:542-6. 
  417.   Treem WR, Ahsan N, Shoup M, Hyams JS. Fecal short-chain fatty acids in children 
with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1994;18:159-64. 
  418.   van Nuenen MH, Venema K, van der Woude JC, Kuipers EJ. The metabolic activity 
of fecal microbiota from healthy individuals and patients with inflammatory bowel 
disease. Dig Dis Sci 2004;49:485-91. 
  419.   Vernia P, Gnaedinger A, Hauck W, Breuer RI. Organic anions and the diarrhea of 
inflammatory bowel disease. Dig Dis Sci 1988;33:1353-8.   339 
  420.   Roediger WE, Heyworth M, Willoughby P, Piris J, Moore A, Truelove SC. Luminal 
ions and short chain fatty acids as markers of functional activity of the mucosa in 
ulcerative colitis. J Clin Pathol 1982;35:323-6. 
  421.   Vernia P, Caprilli R, Latella G, Barbetti F, Magliocca FM, Cittadini M. Fecal lactate 
and ulcerative colitis. Gastroenterology 1988;95:1564-8. 
  422.   Roediger WE. The colonic epithelium in ulcerative colitis: an energy-deficiency 
disease? Lancet 1980;2:712-5. 
  423.   Roediger WE, Nance S. Metabolic induction of experimental ulcerative colitis by 
inhibition of fatty acid oxidation. Br J Exp Pathol 1986;67:773-82. 
  424.   Ahmad MS, Krishnan S, Ramakrishna BS, Mathan M, Pulimood AB, Murthy SN. 
Butyrate and glucose metabolism by colonocytes in experimental colitis in mice. Gut 
2000;46:493-9. 
  425.   Den HE, Hiele M, Evenepoel P, Peeters M, Ghoos Y, Rutgeerts P. In vivo butyrate 
metabolism and colonic permeability in extensive ulcerative colitis. 
Gastroenterology 1998;115:584-90. 
  426.   Santhanam S, Venkatraman A, Ramakrishna BS. Impairment of mitochondrial 
acetoacetyl CoA thiolase activity in the colonic mucosa of patients with ulcerative 
colitis. Gut 2007;56:1543-9. 
  427.   Thibault R, De CP, Daly K et al. Down-regulation of the monocarboxylate 
transporter 1 is involved in butyrate deficiency during intestinal inflammation. 
Gastroenterology 2007;133:1916-27. 
  428.   Butzner JD, Parmar R, Bell CJ, Dalal V. Butyrate enema therapy stimulates 
mucosal repair in experimental colitis in the rat. Gut 1996;38:568-73. 
  429.   D'Argenio G, Cosenza V, Sorrentini I et al. Butyrate, mesalamine, and factor XIII in 
experimental colitis in the rat: effects on transglutaminase activity. Gastroenterology 
1994;106:399-404. 
  430.   Song M, Xia B, Li J. Effects of topical treatment of sodium butyrate and 5-
aminosalicylic acid on expression of trefoil factor 3, interleukin 1beta, and nuclear 
factor kappaB in trinitrobenzene sulphonic acid induced colitis in rats. Postgrad Med 
J 2006;82:130-5. 
  431.   Breuer RI, Soergel KH, Lashner BA et al. Short chain fatty acid rectal irrigation for 
left-sided ulcerative colitis: a randomised, placebo controlled trial. Gut 1997;40:485-
91. 
  432.   Di SA, Morera R, Ciccocioppo R et al. Oral butyrate for mildly to moderately active 
Crohn's disease. Aliment Pharmacol Ther 2005;22:789-94. 
  433.   Vernia P, Monteleone G, Grandinetti G et al. Combined oral sodium butyrate and 
mesalazine treatment compared to oral mesalazine alone in ulcerative colitis: 
randomized, double-blind, placebo-controlled pilot study. Dig Dis Sci 2000;45:976-
81. 
  434.   Hove H, Mortensen PB. Influence of intestinal inflammation (IBD) and small and 
large bowel length on fecal short-chain fatty acids and lactate. Dig Dis Sci 
1995;40:1372-80.   340 
  435.   Vernia P, Annese V, Bresci G et al. Topical butyrate improves efficacy of 5-ASA in 
refractory distal ulcerative colitis: results of a multicentre trial. Eur J Clin Invest 
2003;33:244-8. 
  436.   Scheppach W. Treatment of distal ulcerative colitis with short-chain fatty acid 
enemas. A placebo-controlled trial. German-Austrian SCFA Study Group. Dig Dis 
Sci 1996;41:2254-9. 
  437.   Steinhart AH, Hiruki T, Brzezinski A, Baker JP. Treatment of left-sided ulcerative 
colitis with butyrate enemas: a controlled trial. Aliment Pharmacol Ther 
1996;10:729-36. 
  438.   Patz J, Jacobsohn WZ, Gottschalk-Sabag S, Zeides S, Braverman DZ. Treatment 
of refractory distal ulcerative colitis with short chain fatty acid enemas. Am J 
Gastroenterol 1996;91:731-4. 
  439.   Vernia P, Marcheggiano A, Caprilli R et al. Short-chain fatty acid topical treatment in 
distal ulcerative colitis. Aliment Pharmacol Ther 1995;9:309-13. 
  440.   Vernia P, Cittadini M, Caprilli R, Torsoli A. Topical treatment of refractory distal 
ulcerative colitis with 5-ASA and sodium butyrate. Dig Dis Sci 1995;40:305-7. 
  441.   Steinhart AH, Brzezinski A, Baker JP. Treatment of refractory ulcerative 
proctosigmoiditis with butyrate enemas. Am J Gastroenterol 1994;89:179-83. 
  442.   Senagore AJ, MacKeigan JM, Scheider M, Ebrom JS. Short-chain fatty acid 
enemas: a cost-effective alternative in the treatment of nonspecific 
proctosigmoiditis. Dis Colon Rectum 1992;35:923-7. 
  443.   Scheppach W, Sommer H, Kirchner T et al. Effect of butyrate enemas on the 
colonic mucosa in distal ulcerative colitis. Gastroenterology 1992;103:51-6. 
  444.   Breuer RI, Buto SK, Christ ML et al. Rectal irrigation with short-chain fatty acids for 
distal ulcerative colitis. Preliminary report. Dig Dis Sci 1991;36:185-7. 
  445.   Hove H, Nordgaard-Andersen I, Mortensen PB. Faecal DL-lactate concentration in 
100 gastrointestinal patients. Scand J Gastroenterol 1994;29:255-9. 
  446.   Montgomery RD, Frazer AC, Hood C, Goodhart JM, Holland MR, Schneider R. 
Studies of intestinal fermentation in ulcerative colitis. Gut 1968;9:521-6. 
  447.   Ewe K, Schwartz S, Petersen S, Press AG. Inflammation does not decrease 
intraluminal pH in chronic inflammatory bowel disease. Dig Dis Sci 1999;44:1434-9. 
  448.   Press AG, Hauptmann IA, Hauptmann L et al. Gastrointestinal pH profiles in 
patients with inflammatory bowel disease. Aliment Pharmacol Ther 1998;12:673-8. 
  449.   Fallingborg J, Christensen LA, Jacobsen BA, Rasmussen SN. Very low intraluminal 
colonic pH in patients with active ulcerative colitis. Dig Dis Sci 1993;38:1989-93. 
  450.   Fallingborg J, Pedersen P, Jacobsen BA. Small intestinal transit time and 
intraluminal pH in ileocecal resected patients with Crohn's disease. Dig Dis Sci 
1998;43:702-5. 
  451.   Elson CO, Sartor RB, Tennyson GS, Riddell RH. Experimental models of 
inflammatory bowel disease. Gastroenterology 1995;109:1344-67.   341 
  452.   Moore JW, Babidge W, Millard S, Roediger WE. Effect of sulphide on short chain 
acyl-CoA metabolism in rat colonocytes. Gut 1997;41:77-81. 
  453.   Loubinoux J, Bronowicki JP, Pereira IAC, Mougenel JL, Le Faou AE. Sulfate-
reducing bacteria in human feces and their association with inflammatory bowel 
diseases. Fems Microbiology Ecology 2002;40:107-12. 
  454.   Pitcher MC, Beatty ER, Cummings JH. The contribution of sulphate reducing 
bacteria and 5-aminosalicylic acid to faecal sulphide in patients with ulcerative 
colitis. Gut 2000;46:64-72. 
  455.   Fite A, Macfarlane GT, Cummings JH et al. Identification and quantitation of 
mucosal and faecal desulfovibrios using real time polymerase chain reaction. Gut 
2004;53:523-9. 
  456.   Edmond LM, Hopkins MJ, Magee EA, Cummings JH. The effect of 5-aminosalicylic 
acid-containing drugs on sulfide production by sulfate-reducing and amino acid-
fermenting bacteria. Inflamm Bowel Dis 2003;9:10-7. 
  457.   Moore J, Babidge W, Millard S, Roediger W. Colonic luminal hydrogen sulfide is not 
elevated in ulcerative colitis. Dig Dis Sci 1998;43:162-5. 
  458.   Levine J, Ellis CJ, Furne JK, Springfield J, Levitt MD. Fecal hydrogen sulfide 
production in ulcerative colitis. Am J Gastroenterol 1998;93:83-7. 
  459.   Zinkevich V, V, Beech IB. Screening of sulfate-reducing bacteria in colonoscopy 
samples from healthy and colitic human gut mucosa. FEMS Microbiol Ecol 
2000;34:147-55. 
  460.   Ohge H, Furne JK, Springfield J, Sueda T, Madoff RD, Levitt MD. The effect of 
antibiotics and bismuth on fecal hydrogen sulfide and sulfate-reducing bacteria in 
the rat. FEMS Microbiol Lett 2003;228:137-42. 
  461.   Furne J, Springfield J, Koenig T, DeMaster E, Levitt MD. Oxidation of hydrogen 
sulfide and methanethiol to thiosulfate by rat tissues: a specialized function of the 
colonic mucosa. Biochem Pharmacol 2001;62:255-9. 
  462.   Picton R, Eggo MC, Merrill GA, Langman MJ, Singh S. Mucosal protection against 
sulphide: importance of the enzyme rhodanese. Gut 2002;50:201-5. 
  463.   Roediger WE, Babidge W, Millard S. Methionine derivatives diminish sulphide 
damage to colonocytes--implications for ulcerative colitis. Gut 1996;39:77-81. 
  464.   Lewis S, Brazier J, Beard D, Nazem N, Proctor D. Effects of metronidazole and 
oligofructose on faecal concentrations of sulphate-reducing bacteria and their 
activity in human volunteers. Scand J Gastroenterol 2005;40:1296-303. 
  465.   Zanardo RC, Brancaleone V, Distrutti E, Fiorucci S, Cirino G, Wallace JL. Hydrogen 
sulfide is an endogenous modulator of leukocyte-mediated inflammation. FASEB J 
2006;20:2118-20. 
  466.   Fiorucci S, Orlandi S, Mencarelli A et al. Enhanced activity of a hydrogen sulphide-
releasing derivative of mesalamine (ATB-429) in a mouse model of colitis. Br J 
Pharmacol 2007;150:996-1002.   342 
  467.   Florin T, Neale G, Gibson GR, Christl SU, Cummings JH. Metabolism of dietary 
sulphate: absorption and excretion in humans. Gut 1991;32:766-73. 
  468.   Lewis S, Cochrane S. Alteration of sulfate and hydrogen metabolism in the human 
colon by changing intestinal transit rate. Am J Gastroenterol 2007;102:624-33. 
  469.   Deplancke B, Finster K, Graham WV, Collier CT, Thurmond JE, Gaskins HR. 
Gastrointestinal and microbial responses to sulfate-supplemented drinking water in 
mice. Exp Biol Med (Maywood ) 2003;228:424-33. 
  470.   Jowett SL, Seal CJ, Pearce MS et al. Influence of dietary factors on the clinical 
course of ulcerative colitis: a prospective cohort study. Gut 2004;53:1479-84. 
  471.   D'Haens GR, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P. Early 
lesions of recurrent Crohn's disease caused by infusion of intestinal contents in 
excluded ileum. Gastroenterology 1998;114:262-7. 
  472.   Rutgeerts P, Van AG, Vermeire S et al. Ornidazole for prophylaxis of postoperative 
Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. 
Gastroenterology 2005;128:856-61. 
  473.   Hedin C, Whelan K, Lindsay JO. Evidence for the use of probiotics and prebiotics in 
inflammatory bowel disease: a review of clinical trials. Proc Nutr Soc 2007;66:307-
15. 
  474.   Eckburg PB, Relman DA. The role of microbes in Crohn's disease. Clin Infect Dis 
2007;44:256-62. 
  475.   Subramanian S, Campbell BJ, Rhodes JM. Bacteria in the pathogenesis of 
inflammatory bowel disease. Curr Opin Infect Dis 2006;19:475-84. 
  476.   Sellon RK, Tonkonogy S, Schultz M et al. Resident enteric bacteria are necessary 
for development of spontaneous colitis and immune system activation in interleukin-
10-deficient mice. Infect Immun 1998;66:5224-31. 
  477.   Rath HC, Wilson KH, Sartor RB. Differential induction of colitis and gastritis in HLA-
B27 transgenic rats selectively colonized with Bacteroides vulgatus or Escherichia 
coli. Infect Immun 1999;67:2969-74. 
  478.   Kim SC, Tonkonogy SL, Albright CA et al. Variable phenotypes of enterocolitis in 
interleukin 10-deficient mice monoassociated with two different commensal 
bacteria. Gastroenterology 2005;128:891-906. 
  479.   Madsen KL, Doyle JS, Jewell LD, Tavernini MM, Fedorak RN. Lactobacillus species 
prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 
1999;116:1107-14. 
  480.   Chiodini RJ, Van Kruiningen HJ, Merkal RS, Thayer WR, Jr., Coutu JA. 
Characteristics of an unclassified Mycobacterium species isolated from patients 
with Crohn's disease. J Clin Microbiol 1984;20:966-71. 
  481.   Naser SA, Ghobrial G, Romero C, Valentine JF. Culture of Mycobacterium avium 
subspecies paratuberculosis from the blood of patients with Crohn's disease. 
Lancet 2004;364:1039-44.   343 
  482.   Romero C, Hamdi A, Valentine JF, Naser SA. Evaluation of surgical tissue from 
patients with Crohn's disease for the presence of Mycobacterium avium subspecies 
paratuberculosis DNA by in situ hybridization and nested polymerase chain 
reaction. Inflamm Bowel Dis 2005;11:116-25. 
  483.   Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. 
Molecular-phylogenetic characterization of microbial community imbalances in 
human inflammatory bowel diseases. Proc Natl Acad Sci U S A 2007;104:13780-5. 
  484.   Sartor RB. Does Mycobacterium avium subspecies paratuberculosis cause Crohn's 
disease? Gut 2005;54:896-8. 
  485.   Selby W, Pavli P, Crotty B et al. Two-year combination antibiotic therapy with 
clarithromycin, rifabutin, and clofazimine for Crohn's disease. Gastroenterology 
2007;132:2313-9. 
  486.   Kotlowski R, Bernstein CN, Sepehri S, Krause DO. High prevalence of Escherichia 
coli belonging to the B2+D phylogenetic group in inflammatory bowel disease. Gut 
2007;56:669-75. 
  487.   Baumgart M, Dogan B, Rishniw M et al. Culture independent analysis of ileal 
mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny 
relative to depletion of Clostridiales in Crohn's disease involving the ileum. ISME J 
2007;1:403-18. 
  488.   Darfeuille-Michaud A, Boudeau J, Bulois P et al. High prevalence of adherent-
invasive Escherichia coli associated with ileal mucosa in Crohn's disease. 
Gastroenterology 2004;127:412-21. 
  489.   Fries W, Renda MC, Lo Presti MA et al. Intestinal permeability and genetic 
determinants in patients, first-degree relatives, and controls in a high-incidence area 
of Crohn's disease in Southern Italy. Am J Gastroenterol 2005;100:2730-6. 
  490.   Secondulfo M, de ML, Fiandra R et al. Intestinal permeability in Crohn's disease 
patients and their first degree relatives. Dig Liver Dis 2001;33:680-5. 
  491.   Bush TG, Savidge TC, Freeman TC et al. Fulminant jejuno-ileitis following ablation 
of enteric glia in adult transgenic mice. Cell 1998;93:189-201. 
  492.   Jacobs LR, Huber PW. Regional distribution and alterations of lectin binding to 
colorectal mucin in mucosal biopsies from controls and subjects with inflammatory 
bowel diseases. J Clin Invest 1985;75:112-8. 
  493.   Schultsz C, Van Den Berg FM, Ten Kate FW, Tytgat GN, Dankert J. The intestinal 
mucus layer from patients with inflammatory bowel disease harbors high numbers 
of bacteria compared with controls. Gastroenterology 1999;117:1089-97. 
  494.   Nuding S, Fellermann K, Wehkamp J, Stange EF. Reduced mucosal antimicrobial 
activity in Crohn's disease of the colon. Gut 2007;56:1240-7. 
  495.   Wehkamp J, Harder J, Weichenthal M et al. NOD2 (CARD15) mutations in Crohn's 
disease are associated with diminished mucosal alpha-defensin expression. Gut 
2004;53:1658-64.   344 
  496.   Hampe J, Franke A, Rosenstiel P et al. A genome-wide association scan of 
nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in 
ATG16L1. Nat Genet 2007;39:207-11. 
  497.   Rioux JD, Xavier RJ, Taylor KD et al. Genome-wide association study identifies 
new susceptibility loci for Crohn disease and implicates autophagy in disease 
pathogenesis. Nat Genet 2007;39:596-604. 
  498.   Tamboli CP, Neut C, Desreumaux P, Colombel JF. Dysbiosis in inflammatory bowel 
disease. Gut 2004;53:1-4. 
  499.   Favier C, Neut C, Mizon C, Cortot A, Colombel JF, Mizon J. Fecal beta-D-
galactosidase production and Bifidobacteria are decreased in Crohn's disease. Dig 
Dis Sci 1997;42:817-22. 
  500.   van der Wiel-Korstanje JA, Winkler KC. The faecal flora in ulcerative colitis. J Med 
Microbiol 1975;8:491-501. 
  501.   Giaffer MH, Holdsworth CD, Duerden BI. The assessment of faecal flora in patients 
with inflammatory bowel disease by a simplified bacteriological technique. J Med 
Microbiol 1991;35:238-43. 
  502.   Ruseler-van Embden JG, Both-Patoir HC. Anaerobic gram-negative faecal flora in 
patients with Crohn's disease and healthy subjects. Antonie Van Leeuwenhoek 
1983;49:125-32. 
  503.   Conte MP, Schippa S, Zamboni I et al. Gut-associated bacterial microbiota in 
paediatric patients with inflammatory bowel disease. Gut 2006;55:1760-7. 
  504.   Martinez C, Antolin M, Santos J et al. Unstable composition of the fecal microbiota 
in ulcerative colitis during clinical remission. Am J Gastroenterol 2008;103:643-8. 
  505.   Swidsinski A, Loening-Baucke V, Vaneechoutte M, Doerffel Y. Active Crohn's 
disease and ulcerative colitis can be specifically diagnosed and monitored based on 
the biostructure of the fecal flora. Inflamm Bowel Dis 2008;14:147-61. 
  506.   Sokol H, Lepage P, Seksik P, Dore J, Marteau P. Molecular comparison of 
dominant microbiota associated with injured versus healthy mucosa in ulcerative 
colitis. Gut 2007;56:152-4. 
  507.   Vasquez N, Mangin I, Lepage P et al. Patchy distribution of mucosal lesions in ileal 
Crohn's disease is not linked to differences in the dominant mucosa-associated 
bacteria: a study using fluorescence in situ hybridization and temporal temperature 
gradient gel electrophoresis. Inflamm Bowel Dis 2007;13:684-92. 
  508.   Martinez-Medina M, Aldeguer X, Gonzalez-Huix F, Acero D, Garcia-Gil LJ. 
Abnormal microbiota composition in the ileocolonic mucosa of Crohn's disease 
patients as revealed by polymerase chain reaction-denaturing gradient gel 
electrophoresis. Inflamm Bowel Dis 2006;12:1136-45. 
  509.   Bibiloni R, Mangold M, Madsen KL, Fedorak RN, Tannock GW. The bacteriology of 
biopsies differs between newly diagnosed, untreated, Crohn's disease and 
ulcerative colitis patients. J Med Microbiol 2006;55:1141-9.   345 
  510.   Gophna U, Sommerfeld K, Gophna S, Doolittle WF, Veldhuyzen van Zanten SJ. 
Differences between tissue-associated intestinal microfloras of patients with 
Crohn's disease and ulcerative colitis. J Clin Microbiol 2006;44:4136-41. 
  511.   Ott SJ, Schreiber S. Reduced microbial diversity in inflammatory bowel diseases. 
Gut 2006;55:1207. 
  512.   Sokol H, Seksik P, Rigottier-Gois L et al. Specificities of the fecal microbiota in 
inflammatory bowel disease. Inflamm Bowel Dis 2006;12:106-11. 
  513.   Manichanh C, Rigottier-Gois L, Bonnaud E et al. Reduced diversity of faecal 
microbiota in Crohn's disease revealed by a metagenomic approach. Gut 
2006;55:205-11. 
  514.   Scanlan PD, Shanahan F, O'Mahony C, Marchesi JR. Culture-independent 
analyses of temporal variation of the dominant fecal microbiota and targeted 
bacterial subgroups in Crohn's disease. J Clin Microbiol 2006;44:3980-8. 
  515.   Seksik P, Lepage P, de la Cochetiere MF et al. Search for localized dysbiosis in 
Crohn's disease ulcerations by temporal temperature gradient gel electrophoresis of 
16S rRNA. J Clin Microbiol 2005;43:4654-8. 
  516.   Mylonaki M, Rayment NB, Rampton DS, Hudspith BN, Brostoff J. Molecular 
characterization of rectal mucosa-associated bacterial flora in inflammatory bowel 
disease. Inflamm Bowel Dis 2005;11:481-7. 
  517.   Swidsinski A, Weber J, Loening-Baucke V, Hale LP, Lochs H. Spatial organization 
and composition of the mucosal flora in patients with inflammatory bowel disease. J 
Clin Microbiol 2005;43:3380-9. 
  518.   Lepage P, Seksik P, Sutren M et al. Biodiversity of the mucosa-associated 
microbiota is stable along the distal digestive tract in healthy individuals and 
patients with IBD. Inflamm Bowel Dis 2005;11:473-80. 
  519.   Bullock NR, Booth JC, Gibson GR. Comparative composition of bacteria in the 
human intestinal microflora during remission and active ulcerative colitis. Curr 
Issues Intest Microbiol 2004;5:59-64. 
  520.   Ott SJ, Musfeldt M, Wenderoth DF et al. Reduction in diversity of the colonic 
mucosa associated bacterial microflora in patients with active inflammatory bowel 
disease. Gut 2004;53:685-93. 
  521.   Prindiville T, Cantrell M, Wilson KH. Ribosomal DNA sequence analysis of mucosa-
associated bacteria in Crohn's disease. Inflamm Bowel Dis 2004;10:824-33. 
  522.   Mangin I, Bonnet R, Seksik P et al. Molecular inventory of faecal microflora in 
patients with Crohn's disease. Fems Microbiology Ecology 2004;50:25-36. 
  523.   Seksik P, Rigottier-Gois L, Gramet G et al. Alterations of the dominant faecal 
bacterial groups in patients with Crohn's disease of the colon. Gut 2003;52:237-42. 
  524.   Kleessen B, Kroesen AJ, Buhr HJ, Blaut M. Mucosal and invading bacteria in 
patients with inflammatory bowel disease compared with controls. Scand J 
Gastroenterol 2002;37:1034-41.   346 
  525.   Swidsinski A, Ladhoff A, Pernthaler A et al. Mucosal flora in inflammatory bowel 
disease. Gastroenterology 2002;122:44-54. 
  526.   Ott SJ, Kuhbacher T, Musfeldt M et al. Fungi and inflammatory bowel diseases: 
Alterations of composition and diversity. Scand J Gastroenterol 2008;43:831-41. 
  527.   Macfarlane S, Furrie E, Cummings JH, Macfarlane GT. Chemotaxonomic analysis 
of bacterial populations colonizing the rectal mucosa in patients with ulcerative 
colitis. Clin Infect Dis 2004;38:1690-9. 
  528.   Sokol H, Lepage P, Seksik P, Dore J, Marteau P. Temperature gradient gel 
electrophoresis of fecal 16S rRNA reveals active Escherichia coli in the microbiota 
of patients with ulcerative colitis. J Clin Microbiol 2006;44:3172-7. 
  529.   Whelan K, Judd PA, Preedy VR, Taylor MA. Enteral feeding: the effect on faecal 
output, the faecal microflora and SCFA concentrations. Proc Nutr Soc 2004;63:105-
13. 
  530.   Ruemmele FM, Roy CC, Levy E, Seidman EG. Nutrition as primary therapy in 
pediatric Crohn's disease: fact or fantasy? J Pediatr 2000;136:285-91. 
  531.   Lionetti P, Callegari ML, Ferrari S et al. Enteral nutrition and microflora in pediatric 
Crohn's disease. JPEN J Parenter Enteral Nutr 2005;29:S173-S175. 
  532.   Leach ST, Mitchell HM, Eng WR, Zhang L, Day AS. Sustained modulation of 
intestinal bacteria by exclusive enteral nutrition used to treat children with Crohn's 
disease. Aliment Pharmacol Ther 2008. 
  533.   Day AS, Whitten KE, Sidler M, Lemberg DA. Systematic review: nutritional therapy 
in paediatric Crohn's disease. Aliment Pharmacol Ther 2008;27:293-307. 
  534.   Schneider SM, Le GP, Girard-Pipau F et al. Total artificial nutrition is associated 
with major changes in the fecal flora. Eur J Nutr 2000;39:248-55. 
  535.   Verhoef MJ, Sutherland LR, Brkich L. Use of alternative medicine by patients 
attending a gastroenterology clinic. CMAJ 1990;142:121-5. 
  536.   Hilsden RJ, Meddings JB, Verhoef MJ. Complementary and alternative medicine 
use by patients with inflammatory bowel disease: An Internet survey. Can J 
Gastroenterol 1999;13:327-32. 
  537.   Burgmann T, Rawsthorne P, Bernstein CN. Predictors of alternative and 
complementary medicine use in inflammatory bowel disease: do measures of 
conventional health care utilization relate to use? Am J Gastroenterol 2004;99:889-
93. 
  538.   Furrie E, Macfarlane S, Kennedy A et al. Synbiotic therapy (Bifidobacterium 
longum/Synergy 1) initiates resolution of inflammation in patients with active 
ulcerative colitis: a randomised controlled pilot trial. Gut 2005;54:242-9. 
  539.   Joos S, Rosemann T, Szecsenyi J, Hahn EG, Willich SN, Brinkhaus B. Use of 
complementary and alternative medicine in Germany - a survey of patients with 
inflammatory bowel disease. BMC Complement Altern Med 2006;6:19. 
  540.   Thompson T, Feder G. Complementary therapies and the NHS. BMJ 2005;331:856-
7.   347 
  541.   Hilsden RJ, Scott CM, Verhoef MJ. Complementary medicine use by patients with 
inflammatory bowel disease. Am J Gastroenterol 1998;93:697-701. 
  542.   Angell M, Kassirer JP. Alternative medicine--the risks of untested and unregulated 
remedies. N Engl J Med 1998;339:839-41. 
  543.   Miller LG. Herbal medicinals: selected clinical considerations focusing on known or 
potential drug-herb interactions. Arch Intern Med 1998;158:2200-11. 
  544.   Otley A, Verhoef MJ, Best A. Prevalence and determinants of use of 
complementary and alternative medicine in a Canadian pediatric inflammatory 
bowel disease population. Gastroenterology 2001;120 (abstr). 
  545.   Green TJ, Issenman RM, Jacobson K. Patients' diets and preferences in a pediatric 
population with inflammatory bowel disease. Can J Gastroenterol 1998;12:544-9. 
  546.   Jowett SL, Seal CJ, Phillips E, Gregory W, Barton JR, Welfare MR. Dietary beliefs 
of people with ulcerative colitis and their effect on relapse and nutrient intake. Clin 
Nutr 2004;23:161-70. 
  547.   Belluzzi A, Brignola C, Campieri M, Pera A, Boschi S, Miglioli M. Effect of an 
enteric-coated fish-oil preparation on relapses in Crohn's disease. N Engl J Med 
1996;334:1557-60. 
  548.   Moser G, Tillinger W, Sachs G et al. Relationship between the use of 
unconventional therapies and disease-related concerns: a study of patients with 
inflammatory bowel disease. J Psychosom Res 1996;40:503-9. 
  549.   Quattropani C, Ausfeld B, Straumann A, Heer P, Seibold F. Complementary 
alternative medicine in patients with inflammatory bowel disease: use and attitudes. 
Scand J Gastroenterol 2003;38:277-82. 
  550.   Spigelblatt L, Laine-Ammara G, Pless IB, Guyver A. The use of alternative medicine 
by children. Pediatrics 1994;94:811-4. 
  551.   Verhoef MJ, Scott CM, Hilsden RJ. A multimethod research study on the use of 
complementary therapies among patients with inflammatory bowel disease. Altern 
Ther Health Med 1998;4:68-71. 
  552.   Hayden CW, Bernstein CN, Hall RA, Vakil N, Garewal HS, Fass R. Usage of 
supplemental alternative medicine by community-based patients with 
gastroesophageal reflux disease (GERD). Dig Dis Sci 2002;47:1-8. 
  553.   Day AS, Whitten KE, Bohane TD. Childhood inflammatory bowel disease: parental 
concerns and expectations. World J Gastroenterol 2005;11:1028-31. 
  554.    American Academy of Pediatrics: Counseling families who choose complementary 
and alternative medicine for their child with chronic illness or disability. Committee 
on Children With Disabilities. Pediatrics 2001;107:598-601. 
  555.   Finch CA, Bellotti V, Stray S et al. Plasma ferritin determination as a diagnostic tool. 
West J Med 1986;145:657-63. 
  556.   Wells JC, Fuller NJ, Dewit O, Fewtrell MS, Elia M, Cole TJ. Four-component model 
of body composition in children: density and hydration of fat-free mass and 
comparison with simpler models. Am J Clin Nutr 1999;69:904-12.   348 
  557.   Ellis KJ. Human body composition: in vivo methods. Physiol Rev 2000;80:649-80. 
  558.   Wells JC, Fewtrell MS, Williams JE, Haroun D, Lawson MS, Cole TJ. Body 
composition in normal weight, overweight and obese children: matched case-control 
analyses of total and regional tissue masses, and body composition trends in 
relation to relative weight. Int J Obes (Lond) 2006;30:1506-13. 
  559.   Piers LS, Soares MJ, Frandsen SL, O'Dea K. Indirect estimates of body 
composition are useful for groups but unreliable in individuals. Int J Obes Relat 
Metab Disord 2000;24:1145-52. 
  560.   Foster KR, Lukaski HC. Whole-body impedance--what does it measure? Am J Clin 
Nutr 1996;64:388S-96S. 
  561.   Going S, Nichols J, Loftin M et al. Validation of bioelectrical impedance analysis 
(BIA) for estimation of body composition in Black, White and Hispanic adolescent 
girls. Int J Body Compos Res 2006;4:161-7. 
  562.   Kriemler S, Puder J, Zahner L, Roth R, Braun-Fahrlander C, Bedogni G. Cross-
validation of bioelectrical impedance analysis for the assessment of body 
composition in a representative sample of 6- to 13-year-old children. Eur J Clin Nutr 
2008. 
  563.   Nielsen BM, Dencker M, Ward L et al. Prediction of fat-free body mass from 
bioelectrical impedance among 9- to 11-year-old Swedish children. Diabetes Obes 
Metab 2007;9:521-39. 
  564.   Nunez C, Gallagher D, Visser M, Pi-Sunyer FX, Wang Z, Heymsfield SB. 
Bioimpedance analysis: evaluation of leg-to-leg system based on pressure contact 
footpad electrodes. Med Sci Sports Exerc 1997;29:524-31. 
  565.   Kyle UG, Genton L, Karsegard L, Slosman DO, Pichard C. Single prediction 
equation for bioelectrical impedance analysis in adults aged 20--94 years. Nutrition 
2001;17:248-53. 
  566.   Newton RL, Jr., Alfonso A, York-Crowe E et al. Comparison of body composition 
methods in obese African-American women. Obesity (Silver Spring) 2006;14:415-
22. 
  567.   Rush EC, Chandu V, Plank LD. Prediction of fat-free mass by bioimpedance 
analysis in migrant Asian Indian men and women: a cross validation study. Int J 
Obes (Lond) 2006;30:1125-31. 
  568.   Xie X, Kolthoff N, Barenholt O, Nielsen SP. Validation of a leg-to-leg bioimpedance 
analysis system in assessing body composition in postmenopausal women. Int J 
Obes Relat Metab Disord 1999;23:1079-84. 
  569.   Pichard C, Kyle UG, Slosman DO. Fat-free mass in chronic illness: comparison of 
bioelectrical impedance and dual-energy x-ray absorptiometry in 480 chronically ill 
and healthy subjects. Nutrition 1999;15:668-76. 
  570.   Pietrobelli A, Andreoli A, Cervelli V, Carbonelli MG, Peroni DG, De LA. Predicting 
fat-free mass in children using bioimpedance analysis. Acta Diabetol 2003;40 Suppl 
1:S212-S215.   349 
  571.   Jartti L, Hakanen M, Paakkunainen U, Raittinen P, Ronnemaa T. Comparison of 
hand-to-leg and leg-to-leg bioelectric impedance devices in the assessment of body 
adiposity in prepubertal children. the STRIP study. Special Turku coronary Risk 
factor Intervention Project. Acta Paediatr 2000;89:781-6. 
  572.   Jebb SA, Cole TJ, Doman D, Murgatroyd PR, Prentice AM. Evaluation of the novel 
Tanita body-fat analyser to measure body composition by comparison with a four-
compartment model. Br J Nutr 2000;83:115-22. 
  573.   Hosking J, Metcalf BS, Jeffery AN, Voss LD, Wilkin TJ. Validation of foot-to-foot 
bioelectrical impedance analysis with dual-energy X-ray absorptiometry in the 
assessment of body composition in young children: the EarlyBird cohort. Br J Nutr 
2006;96:1163-8. 
  574.   Parker L, Reilly JJ, Slater C, Wells JC, Pitsiladis Y. Validity of six field and 
laboratory methods for measurement of body composition in boys. Obes Res 
2003;11:852-8. 
  575.   Cole TJ, Freeman JV, Preece MA. British 1990 growth reference centiles for weight, 
height, body mass index and head circumference fitted by maximum penalized 
likelihood. Stat Med 1998;17:407-29. 
  576.   Jebb SA. Measurement of soft tissue composition by dual energy X-ray 
absorptiometry. Br J Nutr 1997;77:151-63. 
  577.   Laskey MA. Dual-energy X-ray absorptiometry and body composition. Nutrition 
1996;12:45-51. 
  578.   Bland JM, Altman DG. Statistical methods for assessing agreement between two 
methods of clinical measurement. Lancet 1986;1:307-10. 
  579.   McCarthy HD, Cole TJ, Fry T, Jebb SA, Prentice AM. Body fat reference curves for 
children. Int J Obes (Lond) 2006;30:598-602. 
  580.   Lazzer S, Boirie Y, Meyer M, Vermorel M. Evaluation of two foot-to-foot bioelectrical 
impedance analysers to assess body composition in overweight and obese 
adolescents. Br J Nutr 2003;90:987-92. 
  581.   Sung RY, Lau P, Yu CW, Lam PK, Nelson EA. Measurement of body fat using leg 
to leg bioimpedance. Arch Dis Child 2001;85:263-7. 
  582.   Fomon SJ, Haschke F, Ziegler EE, Nelson SE. Body composition of reference 
children from birth to age 10 years. Am J Clin Nutr 1982;35:1169-75. 
  583.   Wong WW, Hergenroeder AC, Stuff JE, Butte NF, Smith EO, Ellis KJ. Evaluating 
body fat in girls and female adolescents: advantages and disadvantages of dual-
energy X-ray absorptiometry. Am J Clin Nutr 2002;76:384-9. 
  584.   Marcus MA, Wang J, Thornton JC, Ma R, Burastero S, Pierson RN, Jr. 
Anthropometrics do not influence dual X-ray absorptiometry (DXA) measurement of 
fat in normal to obese adults: a comparison with in vivo neutron activation analysis 
(IVNA). Obes Res 1997;5:122-30. 
  585.   Milliken LA, Going SB, Lohman TG. Effects of variations in regional composition on 
soft tissue measurements by dual-energy X-ray absorptiometry. Int J Obes Relat 
Metab Disord 1996;20:677-82.   350 
  586.   Testolin CG, Gore R, Rivkin T et al. Dual-energy X-ray absorptiometry: analysis of 
pediatric fat estimate errors due to tissue hydration effects. J Appl Physiol 
2000;89:2365-72. 
  587.   Wright CM, Sherriff A, Ward SC, McColl JH, Reilly JJ, Ness AR. Development of 
bioelectrical impedance-derived indices of fat and fat-free mass for assessment of 
nutritional status in childhood. Eur J Clin Nutr 2008;62:210-7. 
  588.   Elberg J, McDuffie JR, Sebring NG et al. Comparison of methods to assess change 
in children's body composition. Am J Clin Nutr 2004;80:64-9. 
  589.   Jebb SA, Siervo M, Murgatroyd PR, Evans S, Fruhbeck G, Prentice AM. Validity of 
the leg-to-leg bioimpedance to estimate changes in body fat during weight loss and 
regain in overweight women: a comparison with multi-compartment models. Int J 
Obes (Lond) 2007;31:756-62. 
  590.   King S, Wilson J, Kotsimbos T, Bailey M, Nyulasi I. Body composition assessment 
in adults with cystic fibrosis: comparison of dual-energy X-ray absorptiometry with 
skinfolds and bioelectrical impedance analysis. Nutrition 2005;21:1087-94. 
  591.   Williams JE, Wells JC, Wilson CM, Haroun D, Lucas A, Fewtrell MS. Evaluation of 
Lunar Prodigy dual-energy X-ray absorptiometry for assessing body composition in 
healthy persons and patients by comparison with the criterion 4-component model. 
Am J Clin Nutr 2006;83:1047-54. 
  592.   Dung NQ, Fusch G, Armbrust S, Jochum F, Fusch C. Use of bioelectrical 
impedance analysis and anthropometry to measure fat-free mass in children and 
adolescents with Crohn disease. J Pediatr Gastroenterol Nutr 2007;44:130-5. 
  593.   Cole TJ. Growth charts for both cross-sectional and longitudinal data. Stat Med 
1994;13:2477-92. 
  594.   Sandstead HH, Howard L. Zinc deficiency in Crohn's disease. Nutr Rev 
1982;40:109-12. 
  595.   Gray A, McMillan DC, Wilson C, Williamson C, O'Reilly DS, Talwar D. The 
relationship between plasma and red cell concentrations of vitamins thiamine 
diphosphate, flavin adenine dinucleotide and pyridoxal 5-phosphate following 
elective knee arthroplasty. Clin Nutr 2004;23:1080-3. 
  596.   Gray A, McMillan DC, Wilson C, Williamson C, O'Reilly DS, Talwar D. The 
relationship between the acute changes in the systemic inflammatory response, 
lipid soluble antioxidant vitamins and lipid peroxidation following elective knee 
arthroplasty. Clin Nutr 2005;24:746-50. 
  597.   Oakes EJ, Lyon TD, Duncan A, Gray A, Talwar D, O'Reilly DS. Acute inflammatory 
response does not affect erythrocyte concentrations of copper, zinc and selenium. 
Clin Nutr 2008;27:115-20. 
  598.   Vermeire S, Van AG, Rutgeerts P. Laboratory markers in IBD: useful, magic, or 
unnecessary toys? Gut 2006;55:426-31. 
  599.   Poullis A, Foster R, Northfield TC, Mendall MA. Review article: faecal markers in 
the assessment of activity in inflammatory bowel disease. Aliment Pharmacol Ther 
2002;16:675-81.   351 
  600.   Tibble J, Teahon K, Thjodleifsson B et al. A simple method for assessing intestinal 
inflammation in Crohn's disease. Gut 2000;47:506-13. 
  601.   Bunn SK, Bisset WM, Main MJ, Gray ES, Olson S, Golden BE. Fecal calprotectin: 
validation as a noninvasive measure of bowel inflammation in childhood 
inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001;33:14-22. 
  602.   Roseth AG. Determination of faecal calprotectin, a novel marker of organic 
gastrointestinal disorders. Dig Liver Dis 2003;35:607-9. 
  603.   Sipponen T, Karkkainen P, Savilahti E et al. Correlation of faecal calprotectin and 
lactoferrin with an endoscopic score for Crohn's disease and histological findings. 
Aliment Pharmacol Ther 2008;28:1221-9. 
  604.   Sipponen T, Savilahti E, Kolho KL, Nuutinen H, Turunen U, Farkkila M. Crohn's 
disease activity assessed by fecal calprotectin and lactoferrin: correlation with 
Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis 
2008;14:40-6. 
  605.   Canani RB, Terrin G, Rapacciuolo L et al. Faecal calprotectin as reliable non-
invasive marker to assess the severity of mucosal inflammation in children with 
inflammatory bowel disease. Dig Liver Dis 2008;40:547-53. 
  606.   Costa F, Mumolo MG, Bellini M et al. Role of faecal calprotectin as non-invasive 
marker of intestinal inflammation. Dig Liver Dis 2003;35:642-7. 
  607.   Fagerberg UL, Loof L, Myrdal U, Hansson LO, Finkel Y. Colorectal inflammation is 
well predicted by fecal calprotectin in children with gastrointestinal symptoms. J 
Pediatr Gastroenterol Nutr 2005;40:450-5. 
  608.   Fagerberg UL, Loof L, Lindholm J, Hansson LO, Finkel Y. Fecal calprotectin: a 
quantitative marker of colonic inflammation in children with inflammatory bowel 
disease. J Pediatr Gastroenterol Nutr 2007;45:414-20. 
  609.   Sipponen T, Savilahti E, Karkkainen P et al. Fecal calprotectin, lactoferrin, and 
endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's 
disease. Inflamm Bowel Dis 2008;14:1392-8. 
  610.   Bunn SK, Bisset WM, Main MJ, Golden BE. Fecal calprotectin as a measure of 
disease activity in childhood inflammatory bowel disease. J Pediatr Gastroenterol 
Nutr 2001;32:171-7. 
  611.   D'Inca R, Dal PE, Di L, V et al. Can calprotectin predict relapse risk in inflammatory 
bowel disease? Am J Gastroenterol 2008;103:2007-14. 
  612.   Walkiewicz D, Werlin SL, Fish D, Scanlon M, Hanaway P, Kugathasan S. Fecal 
calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel 
disease. Inflamm Bowel Dis 2008;14:669-73. 
  613.   Hollander D. Intestinal permeability in patients with Crohn's disease and their 
relatives. Dig Liver Dis 2001;33:649-51. 
  614.   Thjodleifsson B, Sigthorsson G, Cariglia N et al. Subclinical intestinal inflammation: 
an inherited abnormality in Crohn's disease relatives? Gastroenterology 
2003;124:1728-37.   352 
  615.   Beattie RM, Bentsen BS, MacDonald TT. Childhood Crohn's disease and the 
efficacy of enteral diets. Nutrition 1998;14:345-50. 
  616.   Laurentin A, Edwards CA. Differential fermentation of glucose-based carbohydrates 
in vitro by human faecal bacteria--a study of pyrodextrinised starches from different 
sources. Eur J Nutr 2004;43:183-9. 
  617.   Strocchi A, Furne JK, Levitt MD. A modification of the methylene blue method to 
measure bacterial sulfide production in feces. Journal of Microbiological Methods 
1992;15:75-82. 
  618.   Cline JD. Spectrophotometric determination of hydrogen sulfide in natural waters. 
Limnol Oceanogr 1969;14:454-8 (abstr). 
  619.   Florin TH. Hydrogen sulphide and total acid-volatile sulphide in faeces, determined 
with a direct spectrophotometric method. Clin Chim Acta 1991;196:127-34. 
  620.   Richardson CJ, Magee EA, Cummings JH. A new method for the determination of 
sulphide in gastrointestinal contents and whole blood by microdistillation and ion 
chromatography. Clin Chim Acta 2000;293:115-25. 
  621.   Godon JJ, Zumstein E, Dabert P, Habouzit F, Moletta R. Molecular microbial 
diversity of an anaerobic digestor as determined by small-subunit rDNA sequence 
analysis. Appl Environ Microbiol 1997;63:2802-13. 
  622.   Hove H, Holtug K, Jeppesen PB, Mortensen PB. Butyrate absorption and lactate 
secretion in ulcerative colitis. Dis Colon Rectum 1995;38:519-25. 
  623.   Geypens B, Claus D, Evenepoel P et al. Influence of dietary protein supplements on 
the formation of bacterial metabolites in the colon. Gut 1997;41:70-6. 
  624.   Torres-Pinedo R, Lavastida M, Rivera CL, Rodriguez H, Ortiz A. Studies on infant 
diarrhea. I. A comparison of the effects of milk feeding and intravenous therapy 
upon the composition and volume of the stool and urine. J Clin Invest 1966;45:469-
80. 
  625.   Gerasimidis K, McGrogan P, Hassan K, Edwards CA. Dietary modifications, 
nutritional supplements and alternative medicine in paediatric patients with 
inflammatory bowel disease. Aliment Pharmacol Ther 2008;27:155-65. 
  626.   Skrivanova E, Molatova Z, Marounek M. Effects of caprylic acid and triacylglycerols 
of both caprylic and capric acid in rabbits experimentally infected with 
enteropathogenic Escherichia coli O103. Vet Microbiol 2008;126:372-6. 
  627.   El OL, Flourie B, Bruley d, V et al. Relations between transit time, fermentation 
products, and hydrogen consuming flora in healthy humans. Gut 1996;38:870-7. 
  628.   Andrieux C, Membre JM, Cayuela C, Antoine JM. Metabolic characteristics of the 
faecal microflora in humans from three age groups. Scand J Gastroenterol 
2002;37:792-8. 
 
 
 
   353 
APPENDIX 
 
·  Paediatric Crohn’s disease activity index 
·  Laboratory micronutrient reference range 
·  Advertisement leaflet 
·  Instructions how to collect and store a stool sample 
·  Study information leaflets 
·  Study consent forms 
 
   354 
 
 
 
   355 
Micronutrient reference range from the Trace Element unit, Glasgow Royal Infirmary 
- copper  10-22 µmol/L (adults) 
  1.5 to 7.0 (0 to 3 mth) 
  4.0 to 17.0 (4 to 6 mth) 
  8.0 to 20.5 (7 to 12 mth) 
  12.5 to 23.5 (1 to 5 y) 
  13.0 to 21.5 (6 to 9 y) 
  12.5 to 19.0 (10 to 13 y) 
- selenium  0.8 - 2.0 µmol/L (adult)  
  0.2 - 0.9 µmol/L (0 to 2 y) 
  0.5 - 1.3 µmol/L (2 to 4 y) 
  0.7 - 1.7 µmol/L (4 to 16 y) 
- magnesium  0.7 to 1.0 mmol/L 
- zinc  12-18 µmol/L  
- vitamin A  1.0 to 3.0 µmol/L (adults) 
  0.5 to 1.5 µmol/L (< 1 y) 
  0.7 to 1.5 µmol/L (1 to 6 y) 
  0.9 to 1.7 µmol/L (7 to 12 y) 
  0.9 to 2.5 µmol/L (13 to 18 y) 
Carotenoids  α-carotene: 14 to 60 µg/L 
  β-carotene: 90 to 310 µg/L  
  Lutein: 80 to 200 µg/L  
  Lycopene: 100 to 300 µg/L 
- vitamin B1  275 to 675 ng/g Hb 
- vitamin B2  Whole blood: 220 to 410 nmol/L 
Red cell: 1.0 to 3.4 nmol/g Hb 
- vitamin B6  20 to 140 nmol/L 
234 to 815 pmol/g Hb 
- vitamin C  15 to 90 nmol/L 
- vitamin E  15 to 45 nmol/L 
- vitamin D  25 to 170 nmol/L 
- folate  2.7 to 34 ng/mL 
- ferritin  10 to 275 ng/mL 
- vitamin B12  180 to 883 pg/mL 
- ferritin  > 10  g/l 
- Calcium  2.25 to 2.70 mmol/L 
- Phosphate  0.9 to 1.8 mmol/L 
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